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Abstract 
 
Natural products have driven advancements in many fields for over a century, from methods 
for structural elucidation to the development of new synthetic reactions to replicate their complex 
scaffolds and biological activities. Because enzymes perform challenging synthetic 
transformations with superior chemo-, site- and stereoselectivity, scientists have more recently 
been inspired to leverage Nature’s biosynthetic machinery directly to make new compounds, 
establishing the emerging field of biocatalysis. This thesis describes studies with one broad class 
of proteins, carrier protein-dependent partner enzymes, to perform non-native reactions. 
Specifically, we developed biocatalytic platforms with two partner enzymes (PEs) SxtA AONS 
and AnaB to synthesize chiral amines chemoenzymatically. 
PEs, found in the biosynthetic pathways of polyketides and nonribosomal peptides, catalyze a 
variety of reactions to assemble diverse and elaborate natural products. However, they are not 
often employed to mediate non-native reactions because of the high cost of correct substrate 
activation. By understanding how carrier proteins (CPs) can be used efficiently in tandem with 
PEs or how PEs may operate in the absence of CPs, PEs can be incorporated into the syntheses of 
valuable small molecules. Chapter 1 summarizes multiple approaches toward utilizing PEs for 
synthetic purposes and strategies for employing non-native substrates. 
In Chapter 2, we characterized the native functions of the three PE domains within the 
polyketide-like synthase SxtA. We identified the correct starter unit and order of PE activity. 
Notably, the last domain, AONS transforms an amino acid into an α-amino ketone in a single step. 
 xxi 
We envisioned using this enzyme as a general tool to derivatize amino acids with and without the 
CP. 
We then optimized a CP-PE didomain platform with inexpensive acyl donors in Chapter 3 to 
perform the native reaction of SxtA AONS reaction scalably and to allow economical screening 
of the substrate scope. We observed ketone formation with multiple non-native thioesters and 
seven non-native amino acids but with very low overall conversion. We are improving the activity 
of SxtA AONS in a directed evolution campaign. 
Chapter 4 describes our investigations in alpha-deuteration of amino acids, a CP-free reaction. 
Deuterated amino acids are valuable precursors toward labeled pharmaceutical agents but 
challenging to synthesize. SxtA AONS installs a deuterium atom on the α-carbon of select α-amino 
acids and all α-amino methyl esters assayed. Preparative-scale reactions allowed for 
stereoselective chemoenzymatic synthesis of an isotopically labeled analog of the drug safinamide. 
Two SxtA domains, methyltransferase (MT) and AONS, were studied structurally and 
spectroscopically. In Chapter 5 we identify possible residues that lead to monomethylation in order 
to engineer additional dimethylation activity in SxtA MT. We also discuss UV-Vis studies with 
the AONS domain to understand the ketone-forming mechanism, elucidating the previously 
observed activity limitations and identifying possibilities for enzyme improvement. 
Finally, Chapter 6 details our work with AnaB, a PE that operates on proline, the only 
proteinogenic substrate incompatible with SxtA AONS. AnaB natively oxidizes CP-bound proline 
to an iminium ion that may be stereoselectively functionalized with an exogenous nucleophile in 
the preparation of chiral cyclic amines. We sequentially built a four-step catalytic cycle around 
AnaB to use the CP efficiently. 
 xxii 
The strategies presented in this thesis demonstrate the possibilities of leveraging CP-dependent 
PEs in chemoenzymatic synthesis. We anticipate that these approaches will also be applied to other 
PEs for the efficient, selective generation of chiral amines and other important synthetic building 
blocks. 
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Chapter 1: Introduction 
 
With excerpts from “Carrier Protein-Dependent Biocatalysis”. Chun, S. W.; Narayan, A. R. H. 
Manuscript in preparation. 
Summary 
With their potential to mediate reactions with nearly perfect chemo-, site- and stereoselectivity 
biocatalytic reactions and chemoenzymatic approaches have recently attracted significant attention 
and are now commonly integrated into industrial-scale processes. Carrier protein-dependent 
partner enzymes (PEs) from polyketide synthase and nonribosomal peptide synthetase pathways 
are one large class of biocatalysts that have untapped synthetic potential. To produce complex 
scaffolds, these enzymes function in coordinated assembly lines which could be exploited and 
tuned to afford custom molecules. However, PE reactivity in non-native reactions outside their 
biosynthetic contexts is not well-understood, and the requirement for the acyl substrates to be 
activated and covalently loaded onto small carrier proteins (CPs) is another expensive barrier to 
overcome. This Chapter reviews established methods to leverage PEs biocatalytically through both 
in vivo and in vitro strategies. Additionally, catalytic CP-PE platforms are proposed to enable more 
economical solution to the development of scalable methods using involving PEs. 
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1.1 Biocatalysis 
Under the loosest definition of “biocatalysis”, catalyzing chemical reactions with Nature’s 
catalysts, humanity has been performing biocatalysis for millennia. In the past century, biocatalysis 
has evolved past simple fermentation of certain foods and alcoholic beverages to harnessing 
biocatalysts for chemical synthesis.1,2 Early examples incorporated into industrial processes of 
commodity chemicals include chiral resolution of a racemic mixture by a lipase3 and 
stereoselective synthesis of L-aspartic acid (1.6) from an achiral acid (Fig. 1.1A).4,5 Biocatalysis 
has also found its way into the manufacturing of pharmaceutical products, such as the syntheses  
Figure 1.1. Commercially important biocatalytic reactions and products. 
New bonds and stereocenters formed are highlighted in blue. (A) Selected examples of early 
biocatalytic transformations.3,5 (B) Pharmaceutical products that have at least one enzymatic step 
in their industrial synthesis.6–8 
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of the compounds shown in Figure 1B.6–8 Many of the first enzymes implemented into large-scale 
synthetic routes have focused on group interconversion reactions over more complex 
transformations like C–C bond formation.2,9,10 Since then, enzymatic reactions have found 
increasing use based on several advantages over traditional chemical methods. Biocatalysts can 
mediate reactions with high chemo-, site- and stereoselectivity under mild conditions catalytically, 
resulting in relatively safe protocols that avoid the use of toxic and/or expensive reagents. One 
major challenge to wider incorporation of enzymes in chemical synthesis is in their substrate 
scopes.1,11 Millions of years of selective pressure has provided many useful wild-type biocatalysts 
evolved to perform their native reactions and can therefore have limited activity on the non-native 
scaffolds required for a given synthetic route devised by a chemist. 
 
 
Recent advances in several related fields have facilitated the implementation of biocatalysts 
through directed evolution for more sophisticated chemical transformations and synthetic routes 
Figure 1.2. Advances in related fields enable improved directed evolution campaigns 
toward more active, robust and promiscuous biocatalysts. 
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(Figure 1.2).1 These developments include: (1) improved DNA sequencing and synthesis 
technologies for quickly providing more diverse parent sequences and faster mutagenesis;12–15 (2) 
new higher-throughput assays to screen activity of protein variants;16,17 (3) more computational 
power to model reaction pathways and predict useful mutations;18–20 (4) rapid communication of 
results in online journals; 21,22 and (5) Prof. Frances Arnold winning the Nobel Prize in Chemistry 
in 2018 for directed evolution, which has spotlighted the field of biocatalysis.1 
One broad group of enzymes that has experienced minimal use in preparative-scale reactions 
outside of in vivo processes is proteins from carrier protein-dependent pathways. Because of the 
relatively high cost of building blocks, large-scale carrier protein (CP)-dependent processes have 
largely been restricted to the fermentation of products such as 6-deoxyerythronolide B23 and 
lovastatin (see section 1.2.1).24 
CP-dependent pathways include fatty acid synthases (FASs), types I and II polyketide 
synthases (PKSs), and nonribosomal peptide synthetases (NRPSs) that biosynthesize valuable 
natural products such as antibiotics erythromycin, vancomycin or the siderophore enterobactin 
(Figure 1.3A).25,26 Endogenously, the partner enzymes (PEs) in these pathways operate on 
substrates that are covalently bound to carrier proteins (CPs) and not free molecules in solution 
(Figure 1.3B). Remarkably, CPs across all types of CP-dependent pathways share a conserved 
three-helix structure despite low protein sequence identities across this class of proteins. CPs also 
possess a conserved serine residue, to which a 4’-phosphopantetheine (Ppant) cofactor is post-
translationally attached to activate the CP from the apo to holo form (1.16 to 1.17, Figure 1.3C). 
From here, substrates covalently tethered through a thioester linkage to the thiol of the Ppant arm, 
and then delivered to PE active sites (Figure 1.3D).27,28 
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CP-dependent pathways also are found in interesting architectural arrangements. In type I FAS, 
PKS and NRPS pathways, multiple CPs and PEs are expressed as domains in one polypeptide 
chain to form megasynthases, while these elements are expressed as discrete proteins in type II 
systems.27–29 Type III PKSs also exist but are CP-independent pathways that use solely coenzyme 
A (CoA) thioesters, and thus will not be discussed here.30 Types I and II CP-dependent pathways 
are further organized into modules, each of which is responsible for one cycle of chain initiation 
or elongation (Figure 1.4). Following the selection of the starter unit by the loading module, 
additional modules elongate the acyl or peptidyl chain by incorporating extender units and 
Figure 1.3. CP-dependent PEs assemble complex natural products via intermediates 
covalently bound to carrier proteins. 
(A) Some natural products resulting from CP-dependent pathways. Portions assembled by PEs 
are highlighted in blue, and the black moieties are modified in post-CP segments. (B) PEs are 
inactive on free acids. (C) Post-translational modification of inactive apo-CPs by 
phosphopantetheinyl transferases (PPTases) to form the active holo-protein. (D) General 
reaction cycle of substrate activation into esters or thioesters, loading onto holo-CPs and 
modification by CPs.  
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optionally elaborate on that unit with tailoring PEs. Chain extension can continue in multiple 
cycles until the chain is terminated by one of many offloading mechanisms such as a thioesterase 
(see Du and Lou31 for a comprehensive overview). Further modifications by post-PKS or -NRPS 
enzymes are also possible (black moieties in Figure 1.3A). 
Because most type I pathways react in a predictable assembly line-fashion from the N- to the 
C-termini of each multi-domain protein, scientists have long been interested in designing pathways 
to synthesize custom natural product derivatives.32–34 The simplest approach of splicing together 
the domains of interest has been met with very limited success, as it has become clear that the 
precise timing of PE reactivity is tightly controlled by linkers and complex protein-protein 
interactions between domains and modules.35–40 The interactions themselves are difficult to 
characterize structurally for multiple reasons (limited protein stability, CPs are small and flexible, 
megasynthases are typically too large for x-ray crystallography), so we and many other groups 
have focused on studying individual or a small subset of domains rather than full modules. We 
anticipate that our studies will contribute to the body of literature on PEs operating on non-native 
substrates in order to develop syntheses of novel small molecules by PEs. 
The remainder of this Chapter will discuss previously published examples of utilizing PEs in 
biocatalytic reactions, and the basis of our proposed CP-PE platform. I will then briefly summarize 
the contents of research Chapters 2-6. 
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Figure 1.4. Common features of fatty acid synthase (FAS), polyketide synthase (PKS) and nonribosomal peptide synthetase 
(NRPS) pathways. 
Minimum elongating components are acyltransferase (AT), ketosynthase (KS), ACP in PKS and adenylation (A), condensation (C), and 
PCP in NRPS. 
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1.2 Summary of Established CP-PE Biocatalytic Approaches 
CP-dependent pathways are relatively expensive in their native contexts, requiring ATP and/or 
CoASH for activation of starter and extender units (Figure 1.5A), and the synthesis of sometimes 
very large proteins.28 Even so, synthetic biologists, biochemists and chemists remain fascinated by 
these pathways because they are responsible for the biosyntheses of complex commercially 
valuable scaffolds,41 because CP-dependent PEs can catalyze chemically challenging 
transformations, and because of the future possibility of merging reactions into cascades.34 
Some examples of PE-catalyzed transformations are shown in Figures 1.5B-D. After the 
ketosynthase-catalyzed condensation in PKS proteins (Figure 1.4), PKS ketoreductases (KR) 
reduce the β-keto groups to β-hydroxyl groups stereospecifically with NADPH (nicotinamide 
adenine dinucleotide phosphate hydride), a reducing cofactor. Substituted carbons alpha to the 
thioester are not configurationally stable due to the low pKa; thus, the reduction of β-carbonyls 
sets both α- and β-stereocenters simultaneously.42 KR subtypes that catalyze formation of all four 
combinations of stereocenters have been discovered (Figure 1.5B).43 Optional loss of water by 
dehydratases (DH) may follow the KR-catalyzed reaction, forming α,β or β,γ unsaturated bonds. 
GphF DH1, the first DH in the gephyronic acid biosynthetic pathway, initially forms an α,β-
unsaturated intermediate 1.30 from 1.29 (Figure 1.5B), but then isomerizes 1.30 so that the final 
product 1.31 contains a β,γ double bond and the α-stereocenter is epimerized from its original 
configuration.44 A third PE-catalyzed reaction, that is challenging to accomplish with traditional 
chemical methods is the cyclopropane ring formation in kutzneride biosynthesis.45 Chemical 
cyclopropanation reactions often employ extremely reactive intermediates such as carbenes or 
carbenoids,46 whereas the ring formation is accomplished biosynthetically by a two-enzyme 
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cascade under much milder conditions. An isoleucyl substrate bound to the PCP KtzC 1.32 is first 
chlorinated by the halogenase KtzD and then cyclized by KtzA, eliminating HCl (Figure 1.5D).45,47 
 
 
Figure 1.5. Selected transformations performed by CP-dependent enzymes. 
(A) Preparation of starter and extender units. (B) Stereospecific β-keto reduction by ketoreductases 
(KRs). (C) Dehydratase (DH) elimination of β-hydroxy groups, with optional double bond 
isomeration. (D) Chlorination of an unactivated C-H bond by the α-ketoglutarate (α-KG) non-
heme iron halogenase KtzD, followed by a KtzA-catalyzed cyclization.43,44,47  
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Using natural cascades such as KtzACD or a designed non-native sequence would be ideal in 
synthetic route development; however, many challenges remain to render CP-dependent PEs 
amenable to preparative-scale synthesis, including the aforementioned protein instability, required 
CP post-translational modification and activation cost to form the required CP-bound 
intermediates. Chemists and biochemists have developed multiple methods to mitigate the last 
issue that will be covered here. This Chapter is organized according to strategies using natural 
producer strains in vivo, using native loading mechanisms in vitro, bypassing CP-dependent 
gatekeepers nonenzymatically, and finally engineering a PE away from CP dependence. 
 
1.2.1. CP-dependent pathways in vivo 
Prior to recent advancements in genome sequencing, natural products were discovered and 
elucidated by isolation from bacterial and fungal extracts of field samples or laboratory-grown 
cultures.48 While in silico genomic mining is preferred today for polyketide and nonribosomal 
peptide discovery,49 in vivo methods involving the culturing of natural producers are also used for 
industrial-scale polyketide production and analytical feeding studies to identify a product's 
fundamental building blocks.50 
These methods are particularly useful when the biosynthetic gene cluster encoding a target 
pathway has not yet been located.50 Even if a gene cluster and its associated natural product(s) are 
known, culturing the producing organisms avoids the challenges associated with cloning and 
recombinant expression of megasynthases for in vitro experiments.51 However, employing in vivo 
approaches requires producing strains to be culturable and the gene cluster of interest to be 
expressed under laboratory conditions. This section will discuss examples of culturable strains for 
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commercial fermentation to manufacture polyketide and nonribosomal peptide-based products, 
and smaller-scale instances of native product analogs generated through feeding experiments. 
 
1.2.1A. Commercial fermentation 
In order to supply the billions of dollars' worth of commercial polyketide and nonribosomal 
peptide products, industrial processes obtain valuable compounds such as erythromycin A (1.10, 
see Figure 1.3A) by large-scale fermentation of optimized producing organisms followed by 
isolation of the desired molecules.51 The compounds may be the final product of a full PKS or 
NRPS pathway,51 or for semisynthetic routes, an advanced intermediate that can be further tailored 
chemically.52 Maintaining a constant supply of the required activated starter and extender units 
and reducing equivalents for a CP-dependent pathway is expensive, motivating industrial-scale 
processes to rely on the optimized host strains to produce all required building blocks and perform 
optional difficult post-CP tailoring.53,54 To the best of our knowledge, large-scale fermentation is 
the most cost-effective method to obtain large amounts of compounds from primarily CP-
dependent pathways but has only been applied to use the native reactions of PEs. A selection of 
well-known industrially produced polyketide and nonribosomal peptide products obtained from 
natural producers is listed in Table 1.1, with product titers ranging from milligram to multigram 
quantities per liter of culture. Many of these entries include the post-PKS/NRPS modifications as 
information on the yields of only the CP-dependent portions of pathways were not available. 
Although impressive yields have been reported for products such as oxytetracycline and 
vancomycin (entries 10 and 12),55,56 work to improve industrial strains and product yields are 
ongoing.57 Typically, industrial strains have been and continue to be optimized over decades by 
random mutagenesis;58 therefore, many of these titer values are likely outdated. Recently, efforts 
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to further improve yields by metabolic engineering to increase protein expression and availability 
of building blocks while decreasing competition for precursors, shunt product formation or product 
degradation have been reported, with promising results.59 Some fungal hosts are challenging to 
genetically manipulate, and there is interest in transferring the pathways to E. coli that are simpler 
to culture and manipulate. However, these E. coli strains (entries 1 and 2) are not yet as productive 
as the native hosts.60,61 One notable example is the E. coli BAP1 strain originally developed by 
Pfeifer and Khosla in 2001 for the biosynthesis of 6-deoxyerythronolide B (6-dEB).62 Due to the 
promiscuous phosphopantetheinyl transferase (PPTase) gene sfp inserted into its genome, the 
BAP1 strain has found widespread use as a host to prepare recombinant holo-carrier proteins today.  
 
Table 1.1. Commercial products from CP-dependent pathways obtained by industrial-scale 
fermentation 
Entry Isolated product Pathway Strain Product titer (per L of 
culture) 
1 6-dEB (PKS product) Erythromycin A E. coli BAP1 100-1100 mg23,62,63 
2 
Erythromycin A (final 
pathway product) 
 E. coli LF01 10 mg54,64 
3 Erythromycin A  Saccharopolyspora erythraea 8-10 g51 
4 Tylosin Tylosin Streptomyces fradiae TM-224 7.2 g65 
5 Lovastatin Lovastatin Aspergillus terreus LA414 660 mg24 
6 Penicillins G and V Penicillins 
Penicillium chrysogenum and 
P. rubens 
50 g66 
7 Cephalosporin C Cephalosporin Acremonium chrysogenum 3.1 g67,68 
8 Daunorubicin Doxorubicin Streptomyces peucetius 60 mg69 
9 Tetracycline Tetracyclines Streptomyces lusitanus 11.1 g70 
10 Oxytetracycline  S. rimosus 23833 55 g55 
11 Chlortetracycline  S. aureofaciens F3 14.8 g71 
12 Vancomycin Vancomycin 
Amycolaptosis orientalis 
KCCM-10836P 
11.5 g56 
 
Currently, fermentation is the only scalable method than generates orders of magnitude more 
PKS/NRPS natural products than industrial fermentation. Until significant advancements in 
engineering how PEs utilize substrate surrogates are discovered, fermentation will likely be the 
only economical strategy for lengthy polyketide and nonribosomal peptide production. 
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1.2.1B. Feeding studies and precursor-directed biosynthesis 
On laboratory-scale, polyketide and nonribosomal peptides are routinely isolated from much 
smaller scale cultures. In feeding experiments, the culturable host's biosynthetic pathways still 
generate and activate most of the building blocks, but supplementing culture media with 
isotopically labeled substrates can lead to incorporation into natural products. This has been used 
in all types of biosynthetic pathways for decades to track metabolic processes, including classic 
feeding studies in the 1950s and 1960s to provide clues on the fundamentals of CP-dependent 
biosynthesis.72,73 Isotopic feeding experiments are still employed to identify PKS and NRPS 
extender units, and elucidate structures of the small molecule products.74,75 
Once the precursors are known, their analogs may also be added to cultures of producing strains 
in a process known as precursor-directed biosynthesis (PDB). Provided the biosynthetic enzymes 
are sufficiently promiscuous, the compounds isolated are new product analogs.  
Figure 1.6. Precursor-directed biosynthesis of asperlicin analogs from leucine and 
tryptophan derivatives by the asperlicin producer Aspergillus alliaceus. 
See Houck et al.76. 
 
 
For example, fluorinated leucine (1.35) or methylated tryptophan (1.36) added to the media of 
asperlicin producer Aspergillus alliaceus gave novel asperlicin analogs such as 1.38 and 1.39 
(Figure 1.6).76 PDB has been used to produce new analogs of cyclosporins,77  among others. 
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Analogs of the balhimycin78, salinosporamide,79 and many other natural products have been 
synthesized by mutasynthesis,38 a variation of PDB using mutant or auxotrophic host strains. 
 
1.2.2. In vitro strategies with native loading methods 
PDB and mutasynthesis require potential building blocks to be stable and taken into host cells, 
properties that all desired precursors may not possess. Additionally, recently published genome 
sequences of potential natural product producers have revealed the presence of many silent 
biosynthetic gene clusters that are not expressed under normal laboratory conditions.48 Fortunately, 
advances in cloning and heterologous protein expression now permit more direct probing of CP-
dependent pathways.80 For in vitro reactions with purified enzymes, studying PEs in a simplified 
system without competing host reactions can provide advantages, but the gene cluster must be 
known before this can be used as a viable approach.81 However, unlike the in vivo processes 
described in Section 1.2.1 where the host organism pathways activate building block precursors, 
employing native loading machinery in vitro also requires the addition of activating cofactors. The 
most common loading PEs, NRPS adenylation proteins (A) and PKS acyltransferases (AT), 
require ATP and CoASH, respectively, which may be prohibitively expensive at larger scales.82 
 
1.2.2A. Partial pathway reconstruction with NRPS adenylation domains 
Whereas the in vivo strategies discussed previously (Section 1.2.1) primarily use complete 
pathways, smaller subsets of PEs have been probed through in vitro experiments. If an interesting 
PE is found within the first module of a CP-dependent pathway, one direct method of generating 
loaded CP substrates in situ is through the native loading domains.83 For example, to probe the 
halogenation activity of PltA, Dorrestein and coworkers used a three-enzyme cascade to first 
 15 
adenylate and load the starter unit L-proline (1.40) onto the holo-PCP PltL, which is subsequently 
oxidized from pyrrolidine 1.41 to pyrrole (1.42) by PltE (Figure 1.7A).84 PltA was then 
demonstrated to incorporate both bromide ions in addition to its native chlorination activity.85 In 
another report, Mann and coworkers examined the substrate scope of a PltE-related oxidase, AnaB, 
by adenylating and loading the native L-Pro substrate as well as substituted derivatives onto the 
cognate PCP.86,87 Stachelhaus and Walsh studied a longer sequence involving the putative  
Figure 1.7. In vitro PE studies with native loading methods. 
(A) Probing the initial steps of pyoluteorin biosynthesis – loading of the L-Pro (1.40) starter unit 
onto PltL, followed by a four-electron oxidation and chlorination.84,85 (B) The epimerase domain 
of the gramicidin S initiation module GrsA epimerizes L-Phe (1.44) to the D-enantiomer.88 (C) 
One-pot biocatalytic total synthesis of ikarugamycin acyl-CoA and L-ornithine building blocks.89 
A: adenylation; E: epimerase; FAD: flavin adenine dinucleotide. 
 
 
epimerase domain of GrsA (Figure 1.7A) and condensation by the next module by incubating 
GrsA, GrsB module 2, ATP, L-Phe (1.44) and L-Pro (1.40) together.88 They found that the 
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dipeptide was released spontaneously, forming an L-Phe- D-Pro diketopiperazine (1.45) that was 
verified by comparison to enantiopure authentic standards.  
 
1.2.2B. Biocatalytic total synthesis 
Biocatalytic total synthesis (sometimes known as in vitro reconstitution or total biosynthesis) 
with the goal of isolating and characterizing the fully assembled product, is a greater challenge 
than the partial pathway studies described in the previous section. Analogous to chemical total 
synthesis, this method aims to completely build a target molecule from fundamental building 
blocks but is possible to perform in one pot. Among the earliest biocatalytic total syntheses for 
PKS were tetracenomycin90 and actinorhodin,91,92 and more recent reports have been published on 
the total biocatalytic synthesis of RK-682,93 cladosporin94 and one example of 6-
deoxyerythronolide (6-dEB) where methylmalonyl-CoA building blocks could be substituted by 
ethylmalonyl-CoA to biosynthesize new 6-dEB analogs.95 Reconstitutions have been reported for 
NRPS pathways of malbrancheamide,96 asperlicins C and D97 and vibriobactin,98 among others. 
The ikarugamycin gene cluster contains IkaA, a hybrid PKS-NRPS protein, and IkaBC, two-post 
PKS tailoring enzymes.89 Incubation of the three proteins with acyl-CoAs and L-ornithine (1.46-
1.48, Figure 1.7B), the PPTase Sfp and required cofactors in one pot afforded the final product 
ikarugamycin in a 9% isolated yield. Although not quantitative, it is a significant improvement 
over the most efficient total synthesis reported to date requiring a linear sequence of 27 steps to 
afford an overall yield of 0.11%.99,100 The cost of the biocatalytic reaction was further reduced by 
adding the CoA ligase MatB to biosynthesize the acyl-CoA units in situ from free acids, ATP and 
CoASH, which also decreased the CoASH to catalytic amounts. 
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In a more dramatic example, Moore and coworkers biosynthesized the polyketides enterocin 
and wailupemycin in vitro from a mixture of twelve proteins, malonyl-CoA, benzoic acid, ATP, 
S-adenosylmethionine (SAM) and NADPH for a final yield of 25%.101 The chemical total 
synthesis of enterocin has not been accomplished yet.102  For more exhaustive lists of biocatalytic 
total syntheses in CP-dependent systems, detailed reviews have been published.103,104 
Despite the advantages of these biocatalytic methods with native loading enzymes over 
traditional synthesis, the activation cost by ATP and CoASH may be prohibitive, particularly when 
utilizing less efficient non-native substrates. Other cost-effective chemoenzymatic and 
nonenzymatic methods have also been developed in parallel to these strategies to study CP-
dependent pathways (see Section 1.2.3). 
 
1.2.3. Chemoenzymatic methods 
1.2.3A. Substrate surrogates 
Exploiting traditional chemical methods to study PEs can also be an effective strategy, 
providing opportunities including: (1) lower costs for preparation of substrate surrogates, (2) 
investigation of PEs on advanced intermediates, and (3) utilization of non-native substrates. 
The CP attachment is not absolutely required for all PEs, as some enzymes catalyze reactions 
on free substrates activated by a selection of surrogates that are far less complex than a CP (Figure 
1.8A). Generally, these mimic the Ppant arm of holo-CPs (1.13) or use CoASH-derived 
thioesters.105 PEs such as E. coli BioF106 have been reported to operate on CoA thioesters as well, 
whereas the squalestatin tetraketide synthase (SQTKS) enoylreductase (ER) reduces a shorter 
panthetheine thioester stereoselectively (1.57, Figure 1.8B).107 A simplified thiol, N-
acetylcysteamine (SNAC), was originally used to study FAS systems and is now the most common 
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surrogate.105,108 Many PEs mediate reactions directly on SNAC thioesters, as Keatinge-Clay 
reported for six related excised C-methyltransferase (C-MT) domains that methylated 1,3-
dicarbonyl substrates at the alpha position (1.59 to 1.60).109 Typically, NRPS condensation (C) 
domains catalyze peptide bond formation of a growing nonribosomal peptide from two aminoacyl-
PCP substrates, but Ding and coworkers demonstrated that one of the two CP-bound substrates 
could be replaced by the corresponding SNAC thioester.110 The C domain of cryptophycin 
biosynthesis module 6 (CrpD) formed an unusual ester bond between an PCP-bound α-hydroxy 
extender unit and an SNAC analog of the module 5 product. Other examples of free thioester 
substrates have been published for CP-dependent ketoreductases (KR),43 dehydratases (DH)111, 
oxidases112 and additional PEs.113,114 
Substrate surrogates have a second mode of action: ketosynthases (KS) and thioesterases (TE) 
may mediate their respective reactions after surrogate molecules have transacylated PE catalytic 
residues (Cys or Ser, Figure 1.8C). In many reports, surrogate molecules acylate a KS active site 
Cys residue while its cognate CP is enzymatically loaded with an extender unit. The KS can then 
catalyze the expected chain extension.115–117 In one example, the Khosla and Cane groups acylated 
the sixth and final KS of 6-dEB synthase 3 (DEBS 3) with non-native diketide SNAC 1.61, while 
the associated AT domain loaded ACP6 from a methylmalonyl-SNAC (1.62) extender unit 
source.118 After KS-mediated extension and further reduction by KR6, the DEBS TE domain 
cyclized the triketide intermediate 1.64 to lactone 1.65. In addition to their inexpensive preparation 
relative to the corresponding CoA thioesters (methylmalonyl-CoA was 4000 times more expensive 
per mole than methylmalonyl-SNAC 1.62 in 1998),118 these small molecules are employed in 
whole-cell applications as they are frequently cell-permeable, whereas CoA compounds and CPs 
are not.119  
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Figure 1.8. Chemoenzymatic PE methods with substrate surrogates and acyl donors. 
(A) Comparison of holo-CP and common CP surrogate structures.105 (B) Selected examples of PE activity on free surrogates.107,109 (C) 
Selected examples of PE activity after transacylation by substrate surrogates.118,120 SQTKS ER: squalestatin tetraketide synthase 
enoylreductase domain; SAM: S-adenosylmethionine; DEBS: 6-deoxyerythronolide B synthase; KS: ketosynthase; TE: thioesterase. 
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Although substrate surrogates are a widely used tool to probe late-stage PEs, it is unfortunately 
not yet possible to predict whether a PE is compatible with surrogates or predict the PEs for which 
the protein-protein interactions with their cognate CP are critical. A number of reports disclose PE 
and free substrate incompatibility,121–123  and it is likely that many other similar negative results 
have gone unpublished. Additionally, PE activity may be dependent on the identity of surrogate 
activating group. Sieber and coworkers observed that fengycin TE was not active with an SNAC 
thioester source, but the active site Ser residue could be acylated by the more reactive thiophenol 
esters (1.66, see Figure 1.8C), leading to the desired macrocylized products.120 When incubated 
with the KS6-AT6-ACP6 tridomain in PikAIV and TE PikAV, Hansen and coworkers reported that 
the distribution of hexaketide substrates directly cyclized by the TE or that acylated the KS for 
elongation to a heptaketide and later cyclization shifted dramatically among the five activating 
groups investigated.124
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1.2.3B. Generation of acyl-CP substrates by non-native enzymatic methods 
For completely-CP dependent systems, there are both enzymatic and nonenzymatic methods 
reported to prepare acyl-CP substrates. Enzymatic methods utilize the post-translational 
modification necessary for native CP activity: promiscuous PPTases and CoA coupled to a desired 
substrate can be incubated to prime and load a CP in a single step (Figure 1.9A).125 The most 
commonly used PPTases are Svp from Streptomyces vertilicus and Sfp Bacillus subtilis, which are 
compatible with many ACP, PCP and CoA derivative combinations.126–128 
Figure 1.9. Chemoenzymatic methods to generate loaded CPs. 
(A) Enzymatic loading via promiscuous PPTases from apo-CP.125 (B) Nonenzymatic loading by 
small molecules.129–131 
 
 
The acyl groups may be putative starter units,132 non-native substrates,133 advanced 
ketides134,135 or oligopeptides,136 among others.125 These substrates are used to bypass the native 
loading mechanisms that limit the incorporation non-native building blocks and to examine PE 
substrate scopes, especially in later modules. The Burkart group has done extensive research with 
highly modified CoA derivatives, employing fluorescent, non-thioester and non-hydrolyzable 
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CoA-based compounds to identify CP active sites or capture interactions between a PE and a CP 
loaded with a cross-linking substrate (Figure 1.9A).137 The latter has been utilized to elucidate PE 
mechanisms and helped to solve new structures of CP-dependent enzymes.125,138 
CoA derivatives are typically prepared by traditional organic synthetic strategies or 
oligopeptides by solid-phase peptide synthesis, followed by coupling to CoASH or an analog.139 
The cost can be reduced further by coupling to a pantetheinyl derivative (Figure 1.9A) and 
generating the CoA derivative in situ through the CoA biosynthetic enzymes CoaADE.140 Any of 
the above uses of acyl-CPs to study PE activity without a method to regenerate apo-CP are limited 
to one CP turnover. 
 
1.2.3C. Generation of acyl-CP intermediates by nonenzymatic methods 
As a cheaper alternative to complex CoA derivatives, acyl-CPs may be generated 
nonenzymatically through thioesterification and transthioesterification reactions between the 
reactive thiol of a Ppant arm and activated acyl substrates. These methods only react with holo-
CP, requiring recombinant apo-CPs to be primed in vitro if the in vivo post-translational 
modification is incomplete.128 
First reported in 1981 for loading FAS ACPs, N-acylimidazolides (1.73, Figure 1.9B) have 
also been used to nonenzymatically acylate oxytetracycline and griseusin PKS ACPs.141,142 Crosby 
and coworkers found that the imidazolides also reacted with exposed cysteine residues, 
necessitating a Cys to Ser mutation in ACP substrates before Ppant-specific labeling occurred. The 
Schnarr group has explored β-lactams and -lactones as activating groups and similarly observed 
competition between the Ppant thiol and other reactive nucleophilic residues, notably KS catalytic 
cysteines.129,130 As described in section 1.2.3A, activated small molecule surrogates react 
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preferentially with KS domains over ACPs in PKS systems.143 Likewise, when Sieber attempted 
to load PCP-TE didomains from aminoacyl-thiophenol esters, only acylation of the TE domain 
was observed (see Figure 1.9B).120 Thus, until extremely selective activating groups are 
discovered, diffusive loading is limited to systems without competition from other exposed 
residues that can be nonspecifically labeled. Our group reported one example recently for the non-
KS-containing polyketide-like synthase SxtA, where the excised ACP was loaded by a thiophenol-
activated substrate. The resulting acyl-ACP could then react with a condensing PE to release a 
small molecule product (1.77).129,130131 
 
1.2.4. Directed evolution to reduce CP-dependence 
For PEs that already accept small molecule substrate surrogates, perhaps the most economical 
strategy for their use may be an engineered variant possessing enhanced activity in the absence of 
CPs. Tang and coworkers have demonstrated this once in LovD. The wild-type enzyme is an 
acyltransferase that natively transfers a LovF ACP-activated acyl group (1.78) monacolin J acid 
(1.80) to produce lovastatin precursor 1.81 (Figure 1.10).144 LovD also accepts an α-
dimethylbutyryl substrate surrogate (1.82) as well that leads to a precursor (1.84) of simvastatin,145 
which is more active than statin 1.81. 
The native LovF-based reaction is reported to be 1300x more active than the surrogate reaction 
but through directed evolution, LovD was evolved to increase protein expression levels and 
stability. the wild-type LovD-LovF transformation remains superior, the final seventh generation 
LovD Each successive generation was more active toward 1.82 and less active with acyl-LovF 
1.78. The final variant showed 11-fold whole-cell activity improvement and converted >30 g/L of 
monacolin J acid 1.84 to simvastatin acid per day.146 
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Figure 1.10. Directed evolution of the acyltransferase LovD. 
Evolution from the native LovF ACP-dependent reaction (top), to increased reactivity with 
substrate surrogate thioester 1.82 (bottom).146 
 
 
To the best of our knowledge, this is the only reported example of engineering toward 
removing a PE’s CP requirement, but with the recent spotlight on directed evolution, we anticipate 
that more reports are forthcoming. 
 
1.2.5. Outlook 
CP-dependent biosynthetic pathways are the source of many important natural products and 
synthetically interesting partner enzymes. Harnessing CP-dependent PEs for biocatalysis, 
particularly as cascades, has the potential to help develop new routes to useful compounds. The 
challenges associated with PKS and NRPS PEs substrate activation are different than most other 
enzymes classes commonly used for biocatalysis, but the general methods presented here, 
fermentation, in vitro reconstitution, chemoenzymatic loading and directed evolution provide the 
basis for future efforts for wider applications of CP-dependent enzymes. 
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We anticipate that the most economical approaches, the chemoenzymatic methods with 
substrate surrogates to acylate KSs and ACPs and provide extender units for ATs will be the most 
fruitful in the near future. These incorporate advantages in chemical synthesis (large-scale 
preparation and diversification) with biosynthesis (high chemo-, site- and stereoselectivity). For 
PEs that are absolutely CP-dependent, building catalytic cycles to recycle CPs may be the most 
fruitful initially, later followed by evolution away from CPs. When our understanding of 
engineering PKS and NRPS modules pathways has progressed, fermentation may eventually be 
the most productive option. 
 
1.3 Biocatalytic CP-PE Platforms 
Although many PEs discussed in Section 1.2 have some flexibility in their native hosts and in 
in vitro reactions, bypassing native gatekeepers to use non-native substrates can be challenging. 
Synthetically interesting PEs are found throughout CP-dependent pathways, not just at the 
beginning or end. Without consideration for both loading substrates onto a CP and offloading a 
product, PEs are only useful for a single turnover of CP. My thesis will summarize studies with 
PEs to catalyze non-native reactions in the chemoenzymatic synthesis of chiral amines. My work 
investigates both reactions on non-native CP-bound substrates and new CP-independent pathways. 
Our strategies for applying PEs synthetically must address the CP dependence, by multiple 
possible options: removing the dependence, exploiting a CP-independent mode, discovering a 
robust small molecule surrogate, or by incorporating loading and offloading into our catalytic 
cycles to also utilize CPs in catalytic amounts (Figure 1.11). 
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Dissertation Outline 
The following Chapters will cover my research on various CP-dependent enzymes toward 
developing platforms that utilize those PEs biocatalytically (Figure 1.12). 
Chapter 2, “Characterization of the Polyketide-Like synthase SxtA”, summarizes our 
studies on characterizing the native functionality on the first protein in saxitoxin biosynthesis, 
SxtA. This four-domain enzyme first caught our interest because it appeared to have its own 
loading domain and a rare C–C bond-forming α-oxoamine synthase (AOS) domain as its 
offloading mechanism. Through small molecule and intact protein MS, we elucidate on how 
SxtA’s starter unit malonyl-CoA is likely loaded by a different acyltransferase protein onto the 
ACP domain and elaborated by two other PE domains into propionyl-ACP. Acyl groups are 
offloaded by the AOS protein member, the 8-amino-7-oxononanoate synthase (AONS) domain, 
which performs a Claisen-like condensation with propionyl-ACP and the amino acid L-Arg. Our 
initial characterization of the SxtA domains was then used to develop SxtA AONS as a tool for 
derivatizing α-amino acids and further investigate the mechanisms of the SxtA methyltransferase 
(MT) and AONS domains. 
Figure 1.11. A scalable CP-PE biocatalytic platform 
This will require including loading and offloading steps in the same pot such that the carrier 
protein is used in catalytic amounts as well. 
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Chapter 3, “Chemoenzymatic Synthesis of α-Amino Ketones”, covers our efforts to utilize 
SxtA AONS as a biocatalyst to synthesize multiple α-amino ketones from different combinations 
of amino acids and acyl-thioesters. First, we optimized the conditions to generate SxtA’s native 
arginine-based ketone product on a larger scale. Additionally, we explored SxtA AONS’ ability to 
synthesize other ketone products from non-native amino acids and acyl group substrates. We began 
a directed evolution campaign to engineer a SxtA AONS variant to synthesize a tryptophan-based 
ketone product. 
In the second direction of amino acid elaboration, we also used wild-type SxtA AONS to install 
deuterium at the alpha carbon of amino acids in Chapter 4, “SxtA AONS-Mediated Deuterium 
Figure 1.12. Biocatalytic reactions studied in Chapters 2-6. 
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labeling”. The substrate scope for deuterium incorporation into amino acids was initially small, 
but esterification to methyl esters greatly increased the breadth of side chains accepted, including 
some D-methyl esters. A preparative-scale deuteration reaction provided deuterated alanine methyl 
ester for the chemoenzymatic synthesis of an isotopically labeled analog of the drug safinamide. 
The last section on saxitoxin biosynthetic proteins, Chapter 5, “Structural and 
Spectroscopic Characterization of SxtA”, includes our efforts to understand the finer 
mechanistic details of SxtA. Two of its PE domains, MT and AONS, belong to enzyme subclasses 
that are underexplored. In collaboration with the laboratory of Prof. Janet Smith, we have begun 
exploring the structural details of SxtA MT to understand its mechanism. We also report some 
preliminary spectroscopic properties of SxtA AONS, which may provide the basis for improving 
the enzyme as a biocatalyst. 
Chapter 6, “Synthesis of Chiral Cyclic Amines with Oxidase AnaB”, is focused on an 
entirely different system. The flavin-dependent oxidase AnaB is from the type II segment of the 
anatoxin-a biosynthetic pathway and performs a two-electron oxidation on a prolyl substrate bound 
to the PCP AnaD. The resulting iminium product could potentially be attacked by a nucleophile to 
provide chiral cyclic amines, but without loading and offloading steps added like SxtA, the final 
yield would be restricted to one turnover of AnaD. Therefore, we built two catalytic cycles to 
utilize AnaD and AnaB catalytically, with different approaches to loading and offloading. 
The concluding section, Chapter 7, “Conclusions and Future Directions”, will discuss my 
thoughts on the future of PE-mediated reactions and biocatalysis in general. 
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Chapter 2: Characterization of the Polyketide-Like Synthase SxtA 
 
Reprinted (adapted) with permission from “Chemistry of a Unique Polyketide-like Synthase”. 
Chun, S. W.; Hinze, M. E.; Skiba, M. A.; Narayan, A. R. H. J. Am. Chem. Soc. 2018, 140, 2430-
2433. Copyright © 2018, American Chemical Society. 
and “Biocatalytic synthesis of α-amino ketones”. Chun, S. W.; Narayan, A. R. H. Synlett, 2019, 
30, 1269-1274. Copyright © 2019, Georg Thieme Verlag KG. 
Summary 
As in the case of many complex natural products, the intricate architecture of saxitoxin (STX) 
has hindered full exploration of this scaffold’s utility as a tool for studying voltage-gated sodium 
ion channels and as a pharmaceutical agent. Established chemical strategies can provide access the 
natural product; however, a chemoenzymatic route to saxitoxin that could provide expedited access 
to related compounds has not been devised. The first step toward realizing a chemoenzymatic 
approach toward this class of molecules is the elucidation of the saxitoxin biosynthetic pathway. 
To date, a biochemical link between STX and its putative biosynthetic enzymes has not been 
demonstrated. Herein, we report the first biochemical characterization of any enzyme involved in 
STX biosynthesis. Specifically, the chemical functions of a polyketide-like synthase, SxtA, from 
the cyanobacteria Cylindrospermopsis raciborskii T3, are elucidated. This unique megasynthase 
is comprised of four domains: methyltransferase (MT), GCN5 N-acetyltransferase (GNAT), acyl 
carrier protein (ACP), and a rare example of an 8-amino-7-oxononanoate synthase (AONS) 
associated with a multidomain synthase. We have stablished that this single polypeptide carries 
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out the formation of two carbon–carbon bonds, two decarboxylation events and a stereospecific 
protonation to afford the linear biosynthetic precursor to STX from malonyl-coenzyme A, S-
adenosylmethionine and L-arginine. 
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2.1 Introduction 
SxtA, a carrier protein (CP)-containing enzyme from the biosynthetic pathway of saxitoxin 
(STX) is the major focus of this dissertation. STX is the causative agent of paralytic shellfish 
poisoning (PSP), an illness that was first documented in 1793 during George Vancouver’s 
exploratory voyages.1 In his 1798 book, Vancouver recounted how one crewmember passed away 
and four others fell ill after consuming shellfish in what is now British Columbia. Over the next 
180+ years, multiple instances of PSP outbreaks were reported along the North American Pacific 
coasts, even as researchers continued to discover more about STX. 
Figure 2.1. The paralytic shellfish toxin saxitoxin.  
(A) The structure of saxitoxin (2.1) and a selection of related derivatives. IC50 values listed are for 
sodium channels in rat skeletal muscle.2 (B) STX blocks the pore of voltage-gated sodium ion 
channels. Figure adapted from Shinohara et al.3 
 
 
In the early to mid-1800s, scientists speculated that PSP was caused by an organic small 
molecule produced by mussels and clams.4 Sommer first demonstrated in 1937 that the toxin, then 
often referred to as “mussel poison”, was produced by some marine dinoflagellates, and that filter 
feeders, such as the Alaskan butter clam (Saxidomus giganteus), accumulated the toxin in their 
tissues.5,6 Later studies found that some freshwater cyanobacteria also produced the PSP toxin.7 
The first pure sample of toxin was isolated from shellfish by Schantz in 1957, which also allowed 
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for the determination of the molecular formula, C10H17O4N7·2HCl.
8,9 Saxitoxin was officially 
named in 1962, but due to difficulties with its size and amorphous salt forms, it was not until 1975 
that Clardy/Schantz and Rapoport separately reported x-ray crystal structures (2.1, Figure 2.1A) 
of the molecule.10,11 The structures revealed STX to be a tricycle with one hydrated ketone, one 
carbamoyl and two guanidinium groups, accounting for the compound’s extremely polar nature. 
Kishi’s racemic total synthesis of STX quickly followed in 1977.12 
 
Table 2.1. Function of different human Nav isoforms 1.1-1.9 and sensitivity to STX  
Human Nav isoform IC50 of STX (nM) Associated diseases (partial list) 7,13 
Nav1.1 2.3 Epilepsy, migraine, autism 
Nav1.2 1.0 Epilepsy, autism 
Nav1.3 13 Epilepsy 
Nav1.4 19 Paralysis, myotonia 
Nav1.5 21 Cardiac arrythmia 
Nav1.6 1.1 Central nervous system disorders 
Nav1.7 410 Pain sensation 
Nav1.8 >10,000 Pain sensation 
Nav1.9 >10,000 Pain sensation 
 
 
Subsequently, STX’s mechanism of action in humans has been established as binding of 
voltage-gated sodium ion channels (Nav).
7 STX binds near the outer lip of Nav pores, where the 
positively charged molecule interacts strongly with the negatively charged channel residues 
(Figure 2.1B) to block the inward flow of Na+ ions. This leads to respiratory paralysis and 
sometimes death. However, STX and its derivatives’ specificity of binding to rat skeletal muscle 
(Figure 2.1A)2 and different Nav isoforms varies widely (Table 2.1).
14 Naturally occurring STX 
derivatives, the gonyautoxins have been investigated previously for the treatment of muscle 
tension (2.2) and pain (2.3), respectively, and research is ongoing to discover potentially 
therapeutic saxitoxins that selectively target Nav isoforms, with particular focus on pain 
relief.13,15,16  
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Figure 2.2. Early studies on STX biosynthesis. 
(A) Neilan’s studies with C. raciborskii T3 to discover the first sxt biosynthetic gene cluster.17,18 
(B) Shimizu’s feeding studies with labeled precursors.19 
 
Obtaining sufficient amounts of saxitoxin and analogs for assays and potential clinical trials 
remains a challenge. Isolation from natural sources requires a huge amount of sample (5000 L of 
seawater for 90 mg of impure STX, or 8 American tons of butter clams for 1 g);1 this and in vitro 
biosynthesis with toxin-producing cyanobacterial or dinoflagellate extracts are limited to naturally 
occurring molecules. Asymmetric syntheses of STX are long, requiring protecting group 
manipulations for the numerous heteroatoms.7 However, new derivatives could potentially be 
produced using biosynthetic machinery and more sustainably through manipulation of saxitoxin 
biosynthetic proteins. Four cyanobacterial putative gene clusters had been sequenced at the 
beginning of our studies in 2016 and a pathway had been proposed, though none of the enzymes 
had been biochemically characterized.18,20,21 
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Figure 2.3. Ketone 2.13, an intermediate in STX biosynthesis. 
(A) The first proposal of SxtA’s substrates and native product, ketone 2.13, by Neilan and 
coworkers in 2008.18 (B) Confirmation by the Yotsu-Yamashita group of 2.13 into saxitoxins.22 
MTF: methyltransferase; ACTF: acetyltransferase; ACP: acyl carrier protein; AONS: 8-amino-7-
oxononanoate synthase. 
 
 
Prior to their report of the first STX biosynthetic gene cluster, Neilan and coworkers added 
potential STX precursors to clarified cell lysates of toxin-producing cyanobacteria 
Cylindrospermopsis raciborskii T3 and found that STX biosynthesis likely required carbamoyl 
phosphate (Figure 2.2A).17 Sequencing of the C. raciborskii genome identified an O-
carbamoyltransferase and a surrounding gene cluster postulated to be responsible for STX 
biosynthesis, which was then named sxt.18 From the hypothetical protein families in the sxt cluster 
and feeding experiments by Shimizu and others (Figure 2.2B),19 the Neilan group proposed a STX 
biosynthetic pathway. The largest gene, sxtA, encodes for a polyketide synthase-related protein 
with four domains predicted to initiate STX biosynthesis by producing ketone 2.13 from acetyl-
CoA, S-adenosylmethionine (SAM), and L-arginine (Figure 2.3). Supporting evidence for 2.13 as 
an intermediate to STX was reported by Yotsu-Yamashita and coworkers, who identified 2.13 in 
lysates of toxin-producing microorganisms23 and that an 15N-labeled precursor was incorporated 
into labeled STX derivatives (see 2.4 and 2.5, Figure 2.3).22 
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SxtA was the most attractive protein for initial investigations not only as the first protein in the 
STX biosynthetic pathway, but also as the only CP-dependent protein in the cluster. The enzyme 
appeared to be a single self-contained module with its own loading and offloading domains and to 
catalyze formation of a C–C bond stereospecifically. Additionally, SxtA’s fourth domain was 
predicted to catalyze the transformation of an α-amino acid to α-amino ketone, a synthetically 
challenging process (see section 2.2 and Chapter 3). We first intended to search for the annotation 
each domain within the BLAST (Basic Local Alignment Search Tool) database to possibly update 
Neilan’s proposal, then perform in vitro experiments with the SxtA module and finally verify the 
activity of each domain with individual subcloned standalone proteins. 
 
2.2 Previously Known Details about SxtA Domain Classes 
At the time of our initial studies of SxtA in 2016, four cyanobacterial homologs had been 
deposited in the Uniprot database. With the help of Dr. Meredith Skiba, the boundaries of SxtA’s 
four domains were roughly defined. Performing a BLAST search on each domain turned up the 
following results: (1) SxtA contained no ketosynthase (KS) domain to condense multiple ketide 
units, classifying the protein as a polyketide-like synthase rather than a true PKS; and (2) the four 
SxtA domains, from the N- to C-termini, were a putative methyltransferase, a GCN5-related N-
acetyltransferase, an acyl carrier protein, and an α-oxoamine synthase. There did not appear to be 
any major changes in the BLAST database from the Neilan group’s findings from 2008, but we 
chose to adjust the domain abbreviations from MTF-ACTF-ACP-AONS to the more commonly 
seen MT-GNAT-ACP-AONS. 
SxtA’s second domain, the GCN5-related N-acetyltransferase (GNAT), belongs to the GNAT 
superfamily. Identified in all kingdoms of life, GNATs have low sequence identity to each other 
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across this family but typically transfer an acetyl group from acetyl-CoA to both small molecule 
and protein targets.24 By sequence, SxtA GNAT is most closely related to other GNAT domains 
within PKS proteins. The most well-characterized member of this subclass is CurA GNAT from 
the curacin A biosynthetic pathway, which has been studied by three labs at the University of 
Michigan (Håkansson, Sherman and Smith).25 CurA GNAT is found in the loading module of 
CurA, and was reported to decarboxylate malonyl-CoA (2.14) rapidly to acetyl-CoA (2.15), and 
load the acetyl group onto holo-ACP relatively slowly (Figure 2.4A). Decarboxylation of malonyl-
ACP to acetyl-ACP was also noted, but the rate was slower than that of malonyl-CoA. Loading 
directly from acetyl-CoA without malonyl-CoA present was observed as well (i.e., 2.15 to 2.16 in 
Figure 2.4A). Based on a CurA GNAT crystal structure, Thr335 and His389 (CurA numbering, 
Figure 2.4B) in the active site were proposed to mediate only decarboxylation. Substitutitons to 
these residues did not affect the loading activity. 
Figure 2.4. GNATs in polyketide synthases. 
(A) Initially reported loading and decarboxylation activity of the CurA GNAT domain. (B) 
Proposed mechanism of CurA GNAT-mediated decarboxylation.25 
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The reports of CurA GNAT activity and the C. raciborskii sxt gene cluster were published at 
approximately the same time. In accordance with the original GNAT name, the Neilan lab 
proposed that SxtA GNAT catalyzed acetyl group transfer from the CoA thioester to holo-ACP, 
although we also surmised that the domain could also use malonyl-CoA as a starter unit in the 
same fashion as CurA GNAT (see 2.14 to 2.26, Figure 2.6). 
The first domain of SxtA, methyltransferase (MT), has the highest resemblance to MTL 
domains adjacent to GNATs (both complete and truncated)26,27 within PKS loading modules. 
These domains are distantly related to general PKS MTs and were not predicted to possess the 
[4Fe–4S] clusters in radical SAM enzymes.28 Because SxtA MT reacts at a partially activated 
position alpha to a carbonyl, we assumed that it and other MTs in this class operate with a two-
electron mechanism (Figure 2.5A). 
Other pathways containing GNAT-associated MT, also known as MTL domains,
27 include 
myxovirescin A,29 gephyronic acid,30 bryostatin31 and apratoxin A32 (Figure 2.5B). Based on the 
final natural product structures, some of these MT domains were hypothesized to methylate acetyl-
ACP or malonyl-ACP twice.30,33 At the time of our first reactions with SxtA, the methylation 
activity of MTLs had not been recapitulated in vitro. From the acetyl-ACP product of the GNAT 
domain, Neilan and coworkers proposed that SxtA MT methylates at the α-carbon to afford 
propionyl-ACP (see 2.26 to 2.27, Figure 2.6). 
As we found more GNAT literature that had been published after the C. raciborskii sxt gene 
cluster report, we found less favor with the hypothesis that acetyl-CoA (2.15) is the SxtA starter 
unit, or that acetyl-ACP (2.26) is the MT substrate (Route 1 in Figure 2.6). Instead, malonyl-CoA 
(2.14) appeared increasingly likely to be the true starter unit, and malonyl-ACP (2.28) to be the  
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Figure 2.5. GNAT-associated MTs (MTLs) in natural product biosynthesis. 
(A) Putative methylation mechanism. (B) A selection of mono-, di-, and trimethylated acyl-ACP 
intermediates with final polyketide products.26,29,34 
 
 
MT substrate, as Taylor and Keatinge-Clay have previously suggested.30,33 First, SxtA’s second 
domain is not annotated as a typical PKS acyltransferase (AT) domain which can simply load an 
acetyl group from acetyl-CoA; rather, the domain is related to the PKS GNATs which were 
reported to favor malonyl-CoA substrates.25 Second, Route 1 proposes that both decarboxylation 
and loading activities by GNAT occur before the MT, whereas partner enzyme (PE) domains in 
type I PKS typically catalyze their reactions in order from the N-terminus to the C-terminus.35 
Finally, because SxtA MT presumably deprotonates the α-carbon of the acyl-ACP substrate to 
generate a nucleophile that can attack the SAM methyl group (Figure 2.5A), we also considered 
the pKa at that site. The α-carbon of acetyl-CoA with a pKa around 19-20 can be deprotonated 
under biological conditions (cf. citrate synthase),36 but the value at the analogous position is 
several units lower in malonyl-CoA/-ACP.37 A second route of MT-GNAT activity (Figure 2.6) 
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could use a malonyl-CoA starter unit and holo-ACP by the GNAT domain or another 
acyltransferase protein. Malonyl-ACP 2.28 is a better substrate for the MT domain and the next 
intermediate, methylmalonyl-ACP 2.29 could be decarboxylated by the GNAT domain, which 
catalyzed decarboxylation faster than apparent loading in CurA. Methylmalonyl-ACP 2.29 is also 
a β-keto acid which could readily decarboxylate spontaneously, meaning it is likely that the AONS 
thioester substrate is still propionyl-ACP (2.27). Except for GNAT-mediated loading, Route 2 
circumvents the concerns about the starter unit and relative reactivity we had with Route 1. 
 
SxtA ACP did not appear to have any unusual features. The protein sequence SxtA AONS’ is 
most closely related to a protein from biotin biosynthesis, 8-amino-7-oxononanoate synthase or 
BioF, from which the domain takes its name.18,38 SxtA AONS and BioF belong to the small α-
oxoamine synthase (AOS) class of pyridoxal phosphate (PLP)-dependent enzymes. These proteins 
perform a decarboxylative Claisen-like condensation between an α-amino acid and an acyl 
thioester to afford an α-amino ketone, carbon dioxide and a thiol.39 The proposed mechanism 
Figure 2.6. Two proposed routes to propionyl-ACP (2.27). 
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begins with the internal aldimine intermediate (2.30, see Figure 2.7) with PLP covalently bound 
to a catalytic lysine residue (Lys1077 in C. raciborskii SxtA). An amino acid substrate such as L-
Arg (2.9) in SxtA displaces the lysine residue to form external aldimine I (2.31), which now has a 
much more acidic proton alpha to the carboxylate group. Deprotonation by lysine or another base 
affords the nucleophilic quinonoid intermediate I (2.32), which attacks the thioester partner 
(propionyl-ACP in SxtA). Collapse of the tetrahedral intermediate eliminates holo-ACP to give a 
1,3-dicarbonyl (2.35) that is easily decarboxylated and reprotonated stereospecifically (see 2.36 to 
2.37). Displacement of the ketone product 2.13 returns to the resting state. In 2016, there were five 
other ACP-associated AOS family members, six that used CoA thioester substrates, and two with 
either ACP or CoA substrates. 
Our synthetic interest in SxtA was primarily in the AONS domain, which forms a new C–C 
bond, retains the L stereocenter through stereospecific proton transfer steps to synthesize α-amino 
ketones in a single step, and also functions as SxtA’s offloading mechanism. Furthermore, SxtA-
mediated synthesis of 2.13 analogs could serve as precursors to STX derivatives. 
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Figure 2.7. Proposed mechanism of PLP-dependent AOS proteins. 
Based on Webster et al.39
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2.3 Enzymatic Reactions with the Wild-Type SxtA Module 
sxtA from C. raciborskii T3 (gDNA sequence) cloned into a pET28 vector was transformed 
into the E. coli strain BAP1, which the Khosla lab engineered to genomically encode an inducible 
copy of the phosphopantetheinyltransferase sfp.40 The protein expressed well, but the majority was 
lost with the insoluble material during purification. After FPLC purification on Ni-NTA resin, a 
pale-yellow protein of approximately 140 kDa was isolated. Although SxtA did not ionize 
sufficiently to analyze by intact protein MS, we assumed complete post-translational modification 
of apo-ACP to holo. 
 
Table 2.2. Screen of potential CoA starter units with wild-type SxtA 
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We first attempted to determine the CoA starter unit for STX biosynthesis from a candidate 
pool of acetyl-, propionyl-, malonyl-, and methylmalonyl-CoA thioesters. Purified SxtA was 
incubated with SAM, L-Arg and each of the four thioesters for 2 h before analysis of the small 
molecule products by liquid chromatography-mass spectrometry (LC-MS).  With an acetyl-CoA 
starter unit, we observed none of the expected product (Table 2.2, entry 1), but instead another 
peak was detected corresponding to 173.14 m/z, a difference of 14 m/z or one methylene group 
from the predicted ketone product at 187.15 m/z. This lower mass matched the structure of methyl 
ketone 2.38, which could form by an acetyl group bypassing the MT domain and being processed 
directly by the AONS domain. The alternate product was confirmed as 2.38 by comparison to an 
authentic standard synthesized by Dr. Meagan Hinze. If this were an on-pathway intermediate to 
STX, the terminal methyl group would need to be extended by one carbon by a downstream 
enzyme such as the putative standalone methyltransferase SxtX.18 We briefly considered the idea 
that SxtA MT may be vestigial or currently inactive, as solely the originally predicted ethyl ketone 
2.13 was detected when the longer propionyl-CoA thioester was used as a possible CoA starter 
unit. Like the acetyl substrate, the propionyl group only underwent AONS-catalyzed condensation, 
skipping the MT domain that would have resulted in isopropyl ketone 2.39. 
Third, malonyl-CoA, the proposed GNAT domain starter unit, was tested. In these reactions, 
a mixture of the truncated methyl (2.38) and full-length ethyl (2.13) ketones was observed. In the 
product mixture, 45% had been methylated by the MT domain and decarboxylated at some point 
en route to 2.13, while the remaining 55% was only decarboxylated (either spontaneously or 
GNAT-mediated) and not methylated before the condensation reaction to afford 2.38. Control 
reactions with malonyl-CoA but omitting either SAM or L-Arg were also performed (entries 5 and 
6). Without SAM, no methylation occurred and only 2.38 was detected, supporting the proposal 
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that STX C13 is SAM-derived. We observed only the full-length ketone 2.13 even when L-Arg 
was not added to reactions, likely forming from amino acid that had copurified with SxtA. Fourth, 
methylmalonyl-CoA was only decarboxylated (entry 4), eventually forming the proposed native 
product 2.13 and no other ketones with further methylation such as 2.39. 
Among the four CoA thioesters, only malonyl-CoA or an intermediate resulting from it was 
methylated by the MT domain, suggesting that malonyl-ACP 2.28 was indeed the MT substrate. 
The product of this reaction is methylmalonyl-ACP 2.29, which can be decarboxylated by the 
GNAT domain to propionyl-ACP (2.27). The total relative full-length ketone yields in Table 2.2 
also support the malonyl- to methylmalonyl- to propionyl-ACP order of intermediates. In this 
sequence, acetyl-CoA or -ACP does not fit. We were unable to determine the extent of ACP 
loading with the full SxtA module by intact protein MS. Acetyl thioesters were never methylated 
by the MT domain under any conditions in our hands to afford ketone 2.13, and addition of putative 
methyltransferase SxtX did not increase the yield of 2.13 relative to the truncated ketone 2.38. 
Furthermore, 2.38 or STX derivatives missing C13 have not been identified from natural 
producers. Therefore, acetyl-CoA was excluded as a possible SxtA starter unit, along with 
methylmalonyl-CoA, which is not produced in cyanobacteria such as C. raciborskii.41 Since 
propionyl-CoA/-ACP was only processed by the AONS domain and not the MT domain, it was 
also excluded as the SxtA starter unit, leaving only malonyl-CoA as the only plausible on-pathway 
substrate. This thioester is biosynthesized from acetyl-CoA in a reaction catalyzed by acetyl-CoA 
carboxylase,42 supporting the observation by Shimizu that acetic acid is the source of C5-6 on STX 
(2.1) and that only one deuterium atom is retained from the deuterium labeled acetic acid (see 2.10, 
Figure 2.2B). 
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From this screen of SxtA with four possible starter units, malonyl-CoA 2.14 was identified as 
the most likely candidate, and a partial sequence of domain activity was determined in agreement 
with Route 2 (Figure 2.6): (1) loading of the malonyl group from 2.14 onto holo-ACP, (2) 
methylation of malonyl-ACP to methylmalonyl-ACP, (3) GNAT-catalyzed decarboxylation to 
propionyl-ACP, and (4) AONS-mediated condensation with L-Arg to form ketone 2.13. The 
loading mechanism could not be determined with full module experiments and was explored 
through reactions with standalone SxtA domains. 
 
2.4 Verification of Domain Activity 
From the SxtA module experiments, the three catalytic domains, MT, GNAT and AONS 
appear to be active, but we could not analyze any ACP-bound intermediates due to the size of the 
protein. Standalone single and didomains were first subcloned from the wild-type SxtA module by 
ligation-independent cloning,43 then expressed and purified on Ni-NTA resin to verify the activity 
of each domain. 
Potential acyl-CoA species present are difficult to detect on the mass spectrometers available 
to us but could be separated and analyzed by a relatively low-throughput liquid chromatography 
method (66 min per sample).26 However, at 13.5 kDa, SxtA ACP constructs ionize very well 
compared to the full module. ACP-bound intermediates are analyzed more rapidly by intact protein 
MS (15 min per sample) and the secondary Ppant ejection assay, an MS/MS method that detects 
the Ppant cofactor, along with any loaded acyl groups.44 
The Smith lab had previously found that all constructs of AprA MTL,
26 a homolog of SxtA 
MT, were insoluble, so we cloned SxtA MT-GNAT instead, which resulted in soluble and well-
behaved protein. Other constructs included SxtA GNAT, ACP (apo and holo), AONS and 
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ACP(knockout)-AONS. Like the full module, SxtA AONS and ACP(knockout)-AONS had high 
expression but a significant amount was lost in the insoluble pellet during purification. The 
didomain that included an inactive ACP was slightly more soluble. Purified SxtA GNAT tended 
to precipitate at temperatures above rt. 
Additionally, single-point variants of the SxtA module were also prepared, each removing or 
reducing activity in one domain by substituting proposed catalytic residues in the active sites: 
S773A (ACP knockout), H372A (in the MT domain), T637V, H671A (GNAT residues), and 
K1077L (AONS substitution). 
 
Loading of Malonyl-CoA 
The loading mechanism of malonyl-ACP formation from malonyl-CoA and holo-ACP was 
examined first. From the CurA GNAT precedent, SxtA GNAT was still our initial hypothesis for 
the loading enzyme. When malonyl-CoA, holo-ACP, and SxtA GNAT or MT-GNAT were 
incubated together, a mixture of malonyl- and acetyl-ACP was observed (Figure 2.8A) by intact 
protein MS. At early timepoints, the loading levels appeared to be dependent on the concentration 
of GNAT constructs present and plateaued around 80% loading after 2 h reactions. To our surprise, 
loaded ACP was also detected in the negative control in the absence of GNAT or MT-GNAT. 
Loading reached 80% in 2 h, compared to 1 h or less in the MT-GNAT/GNAT-containing 
reactions.  
After searching the PKS literature further, we found that other laboratories had observed this 
apparent self-loading for type II ACPs in vitro with malonyl-CoA with two potential explanations 
for the mechanism. Many type II PKS gene clusters do not encode an acyltransferase (AT) protein 
to transfer malonyl extender units from malonyl-CoA, leading some, including Crosby and 
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Simpson labs to postulate that these pathways function by ACP self-loading.45,46 Other labs such 
as the Reynolds and Khosla groups eliminated the “self-loading” activity of type II ACPs after 
further purification by anion exchange chromatography. They proposed that AT-less pathways co-
opt FabD, a malonyl-CoA:ACP transacylase protein from fatty acid biosynthesis instead.47,48 In 
vitro cascade reactions with extra pure ACPs and their associated PEs required the addition of 
nanomolar concentrations of FabD to proceed; therefore, the apparent self-malonating activity was 
a side effect of miniscule amounts of endogenous host E. coli FabD or some other acyltransferase 
contaminating the recombinant enzymes of interest.47 Indeed, SxtA holo-ACP that was more 
rigorously purified by nickel affinity, anion exchange and size-exclusion chromatography no 
longer exhibited the self-loading activity in vitro (Figure 2.8B). In the presence of 50 nM E. coli 
FabD or Moorea producens FabD (kindly provided by Dr. Meredith Skiba of the Janet Smith lab), 
Figure 2.8. Loading of holo-ACP from malonyl-CoA. 
Formation of malonyl- and acetyl-ACP after incubation of holo-ACP, malonyl-CoA with (A) 
GNAT constructs or (B) FabD. 
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100 µM holo-ACP and 500 µM malonyl-CoA, the ACP now reached 80% loading within 5 
minutes. Including FabD with a full SxtA reaction was also favorable, as its presence changed the 
distribution of products to 93% of full-length ethyl ketone 2.13 and 7% truncated ketone 2.38. 
Finally, after publication of our initial SxtA manuscript,49 the Smith lab also cultured E. coli 
containing an empty expression plasmid and enriched for divalent cation-binding proteins by Ni-
NTA affinity purification. The mixture of endogenous E. coli proteins isolated catalyzed acylation 
of CurA holo-ACP but did not effect the decarboxylation of malonyl-ACP to acetyl-ACP.50 From 
these data, SxtA is likely natively loaded by FabD or a similar acyltransferase, not its GNAT 
domain. The apparent GNAT-mediated loading or self-loading of malonyl groups onto SxtA holo-
ACP is the result of contaminating E. coli proteins co-purifying with our proteins of interest, while 
the GNAT domain’s principal function is decarboxylation. The 2013 discovery that malonyl-CoA 
decarboxylases have the same fold as acyl-transferring GNAT proteins also support this 
proposal.51,52 
 
Methylation of Malonyl-ACP 
Following loading of a malonyl group onto holo-ACP, the next steps in our proposed SxtA 
catalytic cycle are methylation by the MT domain and GNAT-catalyzed decarboxylation. Acyl-
ACP substrates to verify MT and GNAT activity were prepared enzymatically from apo-ACP, 
phosphopantetheinyltransferase Sfp and acyl-CoA. Loaded ACP was separated from PPTase and 
excess CoA by size-exclusion chromatography before use. 
To assess the didomain cascade, wild-type MT-GNAT, malonyl-ACP and SAM were 
incubated together for 3 h, and the levels of each possible acyl-ACP intermediate (malonyl, 
methylmalonyl, propionyl and acetyl) were compared by intact protein MS. At early timepoints 
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(Figure 2.9), methylmalonyl-ACP could clearly be observed, but then the intermediate 
decarboxylated to accumulate propionyl-ACP over time. Some acetyl-ACP was present in the 
initial malonyl-ACP sample due to spontaneous decarboxylation, and the relative fraction 
remained around 20% throughout the experiment. Even when all malonyl-ACP had been 
consumed, acetyl-ACP was not converted to propionyl-ACP (see 2 to 3 h). Dimethylated species  
dimethylmalonyl-ACP or its decarboxylated product isobutyryl-ACP were not detected. In control 
experiments lacking MT-GNAT, we did not observe methylation of malonyl-ACP. 
 
From these data, SxtA MT’s function is to methylate malonyl-ACP once to afford 
methylmalonyl-ACP. The stereochemistry of this reaction can be predicted from the crystal 
structures of the SxtA MT homolog, AprA MTL (see Chapter 5),
26 but was not investigated because 
Figure 2.9. Methylation and decarboxylation of malonyl-ACP. 
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α-alkyl-β-keto-ACP intermediates like methylmalonyl-ACP are configurationally unstable and 
prone to decarboxylation, eroding any stereochemical information. 
 
GNAT with Carboxylated ACPs 
The next step to be examined in isolation was the decarboxylation activity of the GNAT 
domain. The previously generated malonyl-ACP and methylmalonyl-ACP (assumed to be 
racemic) were incubated with GNAT. Over 3 h, we observed conversion of malonyl- to acetyl-
ACP and methylmalonyl- to propionyl-ACP (Figure 2.10). The activity was concentration-
dependent, with increasing decarboxylation detected when more GNAT was present. However, it 
was difficult to determine from this assay alone whether methylmalonyl-ACP was the preferred 
GNAT substrate. Due to the relative instability of methylmalonyl groups, 54% of acyl-ACP 
present had already spontaneously decarboxylated propionyl-ACP at 0 min, leaving only 46% of 
methylmalonyl-ACP substrate for the GNAT to react with, compared to a 19:81 ratio of acetyl-
/malonyl-ACP. Additionally, the enzymatic decarboxylation of carboxylated-ACP was also 
competing with the background spontaneous reactions, which were subtracted from the values 
shown in Figure 2.10. 
 
 
Nevertheless, this assay demonstrated that both malonyl- and methylmalonyl-ACP are 
substrates for GNAT-mediated decarboxylation. We attribute the formation of truncated ketone 
2.38 observed previously in the full module reactions to the AONS processing acetyl-ACP/-CoA 
that arose from a combination of the GNAT reacting prematurely with malonyl-ACP/-CoA and 
the background nonenzymatic decarboxylation. In the endogenous STX pathway, we hypothesize 
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that methylmalonyl-ACP is the preferred GNAT substrate over malonyl-ACP, and a competition 
experiment between malonyl- and methylmalonyl-ACP in the same pot will be tested in the future. 
 
α-Amino Ketone Formation Catalyzed by SxtA AONS 
The final step of the proposed SxtA catalytic cycle is the Claisen-like condensation catalyzed 
by the AONS domain. The C. raciborskii standalone AONS was active but not very soluble, so 
we also cloned a didomain variant ACP(KO)-AONS containing an inactive ACP domain. This 
construct was subcloned from SxtA(S773A) and was slightly more soluble than the single domain. 
We first aimed to compare AONS condensation activity on acyl-ACP intermediates, from the 
four CoA thioesters in our possession: acetyl-, propionyl-, malonyl-, and methylmalonyl-ACP. L-
Arg, acyl-CoA, apo-ACP, Sfp and ACP(KO)-AONS were incubated in a single pot (Table 2.3). 
Small molecule analysis after 2 h showed the same two methyl and ethyl ketones (2.38 and 2.13, 
respectively) we had observed previously, and no carboxyl ketones. The relative yield was highest 
with a propionyl-CoA substrate, followed by methylmalonyl, acetyl, and just a small amount of 
Figure 2.10. GNAT-catalyzed decarboxylation of malonyl- and methylmalonyl-ACP. 
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2.38 from malonyl-CoA. Yields of the alkyl substituents were higher than the corresponding 
carboxylated substrates, suggesting that SxtA AONS does not process or strongly disfavors the 
bulkier charged malonyl- and methylmalonyl-thioesters. If the carboxylated groups were to form 
α-amino ketones, they would likely decarboxylate spontaneously before we could observe them. 
 
Table 2.3. AONS-mediated ketone formation via acyl-ACP and acyl-CoA thioesters 
 
Entry Thioester Substrate Product Relative Yield 
1 acetyl-CoA (2.15) 2.38 22 ± 3 
2 propionyl-CoA 2.13 100 ± 12 
3 malonyl-CoA (2.14) 2.38 1.8 ± 0.1 
4 methylmalonyl-CoA 2.13 74 ± 1 
 
 
Intact protein MS indicated, apo-ACP was completely modified to acyl- or holo-ACP, but 
because the CoA thioesters were present in 10-fold excess relative to the concentration of apo-
ACP, it was possible that the AONS used both CoA and ACP-bound substrates. Therefore, 
standalone SxtA ACP was eliminated entirely, and the AONS domain tested directly with the same 
CoA substrates (Table 2.4). In these reactions, propionyl-CoA was the vastly preferred substrate, 
and low amounts of the other three groups were processed. 
 
Table 2.4. Direct AONS-mediated ketone formation from acyl-CoA thioesters 
 
Entry Thioester Substrate Product Relative Yield 
1 acetyl-CoA (2.15) 2.38 11 ± 1 
2 propionyl-CoA 2.13 100 ± 17 
3 malonyl-CoA (2.14) 2.38 0.8 ± 0.2 
4 methylmalonyl-CoA 2.13 4.6 ± 0.8 
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SxtA AONS catalyzes the formation of at least two ketones, the predicted native product 2.13, 
and a truncated version 2.38. Due to the higher relative yields of 2.13 over 2.38 in all assays, we 
propose that propionyl-ACP is the AONS thioester substrate, and that 2.13 is the true native SxtA 
product. 
 
SxtA Single-Point Variants 
For final verification of each domain’s activity relative to the SxtA module, we assessed five 
variants of the SxtA module, each with a single substitution in the respective active site. The ACP 
variant, S773A, removes the serine residue where the Ppant cofactor is attached. This construct 
was cloned by site-directed mutagenesis of wild-type SxtA and also served as the parent for 
ACP(KO)-AONS (see above). The other four substitutions in the PE domain active sites were 
cloned by splicing by overlap extension (SOE) due to the 3.8 kb size of the sxtA gene. The His372 
residue was implicated in the methyl transfer reaction based on CurJ MT and was changed to Ala.53 
Thr637 and His671 align with the catalytic residues in CurA GNAT and were also substituted. 
Finally, Lys1077 is proposed to form an imine with the PLP cofactor and may also mediate proton 
transfers (see Figure 2.7). Although PLP intermediates reside in the AONS active site 
noncovalently, the resulting SxtA(K1077L) protein was very pale compared to the wild-type 
enzyme, indicating low or no PLP incorporation. Extra PLP was not added to in vitro reactions. 
Each variant was incubated with malonyl-CoA, SAM and L-Arg, and the small molecule 
ketones were analyzed after 2 h. The reactions of wild-type SxtA and the S773A variant (Table 
2.5, entries 1 and 2) were similar in total product yield, and in the 2.13: 2.38 distribution. These 
reactions indicated that all three PE domains can function on CoA thioesters in addition to ACP-
bound thioesters. When standalone holo-ACP (entry 3) was added to reactions with SxtA(S773A), 
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the yield increased, and the ratio of ketone products shifted to favor the full-length ketone 2.13 
slightly in a 63:27 ratio of 2.13/2.38. The trans-acting ACP used here was not stringently purified 
with the additional ion exchange step and contains the contaminating acyltransferase(s) that 
catalyzes formation of malonyl-ACP. Still, the results suggest that the overall SxtA reaction rate 
is faster on acyl-ACP substrates and that SxtA MT methylates malonyl-ACP more readily than 
malonyl-CoA. Later, we performed a similar reaction with WT SxtA and E. coli FabD as catalysts 
(entry 8). The complete SxtA reaction dominated, affording a 93:7 ratio of 2.13/2.38. 
Table 2.5. Full SxtA reactions with variant proteins to confirm domain activity 
 
See section 2.6.IIIA for full reaction conditions. aThis reaction was performed much later under different reaction 
conditions than entries 1-7, so the yields were not compared. 
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Among the PE domain variants, the MT domain of SxtA(H372A) was inactive, resulting in 
only formation of 2.38 and decreased the overall yield. These values support the proposal that 
methylmalonyl-ACP/-CoA and propionyl-ACP/-CoA are the preferred substrates of GNAT and 
AONS, respectively, over the shorter malonyl and acetyl thioesters. Both GNAT variants (entries 
5 and 6), SxtA(T637V) and SxtA(H671A), lowered the ketone yield significantly to 27 and 9 
relative to the WT reaction, but afforded only full-length ketone. Since previous reactions with the 
AONS domain indicated that it strongly disfavors carboxylated intermediates, any methylmalonyl-
ACP/-CoA must be decarboxylated spontaneously to propionyl thioesters before AONS-mediated 
condensation. No ketone products were observed when SxtA(K1077L) was the catalyst, and we 
were unable to determine if the module had any stalled acyl-ACP intermediates by MS. 
Reactions with variants of the SxtA module demonstrated that each domain was catalyzing the 
reactions predicted from the standalone domain activity and provided further evidence of their 
native substrates. 
 
2.5 Conclusions 
From all of the above reactions, we propose the SxtA catalytic cycle outlined in Figure 2.11 to 
initiate STX biosynthesis, primarily following Route 2 in Figure 2.6. Malonyl-CoA (2.14) is the 
true starter unit of SxtA and is the substrate for an acyltransferase such as FabD to load holo-ACP. 
SxtA MT methylates malonyl-ACP (2.27) to methylmalonyl-ACP (2.28), followed 
decarboxylation by the GNAT domain to propionyl-ACP (27). AONS-mediated condensation 
between 2.27 and L-Arg affords the previously predicted native product ketone 2.13, another 
molecule of CO2, and holo-ACP, closing the catalytic cycle. 
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Acetyl-CoA is not the SxtA starter unit and acetyl-ACP is not an on-pathway intermediate. 
Additionally, the truncated ketone 2.38 and STX derivatives lacking C13 that would result from 
2.38 have not been reported in the extracts of toxin-producing microorganisms. When the module 
reactions were slowed in some manner by the exclusion of added L-Arg or impairment of GNAT 
decarboxylation, only the full-length ethyl ketone 2.13 was detected. Therefore, we hypothesize 
that methyl ketone 2.38 is an in vitro shunt product only. 
In this Chapter, we characterized the native activity of the polyketide-like synthase SxtA 
through bioinformatic sequence analysis of each domain and in vitro reactions with the full module 
and standalone domains. The starter thioester is malonyl-CoA, and the PE domain activity order 
after loading by some trans-acting acyltransferase is MT, then GNAT and AONS to produce 
Figure 2.11. The full proposed catalytic cycle of the SxtA module. 
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ketone 2.13. These results address our concerns about the pKa of the MT substrate and the order 
of domain activity from N- to C-termini and are still in agreement with labeled precursor feeding 
experiments (Figure 2.12). Our experiments provide the basis for the development of SxtA as a 
biocatalyst for enzymatic or chemoenzymatical preparation of STX derivatives, and SxtA AONS 
in particular as a tool for modifying α-amino acids. 
 
  
Figure 2.12. Proposed biosynthesis of neosaxitoxin to account for incorporation of one 
deuterium atom from labeled acetic acid. 
 67 
 
2.6 Experimental 
I. Chemical synthesis 
A. General information 
All reagents were used as received unless otherwise noted. Reactions were carried out under a 
nitrogen atmosphere using standard Schlenck techniques unless otherwise noted. Solvents were 
degassed and dried over aluminum columns on an MBraun solvent system (Inert Corporation, 
Model PS-00-3). Trifluoroacetic acid was distilled prior to use. Reactions were monitored by thin 
layer chromatography using Machery-Nagel 60 F254 precoated silica TLC plates (0.25 mm) or 
Merck Silica Gel 60 RP-18 WF-254S precoated silica TLC plates (0.25 mm) which were 
visualized using UV, ninhydrin, p-anisaldehyde, CAM, DNP, or bromocresol green stain. Flash 
column chromatography was performed using Machery-Nagel 60 μm (230-400 mesh) silica gel. 
All compounds purified by column chromatography were sufficiently pure for use in further 
experiments unless otherwise indicated. 1H and 13C NMR spectra were obtained in CDCl3 or 
CD3OD at rt (25 C), unless otherwise noted, on Varian 400 MHz, Varian 500 MHz or Varian 600 
MHz spectrometers. Chemical shifts of 1H NMR spectra were recorded in parts per million (ppm) 
on the δ scale. High resolution electrospray mass spectra were obtained on an Agilent G6545A 
quadrupole-time of flight mass spectrometer in positive mode with an Agilent 1290 UPLC system. 
Solvent A = water with 0.1% formic acid. Solvent B = 95% acetonitrile, 5% water and 0.1% formic 
acid. IR spectra were recorded on a Perkin-Elmer Spectrum BX FT-IR spectrometer. Optical 
rotations were measured at rt in CH3OH, unless otherwise noted, on a Jasco P-2000 polarimeter. 
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B. Compound synthesis 
All compounds in this Chapter were synthesized and characterized by Dr. Meagan Hinze. 
 
Tri-Boc-protected arginine Weinreb amide (2.S1) and arginine ethyl ketone (2.13) were 
synthesized according to the procedure described by Tsuchiya et al.23 
 
 
Tri-Boc-protected arginine methyl ketone (2.S2): 
To a solution of tri-Boc-protected arginine Weinreb amide (2.S1, 72.0 mg, 0.139 mmol, 1.0 equiv) 
dissolved in THF (6.9 mL) was added a 1 M solution of zinc chloride in diethyl ether (13.9 μL, 
0.013 mmol, 0.1 equiv) at 0 °C. After five min, a 3 M solution of methyl magnesium bromide in 
diethyl ether (695 μL, 2.09 mmol, 15.0 equiv) was added at 0 °C. The reaction was allowed to 
warm to room temperature and stirred for 14 h. The reaction was poured into 21 mL of 0.1 M HCl. 
The acidified aqueous phase was extracted with EtOAc (3x). The organic layers were combined, 
washed with brine, dried over Na2SO4, filtered, and evaporated under reduced pressure to afford 
an oil. The crude residue was purified by flash column chromatography (2:1 hexanes/EtOAc v/v) 
to afford 28.5 mg of the title compound (43% yield) as a white foam. Rf = 0.52 (2:1 hexanes/EtOAc 
v/v); 1H NMR (300 MHz, CDCl3) δ 11.46 (s, 1H), 8.33 (t, J = 5.4, 1H), 5.36 (d, J = 7.6, 1H), 4.35-
4.28 (m, 1H), 3.42 (q, J = 6.5, 2H), 2.20 (s, 3H), 1.95-1.85 (m, 1H), 1.66-1.52 (m, 3H), 1.48 (s, 
9H), 1.47 (2, 9H), 1.42 (s, 9H); 13C NMR (150 MHz, CDCl3) δ 207.1, 163.6, 156.4, 155.6, 153.4, 
83.3, 79.9, 79.4, 59.7, 40.3, 28.5, 28.4, 28.2, 27.1, 25.2; IR (thin film, cm-1) 3329, 2978, 1715, 
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1614, 1498, 1414; HRMS (ESI) m/z calculated for C22H41N4O7
+ [M+H]+ 473.2970, found 
473.2977. 
 
 
(S)-1-(4-amino-5-oxohexyl)guanidine (2.38): 
To a solution of tri-Boc protected arginine methyl ketone (2.S2, 28.5 mg, 0.060 mmol, 1.0 equiv) 
dissolved in DCM (1.4 mL) was added trifluoroacetic acid (TFA, 1.4 mL) at rt. The reaction was 
stirred for 3 h. After addition of toluene (2.0 mL), the solution was evaporated under reduced 
pressure to afford 24.0 mg of the title compound as a bis-TFA salt with minor impurities (99% 
yield) as a brown foam. Rf = 0.10 (RP18 TLC, 2:1 MeCN/H2O v/v); [𝛼]𝐷
24 = 0.310 (c = 0.014 g/mL, 
MeOH); 1H NMR (600 MHz, CD3OD) δ 4.22-4.17 (m, 1H), 3.24 t, J = 6.3, 2H), 2.28 (s, 3H), 2.08 
(t, J = 13.0, 1H), 1.91-1.81 (m, 1H), 1.76-1.67 (m, 1H), 1.67-1.57 (m, 1H); 13C NMR (150 MHz, 
CD3OD) δ 204.2, 158.7, 60.0, 41.7, 27.5, 26.4, 25.2; IR (thin film, cm-1) 3363, 3187, 1670, 1199, 
1133; HRMS (ESI) m/z calculated for C7H17N4O
+ [M+H]+ 173.1397, found 173.1398. 
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C. 1H NMR and 13C NMR spectra of compounds 
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II. Cloning, protein expression and purification 
A. General information 
Escherichia coli cloning strains DH10B or DH5α (Invitrogen) were used for DNA propagation. 
Proteins were expressed in E. coli strains BL21(DE3) (New England BioLabs), BL21(DE3) 
pRARE (customized for streptomycin and spectinomycin resistance by the University of Michigan 
Center for Structural Biology) or BAP140 after transformation with genes subcloned into pET24b, 
pET28b (Novagen) or pMCSG7 (provided by the University of Michigan Center for Structural 
Biology) plasmids. Cells were grown in either Luria-Bertani broth (LB) or Terrific broth (TB) 
supplemented with the corresponding antibiotics kanamycin (50 μg/mL), ampicillin (100 μg/mL) 
or spectinomycin (80 μg/mL) purchased from Gold Biotechnology. 
 
All primers were purchased from Integrated DNA Technologies (IDT). Phusion HF polymerase 
and DpnI restriction enzyme were purchased from New England BioLabs. Ligation-independent 
cloning (LIC)-qualified T4 DNA polymerase was purchased from EMD Millipore. QIAquick PCR 
purification, gel extraction and miniprep kits were purchased from Qiagen. HisPur nickel-
nitrilotriacetic acid (Ni-NTA) resin was purchased from Thermo Scientific. Fast protein liquid 
chromatography was conducted on a GE Healthcare ÄKTA Pure FPLC with 5 mL HisTrap or 
HiPrep 16/60 Sephacryl S-200 High Resolution columns (GE Healthcare). Proteins were 
concentrated using Amicon centrifugal filters purchased from EMD Millipore at 4,000 x g, 4 °C. 
PD-10 desalting columns were purchased from GE Healthcare. Protein samples were analyzed on 
Mini-PROTEAN TGX Gels (4-15%) from BioRad and visualized with Protein Ark Quick 
Coomassie Stain from Anatrace. Proteins were quantified with the Pierce 660 nm Assay Reagent 
from Thermo Scientific. 
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B. Sequence information 
A pET24b vector encoding the gene for the promiscuous phosphopantetheinyl-transferase Sfp54 
(Bacillus subtilis) was kindly donated by the group of Prof. David Sherman (University of 
Michigan Life Sciences Institute). GenBank accession: BAA09125.1. 
 
pET28b-sxtA (Cylindrospermopsis raciborskii T3) was obtained from the laboratory of Prof. Brett 
Neilan (University of Newcastle). 
 
A gene fragment of E. coli FabD (GenBank accession: AAA23742.1) was purchased from IDT. 
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pET28b-sxtA genomic DNA sequence 
(GenBank accession ABI75094.1; linkers and 6x-His tags are shown in red) 
atgggcagcagccatcatcatcatcatcacagcagcggcctggtgccgcgcggcagccatATGTTACAAAAGATTAA
TCGTTATACTCACGGCTTTGTGGCGGTTCCCGTTATTCTTGCGTGTCGAGAAAAAGGTGTTTTTGAATTACTCGCCG
ATGAAAGTCCTCTCTCTTTAAACCAAATGGTGGAACATCTGGGAGCTAACAGCGGACATTTTCAAGTTGCTTTGAGG
ATGCTCGAGTCTTTACATTGGCTTTCCCGAAATAAGGAGCTTAAATACTCTCTAACCGCAGAAGCAGCGATTCACAA
CAAAATTTCGGAAGACATTCTTCAATTGTACAACCTACCAATTCAGTCTTATTTAGAAGGGAAACAAGGAAATTTGC
TGGGAAGATGGATTGAGCGTTCTTGCCAATTGTGGAACCTGGACAATCCCCTAATGGCAGATTTTTTAGATGGATTA
CTGGTCATCCCACTCCTGCTGGCACTGCACAAACACAACTTGCTTGCAGATTCGGAGGACAAACCTTTGCTCTCCTC
ATTAAGCTCAACAGTGCAAGAAGAGTTGGGTAAGTTATTTCTCCACCTTGGCTGGGCTGACCTTACAGCAGGTCGTT
TGACCATAACCGAACTTGGTCGATTTATGGGAGAGCGAGCCTTGAATACAGCCATAGTGGCGTCCTACACTCCTATG
TTGTCCCGCATTCATGATGTATTGTTTGGCAATTGTCTCTCCGTATTCCAAAGAGATGCTTCCGGTCACGAAAGGCA
CATTGATCGCACCCTTAACGTGATCGGGAGTGGATTTCAACACCAGAAATATTTTGCCGATTTAGAAGAAAGTATCC
TCTCAGTATTCAATCAGTTGCCATTAGAAGAACAACCCAAATACATTACTGACATGGGGTGTGGCGATGGAACTCTC
CTGAAACGAGTCTGGGAAACCATTCAATTTAAGTCTGCTAGGGGAAAAGCACTCGAACAGTATCCCCTGCGTCTTAT
AGGTGTAGATTATAACGAAGCTTCTTTAAAAGCTACCACACGCACCCTTGCTAGCCTTCCCCACTTAGTTTTACAGG
GAGATATTGGGAACCCAGAACAAATGGTGCGTTCTTTAGAAGCTCATGGCATTCATGATCCCGAAAATATCCTGCAC
ATCCGTTCGTTCCTCGACCATGATCGTCTCTTTATTCCTCCTCAGAAAAGAAACGAATTGAAAGAACGTGCTCACTT
ACCTTACCAATCAGTCTGTGTCGATGATCAAGGAGAGCTTATTCCTCCTCATGTTATGGTGCAAAGTTTGGTGGAAC
ACTTAGAAAGATGGTCTCAAGTGGTCAATAAACACGGTTTAATGATTTTGGAGGTCCATTGTTTGGAACCAAGGGTA
GTCTATCAGTTTTTAGACAAAAGCGAAAACTTACATTTCGATGCGTTTCAGGGATTTTCTCAGCAGTATCTTGTGGA
AGCTGAGGTTTTTCTCATGTCTGCTGCACAAGTAGGTCTATTTCCAAAACTAGAGCTTTCTAAAAGATACCCAAAAA
CATTTCCTTTTACTCGCATTACGCTTAATTACTTCGAGAAAAGACCTTACAAAATTAGTCATGCCTATTTGTCAGAT
TTACCTGCCTTAGTTGACTTGGAGGTCAAGTGTTGGCCAGAAAATTTACGGGCATCTACTCATGAAATTCGGCGAAG
ACTTGAGCTAAACCCGCAAGGTAATTTAGTGCTGATTATAGAAGATCAAATTATTGGTGCGATTTATTCCCAAACAA
TTACCAGCACTGAGGCATTAGAGAATGTAAAATATGCGCAAGTGCCGACGTTACATACTCCCCAAGGGTCAGTTATT
CAACTGCTCGCACTAAATATTCTACCTGAGTTTCAGGCGCGGGGGTTAGGAAATGAATTGCGGGACTTTATGCTTTA
CTACTGTACCCTGAAAGGCGGCATTGAGAGCGTGGTGGGTGTAACTCGCTGTCGAAATTATGTCAATTATTCCCAAA
TGCCGATGATGGAGTATTTAAAGCTACACAATGAGCAACGACAGCTTCTGGATCCAATTGTGGGTTTCCATGTGTCG
GGAGGAGCCGAAATTAGGGGAATTATTGCTAATTATCGTCCGGAAGATACAGATAATCTCGGCATGGGTATTTTGAT
TGAATATAACCTGCGCGACAGTGCTTTGCACTCGCCTGGTGATCGCAAAGGACCGTATATTAACTCAGCAATTGGTT
CATTGGTACCAAAAGCAACATCTGCAACTAAGGAAAACAAAACTGTAGCGGATCTCGTTAAAGAATGCATCTTAAAA
GTAATGGGTTCCCAACGTCAGGCAGCCTACGCTCCACAACAAAAACTGCTGGATATGGGATTAGATTCTTTAGATTT
ATTAGAACTGCAAACGCTCCTAGAGGAACGTTTAGGGATCAATCTGTCTGGAACGTTCTTTTTACAAAAGAACACTC
CAACTGCCATCATCACTTATTTCCAAAACCAAGTGGTACAAGAGAAACAATCTGATCTAGCTCCACCTGTTGACTCA
GCCAACGAAATCAACACTCTGGAAAACGTAGTTAACCAACAAAAAATTCCTCAAGTCACAAGAGTCGTCACAGAACA
ACAAGGTCGCAAGGTGCTAATTGACGGACATTGGGTGATAGACTTTGCTTCTTGCAACTATTTAGGTCTTGACTTGC
ATCCAAAAGTTAAGGAAGCAATTCCACCAGCTTTGGATAAATGGGGCACACATCCAAGCTGGACTCGGCTTGTTGCT
TCCCCAGCAATTTATGAGGAATTGGAGGAAGAATTGTCCAAACTTTTAGGCGTACCTGATGTTTTAGTATTTCCAGC
TGTAACACTGCTTCAGATAGGAATTTTACCACTATTAACTGGGAATAATGGTGTCATCTTTGGTGACATAGCTGCAC
ATCGTTGTATTTATGAAGCGTGCTGTCTGGCTCAGCACAAAGGAGCCCAGTTCATCCAATATCGACATAATGATTTG
AACGATTTAGCCGAAAAACTAGCAAAATATCCGCCTGAACAAGTAAAGATTATTGTCATTGATGGCGTGTATTCCAT
GTCGGCAGATTTTCCCGATCTGCCAGCTTACGTGCATCTGGCAAAAGAGTACAATGCCTTAATTTACATGGATGATG
CTCATGGTTTTGGCATTTTGGGCGAAAATCCCAGCAGCGATATGCCTTACGGTTACAAAGGAAACGGGATGGTGAAT
TATTTTGACCTGCGGTTTGCAGAGGATAATATCATCTATGTAGCTGGTTTGTCCAAAGCCTATTCTTCTTACGCAGC
ATTCTTAACTTGTGGCGATCGCCGGATCAAAACCAACTTCCGCAACGCTTGGACTGCCATATTTTCTGGTCCTTCTC
CTGTTGCGAGTTTGGCAAGTGCCTTAGCCGGATTACAGGTGAATCGTCAGGAGGGGGAGCAGTTAAGAAAACAAATT
TATCACCTAACTCACAAATTGGTTACACAAGCAAGAGCCATTGGATTCGAAGTGGATAACTATGGTTACGTTCCCAT
CGTAGGCGTGTTAGTGGGAGATGCTCAACACATGATTGATGTGTGTCAACTCCTTTGGGAATATGGTATTTTAATTA
CTCCTGCTATTTTTCCAATCGTACCTTTAAATAAAAGTGCTTTAAGGTTTTCGATTACAGCCGCCAATACCGAAGAG
GAGATAGACCAAGCAATTAAATCTCTCAAAGCAGTTTGGGATTTGCTACAAAAAAGGAAAGCTTTGCCTTGTAAGCA
GGAGGAAAACATACTCAAGCATgcggccgcactcgagcaccaccaccaccaccactga 
 
 75 
 
SxtA(WT) amino acid sequence 
(linkers and 6x-His tags are shown in red) 
MGSSHHHHHHSSGLVPRGSHMLQKINRYTHGFVAVPVILACREKGVFELLADESPLSLNQMVEHLGANSGHFQVALR
MLESLHWLSRNKELKYSLTAEAAIHNKISEDILQLYNLPIQSYLEGKQGNLLGRWIERSCQLWNLDNPLMADFLDGL
LVIPLLLALHKHNLLADSEDKPLLSSLSSTVQEELGKLFLHLGWADLTAGRLTITELGRFMGERALNTAIVASYTPM
LSRIHDVLFGNCLSVFQRDASGHERHIDRTLNVIGSGFQHQKYFADLEESILSVFNQLPLEEQPKYITDMGCGDGTL
LKRVWETIQFKSARGKALEQYPLRLIGVDYNEASLKATTRTLASLPHLVLQGDIGNPEQMVRSLEAHGIHDPENILH
IRSFLDHDRLFIPPQKRNELKERAHLPYQSVCVDDQGELIPPHVMVQSLVEHLERWSQVVNKHGLMILEVHCLEPRV
VYQFLDKSENLHFDAFQGFSQQYLVEAEVFLMSAAQVGLFPKLELSKRYPKTFPFTRITLNYFEKRPYKISHAYLSD
LPALVDLEVKCWPENLRASTHEIRRRLELNPQGNLVLIIEDQIIGAIYSQTITSTEALENVKYAQVPTLHTPQGSVI
QLLALNILPEFQARGLGNELRDFMLYYCTLKGGIESVVGVTRCRNYVNYSQMPMMEYLKLHNEQRQLLDPIVGFHVS
GGAEIRGIIANYRPEDTDNLGMGILIEYNLRDSALHSPGDRKGPYINSAIGSLVPKATSATKENKTVADLVKECILK
VMGSQRQAAYAPQQKLLDMGLDSLDLLELQTLLEERLGINLSGTFFLQKNTPTAIITYFQNQVVQEKQSDLAPPVDS
ANEINTLENVVNQQKIPQVTRVVTEQQGRKVLIDGHWVIDFASCNYLGLDLHPKVKEAIPPALDKWGTHPSWTRLVA
SPAIYEELEEELSKLLGVPDVLVFPAVTLLQIGILPLLTGNNGVIFGDIAAHRCIYEACCLAQHKGAQFIQYRHNDL
NDLAEKLAKYPPEQVKIIVIDGVYSMSADFPDLPAYVHLAKEYNALIYMDDAHGFGILGENPSSDMPYGYKGNGMVN
YFDLRFAEDNIIYVAGLSKAYSSYAAFLTCGDRRIKTNFRNAWTAIFSGPSPVASLASALAGLQVNRQEGEQLRKQI
YHLTHKLVTQARAIGFEVDNYGYVPIVGVLVGDAQHMIDVCQLLWEYGILITPAIFPIVPLNKSALRFSITAANTEE
EIDQAIKSLKAVWDLLQKRKALPCKQEENILKHAAALEHHHHHH 
 
C. Cloning and Mutagenesis 
Domain boundaries used 
Methyltransferase (MT): Met1 – Tyr504 
GCN5-related N-acetyltransferase (GNAT): Phe505 – Ser721 
Acyl carrier protein (ACP): Ala722 – Gln815 
8-amino-7-oxononanoate synthase (AONS): Glu816 – His1245 
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Table 2.S1. Primers used to generate constructs in this Chapter 
Name Sequence 
Primers for SxtA(S773A) by site-directed mutagenesis of whole plasmids 
SxtA S773A forward 5’-
AAACTGCTGGATATGGGATTAGATGCGTTAGATTTATTAGAACTGCAAACG-
3’ 
SxtA S773A reverse 5’-
CGTTTGCAGTTCTAATAAATCTAACGCATCTAATCCCATATCCAGCAGTTT-
3’ 
Primers for mutagenesis by splicing by overlap extension (SOE) 
SxtA H372A SOE forward 5’-AATATCCTGCACATCCGTTCGTTCCTCGACGCGGATCGTCTCTTTATT-
3' 
SxtA H372 SOE reverse 5’-GAACGGATGTGCAGGATATT-3’ 
SxtA T637V SOE forward 5’-ATTGAGAGCGTGGTGGGTGTAGTTCGCTGTCGAAATTATG-3’ 
SxtA T637 SOE reverse 5’-ACGCTCTCAATGCCGCCTTT-3’ 
SxtA H671A SOE forward 5’-CGACAGCTTCTGGATCCAATTGTGGGTTTCGCGGTGTCGGGAGGAGCC-
3’ 
SxtA H671 SOE reverse 5’-ATTGGATCCAGAAGCTGTCG-3’ 
SxtA K1077L SOE forward 5’-GATAATATCATCTATGTAGCTGGTTTGTCCCTGGCCTATTCTTCTTAC-
3’ 
SxtA K1077 SOE reverse 5’-CAAACCAGCTACATAGATGATATTATC-3’ 
Primers for ligation-independent cloning (LIC) 
SxtA MT M1 LIC forward 5’-TACTTCCAATCCAATGCAATGTTACAAAAGATTAATCG-3’ 
SxtA GNAT F505 LIC forward 5’-TACTTCCAATCCAATGCAATGTTCGAGAAAAGACCTTACAA-3’ 
SxtA GNAT S721 LIC reverse 5’-TTATCCACTTCCAATGCTATGAGTTAATATACGGTCCTT-3’ 
SxtA ACP A722 LIC forward 5’-TACTTCCAATCCAATGCGATGGCAATTGGTTCATTGGTAC-3’ 
SxtA ACP Q815 LIC reverse 5’-TTATCCACTTCCAATGTTATTGTACCACTTGGTTTTGGAAA-3’ 
SxtA AONS H1245 LIC reverse 5’-TACTTCCAATCCAATGCAATGCAAGAGAAACAATCTGATCT-3’ 
SxtA AONS H1245 6H LIC 
reverse 
5’-TTATCCACTTCCAATGTTAGTGGTGGTGGTGGTGGTGCTCGAG-3’ 
EC_FabD LIC forward 5’-TACTTCCAATCCAATGCAATGACCCAATTTGCGTTTGTATTC-3’ 
EC_FabD LIC reverse 5’-TTATCCACTTCCAATGTTACAGTTCCAAAGCGGCAGCC-3’ 
Overhangs for ligation-independent cloning are shown in boldface, mutations underlined 
 
ACP knockout SxtA(S773A): pET28b-sxtA(S773A) was generated by site-directed mutagenesis 
on pET28b-sxtA(WT). 50 μL PCR reaction mixtures contained 10 μL Phusion HF buffer, 2 ng/μL 
WT parent plasmid, 2 μM each of the S773A forward and reverse primers, 200 μM each of dNTPs, 
0.04 U/μL Phusion HF and 6% (v/v) DMSO. Amplification was accomplished with the following 
PCR procedure: 95 °C for 2:00, (95 °C 0:30, 60 °C 1:00, 68 °C 6:00) for 18 cycles, with a final 
extension of 68 °C for 15:00. This was followed by a 10 μL digestion containing 1 μL NEB 
CutSmart buffer, 8 μL of the PCR mixture and 20 units of DpnI. The reaction mixture was 
incubated at 37 °C for 3 h and transformed into chemically competent DH5α cells.  
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SxtA(H372A), SxtA(T637V), SxtA(H671A), and SxtA(K1077L): The remaining mutants were 
generated through splicing by overlap extension (SOE).55 50 μL PCR reaction mixtures for each 
fragment included 10 μL Phusion HF buffer, 2 ng/μL WT plasmid, 2 μM each of forward and 
reverse primers, 200 μM each of dNTPs, and 0.08 U/μL Phusion HF. sxtA fragments were 
amplified according to the following PCR procedure: 95 °C 2:00, (95 °C 0:30, 45-70 °C 1:00, 72 
°C 0:45/kb) for 30 cycles, with a final extension of 72 °C for 15:00. C-terminal fragments included 
an additional 6x-His tag from pET28b-sxtA(WT). The PCR mixtures were purified with the 
QIAquick PCR Purification kit according to the manufacturer’s instructions. The complete sxtA 
insert was assembled in 10 μL Phusion HF buffer, approx. 1:1 ratio of N- and C-terminal 
fragments, 200 μM each of dNTPs and 0.08 U/μL Phusion HF polymerase (50 μL total) according 
to the following PCR procedure: 95 °C 2:00, (95 °C 0:30, 45-65 °C 1:00, 72 °C 0:45/kb) for 15 
cycles, 72 °C 15:00. Forward and reverse LIC primers (to 2 μM each), 200 μM each of additional 
dNTPs and 0.08 U/μL Phusion HF were then added, and the reaction was subjected to further 
amplification: 95 °C 2:00, (95 °C 0:30, 70 °C 1:00, 72 °C 4:00) for 30 cycles, 72 °C 15:00. The 
complete 4 kb PCR product was purified by gel extraction and subcloned into pMCSG7 using 
standard LIC protocols.43 
 
MT-GNAT, GNAT, and ACP: Excised domains were amplified from pET28b-sxtA(WT) in 50 
μL reactions containing 10 μL Phusion HF buffer, 2 ng/μL parent plasmid, 2 μM each of forward 
and reverse LIC primers, 200 μM each of dNTPs, 0.04 U/μL Phusion HF. Excised domains were 
amplified according to the following PCR procedure: 95 °C 2:00, (95 °C 0:30, 46-50 °C 0:30, 72 
°C 0:45/kb) for 30 cycles, 72 °C 10:00. Inserts were purified by gel extraction and subcloned into 
pMCSG7 using standard LIC protocols.43 
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ACP(KO)-AONS: The excised didomain with the ACP knockout and no additional C-terminal 
6x-His tag was amplified from pET28b-sxtA(S773A) in a 50 μL reaction containing 10 μL Phusion 
HF buffer, 2 ng/μL parent plasmid, 2 μM each of forward and reverse LIC primers, 200 μM each 
of dNTPs, 0.04 U/μL Phusion HF. The didomain was amplified according to the following PCR 
procedure: 95 °C 2:00, (95 °C 0:30, 55 °C 1:00, 72 °C 2:00) for 30 cycles, 72 °C 10:00. The insert 
was purified by gel extraction and subcloned into pMCSG7 using standard LIC protocols.43 
 
E. coli FabD: The synthetic gene was amplified in a 50 µL reaction containing 10 μL Phusion HF 
buffer, 2 ng/μL fabD, 2 μM each of forward and reverse LIC primers, 200 μM each of dNTPs, 
0.04 U/μL Phusion HF. The didomain was amplified according to the following PCR procedure: 
95 °C 2:00, (95 °C 0:30, 62 °C 0:45, 72 °C 1:00) for 25 cycles, 72 °C 10:00. The insert was purified 
by gel extraction and subcloned into pMCSG7 using standard LIC protocols. 
 
All mutations were confirmed by Sanger sequencing at the University of Michigan DNA 
Sequencing Core. 
 
D. Protein overexpression and purification 
Overexpression of full SxtA modules (WT, H372A, T637V, H671A, and K1077L) and 
stringently purified holo-ACP: pET28b or pMCSG7 plasmids containing complete sxtA were 
transformed into chemically competent BAP1 E. coli. A single colony was picked to inoculate a 5 
mL LB starter culture grown overnight at 37 °C, 200 rpm. The following day, 0.5 L TB media 
supplemented with kanamycin or ampicillin was inoculated with the starter culture and incubated 
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at 37 °C, 250 rpm until the OD600 reached 1.0. Cultures were equilibrated at 20 °C for 1 h prior to 
induction by addition of isopropyl-β-D-thiogalactopyranoside (IPTG, final concentration 200 
μM). Cultures were incubated at 20 °C, 200 rpm for 18 h. 
 
Overexpression of SxtA(S773A) and excised domains (MT-GNAT, GNAT, apo-ACP, 
ACP(KO)-AONS): pET28b or pMCSG7 plasmids containing the desired insert were transformed 
into pRARE-containing chemically competent BL21(DE3) E. coli cells. A single colony was 
picked to inoculate a 5 mL LB starter culture grown overnight at 37 °C, 200 rpm. The following 
day, 0.5 L TB media supplemented with spectinomycin and either kanamycin or ampicillin, was 
inoculated with the starter culture and incubated at 37 °C, 250 rpm until the OD600 reached 1.0. 
For apo-ACP, the media was also supplemented with a trace metals mixture (final concentrations: 
50 μM FeCl3, 20 μM CaCl2, 10 μM MnCl2, 10 μM ZnCl2, 2 μM CoCl2, 2 μM CuCl2, 2 μM NiCl2, 
2 μM Na2MoO4, 2 μM Na2SeO3, 2 μM B(OH)3). Cultures were equilibrated at 20 °C for 1 h. 
Expression was induced by addition of IPTG (final concentration 200 μM). Cultures were 
incubated at 20 °C, 200 rpm for 18 h. 
 
Overexpression of holo-ACP, Sfp, E. coli FabD: pMCSG7-sxtA_ACP, pET24b-sfp, and 
pMCSG7-ECfabD were transformed into chemically competent BAP1 and BL21(DE3), 
respectively. A single colony was picked to inoculate a 10 mL LB starter culture grown overnight 
at 37 °C, 200 rpm. The following day, 1 L LB cultures of holo-ACP and Sfp were supplemented 
with ampicillin or kanamycin, respectively, inoculated with the starter cultures, and incubated at 
37 °C, 200 rpm until the OD600 reached 0.6. The culture was cooled to rt and expression was 
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induced by addition of IPTG (final concentration 100 μM). Cultures were incubated at 18 °C, 200 
rpm for 18 h. 
FPLC purification of SxtA(WT) and SxtA(S773A): Cell pellets were resuspended in 4 mL of 
lysis buffer (50 mM HEPES, 300 mM NaCl, 10 mM imidazole, 1 mM pyridoxal phosphate (PLP), 
10% (v/v) glycerol, pH 8.0) per gram of wet cell mass. Protease inhibitors pepstatin A (1 μg/mL), 
benzamidine hydrochloride (15 μg/mL), and phenylmethylsulfonyl fluoride (PMSF, 1 mM) were 
added to the resuspension mixture before incubation at 4 °C for 20 min with gentle shaking. The 
resuspended mixture was lysed by homogenization (Avestin EmulsiFlex-C3, 15,000 psi, 4 passes). 
Insoluble material was removed by centrifugation twice (20,000 x g for 20 min and 30,000 x g for 
30 min, both at 4 °C). The clarified lysate was sterile filtered (0.45 μm syringe filters, 
CELLTREAT Scientific Products) and loaded onto a 5 mL HisTrap column. FPLC buffers: Buffer 
A = 50 mM HEPES, 300 mM NaCl, 10 mM imidazole, 10% (v/v) glycerol, pH 8.0; buffer B = 50 
mM HEPES, 300 mM NaCl, 300 mM imidazole, 10% (v/v) glycerol, pH 8.0. The column was 
washed with 6 column volumes (CV) of 10% B followed by a linear gradient of 10-25% B over 2 
CV. The desired protein was eluted with 25% B over 4 CV followed by a linear gradient of 25-
75% B over 7 CV. Fractions containing the protein of interest were pooled, concentrated using 50 
kDa centrifugal cutoff filters, and exchanged into a storage buffer consisting of 50 mM HEPES, 
200 mM NaCl, and 10% (v/v) glycerol) at pH 7.4 using a PD-10 column. The desalted protein was 
concentrated further using a 50 kDa centrifugal cutoff filter, aliquoted, flash frozen in liquid 
nitrogen, and stored at -80 °C. 
 
Stringent purification of holo-ACP: Cell pellets were resuspended in 4 mL of lysis buffer (50 
mM HEPES, 300 mM NaCl, 10 mM imidazole, and 10% (v/v) glycerol at pH 8.0) per gram of wet 
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cell mass. Cells were lysed by sonication (3 s on, 6 s off, 5 min total). Insoluble material was 
removed by centrifugation (30,000 x g for 30 min at 4 °C). The clarified lysate was sterile filtered 
(0.45 μm syringe filters, CELLTREAT Scientific Products) and loaded onto a 5 mL HisTrap 
column (GE Healthcare). Nickel affinity FPLC buffers: buffer A = lysis buffer; buffer B = 50 mM 
HEPES, 300 mM NaCl, 300 mM imidazole, 10% (v/v) glyercol, pH 8.0. The column was washed 
with 3 CV of 5 % B, followed by a linear gradient of 5-100% B over 5 CV. Fractions containing 
ACP were pooled and concentrated using 10 kDa centrifugal cutoff filters. The concentrated 
protein was diluted with anion exchange binding buffer (50 mM HEPES, 10% (v/v) glycerol, pH 
8.0) and loaded onto a 5 mL HiTrap Q HP column (GE Healthcare). Anion exchange FPLC 
buffers: buffer C = binding buffer; buffer D = 50 mM HEPES, 1 M NaCl, 10% (v/v) glycerol, pH 
8.0. The column was washed with 5 CV of buffer C. The desired protein was eluted with a linear 
gradient 0-100% D over 10 CV. Fractions containing ACP were pooled, concentrated using 10 
kDa centrifugal cutoff filters and further purified by size exclusion chromatography (GE 
Healthcare Superdex 75 Increase 10/300 GL) into the storage buffer (50 mM HEPES, 200 mM 
NaCl, pH 7.4). Fractions containing ACP were pooled and analyzed by mass spectrometry (see 
section “Enzymatic reactions and data” below for details). The purified ACP was found to be 72% 
holo, 28% apo. The remaining apo-ACP was enzymatically converted to holo-ACP in a 1 mL 
reaction containing 2 mM CoASH, 500 μM ACP, 25 μM Svp (from Streptomyces verticillus, 
kindly donated by the group of Janet Smith)56 in 50 mM Tris, 150 mM NaCl, 20 mM MgCl2, 10% 
(v/v) glycerol at pH 7.4 at 30° C for 2 h. Holo-ACP was separated by exclusion chromatography 
again into the storage buffer. Fractions containing pure ACP were pooled, concentrated using 10 
kDa centrifugal cutoff filters, aliquoted, flash frozen in liquid nitrogen, and stored at -80 °C. 
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Purification of all other SxtA constructs: Cell pellets were resuspended in 4 mL of lysis buffer 
(50 mM HEPES, 300 mM NaCl, 10 mM imidazole, and 10% (v/v) glycerol at pH 8.0) per gram 
of wet cell mass. For AONS-containing constructs (except SxtA(K1077L)), 1 mM PLP was added 
to the lysis buffer. Protease inhibitors pepstatin A (1 μg/mL), benzamidine hydrochloride (15 
μg/mL), and PMSF (1 mM) were added to the resuspension mixture before incubation at 4 °C for 
20 min with gentle shaking. Cells were lysed by sonication (3 s on, 6 s off, 5 min total). Insoluble 
material was removed by centrifugation (30,000 x g for 30 min at 4 °C). The clarified lysate was 
incubated with gentle shaking along with 1-2 mL of nickel-NTA resin for 1 h at 4 °C and poured 
into a column. The resin-bound protein was washed with 25 mL wash buffer (50 mM HEPES, 300 
mM NaCl, 25 mM imidazole, 10% (v/v) glycerol, pH 8.0). The desired protein was eluted with 6 
mL elution buffer (50 mM HEPES, 300 mM NaCl, 300 mM imidazole, 10% (v/v) glyercol, pH 
8.0). The eluted protein was concentrated using 3 – 50 kDa centrifugal cutoff filters and exchanged 
into storage buffer (50 mM HEPES, 200 mM NaCl, 10% (v/v) glycerol, pH 7.4) using a PD-10 
column. The desalted protein was concentrated further using 3 – 50 kDa centrifugal cutoff filters, 
aliquoted, flash frozen in liquid nitrogen and stored at -80 °C. 
 
Purification of Sfp and E. coli FabD: Cell pellets were resuspended in 4 mL of lysis buffer (50 
mM Tris, 300 mM NaCl, 10 mM imidazole, and 10% (v/v) glycerol, pH 7.4) per gram of wet cell 
mass. Cells were lysed by sonication (3 s on, 3 s off, 3 min total). Insoluble material was removed 
by centrifugation (30,000 x g for 30 min at 4 °C). The clarified lysate was incubated with 1-2 mL 
of nickel-NTA resin for 1 h at 4 °C and poured into a column. The resin-bound protein was washed 
with 25 mL wash buffer (50 mM Tris, 300 mM NaCl, 20 mM imidazole, 10% (v/v) glycerol, pH 
7.4). The desired protein was eluted with 6 mL elution buffer (50 mM Tris, 300 mM NaCl, 300 
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mM imidazole, 10% (v/v) glycerol, pH 7.4). The eluted protein was concentrated using a 10 kDa 
centrifugal cutoff filter and exchanged into the storage buffer (50 mM Tris, 10% (v/v) glycerol, 
pH 7.4) using a PD-10 column. The desalted protein was concentrated further using a 10 kDa 
centrifugal cutoff filter, aliquoted, flash frozen in liquid nitrogen, and stored at -80 °C. 
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Table 2.S2. SxtA protein constructs and calculated molecular weight with intact initial Met 
Construct name Plasmid Expression line Calculated protein mass (Da) 
SxtA(WT) pET28b BAP1      143,548.8 
SxtA(S773A) pET28b BL21(DE3) pRARE      143,532.8 
SxtA(H372A) pMCSG7 BAP1      144,057.3 
SxtA(T637V) pMCSG7 BAP1      144,121.4 
SxtA(H671A) pMCSG7 BAP1      144,057.3 
SxtA(K1077L) pMCSG7 BAP1      144,108.4 
SxtA MT-GNAT pMCSG7 BL21(DE3) pRARE        84,167.6 
SxtA GNAT pMCSG7 BL21(DE3) pRARE        27,455.3 
SxtA apo-ACP pMCSG7 BL21(DE3) pRARE        13,193.1 
SxtA holo-ACP pMCSG7 BAP1        13,533.2 
SxtA ACP(KO)-AONS pMCSG7 BL21(DE3) pRARE        60,974.0 
 pET24b BL21(DE3)        28,544.9 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.S1. Denatured SDS-PAGE protein gels. 
Proteins of interest are highlighted in red. Common co-purifying proteins (blue), potentially 
carbonic anhydrase (25.1 kDa), RplB (29.9 kDa) and DnaK (69.1 kDa).57 Further purification 
diminished activity. 
 
 
1: ladder (kDa) 
2: SxtA(WT) 
3: SxtA(S773A) 
4: SxtA(H372A) 
5: SxtA(T637V) 
6: SxtA(H671A) 
7: SxtA(K1077L) 
 
8: ladder (kDa) 
9: SxtA MT-GNAT 
10: SxtA GNAT 
11: SxtA apo-ACP 
12: SxtA holo-ACP 
13: SxtA ACP(KO)-AONS 
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III. Enzymatic reactions 
A. General information 
CoASH, butyryl-, isobutyryl-, isovaleryl-, octanoyl- and benzoyl-CoA were purchased from 
Sigma-Aldrich. Acetyl-, malonyl-, propionyl-, methylmalonyl-, and hexanoyl-CoA were obtained 
from CoALA Biosciences. S-adenosylmethionine was purchased as the tosyl salt from Carbosynth 
and prepared as a 50 mM aqueous solution immediately before use. Electrospray liquid 
chromatography-mass spectrometry (LC-MS) analysis was performed on an Agilent G6545A 
quadrupole-time of flight mass spectrometer in positive mode with an Agilent 1290 UPLC system. 
Solvent A = water with 0.1% formic acid. Solvent B = 95% acetonitrile, 5% water and 0.1% formic 
acid. MS data were analyzed using the Agilent Qualitative Mass Hunter software. Intact proteins 
were deconvoluted with the maximum entropy algorithm. 
 
Table 2.S3. Acyl-ACP masses 
Species Calculated intact 
protein mass (Da) 
Observed mass 
(Da) 
Calculated Ppant 
ejection44 
fragment (m/z) 
Observed Ppant 
ejection mass 
(m/z) 
Apo-ACP 
13,193.1 13,193.2 N/A N/A 
Holo-ACP 
 
13,533.2 13,533.2 261.13 261.13 
Acetyl-ACP 
 
13,575.2 13,575.4 303.14 303.14 
Malonyl-ACP 
 
13,619.2 13,619.4 347.13 347.13 
Propionyl-ACP 
 
13,589.2 13,589.5 317.15 317.15 
Methylmalonyl-ACP 
 
13,633.2 13,633.1 361.14 361.14 
Dimethylmalonyl-ACP 
 
13,647.2 ND 375.16 ND 
ND: not detected 
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B. Enzymatic reactions and data 
 
Loading of holo-ACP (Figure 2.8): 500 μM acyl-CoA, 100 μM holo-ACP, optional catalysts, in 
50 mM HEPES pH 7.4, 150 mM NaCl, 1 mM MgCl2, 0.5 mM MnCl2 were combined to a final 
volume of 60 μL, adding acyl-CoA last. Catalysts: 0 – 15 μM GNAT construct, or 50 nM FabD 
from Moorea producens or E. coli. Reactions were incubated at 30 °C for 2 h. At 1, 2, 10, 30, 60 
and 120 min, 10 μL aliquots were removed and quenched by diluting 12.5x with 1% formic acid 
in water. Samples were analyzed using a Ppant ejection assay of intact proteins.44 LC-MS analysis: 
column = Phenomenex Aeris 3.6 μm WIDEPORE C4 2.1 x 50 mm; method = 5% B at 0.5 mL/min 
for 2 min, followed by a linear gradient to 100% B over 4 min, 100% B for 2 min, followed by a 
0.1 min linear gradient to 5% B and 1.9 min equilibration at 5% B (total time 10 min). tR = 4.1 
min. 
 
For malonyl-CoA and methylmalonyl-CoA, the relative abundance of ejected Ppant ions for holo, 
and decarboxylated (acetyl or propionyl) plus carboxylated (malonyl or methylmalonyl) ACP were 
used to calculate the percentage of loaded ACP. 
 
For all other acyl-CoAs, the percentage of loaded ACP was calculated from the relative abundance 
of holo- and acyl-ACP ejected Ppant ions. 
 
All loading reactions were run in duplicate. 
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Figure 2.S2. Representative LC-MS analysis of holo-ACP loading with malonyl-CoA. 
(A) Total ion chromatogram; (B) mass spectrum of ejected Ppant ions at 4.1 min; (C) 
deconvolution of the peak at 4.1 min. Minor species resulting from the loss of the initial N-terminal 
methionine were also observed (-131 Da). 
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Figure 2.S3. SxtA ACP is likely loaded by an acyltransferase favoring malonyl-CoA. 
(A) Loading of holo-ACP with malonyl-CoA, GNAT constructs added. (B) Loading of holo-ACP 
with malonyl-CoA, in the presence of FabD. (C) Loading of holo-ACP with additional acyl-CoAs 
(no GNAT constructs added). 
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Preparation of malonyl-ACP and methylmalonyl-ACP (for Figures 2.9 and 2.10): 800 μM 
acyl-CoA, 180 μM apo-ACP, 20 μM Sfp in 50 mM Tris, 150 mM NaCl, 20 mM MgCl2, 10% (v/v) 
glycerol at pH 7.4 were combined to a total volume of 2 mL. Reaction mixtures were incubated at 
30 °C for 4 h. Acyl-ACP was separated by size exclusion chromatography (GE Healthcare HiPrep 
16/60 Sephacryl S-200 High Resolution) using storage buffer (50 mM HEPES, 200 mM NaCl, pH 
7.4) and stored at -80 °C. The modification was verified using a Ppant ejection assay of intact 
proteins.44 LC-MS analysis: column = Phenomenex Aeris 3.6 μm WIDEPORE C4 2.1 x 50 mm; 
method = 5% B at 0.5 mL/min for 2 min, followed by a linear gradient to 100% B over 4 min, 
100% B for 2 min, followed by a 0.1 min linear gradient to 5% B and 1.9 min equilibration at 5% 
B (total time 10 min). tR = 4.1 min. The relative abundance of ejected Ppant ions for carboxylated 
ACP (malonyl or methylmalonyl) to decarboxylated ACP (acetyl or propionyl) were used to 
calculate the fraction of each species. 
 
ACP acylation: 
Malonyl-CoA: 81% malonyl-ACP, 19% acetyl-ACP 
Methylmalonyl-CoA: 46% methylmalonyl-ACP, 54% propionyl-ACP 
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Decarboxylation of malonyl- and methylmalonyl-ACP (Figure 2.10): 100 μM malonyl- or 
methylmalonyl-ACP and 0-15 μM GNAT construct in 50 mM HEPES pH 7.4, 150 mM NaCl, 1 
mM MgCl2, 0.5 mM MnCl2 were combined to a final volume of 35 μL and incubated at 30 °C for 
2 h. At 2, 10, 30, 60, 120 and 180 min, 5 μL aliquots were quenched by diluting 12.5x with 1% 
formic acid in water. Samples were analyzed using a Ppant ejection assay of intact proteins.44 
Decarboxylation reactions were run in duplicate. LC-MS analysis: column = Phenomenex Aeris 
3.6 μm WIDEPORE C4 2.1 x 50 mm; method = 5% B at 0.5 mL/min for 2 min, followed by a 
linear gradient to 100% B over 4 min, 100% B for 2 min, followed by a 0.1 min linear gradient to 
5% B and 1.9 min equilibration at 5% B (total time 10 min). tR = 4.1 min. 
 
The relative abundance of ejected Ppant ions for acetyl-/propionyl- and malonyl-/methylmalonyl-
ACP were used to calculate the average formation of decarboxylated ACP at each time point. The 
background decarboxylation (i.e., negative control with no MT-GNAT or GNAT addition) was 
then subtracted from the reaction to obtain the data in Figure S5. The hydrolysis product holo-
ACP was excluded from the decarboxylation analysis. 
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Figure 2.S4. Representative LC-MS analysis of malonyl-ACP decarboxylation to acetyl-
ACP. 
(A) Total ion chromatogram; (B) mass spectrum of ejected Ppant ions at 4.1 min; (C) 
deconvolution of the peak at 4.1 min. Minor species resulting from the loss of the initial N-terminal 
methionine were also observed (-131 Da). 
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Figure 2.S5. Decarboxylation of carboxylated ACPs. 
(A) Formation of acetyl-ACP from malonyl-ACP with background spontaneous decarboxylation 
subtracted. (B) Formation of propionyl-ACP from methylmalonyl-ACP with background 
spontaneous decarboxylation subtracted. 
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Figure 2.S6. Comparison of propionyl- and acetyl-ACP formation. 
Black bars, from methylmalonyl-ACP; white bars, from malonyl-ACP; over 3 h with background 
spontaneous decarboxylation subtracted. (A) Acyl-ACPs with 5 µM MT-GNAT; (B) with 15 µM 
MT-GNAT; (C) with 5 µM GNAT; (D) with 15 µM GNAT. 
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Methylation of malonyl-ACP (Figure 2.9): 100 μM malonyl-ACP and 0-15 μM MT-GNAT in 
50 mM HEPES pH 7.4, 150 mM NaCl, 1 mM MgCl2, 0.5 mM MnCl2, and 1 mM SAM were 
combined for a total volume of 35 μL and incubated at 30 °C for 3 h. At 15, 30, 45, 60, 120, and 
180 min, 5 μL aliquots were removed and quenched by diluting 12.5x with 1% formic acid in 
water. Samples were analyzed using a Ppant ejection assay of intact proteins.44 LC-MS analysis: 
column = Phenomenex Aeris 3.6 μm WIDEPORE C4 2.1 x 50 mm; method = 5% B at 0.5 mL/min 
for 2 min, followed by a linear gradient to 100% B over 4 min, 100% B for 2 min, followed by a 
0.1 min linear gradient to 5% B and 1.9 min equilibration at 5% B (total time 10 min). tR = 4.1 
min. The relative abundance of ejected Ppant ions for acetyl-, malonyl-, propionyl- and 
methylmalonyl-ACP were used to calculate the fraction of each acyl-ACP species. They hydrolysis 
product holo-ACP was excluded from the methylation analysis. Methylation reactions were run in 
duplicate. 
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Figure 2.S7. Representative LC-MS analysis of malonyl-ACP methylation. 
(A) Total ion chromatogram; (B) mass spectrum of ejected Ppant ions at 4.1 min; (C) 
deconvolution of the peak at 4.1 min. Minor species resulting from the loss of the initial N-terminal 
methionine were also observed (-131 Da). 
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Figure 2.S8. Total methylation of malonyl-ACP. 
(A) Malonyl-ACP without MT-GNAT; (B) malonyl-ACP with 5 μM MT-GNAT; (C) malonyl-
ACP with 15 μM MT-GNAT; (D) total fraction of methylated ACP (methylmalonyl- and 
propionyl-ACP). 
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Full SxtA module reactions (Tables 2.2 and 2.5): 250 μM acyl-CoA, 1 mM SAM, 2 mM Arg, 
10 μM SxtA (with 50 μM holo-ACP where applicable) in 50 mM HEPES pH 7.4, 150 mM NaCl, 
1 mM MgCl2, 0.5 mM MnCl2 (total volume 25 μL) were combined and incubated at 30 °C for 2 
h. Reactions were quenched by diluting 5x with acetonitrile. Precipitate was pelleted at 12,000 x 
g for 20 min. The supernatant was diluted 20x with acetonitrile, 1% formic acid, and aqueous 10 
μg/mL 15N Arg·HCl. The final ratios (v/v) for analysis were 5% quenched reaction, 2.5% of 
aqueous 10 μg/mL 15N Arg·HCl (Cambridge Isotope Laboratories), 46% acetonitrile, 46.5% of 
1% formic acid in water (e.g., 10 μL of quenched reaction, 5 μL of 10 μg/mL 15N Arg·HCl, 92 μL 
acetonitrile, 93 μL of 1% formic acid in water for a total volume of 200 μL). Samples were 
analyzed by LC-MS: column = Waters Acquity 1.7 μm UPLC BEH Amide HILIC 2.1 x 100 mm 
column; method = 85% B at 0.3 mL/min for 2 min, followed by a linear gradient to 75% B at 0.4 
mL/min over 3 min and a second linear gradient to 60% B over 0.5 min, 60% B for 1 min and then 
6.5 min re-equilibration at 85% B at 0.3 mL/min (total time 15 min). tR (2.13): 1.94 min; tR (2.38): 
2.35 min; tR (
15N Arg): 4.0 min. Yields were calculated by comparing the areas under the curve of 
the extracted ion chromatograms to the 15N Arg internal standard and normalized to the SxtA(WT) 
reaction with malonyl-CoA, SAM and Arg (Table 1, entry 3 or Table 2, entry 1). Reactions were 
run in triplicate. 
Entry 8 was performed about a year later: 4 mM ATP, 2 mM methionine, 1.5 mg/mL E. coli MetK 
(provided by the laboratory of Jennifer Bridwell-Rabb at the University of Michigan) in 100 mM 
Tris pH 7.7, 200 mM KCl, 20 mM MgCl2 (total volume 25 µL) were combined and incubated for 
3 h at 37 °C. 0.5 mM MnCl2, 0.1 mM PLP, 2 mM Arg, 500 µM malonyl-CoA and 50 nM of E. 
coli FabD were added to a final volume of 50 µL and incubated further for 2 h at 30 °C. The 
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reaction was quenched instead by diluting 5x with methanol, but the rest of the sample preparation 
and MS analysis was the same as above. 
 
Figure 2.S9. Representative LC-MS analysis of full SxtA module reactions. 
(A) Total ion chromatogram; (B) combined extracted ion chromatograms of products ethyl ketone 
(2.13, red), methyl ketone (2.38, green), and the 15N Arg internal standard (blue). (C) Extracted 
ion chromatograms for 187 m/z of the synthetic standard of 2.13 (gray) and the reaction (red). (D) 
Extracted ion chromatograms for 173 m/z of the synthetic standard of 2.38 (gray) and the reaction 
(green).
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Figure 2.S10. Clustal Omega alignment of the SxtA and CurA GNAT domains.  
The catalytic residues of SxtA GNAT are boxed in red. 
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AONS-mediated condensation of arginine and acyl-ACPs (Table 2.3): 500 μM acyl-CoA, 2 
mM Arg, 50 μM apo-ACP, 10 μM Sfp, 8 μM ACP(KO)-AONS in 50 mM HEPES pH 7.4, 150 
mM NaCl, 1 mM MgCl2, 0.5 mM MnCl2 (total volume 25 μL) were combined and incubated at 
30 °C for 2 h. Reactions were quenched by diluting 5x with acetonitrile. Precipitate was pelleted 
at 12,000 x g for 20 min. The supernatant was diluted 20x with the LC-MS analysis mixture for a 
final ratio of 5% quenched reaction, 2.5% of aqueous 10 μg/mL 15N Arg·HCl (Cambridge Isotope 
Laboratories), 46% acetonitrile, 46.5% of 1% formic acid in water (e.g., 10 μL of quenched 
reaction, 5 μL of 10 μg/mL 15N Arg·HCl, 92 μL acetonitrile, 93 μL of 1% formic acid in water for 
a total volume of 200 μL). Samples were analyzed by LC-MS: column = Waters Acquity 1.7 μm 
UPLC BEH HILIC 2.1 x 100 mm column; method = 85% B at 0.3 mL/min for 2 min, followed by 
a linear gradient to 75% B at 0.4 mL/min over 3 min and a second linear gradient to 60% B over 
0.5 min, 60% B for 1 min and then 6.5 min re-equilibration at 85% B at 0.3 mL/min (total time 15 
min). tR (
15N Arg): 4.0 min. Yields were calculated by comparing the areas under the curve of the 
product extracted ion chromatograms to the 15N Arg internal standard and normalized to the 
propionyl-CoA reaction (Table 2.3, entry 2). Reactions were run in triplicate. 
 
The ACP(KO)-AONS didomain was chosen over the standalone AONS due to the increased 
solubility of the didomain. Only the catalytically active AONS is shown in the scheme above. 
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AONS-mediated condensation of arginine and acyl-CoAs (Table 2.4): 500 μM acyl-CoA, 2 
mM Arg, 8 μM ACP(KO)-AONS in 50 mM HEPES pH 7.4, 150 mM NaCl, 1 mM MgCl2, 0.5 
mM MnCl2 (total volume 25 μL) were combined and incubated at 30 °C for 2 h. Reactions were 
quenched by diluting 5x with acetonitrile. Precipitate was pelleted at 12,000 x g for 20 min. The 
supernatant was diluted 20x with the LC-MS analysis mixture for a final ratio of 5% quenched 
reaction, 2.5% of aqueous 10 μg/mL 15N Arg·HCl (Cambridge Isotope Laboratories), 46% 
acetonitrile, 46.5% of 1% formic acid in water (e.g., 10 μL of quenched reaction, 5 μL of 10 μg/mL 
15N Arg·HCl, 92 μL acetonitrile, 93 μL of 1% formic acid in water for a total volume of 200 μL). 
Samples were analyzed by LC-MS: column = Waters Acquity 1.7 μm UPLC BEH HILIC 2.1 x 
100 mm column; method = 85% B at 0.3 mL/min for 2 min, followed by a linear gradient to 75% 
B at 0.4 mL/min over 3 min and a second linear gradient to 60% B over 0.5 min, 60% B for 1 min 
and then 6.5 min re-equilibration at 85% B at 0.3 mL/min (total time 15 min). tR (
15N Arg): 4.0 
min. Yields were calculated by comparing the areas under the curve of the product extracted ion 
chromatograms to the 15N Arg internal standard and normalized to the propionyl-CoA reaction 
(Table 2.4, entry 2). Reactions were run in triplicate. 
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Chapter 3: Chemoenzymatic Synthesis of α-Amino Ketones with SxtA AONS 
 
Reprinted (adapted) with permission from “Chemistry of a Unique Polyketide-like Synthase”. 
Chun, S. W.; Hinze, M. E.; Skiba, M. A.; Narayan, A. R. H. J. Am. Chem. Soc. 2018, 140, 2430-
2433. Copyright © 2018, American Chemical Society. 
and “Biocatalytic synthesis of α-amino ketones”. Chun, S. W.; Narayan, A. R. H. Synlett, 2019, 
30, 1269-1274. Copyright © 2019, Georg Thieme Verlag KG. 
Summary 
α-amino ketones are an important building block in pharmaceutical products and total synthesis 
efforts. In contrast to the 4-6 step synthetic routes to stereospecifically prepare α-amino ketones 
from α-amino acids, the analogous transformations mediated by α-oxoamine synthases (AOS) are 
a single step, under mild protecting group-free conditions. We recently demonstrated that one AOS 
enzyme, SxtA AONS (8-amino-7-oxononanoate synthase) affords α-amino ketones from the 
amino acid L-Arg and acyl-ACP or -CoA thioesters. This Chapter summarizes our work to develop 
SxtA AONS as a biocatalyst to synthesize α-amino ketones chemoenzymatically on preparative-
scale. Reactions were optimized by leveraging the SxtA ACP-AONS didomain as a carrier protein-
partner enzyme platform and thiophenol esters as inexpensive acyl donors. However, we also 
observed that SxtA AONS is only active for fewer than 4 h and approximately 30 turnovers, which 
is too low for preparative-scale reactions. The final stereoselectivity of the AONS-mediated 
condensation reaction therefore cannot be determined yet. Additionally, homologs of SxtA ACP-
AONS were screened with other amino acids and acyl thioesters to interrogate SxtA AONS' ability 
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to synthesize a variety of ketones. The enzyme operated on several non-native substrates, but with 
very low conversion. To evolve variants that operate on the indole-containing tryptophan, we 
began collaborating with the group of Prof. Robert Kennedy at the University of Michigan on a 
protein engineering campaign. Two potential hits in a first-generation random mutagenesis library 
were found, and efforts to further engineer this protein are ongoing. 
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3.1 Introduction 
Amino acids serve many important roles in biology, where they are primarily the building 
blocks of proteins, but also incorporated into nonribosomal peptide and ribosomally synthesized 
and post-translationally modified peptide (RiPP) natural products (Figure 3.1).1,2 In synthetic 
chemistry, amino acids are employed as catalysts and precursors to chiral auxiliaries (3.3) and 
pharmaceutical compounds.3–6 The twenty proteinogenic amino acids are an economical class of 
chiral pool molecules, and a diverse array of non-proteinogenic amino acids are also commercially 
available.7,8 
 
Figure 3.1. Uses of α-amino acids in biology and chemistry. 
Figure 3.2. The polyketide-like synthase SxtA natively mediates assembly of ketone 3.8. 
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Free amino acids and protein residues are often modified to adjust the structure and function 
of the final products;1,9,10 there are thousands of enzymes that mediate these transformations 
endogenously, but synthetic methods to derivatize amino acid functions are fewer and generally 
more challenging.11 The amino and carboxylic acid motifs usually require protection, as do 
reactive side chains, adding more steps to a synthetic sequence.12 Therefore, the development of 
synthetic methods that are selective and protecting group-free would be valuable.  
 
Based on our previous experiments described in Chapter 2 demonstrating that SxtA AONS 
converted the amino acid L-Arg to α-amino ketones in a single step, we envisioned developing the 
domain as a general biocatalyst to modify amino acids. The key reactive intermediate in the 
mechanism of SxtA AONS is the nucleophilic quinonoid I (see 3.11, Figure 3.3).13,14 In the native 
reaction, quinonoid 3.11 attacks an electrophilic acyl-ACP thioester, eventually affording three 
products: ketone 3.13, carbon dioxide, and holo-ACP. Replacing thioesters with other 
Figure 3.3. AONS-catalyzed diversification of α-amino acids stemming from a 
nucleophilic intermediate. 
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electrophiles, would lead to other types of derivatized products, such as α-deuterated amino acids 
(3.14, discussed in Chapter 4), or tetra-substituted molecules (3.15). 
Figure 3.4. Synthetic methods toward α-amino ketones. 
(A) α-amino ketone-forming steps in pharmaceutical products are not stereoselective and proceed 
but could potentially be synthesized from an amino acid precursor.15–17 (B) Stereoselective 
transformation of an α-amino acid to a ketone requires a multi-step synthetic route using traditional 
chemical methods.18–23 
 
 
We chose to develop the native reaction type of SxtA AONS, a decarboxylative Claisen-like 
condensation from an amino acid to a ketone, first. α-amino ketones are valuable precursors in the 
total syntheses of natural products,18,24 and are also found in some pharmaceutical products which 
can be synthesized through various methods (Figure 3.4A). Pyrovalerone (3.18) was initially 
prepared from α-bromo ketone 3.16, without control over the enantioselectivity, despite only the 
2S-isomer being bioactive.15,16 The early syntheses of Keto-ACE (3.21) also used the non-selective 
Dakin-West reaction to synthesize the α-amino ketone segment.17 The more intuitive option is 
synthesis from the corresponding amino acids, forming the bonds highlighted in red in Figure 
3.4A. These have their own set of drawbacks, including protection of the amino group, and correct 
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activation of the carbonyl such that any carbon nucleophiles only add once (Figure 3.4B).18–23 
These considerations all add to the step counts, leading to longer inefficient synthetic sequences. 
As an example, the synthetic standards of SxtA’s native full-length product and one shunt product, 
ketones 3.8 and 3.9, were prepared in six steps from L-ornithine, compared to the one-step SxtA 
AONS transformation.14,25 
The α-oxoamine synthase (AOS) enzyme class to which SxtA AONS belongs is a potential 
biocatalytic solution to this synthetic challenge, mediating ketone formation that is likely 
stereospecific. The protein class has been studied for decades for links to human diseases or as 
potential drug targets.26–28 There is a common accepted mechanism (see Figure 2.7), but many 
finer details about AOSs have not been elucidated yet.29 The substrate scopes of the sixteen known 
AOS members (Table 3.1) have not been exhaustively probed. Chapter 2 describes preliminary 
reactions with SxtA AONS, demonstrating that it can employ multiple thiol (ACP, CoA) and acyl 
group (propionyl, acetyl) sources to enzymatically synthesize 3.8 and 3.9 in vitro, suggesting that 
the domain may also catalyze ketone formation from other non-native combinations of amino acids 
and thioesters.  
In this Chapter, we discuss our efforts to optimize experiments with SxtA AONS for 
preparative-scale experiments and verify the stereoselectivity of the overall ketone-forming 
reaction (section 3.2). Additionally, we examined the promiscuity of wild-type SxtA AONS and 
began a directed evolution campaign to discover a variant protein that operates more on the non-
native substrate L-tryptophan (section 3.3). 
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Table 3.1. Summary of known AOS enzymes 
Protein name(s) 
Biosynthetic 
pathway 
Amino acid 
substrate 
Thioester Product Notes 
SxtA AONS14 
(domain 4) 
Saxitoxin L-Arg 
 
 
 
BioF or 8-amino-7-
oxononanoate 
synthase30 
Biotin L-Ala 
  
Some species use 
ACP thioesters31 
FUM832,33 Fumonisin B1 L-Ala 
  
 
CuaB34 Curvulamine L-Ala 
 
 
CuaB also appears 
to be an oxygenase; 
released product 
cyclizes 
2-amino-3-
ketobutyric acid 
ligase (KBL)35 
L-Thr Gly 
  
No decarboxylation 
HemA or 
aminolevulinic acid 
synthase (ALAS)26,36 
Porphyrins Gly 
  
 
ORF34, AsuA37,38 C5N heterocycles Gly 
  
Also have 
downstream 
cyclization activity 
RedL domain 639,40 Prodigiosins Gly 
 
 
Released product 
cyclizes 
Serine 
palmitoyltransferase 
(SPT)41 
Sphingosines L-Ser 
  
 
PigH and RedN 
domain 342,43 
Prodigiosins and 
prodiginines, 
respectively 
L-Ser 
  
Released product 
cyclizes 
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TamD domain 244 Tamjamine L-Ser 
  
Released product 
cyclizes 
PqrA45 Perquinolines L-Phe 
  
 
KtmB46 
Ketomemicins and 
arphamenines 
L-Phe and L-Tyr 
  
 
PapD47 Pyrazines L-4-amino-Phe 
  
 
CqsA48,49 CAI-1 SAM 
  
Eliminates (S)-
methyl-5’-
thioadenosine first 
LqsA50 LAI-1 SAM? 
  
 
JqsA51 JAI-1 Unknown Unknown Unknown 
JAI-1 final product 
structure is 
unknown 
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3.2 Optimization for Preparative-Scale Reactions of the Condensation Reaction to 
Arginine-Based Ketones 
Like the partner enzymes described in Chapter 1, the major barrier to leveraging those 
enzymes and AOS proteins on a synthetically useful scale is the cost of the activated building 
blocks. Both routes toward the native SxtA product ketone 3.8 we previously investigated in 
Chapter 2 originate from a CoA source (Figure 3.5). These thioesters are commercially 
available but extremely expensive compared to amino acids, and not atom-economical due to 
the high molecular weight of the CoASH byproduct. We first sought to identify the propionyl 
thioester with the best balance between cost and activity with SxtA AONS. 
Figure 3.5. Biosynthesis of ketone 3.8 from CoA thioesters. 
Reaction Optimization 
Eight propionyl thioesters, prepared from thiols of varying cost and size were tested. N-
acetylcysteamine (SNAC), which resembles the Ppant cofactor of holo-ACP, was synthesized by 
a coupling reaction to propionic acid (Figure 3.6). The thiophenol ester (3.37) was easily 
synthesized in one step from thiophenol and propionic anhydride (Figure 3.6B).52 The product was 
then used to prepare the pantetheine and ACP thioesters (3.38 and 3.39) by aqueous  
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Figure 3.6. Thiol activating groups tested with SxtA AONS. 
(A) Comparison of thiols to the native activator, holo-ACP. (B) Synthesis of selected propionyl 
thioesters. 
 
 
transthioesterification,53 with separation of the excess small molecules on a PD-10 desalting and 
size-exclusion column for the protein (about 80% loading, as measured by intact protein MS). 
Next, thioesters 3.31-3.34 were enzymatically generated in situ by the CoA biosynthetic enzymes 
CoaADE: phosphopantetheine 3.31 (Ppant) using CoaA only, 3’-desphospho-CoA 3.32 by CoaAD 
and CoA 3.33 (commercially available but here was formed by CoaADE).54 
After running the CoA biosynthesis reactions for 3 hours, L-Arg and SxtA AONS were 
incubated with the thioesters for an additional 4 hours, and the relative yields of 3.8 were compared 
(Figure 3.7). At this time, we were using SxtA AONS constructs from C. raciborskii, and found 
that the simplest thiols (thiophenol, thiopyridine, SNAC) were not directly compatible with the 
standalone domain. In contrast, the pantetheine thioester 3.38 did lead to the desired product 
formation, indicating that pantetheine was the minimum thiol activator. The CoA thioester positive 
control afforded 3.8, as did the CoA biosynthetic intermediates Ppant and 3’-dephospho-CoA. The 
native thiol activator holo-ACP was the highest converting, as expected.  
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Although the most cost-effective thiol activators thiophenol, thiopyridine and SNAC were not 
substrates, employing stoichiometric CoA or holo-ACP is still economically unfeasible. However, 
thiophenol and SNAC thioesters are known to transesterify holo-ACPs as well;55,56 therefore, these 
could serve as the indirect but inexpensive acyl donors, generating the active acyl-ACP or -CoA 
in situ and allowing the most expensive component, holo-ACP or CoASH, to be used in catalytic 
amounts. 
The stoichiometry between ACP and AONS was tested next (Figure 3.8). The relative protein 
concentration is more easily controlled with standalone trans-acting domains, but the cis-acting 
ACP-AONS didomain more closely resembles the native context of SxtA. Of the two possible acyl 
donors, propionyl-SPh 3.37 afforded a higher relative conversion of ketone 3.8 than the SNAC 
thioester (3.40). Increasing the concentration of holo-ACP from 1 equivalent to 6.3 equivalents of 
Figure 3.7. Activity test of SxtA AONS with various activating thiols to synthesize ketone 
3.8. 
Conditions: 250 μM propionyl-pantetheine (3.38) or propionyl thioester, 2 mM Arg, 8 mM 
ATP, 0.2 mg/mL CoaADE. 
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AONS also increased conversion, but the didomain still had the highest relative yield. Adding the 
thiol scavenger 2-vinylpyridine (2-VP)57 to react with the thiol byproducts significantly suppressed 
conversion. 
 
This semi-optimized reaction format was used to test the acyl group substrate scope of AONS. 
A panel of ten commercially available acyl-CoA thioesters was screened initially, eight of which 
formed the corresponding arginine ketones (Table 3.2). Propionyl- and acetyl-CoA gave the ethyl 
3.8 and methyl ketones 3.9, respectively, as described previously in Chapter 2 (entries 1 and 2). 
Figure 3.8. Optimization of ACP and AONS stoichiometry with small molecule acyl 
donors generating propionyl-ACP in situ. 
+: the catalyst or reagent was present; -: the catalyst or reagent was absent. For holo-ACP, + 
indicates 1 equivalent of protein, and 6.3 equivalents were added in reactions labeled ++. 
Conditions: 2 mM propionyl thioesters, 4 mM 2-vinylpyridine, 2 mM Arg, 8 µM C. raciborskii 
ACP(KO)-AONS or ACP-AONS, 8 or 50 µM holo-ACP. 
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Other straight-chain alkyl groups were accepted (entries 3-5), but the relative yields of the 
branched chain substrates isobutyryl and isovaleryl (entries 6 and 7) were low. The case of 
isobutyryl-CoA was particularly illuminating. If the isobutyryl group were formed in our SxtA 
module experiments (either by dimethylation of malonyl-CoA/-ACP by the SxtA MT domain or 
monomethylation of the methylmalonyl thioester), it is difficult for the AONS domain to process 
this substrate. There was slightly more conversion for the larger but more rigid benzoyl-CoA (entry 
8). The two polar or negatively charged substrates, succinyl-CoA and 3-hydroxymethylglutaryl- 
were not productive for ketone formation (entries 9 and 10). 
Table 3.2. Activity of acyl-CoA thioesters with SxtA AONS 
 
Entry R = Normalized yielda 
1 Me 11 ± 2 
2 Et 100 ± 17 
3 n-Pr 190 ± 10 
4 n-pentyl 9.2 ± 0.6 
5 n-heptyl 67 ± 5 
6 iPr 2.3 ± 0.5 
7 iBu 39 ± 2 
8 Ph 2.9 ± 0.2 
9 
 
ND 
10 
 
ND 
ND: not detected. aYields of ketones were calculated by comparing the area under the curve of extracted ion 
chromatograms to an internal standard, 15N Arg, and normalized to the native product (entry 2). 
 
 
Employing these CoA thioester substrates is still too expensive for preparative-scale reactions, 
motivating a screen of so the thiophenol esters of the eight converted acyl groups, as well as 
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cyclopentyl, cyclohexyl and glycyl substrates. In reactions with ACP-AONS and L-Arg, nine of 
the eleven substrates were converted to arginine ketones (Table 3.3), generally with a similar 
reactivity trend as the CoA thioesters. The cyclopropyl group (entry 9) was active with SxtA 
AONS, but the slightly larger cyclohexyl group (entry 10) and the charged glycine-based 
aminoacyl group (entry 11) showed no conversion. When the thiophenol esters were incubated 
separately with holo-ACP for 1 h to inspect the loading levels by intact protein MS, the amount of  
Table 3.3. Activity of SxtA ACP-AONS with acyl-ACP generated in situ from thiophenol 
esters. 
 
              
Entry R = Normalized yielda 
Loading of 
holo-ACP 
1 Me 16 ± 2 94% 
2 Et 100 ± 4 89% 
3 n-Pr 8.3 ± 0.3 39% 
4 n-pentyl 1.5 ± 0.1 8% 
5 n-heptyl 0.7 ± 0.1 ND 
6 iPr 1.9b 29% 
7 iBu 0.4 ± 0.1 3% 
8 Ph 1.8 ± 0.1 31% 
9 cyclopentyl 1.5 ± 0.1 13% 
10 cyclohexyl ND ND 
11 -CH2NH3
+ (Gly) ND 48% 
ND: not detected. aYields of ketones were calculated by comparing the area under the curve of extracted ion 
chromatograms to an internal standard, 15N Arg, and normalized to the native product (entry 2). bNo duplicate of this 
reaction run. 
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acyl-ACP generally decreased as the size and hydrophobicity of the acyl group increased. The 
native group, propionyl, had very high loading (89%), while the largest substrate, octanoyl (entry 
5), was loaded in negligible amounts to provide very little active acyl-ACP. The glycyl group 
(entry 11) had modest loading, but showed no ketone formation, indicating that the AONS also 
does not appear to process positively charged substrates. Adding methanol or THF cosolvents (5% 
v/v) to increase the solubility of the larger substrates also only suppressed the condensation 
reaction. 
Because synthetic transthioesterification reactions typically occur at more basic pH, we then 
screened reactions from a range of pH 6.6-8.6 to possibly generate more of the active acyl-ACP 
species in situ (Figure 3.9). A higher pH generally did lead to increase the level of loading (by 
about 10% for propionyl- and octanoyl-SPh, and over 30% for cyclopentanoyl and isovaleryl-SPh, 
Figure 3.9. Activity of SxtA domains between pH 6.8 and 8.8. 
(A) Loading of four acyl groups onto holo-ACP. (B) Loading and condensation pH screen with 
the ACP-AONS didomain. Conditions: 1 mM acyl-SPh, 4 mM Arg, and 10 µM C. raciborskii 
ACP-AONS. 
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see Figure 3.9A), the ketone yields simultaneously decreased (Figure 3.9B). Thus, SxtA ACP more 
readily undergoes transthioesterification at basic pH, most likely due to the shift in the 
thiol/thiolate equilibrium, but the AONS domain becomes less active. The best balance of 
maximum loading and AONS activity for the native propionyl group was at neutral pH 7.0. 
From these data, it appeared that only propionyl thioesters that form the native arginine ethyl 
ketone product 3.8 are feasible for a preparative-scale reaction. When tracking the ketone 
formation, however, no additional product was converted after 4 h (Figure 3.10). Adding extra 
equivalents of holo-ACP, AONS, propionyl-SPh and L-Arg to find the limiting reagent showed 
that the AONS was responsible for the stalled reaction. Thus, our current AONS was not robust 
enough yet to use for semi-preparative or preparative-scale condensation. 
 
  
Figure 3.10. Identification of the bottleneck in formation of ketone 3.8. 
Conditions: 1 mM propionyl-SPh (3.37), 4 mM Arg, 10 µM C. raciborskii ACP-AONS, with 
extra 1 mM propionyl-SPh, 50 µM holo-ACP, 10 µM ACP-AONS, or 10 µM ACP(KO)-
AONS. 
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Determination of the product configuration 
While the preparative-scale generation experiments of native product ketone 3.8 were paused, 
we also screened the substrate scopes of three cyanobacterial SxtA AONS homologs for 
condensation to new ketones (see section 3.3). The homolog from Microseira wollei was the most 
promiscuous with other L-amino acids. Furthermore, when we conducted a presumed negative 
control condensation reaction with D-Arg and propionyl-pantetheine thioester 3.38, a small amount 
of a product matching the mass and retention time of ketone 3.8 was unexpectedly observed 
(Figure 3.11). 
 
 
Although little is known about how amino acid substrates bind in AOS active sites, only one 
binding mode relative to the PLP cofactor has been observed in AOS-amino acid co-crystal 
structures, reinforced by a conserved Arg residue (Arg1208 in M. wollei SxtA) that interacts with 
the amino acid carboxylate group.26,29,58 Additionally, in our homology model of SxtA AONS and 
published AOS crystal structures, the catalytic Lys residue (M. wollei SxtA Lys1083) is located 
on the si face of the PLP cofactor. This only allows an α-proton from an L-substrate in the observed 
Figure 3.11. Unexpected formation of ketone 3.8 from D-Arg. 
Conditions: 1 mM propionyl-panthetheine (3.38), 4 mM D- or L-arginine, 10 µM M. wollei 
ACP-AONS. 
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binding mode and correctly aligned with the PLP p orbitals to be deprotonated (Figure 3.12).59 
The acyl-CoA/-ACP binding site is located on the re face of PLP, and addition of the acyl group 
is proposed to push the carboxylate substituent into the position originally occupied by the alpha 
proton to promote decarboxylation.27 The catalytic Lys residue can then reprotonate quinonoid II 
(3.53) again from the si face, affording an L-ketone product. From these data, AOS enzymes have 
been proposed to only catalyze stereospecific L-ketone formation. 
It seems unlikely that a D-Arg substrate is utilizing an alternate binding mode with the α-proton 
in the same location and swapping the relative orientation of the carboxylate and side chain groups. 
First, the SxtA AONS residues that interact with a positively charged L-Arg side chain are likely 
to disfavor interactions with the negatively charged carboxyl group. In addition, the flipped 
binding mode would place the D-Arg side chain near Arg1208 or in the propionyl group binding 
tunnel. Again, the positively charged side chain would be repelled by Arg1208, and we never 
Figure 3.12. Deprotonation and acyl group addition are proposed to occur on opposite 
faces of the PLP-amino acid complexes in AOS enzymes. 
 124 
 
observed ketone formation with polar or charged acyl groups, indicating that the propionyl binding 
tunnel probably only allows aliphatic substrates. A second possibility for the initial deprotonation 
step is via some base on PLP’s re face in the vicinity of thioester binding site. We could not locate 
a relevant side chain in our SxtA AONS homology model. In whatever manner the quinonoid and 
tetra-substituted intermediates are being formed, it is the reprotonation step that sets the product 
stereocenter. This could be through Lys1083, the thiol byproduct, or another undetermined proton 
source such as a conserved water molecule. 
 
 
Of the few AOS proteins that have had their amino acid substrate scopes partially probed, they 
all use L-configured substrates, or remove the equivalent pro-R proton in the case of Gly.60 Ketone 
products have also been confirmed with the L-configuration by co-crystallization inside the 
enzyme active site.35,61 However, the Mycobacterium tuberculosis BioF homolog has been 
reported to have low levels of activity of D-Ala relative to L-Ala in vitro. The final product 
configuration was not reported.62 One major challenge to enantiomeric determination is that many 
α-amino ketones are not configurationally stable in aqueous solution. Indeed, when we incubated 
our L-synthetic standard of 3.8 overnight in buffered D2O, we observed incorporation of at least 
Figure 3.13. Possibilities for deprotonating D-amino acid substrates and reprotonating 
quinonoid intermediate 3.53. 
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one deuterium atom by MS in 15% of the population, most likely a mixture of deuteration at both 
alpha carbons (more detailed discussion in Chapter 4). In order to determine the configuration of 
the ketones generated from both D- and L-Arg the enantioenrichiment, we would need to trap the 
product with chiral derivatizing agents as Ploux and coworkers did for BioF to reduce 
nonenzymatic racemization.63 An alternative would be reduction of the carbonyl to a hydroxyl 
group raise the pKa of the alpha carbons as the sphingosine pathway does.
64 The stereoselectivity 
of the SxtA AONS reaction cannot be deduced from the structure of the final pathway product, 
saxitoxin, as we now know that the steps following SxtA catalyzed by SxtG and SxtB erode the 
alpha stereocenter.65 
 
Figure 3.14. Determination of α-amino ketone configurations. 
(A) The configuration of the SxtA AONS product ketone 3.8 is not stable in buffered solution. (B) 
Chiral resolution of the BioF product ketone 3.58 by Ploux and coworkers.63 
 
 
As discussed previously, our SxtA AONS constructs are not robust enough to produce enough 
ketone product from either arginine enantiomer to analyze the chiral composition. The AONS 
homology model provides limited information, and we are pursuing a crystal structure with 
Yongtong Shero Lao in the laboratory of Prof. Janet L. Smith at the University of Michigan. 
Therefore, investigation of preparative-scale SxtA AONS-catalyzed condensation reactions from 
arginine was put on hold and we turned our attention toward a directed evolution campaign to 
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discover more active AONS variants. A more robust enzyme variant hit would produce more of 
the ketone 3.8 to show any enantioenrichment AONS-catalyzed condensation reactions. 
 
3.3 Condensation to Ketones with Other Side Chains 
In Chapter 2 and section 3.2, we demonstrated that SxtA AONS is promiscuous enough to 
accept a variety of acyl groups and thiol activators. The last possible substrate type to screen was 
amino acids, which are readily available. However, when C. raciborskii SxtA AONS was tested 
with the remaining nineteen proteinogenic L-amino acids, ornithine and the Arg mimic L-
canavanine, only canavanine showed conversion to the corresponding ethyl ketone, as detected by 
LC-MS. 
This substrate scope was disappointingly narrow but can potentially be widened through 
directed evolution. It is significantly more difficult to start a campaign to evolve for non-native 
activity when the parent has none, rather than from a low level of activity. Consequently, we 
obtained the ACP-AONS genes for the other three known cyanobacterial SxtA homologs at the 
time, Aphanizomenon gracile, Dolichospermum circinale and Microseira wollei, and expressed 
the proteins.66,67 A newly reported fifth homolog from Heteroscytonema crispum, has been 
obtained though not expressed.68 
Some differences with the C. raciborskii were immediately visible. While the C. raciborskii, 
D. circinale, and A. gracile constructs yielded about 20-30 mg of yellow ACP-AONS from 1 L 
cultures of BAP1 E. coli, about 140 mg of M. wollei very concentrated orange protein was isolated 
from the same culture size (Figure 3.15A). C. raciborskii protein was still the highest-converting 
biocatalyst in the native arginine-based reaction (Figure 3.15B), followed by D. circinale 
(DC_AONS), A. gracile (AG_AONS) and then M. wollei (MW_AONS). In reactions with ten 
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acyl-SPh thioesters, the three homologs converted the same nine substrates as CR_AONS, and one 
new acyl group, cyclohexyl. 
The three new homologs were tested for productive condensation reactions with nineteen 
proteinogenic L-amino acids and other Arg-related substrates, L-canavanine, L-citrulline, and L-
homoarginine (Figure 3.16). CR_AONS and AG_AONS were similar, only affording arginine and 
canavanine ethyl ketones. In reactions with DC_AONS and MW_AONS, we observed new peaks 
corresponding to ethyl ketones of Ala, Leu, His, Trp and MW_AONS showed additional possible 
Ser and Gly products that were not in the negative controls lacking enzyme. We did not observe 
any decarboxylation or transamination products only. The Ala, Leu and Trp products were verified 
by LC-MS and MS/MS comparison to synthetic standards prepared by myself and rotation student 
Jennie Lin. The His, Ser and Gly products have not been confirmed yet. The ketone yields were 
not quantified, but qualitatively estimated at <1% conversion. Considering the number of natural 
products and other bioactive compounds containing an indole group, we picked Trp ketone 3.69 
as our initial synthetic target for directed evolution (Figure 3.18). 
Figure 3.15. Comparison of cyanobacterial SxtA ACP-AONS homologs. 
(A) C. raciborskii (left) and M. wollei (right) protein bound to Ni-NTA resin. (B) Activity of 
ACP-AONS homologs in formation of ketone 3.8. 
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Figure 3.16. Amino acid substrate scope of SxtA ACP-AONS homologs. 
 
 
 
Figure 3.17. Acyl group substrate scope of SxtA ACP-AONS homologs. 
The A. gracile (AG) homolog was not tested. 
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Figure 3.18. Biocatalytic platform for synthesis of tryptophan ethyl ketone 3.69. 
 
 
With the highest protein yield and widest amino acid substrate scope, M. wollei ACP-AONS 
was selected as our parent biocatalyst for directed evolution with propionyl-S Ph (3.37) as the acyl 
donor. To avoid most of the lengthy protein purification process, we chose to use a crude format. 
Figure 3.19. Conversion of arginine to the native ketone product in crude formats. 
(A) With C. raciborskii, comparison of whole-cell and lysates with organic solvents in BAP1 
and BAP1 pGro7 E. coli. (B) Whole-cell activity with SxtA ACP-AONS homologs. (C) An 
SDS-PAGE gel of crude lysate and purified protein reactions shows that they contain similar 
catalyst loading (expected molecular weight: 61 kDa). 
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Before we obtained the new SxtA ACP-AONS homologs, we had compared the relative yields of 
native product ketone 3.8 for whole-cell, crude lysate, and clarified lysate reactions with 
C.raciborskii ACP-AONS (Figure 3.19A). The less processing, the more active the biocatalyst, so 
whole cells in a 96-well format were also used for M. wollei ACP-AONS. Switching from the base 
BAP1 E. coli strain to one also containing the pGro7 plasmid (Takara Biosciences) that encodes 
for GroES and GroEL chaperone proteins also increased conversion to 3.69 (Figure 3.19B). As in 
the in vitro purified protein reactions, the addition of organic co-solvents gave no advantage. 
With the target, biocatalyst, and reaction format decided, the next challenge was the high-
throughput screening of the enzymatic reactions to identify improved variants. Our normal LC-
MS method was 12 min in total, processing five samples an hour and a 96-well plate in 20 hours.  
 
Figure 3.20. Mass spectrometry analysis of the SxtA ACP-AONS random mutagenesis 
library. 
(A) Low-throughput LC-MS (sample identification and quantification by 6 min, total time with 
re-equilibration: 12 min). (B) Representative high-throughput droplet MS trace, (first droplet 
readout around 15 s). Each peak represents one droplet.69 Data courtesy of LeeAnne Wang. 
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This was far too low throughput for effective analysis, so we began a collaboration with LeeAnne 
Wang and Emory Payne of Prof. Robert Kennedy’s lab at the University of Michigan for rapid 
screening. Their droplet microfluidic MS platform up to a thousand samples69,70 an hour, a much 
higher-throughput than our TOF and Q-TOF LC-MS instruments (Figure 3.20). The Kennedy lab 
was able to optimize detection of our synthetic standard of ketone 3.69 relative to the buffer and 
other cell material. Droplet MS is less sensitive than LC-MS at detecting our product among the 
complex reaction buffer, so any potential hits must be verified by LC-MS in a secondary screen. 
In our first round of directed evolution, we employed error-prone PCR to introduce random 
mutations in the AONS domain. This generated a 1.5 kb “megaprimer” for whole-plasmid PCR 
with wild-type ACP-AONS using the MEGAWHOP71 method. After digestion of the parent 
plasmid, ligation and transformation into BAP1 pGro7 E. coli, we picked colonies for ten 96-well 
plates (Figure 3.21). Sanger sequencing of a few random clones revealed 1-3 mutations per library 
member. 
 
 
Figure 3.21. Library generation and high-throughput screening for directed evolution of 
SxtA ACP-AONS. 
This image was created on Biorender.com. 
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We conducted whole-cell reactions with the first-generation library and prepared sample plates 
for the Kennedy group for analysis. Even in the positive wild-type control wells, the desired Trp 
ketone 3.69 was difficult to detect relative to the empty plasmid negative controls, with SxtA ACP-
AONS preferring to produce its native ketone 3.8 from endogenous Arg instead. Nevertheless, we 
identified three wells with potentially slightly increased Trp ketone formation activity. Sanger 
sequencing for two of the hits showed that the mutations (F979L and I1076T using the whole 
module numbering) were located at seemingly random locations in the AONS domain, distal from 
the active site. A second-generation library from these two sequences has not been generated. 
Because the conversions from these new variants were barely more than those of the wild-type 
enzyme, we temporarily put this particular project on hold. In the meantime, Sarah Ackenhusen in 
our lab has designed a new site-saturation mutagenesis (SSM) library for the standalone AONS 
domain, targeting 96 sites near the active site. These libraries will be screened first for their ability 
to catalyze formation of tetra-substituted amino acid derivatives similar to 3.15 (see Figure 3.3). 
They can also be adapted to the Trp ketone condensation reaction with some modification. 
At the equivalent of 1% conversion (10 µM) of the synthetic ketone 3.69 standard relative to 
the reaction matrix, the signal-to-noise ratio was good, so future adjustments would begin by 
optimizing detection for even lower conversions. Adjustments to improve the low signal in the 
next rounds of screening include using nano-electrospray ionization for higher sensitivity72 or 
employing solid phase extraction (SPE) cartridges prior to the MS. SPE cleanup is faster than 
liquid chromatography separation and would remove many of the competing buffer components. 
This process is possible in-line with the MS on a system such as the Agilent RapidFire 365 in the 
University of Michigan’s Chemistry Department. 
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Figure 3.22. Homology models of M. wollei SxtA AONS. 
All AOS members have been found to be homodimers. The AONS homology model was generated 
by the Phyre2 server (based on PDB 1DJ9, 27% identity with SxtA AONS).29 ACPs tend to be 
very flexible and were not modeled. (A) Close-up of the AONS active site, which lies near the 
boundary of the two monomers. The lysine-bound PLP cofactor of the teal monomer is shown in 
gray; the second monomer is in green. The two mutated residues found thus far are highlighted as 
magenta spheres. (B) The 96 residues within 12 Å of the active site chosen for site-saturation 
mutagenesis are shown as teal spheres. Image by Sarah Ackenhusen. 
 
 
Due to the small volumes of droplet microfluidics (e.g. 45 nL per droplet vs. 0.5 µL for LC-
MS after a 100x dilution from a 250 µL whole-cell reaction), our enzymatic reactions can similarly 
be miniaturized further. With recent advances in reagent addition techniques and other reaction 
methods73 at droplet scales, it may be possible to run the whole-cell reactions in droplets as well. 
Using pantetheine thioester 3.38 becomes more economically feasible at a smaller scale, only 
requiring a few microliters of the acyl donor for the entire experiment instead of microliters per 
well. Additionally, removing the ACP domain decreases the protein weight by 10 kDa and we 
would no longer need to ensure post-translational modification (e.g., the Ppant cofactor), further 
decreasing the cost per reaction. 
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3.4 Conclusions 
As the AONS domain of SxtA domain modifies α-amino acids to α-amino ketones in a single 
protecting group-free step, we saw the potential for this enzyme to serve as a general amino acid-
modifying biocatalyst. This chapter summarizes our efforts to chemoenzymatically synthesize α-
amino ketones, catalyzed by standalone SxtA AONS or AONS with its associated ACP domain 
functioning in tandem as a didomain. 
After extensive screening of the acyl group and activating thiol substrate scope SxtA AONS, 
we optimized the reaction conditions using the ACP-AONS didomain and inexpensive thioester 
donors to generate the active acyl-ACP species in situ. We intended to run preparative-scale 
experiments that synthesize larger amounts of non-native arginine ketone products, which could 
potentially serve as precursors for new saxitoxin derivatives. The native reaction to produce the 
native ketone 3.8 had low conversion, and the generation of non-native ketones was even lower. 
When we later observed that the D-enantiomer of the AONS substrate L-Arg was unexpectedly 
also converted to arginine ethyl ketone, we considered utilizing the same platform to study the 
stereoselectivity of SxtA AONS-catalyzed condensation. The developed our biocatalytic platform 
lowers the cost of these chemoenzymatic α-amino ketone-forming reactions, and efforts are current 
aimed at improving the activity of SxtA AONS activity. 
Furthermore, we screened the amino acid substrate scopes of our original SxtA ACP-AONS 
homolog from C. raciborskii and three other cyanobacterial homologs. M. wollei ACP-AONS 
demonstrated that it was likely also synthesizing ethyl ketones with seven other side chains in 
addition to its native L-arginine substrate. In collaboration with the Kennedy group, we 
commenced a directed evolution campaign to evolve variants that are more active toward one non-
native substrate, L-tryptophan. Two potential variants have been identified in the first generation 
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after random mutagenesis and high-throughput droplet MS screening. An SSM library of SxtA 
AONS instead. 
In our optimized reaction conditions, we fulfilled our original goal of using ACPs at a catalytic 
concentration. However, the main barrier to using AOS enzymes as α-amino ketone-forming 
biocatalysts in this chapter were the limited turnovers of our chosen PE, SxtA AONS. In future 
efforts, we will investigate the potential causes of the AONS’ degrading activity in order to focus 
directed evolution campaigns on improving overall enzyme stability and robustness first, before 
expanding the substrate scopes further. 
As holo-ACPs are still expensive to produce, either using the slower-growing BAP1 strain for 
endogenous post-translational modification or enzymatic modification in vitro with CoASH, we 
also have the opportunity to engineer SxtA AONS to be more active with acyl substrates free in 
solution. Thioester sources such as thiophenols would be much more cost-effective. These projects 
will be further investigated by other lab members. We anticipate that with more engineering, SxtA 
AONS will be a useful tool for the enzymatic transformation of any combination of α-amino acid 
and thioester to α-amino ketones.  
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3.5 Experimental 
I. Chemical synthesis 
A. General information 
All reagents were used as received unless otherwise noted. Reactions were carried out under a 
nitrogen atmosphere using standard Schlenck techniques unless otherwise noted. Solvents were 
degassed and dried over aluminum columns on an MBraun solvent system (Inert Corporation, 
Model PS-00-3). Trifluoroacetic acid was distilled prior to use. Reactions were monitored by thin 
layer chromatography using Machery-Nagel 60 F254 precoated silica TLC plates (0.25 mm) or 
Merck Silica Gel 60 RP-18 WF-254S precoated silica TLC plates (0.25 mm) which were 
visualized using UV, ninhydrin, p-anisaldehyde, CAM, DNP, or bromocresol green stain. Flash 
column chromatography was performed using Machery-Nagel 60 μm (230-400 mesh) silica gel. 
All compounds purified by column chromatography were sufficiently pure for use in further 
experiments unless otherwise indicated. 1H and 13C NMR spectra were obtained in CDCl3 or 
CD3OD at rt (25 C), unless otherwise noted, on Varian 400 MHz, Varian 500 MHz or Varian 600 
MHz spectrometers. Chemical shifts of 1H NMR spectra were recorded in parts per million (ppm) 
on the δ scale. High resolution electrospray mass spectra were obtained on an Agilent G6545A 
quadrupole-time of flight mass spectrometer in positive mode with an Agilent 1290 UPLC system. 
Solvent A = water with 0.1% formic acid. Solvent B = 95% acetonitrile, 5% water and 0.1% formic 
acid. IR spectra were recorded on a Perkin-Elmer Spectrum BX FT-IR spectrometer. Optical 
rotations were measured at rt in CH3OH, unless otherwise noted, on a Jasco P-2000 polarimeter. 
 
The synthesis and characterization of the arginine ketone standards was done by Dr. Meagan 
Hinze. Leucine and alanine ketones were prepared by Jennie Lin.  
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B. Compound synthesis 
 
Tri-Boc-protected arginine Weinreb amide (3.S1) and arginine ethyl ketone (3.8) were synthesized 
according to the procedure described by Tsuchiya et al.25 
 
 
Tri-Boc-protected arginine methyl ketone (3.S2): 
To a solution of tri-Boc-protected arginine Weinreb amide (3.S1, 72.0 mg, 0.139 mmol, 1.0 equiv) 
dissolved in THF (6.9 mL) was added a 1 M solution of zinc chloride in diethyl ether (13.9 μL, 
0.013 mmol, 0.1 equiv) at 0 °C. After five min, a 3 M solution of methyl magnesium bromide in 
diethyl ether (695 μL, 2.09 mmol, 15.0 equiv) was added at 0 °C. The reaction was allowed to 
warm to room temperature and stirred for 14 h. The reaction was poured into 21 mL of 0.1 M HCl. 
The acidified aqueous phase was extracted with EtOAc (3x). The organic layers were combined, 
washed with brine, dried over Na2SO4, filtered, and evaporated under reduced pressure to afford 
an oil. The crude residue was purified by flash column chromatography (2:1 hexanes/EtOAc v/v) 
to afford 28.5 mg of the title compound (43% yield) as a white foam. Rf = 0.52 (2:1 hexanes/EtOAc 
v/v); 1H NMR (300 MHz, CDCl3) δ 11.46 (s, 1H), 8.33 (t, J = 5.4, 1H), 5.36 (d, J = 7.6, 1H), 4.35-
4.28 (m, 1H), 3.42 (q, J = 6.5, 2H), 2.20 (s, 3H), 1.95-1.85 (m, 1H), 1.66-1.52 (m, 3H), 1.48 (s, 
9H), 1.47 (2, 9H), 1.42 (s, 9H); 13C NMR (150 MHz, CDCl3) δ 207.1, 163.6, 156.4, 155.6, 153.4, 
83.3, 79.9, 79.4, 59.7, 40.3, 28.5, 28.4, 28.2, 27.1, 25.2; IR (thin film, cm-1) 3329, 2978, 1715, 
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1614, 1498, 1414; HRMS (ESI) m/z calculated for C22H41N4O7
+ [M+H]+ 473.2970, found 
473.2977. 
 
 
(S)-1-(4-amino-5-oxohexyl)guanidine (3.9): 
To a solution of tri-Boc protected arginine methyl ketone (3.S2, 28.5 mg, 0.060 mmol, 1.0 equiv) 
dissolved in DCM (1.4 mL) was added trifluoroacetic acid (TFA, 1.4 mL) at rt. The reaction was 
stirred for 3 h. After addition of toluene (2.0 mL), the solution was evaporated under reduced 
pressure to afford 24.0 mg of the title compound as a bis-TFA salt with minor impurities (99% 
yield) as a brown foam. Rf = 0.10 (RP18 TLC, 2:1 MeCN/H2O v/v); [𝛼]𝐷
24 = 0.310 (c = 0.014 g/mL, 
MeOH); 1H NMR (600 MHz, CD3OD) δ 4.22-4.17 (m, 1H), 3.24 t, J = 6.3, 2H), 2.28 (s, 3H), 2.08 
(t, J = 13.0, 1H), 1.91-1.81 (m, 1H), 1.76-1.67 (m, 1H), 1.67-1.57 (m, 1H); 13C NMR (150 MHz, 
CD3OD) δ 204.2, 158.7, 60.0, 41.7, 27.5, 26.4, 25.2; IR (thin film, cm-1) 3363, 3187, 1670, 1199, 
1133; HRMS (ESI) m/z calculated for C7H17N4O
+ [M+H]+ 173.1397, found 173.1398. 
 
 
Tri-Boc protected arginine propyl ketone (3.S3): 
To a solution of tri-Boc-protected arginine Weinreb amide (3.S1, 50.0 mg, 0.0966 mmol, 1.0 
equiv) dissolved in THF (4.8 mL) was added a 2 M solution of propyl magnesium chloride in 
diethyl ether (725 μL, 1.45 mmol, 15.0 equiv) at 0 °C. The reaction was allowed to warm to rt and 
stirred for 3.25 h. The reaction was poured into 15 mL of 0.1 M HCl. The acidified aqueous phase 
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was extracted with EtOAc (3x). The organic layers were combined, washed with brine, dried over 
Na2SO4, filtered, and evaporated under reduced pressure to afford an oil. The crude residue was 
purified by flash column chromatography (4:1 hexanes/EtOAc v/v) to afford 30.0 mg of the title 
compound (62% yield) as a colorless oil. Rf = 0.52 (2:1 hexanes/EtOAc v/v); 1H NMR (600 MHz, 
CDCl3) δ 11.47 (s, 1H), 8.32 (d, J = 5.6, 1H), 5.34 (d, J = 7.8, 1H), 4.31 (dt, J = 11.7, 5.5, 1H), 
3.41 (qd, J = 7.1, 3.0, 2H), 2.46 (q, J = 6.8, 6.4, 2H), 1.89 (d, J =15.8, 1H), 1.61 (h, J =7.2, 3H), 
1.57-1.50 (m, 2H), 1.48 (s, 9H), 1.48 (s, 9H), 1.42 (s, 9H), 0.90 (t, J = 7.4, 3H); 13C NMR (150 
MHz, CDCl3) δ 209.3, 163.7, 156.3, 155.6, 153.4, 83.3, 79.9, 79.4, 59.0, 41.7, 40.4, 28.8, 28.5, 
28.4, 28.2, 25.1, 17.1, 13.9; IR (thin film, cm-1) 3331, 2976, 2933, 1714, 1637, 1614, 1573, 1454, 
1413; HRMS (ESI) m/z calculated for C24H45N4O7
+ [M+H]+ 501.3283, found 501.3290. 
 
 
(S)-1-(4-amino-5-oxooctyl)guanidine (3.42a): 
To a solution of tri-Boc protected arginine propyl ketone (3.S3, 26.3 mg, 0.0525 mmol, 1.0 equiv) 
dissolved in DCM (1.2 mL) was added trifluoroacetic acid (TFA, 1.2 mL) at rt. The reaction was 
stirred for 4.3 h. After addition of toluene (2.0 mL), the solution was evaporated under reduced 
pressure to afford 20.9 mg of the title compound as a bis-TFA salt with minor impurities (93% 
yield) as a colorless oil. Rf = 0.23 (RP18 TLC, 3:1 0.1% formic acid in H2O/MeOH v/v); 1H NMR 
(600 MHz, CD3OD) δ 4.18 (dd, J = 7.8, 4.2, 1H), 3.25 (td, J = 6.9, 3.0, 2H), 2.67-2.54 (m, 2H), 
2.11-2.04 (m, 1H), 1.86 (dddd, J = 14.6, 12.1, 7.7, 4.6, 1H), 1.77-1.69 (m, 1H), 1.69-1.60 (m, 3H), 
0.96 (t, J = 7.4, 3H); 13C NMR (150 MHz, CD3OD)* δ 206.6, 158.8, 59.5, 41.7, 27.8, 25.3, 17.7, 
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13.8; IR (thin film, cm-1) 3355, 3177, 2938, 1669, 1558, 1539; HRMS (ESI) m/z calculated for 
C9H21N4O
+ [M+H]+ 201.1710, found 201.1712. 
* The respective 13C signals of C-1 and C-6 coalesce as verified by HSQC. 
 
 
Tri-Boc protected arginine pentyl ketone (3.S4): 
To a solution of tri-Boc-protected arginine Weinreb amide (3.S1, 50.0 mg, 0.0966 mmol, 1.0 
equiv) dissolved in THF (4.8 mL) was added a 2 M solution of pentyl magnesium bromide in 
diethyl ether (725 μL, 1.45 mmol, 15.0 equiv) at 0 °C. The reaction was allowed to warm to rt and 
stirred for 14.2 h. The reaction was poured into 15 mL of 0.1 M HCl. The acidified aqueous phase 
was extracted with EtOAc (3x). The organic layers were combined, washed with brine, dried over 
Na2SO4, filtered, and evaporated under reduced pressure to afford an oil. The crude residue was 
purified by flash column chromatography (4:1 hexanes/EtOAc v/v) to afford 8.0 mg of the title 
compound (16% yield) as a colorless oil. Rf = 0.60 (2:1 hexanes/EtOAc v/v); 1H NMR (400 MHz, 
CDCl3) δ 11.48 (s, 1H), 8.33 (t, J = 5.0, 1H), 5.34 (d, J = 8.1, 1H), 4.32 (s, 1H), 3.42 (dd, J = 9.8, 
4.5, 2H), 2.48 (td, J = 7.3, 2.6, 2H), 1.89 (br s, 1H), 1.62-1.56 (m, 3H), 1.50 (s, 9H), 1.49 (s, 9H), 
1.44 (s, 9H), 1.36-1.22 (m, 6H), 0.88 (t, J = 7.0, 3H); 13C NMR (100 MHz, CDCl3) δ 209.4, 163.7, 
156.4, 155.6, 153.5, 83.3, 79.9, 79.4, 59.0, 40.4, 39.8, 31.5, 28.9, 28.5, 28.4, 28.2, 25.1, 23.4, 22.6, 
14.0; IR (thin film, cm-1) 3331, 2977, 2931, 1717, 1639, 1616, 1573, 1455, 1414; HRMS (ESI) 
m/z calculated for C26H49N4O7
+ [M+H]+ 529.3596, found 529.3602. 
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(S)-1-(4-amino-5-oxodecyl)guanidine (3.42b): 
To a solution of tri-Boc protected arginine pentyl ketone (3.S4, 7.5 mg, 0.014 mmol, 1.0 equiv) 
dissolved in DCM (0.4 mL) was added trifluoroacetic acid (TFA, 0.4 mL) at rt. The reaction was 
stirred for 4.6 h. After addition of toluene (2.0 mL), the solution was evaporated under reduced 
pressure to afford 3.9 mg of the title compound as a bis-TFA salt with minor impurities (60% 
yield) as a colorless oil. Rf = 0.15 (RP18 TLC, 3:1 0.1% formic acid in H2O/MeOH v/v); 1H NMR 
(600 MHz, CD3OD) δ 4.17 (dd, J = 7.7, 4.2, 1H), 3.24 (td, J = 6.9, 3.2, 2H), 2.61 (qt, J = 17.8, 7.3, 
2H), 2.10-2.02 (m, 1H), 1.85 (dddd, J = 14.7, 12.2, 7.7, 4.7, 1H), 1.75-1.67 (m, 1H), 1.65-1.57 (m, 
3H), 1.37-1.31 (m, 4H), 0.91 (t, J = 7.1, 3H); 13C NMR (150 MHz, CDCl3) δ 205.3, 157.3, 58.1, 
40.3, 38.4, 30.9, 26.4, 23.9, 22.5, 22.1, 12.8; IR (thin film, cm-1) 3171, 2932, 2874, 1670, 
1533,1432; HRMS (ESI) m/z calculated for C11H25N4O
+ [M+H]+ 229.2023, found 229.2025. 
 
 
Tri-Boc protected arginine heptyl ketone (3.S5): 
A solution of heptyl magnesium bromide was prepared by the following procedure. To a 
suspension of magnesium turnings (148 mg, 6.11 mmol, 1.2 equiv) and iodine (1.0 mg, 0.0078 
mmol, 0.001 equiv) in diethyl ether (4.0 mL) was added 1-bromoheptane in 100-200 μL portions 
over 45 min at rt until all 1-bromoheptane (800 μL, 5.09 mmol, 1.0 equiv) had been added. After 
3.75 h, the solution was transferred via cannula to a Schlenk flask and determined to be 
approximately 0.5 M by colorimetric titration using the method described by Paquette et al.74 
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To a solution of tri-Boc-protected arginine Weinreb amide (3.S1, 50.0 mg, 0.0966 mmol, 1.0 
equiv) dissolved in THF (4.8 mL) was added a 0.5 M solution of heptyl magnesium bromide in 
diethyl ether (2.90 mL, 1.45 mmol, 15.0 equiv) at 0 °C. The ice bath was removed after 10 min, 
and the reaction flask allowed to warm to rt and stirred for 12.4 h. The reaction was poured into 
15 mL of 0.1 M HCl. The acidified aqueous phase was extracted with EtOAc (3x). The organic 
layers were combined, washed with brine, dried over Na2SO4, filtered, and evaporated under 
reduced pressure to afford an oil. The crude residue was purified by flash column chromatography 
and required two purifications under different conditions (4:1 hexanes/EtOAc and 95:5 DCM/ether 
v/v) to afford 11.3 mg of the title compound (21% yield) as a colorless oil. Rf = 0.58 (2:1 
hexanes/EtOAc v/v), Rf = 0.65 (9:1 DCM/ether v/v); 1H NMR (500 MHz, CDCl3) δ 11.48 (s, 1H), 
8.33 (t, J = 5.3, 1H), 5.34 (d, J = 7.8, 1H), 4.32 (dt, J = 11.6, 5.6, 1H), 3.42 (dh, J = 13.3, 7.2, 2H), 
2.48 (td, J = 7.4, 3.1, 2H), 1.94-1.83 (m, 1H), 1.66-1.51 (m, 5H), 1.49 (s, 9H), 1.48 (s, 9H), 1.43 
(s, 9H), 1.32-1.23 (m, 8H), 0.87 (t, J = 6.7, 3H); 13C NMR (125 MHz, CDCl3) δ 209.4, 163.7, 
156.3, 155.6, 153.4, 83.3, 79.9, 79.4, 59.0, 40.4, 39.9, 31.8, 29.3, 29.2, 28.9, 28.5, 28.4, 28.2, 25.1, 
23.7, 22.7, 14.2; IR (thin film, cm-1) 3333, 2977, 2929, 2856, 1717, 1639, 1616, 1573, 1502, 1454, 
1415; HRMS (ESI) m/z calculated for C28H53N4O7
+ [M+H]+ 557.3909, found 557.3907. 
 
 
(S)-1-(4-amino-5-oxododecyl)guanidine (3.42c): 
To a solution of tri-Boc protected arginine heptyl ketone (3.S5, 11.3 mg, 0.0202 mmol, 1.0 equiv) 
dissolved in DCM (0.5 mL) was added trifluoroacetic acid (TFA, 0.5 mL) at rt. The reaction was 
stirred for 3.2 h. After addition of dichloromethane (2.0 mL), the solution was evaporated under 
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reduced pressure to afford 9.8 mg of the title compound as a bis-TFA salt (quant) as a colorless 
oil. Rf = 0.15 (RP18 TLC, 3:1 0.1% formic acid in H2O/MeOH v/v); 1H NMR (500 MHz, CD3OD) 
δ 4.19 (dd, J = 7.7, 4.2, 1H), 3.24 (td, J = 6.9, 1.8, 2H), 2.71-2.54 (m, 2H), 2.07 (ddt, J = 14.4, 
11.8, 4.6, 1H), 1.90-1.81 (m, 1H), 1.72 (tq, J = 12.2, 6.6, 1H), 1.68-1.56 (m, 3H), 1.36-1.28 (m, 
8H), 0.90 (t, J = 6.7, 3H); 13C NMR (125 MHz, CD3OD) δ 206.8, 158.8, 59.5, 41.7, 39.9, 32.9, 
30.2, 30.1, 27.9, 25.3, 24.3, 23.7, 14.4; IR (thin film, cm-1) 3353, 3179, 2956, 2929, 2858, 1670, 
1533, 1456, 1433; HRMS (ESI) m/z calculated for C13H29N4O
+ [M+H]+ 257.2336, found 
257.2338. 
 
 
Tri-Boc protected arginine isopropyl ketone (3.S6): 
To a solution of tri-Boc-protected arginine Weinreb amide (3.S1, 50.0 mg, 0.0966 mmol, 1.0 
equiv) dissolved in THF (1.9 mL) was added a 2 M solution of isopropyl magnesium chloride in 
tetrahydrofuran (725 μL, 1.45 mmol, 15.0 equiv) at 0 °C. The reaction was heated at 45 °C and 
stirred for 3 h. The reaction was poured into 15 mL of 0.1 M HCl. The acidified aqueous phase 
was extracted with EtOAc (3x). The organic layers were combined, washed with brine, dried over 
Na2SO4, filtered, and evaporated under reduced pressure to afford an oil. The crude residue was 
purified by flash column chromatography (4:1 hexanes/EtOAc v/v) to afford 6.1 mg of the title 
compound (13% yield) as a colorless oil. Rf = 0.61 (2:1 hexanes/EtOAc v/v); 1H NMR (600 MHz, 
CDCl3) δ 11.47 (s, 1H), 8.33 (t, J = 5.5, 1H), 5.33-5.28 (m, 1H), 4.50 (t, J = 6.7, 1H), 3.42 (q, J = 
6.5, 2H), 2.82 (p, J = 6.8, 1H), 1.92-1.85 (m, 1H), 1.59-1.50 (m, 3H), 1.49 (s, 9H), 1.49 (s, 9H), 
1.44 (s, 9H), 1.13 (d, J = 7.0, 3H), 1.09 (d, J = 6.7, 3H); 13C NMR (150 MHz, CDCl3) δ 213.0, 
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163.7, 156.4, 155.5, 153.5, 83.3, 79.9, 79.4, 57.4, 40.5, 37.7, 29.0, 28.5, 28.4, 28.2, 25.2, 19.2, 
17.9; IR (thin film, cm-1) 3331, 2976, 2932, 1718, 1640, 1617, 1415; HRMS (ESI) m/z calculated 
for C24H45N4O7
+ [M+H]+ 501.3283, found 501.3285. 
 
 
(S)-1-(4-amino-6-methyl-5-oxoheptyl)guanidine (3.42d): 
To a solution of tri-Boc protected arginine isopropyl ketone (3.S6, 6.1 mg, 0.012 mmol, 1.0 equiv) 
dissolved in DCM (0.4 mL) was added trifluoroacetic acid (TFA, 0.4 mL) at rt. The reaction was 
stirred for 5.3 h. After addition of dichloromethane (2.0 mL), the solution was evaporated under 
reduced pressure to afford 4.3 mg of the title compound as a bis-TFA salt with minor impurities 
(83% yield) as a colorless oil. Rf = 0.20 (RP18 TLC, 3:1 0.1% formic acid in H2O/MeOH v/v); 1H 
NMR (600 MHz, CD3OD) δ 4.37 (dd, J = 7.8, 4.0, 1H), 3.25 (dq, J = 12.2, 6.8, 2H), 2.96 (h, J = 
6.8, 1H), 2.07 (ddt, J = 14.5, 12.1, 4.5, 1H), 1.85 (dddd, J = 14.6, 12.1, 7.8, 4.6, 1H), 1.77-1.69 
(m, 1H), 1.66-1.58 (m, 1H), 1.18 (d, J = 7.0, 3H), 1.13 (d, J = 6.6, 3H); 13C NMR (150 MHz, 
CD3OD) δ 210.6, 158.8, 58.0, 41.7, 38.3, 27.9, 25.4, 19.5, 17.6; IR (thin film, cm-1) 3350, 3178, 
2978, 1671; HRMS (ESI) m/z calculated for C9H21N4O
+ [M+H]+ 201.1710, found 201.1711. 
 
 
Tri-Boc protected arginine isobutyl ketone (3.S7): 
To a solution of tri-Boc-protected arginine Weinreb amide (3.S1, 50.0 mg, 0.0966 mmol, 1.0 
equiv) dissolved in THF (1.9 mL) was added a 2 M solution of isobutyl magnesium bromide in 
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diethyl ether (725 μL, 1.45 mmol, 15.0 equiv) at 0 °C. The reaction was heated at 45 °C and stirred 
for 3.75 h. The reaction was poured into 15 mL of 0.1 M HCl. The acidified aqueous phase was 
extracted with EtOAc (3x). The organic layers were combined, washed with brine, dried over 
Na2SO4, filtered, and evaporated under reduced pressure to afford an oil. The crude residue was 
purified by flash column chromatography (4:1 hexanes/EtOAc v/v) to afford 10.0 mg of the title 
compound with minor impurities (20% yield) as a colorless oil. Rf = 0.56 (2:1 hexanes/EtOAc 
v/v); 1H NMR (600 MHz, CDCl3) δ 11.47 (s, 1H), 8.33 (d, J = 5.9, 1H), 5.31 (d, J = 8.1, 1H), 4.29 
(dd, J = 11.9, 5.6, 1H), 3.42 (dq, J = 12.2, 6.8, 5.6, 2H), 2.37 (t, J = 6.7, 2H), 2.17 (dp, J = 14.0, 
6.9, 1H), 1.93-1.85 (m, 1H), 1.60 (dd, J = 11.6, 5.9, 1H), 1.58-1.50 (m, 2H), 1.49 (s, 9H), 1.49 (s, 
9H), 1.43 (s, 9H), 0.92 (d, J = 6.8, 3H), 0.91 (d, J = 6.9, 3H); 13C NMR (150 MHz, CDCl3) δ 
208.9, 163.7, 156.4, 155.6, 153.5, 83.3, 79.7, 79.4, 59.2, 48.8, 40.4, 28.7, 28.5, 28.4, 28.2, 25.1, 
24.5, 22.8, 22.7; IR (thin film, cm-1) 3333, 2957, 2930, 2870, 1717, 1639, 1615, 1574, 1414; 
HRMS (ESI) m/z calculated for C25H47N4O7
+ [M+H]+ 515.3439, found 515.3434. 
 
 
(S)-1-(4-amino-7-methyl-5-oxooctyl)guanidine (3.42e): 
To a solution of tri-Boc protected arginine isobutyl ketone (3.S7, 10.0 mg, 0.0194 mmol, 1.0 equiv) 
dissolved in DCM (0.5 mL) was added trifluoroacetic acid (TFA, 0.5 mL) at rt. The reaction was 
stirred for 3.3 h. After addition of dichloromethane (2.0 mL), the solution was evaporated under 
reduced pressure to afford 8.3 mg of the title compound as a bis-TFA salt with minor impurities 
(96% yield) as a colorless oil. Rf = 0.17 (RP18 TLC, 3:1 0.1% formic acid in H2O/MeOH v/v); 1H 
NMR (600 MHz, CD3OD) δ 4.15 (dd, J = 7.8, 4.1, 1H), 3.25 (td, J = 6.9, 4.4, 2H), 2.52 (d, J = 
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6.8, 2H), 2.19 (dp, J = 13.5, 6.7, 1H), 2.07 (ddt, J = 14.5, 12.1, 4.5, 1H), 1.85 (dddd, J = 14.6, 12.1, 
7.8, 4.6, 1H), 1.77-1.67 (m, 1H), 1.67-1.58 (m, 1H), 0.97 (t, J = 6.4, 6H); 13C NMR (150 MHz, 
CD3OD)* δ 206.3, 158.8, 59.8, 48.5, 41.7, 27.8, 25.0, 24.9, 22.7; IR (thin film, cm-1) 3352, 3176, 
2963, 2878, 1671, 1537, 1432; HRMS (ESI) m/z calculated for C10H23N4O
+ [M+H]+ 215.1866, 
found 215.1867.  
*C2 and C7 were coalesced in 13CNMR, as verified by HSQC. C6 was coalesced with the methanol 
signal in 13CNMR and differentiated by HSQC. 
 
 
Tri-Boc protected arginine phenyl ketone (3.S8): 
To a solution of tri-Boc-protected arginine Weinreb amide (3.S1, 50.0 mg, 0.0966 mmol, 1.0 
equiv) dissolved in THF (4.8 mL) was added a 3 M solution of phenyl magnesium bromide in 
diethyl ether (483 μL, 1.45 mmol, 15.0 equiv) at 0 °C. The reaction was allowed to warm to rt and 
stirred for 3.75 h. The reaction was poured into 15 mL of 0.1 M HCl. The acidified aqueous phase 
was extracted with EtOAc (3x). The organic layers were combined, washed with brine, dried over 
Na2SO4, filtered, and evaporated under reduced pressure to afford an oil. The crude residue was 
purified by flash column chromatography (4:1 hexanes/EtOAc v/v) to afford 39.9 mg of the title 
compound (77% yield) as a yellow oil. Rf = 0.54 (2:1 hexanes/EtOAc v/v); 1H NMR (600 MHz, 
CDCl3) δ 11.44 (s, 1H), 8.26 (t, J = 5.2, 1H), 7.95 (d, J = 7.7, 2H), 7.58 (t, J = 7.4, 1H), 7.47 (t, J 
= 7.7, 2H), 5.54 (d, J = 8.2, 1H), 5.30 (td, J = 7.6, 4.1, 1H), 3.38 (q, J = 6.7, 2H), 1.94 (dd, J = 8.2, 
4.7, 1H), 1.72-1.61 (m, 1H), 1.61-1.53 (m, 2H), 1.47 (s, 9H), 1.46 (s, 9H), 1.44 (s, 9H); 13C NMR 
(150 MHz, CDCl3) δ 199.0, 163.7, 156.2, 155.6, 153.3, 134.6, 133.9, 129.0, 128.7, 83.2, 80.0, 
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79.4, 54.8, 40.4, 30.8, 28.5, 28.4, 28.2, 24.9; IR (thin film, cm-1) 3331, 2977, 2932, 1717, 1684, 
1637, 1615, 1578, 1415; HRMS (ESI) m/z calculated for C27H43N4O7
+ [M+H]+ 535.3126, found 
535.3134. 
 
 
(S)-1-(4-amino-5-oxo-5-phenylpentyl)guanidine (3.42f): 
To a solution of tri-Boc protected arginine phenyl ketone (3.S8, 39.9 mg, 0.0746 mmol, 1.0 equiv) 
dissolved in DCM (1.8 mL) was added trifluoroacetic acid (TFA, 1.8 mL) at rt. The reaction was 
stirred for 4.3 h. After addition of dichloromethane (2.0 mL), the solution was evaporated under 
reduced pressure to afford 34.5 mg of the title compound as a bis-TFA salt with minor impurities 
(quant) as a colorless oil. Rf = 0.19 (RP18 TLC, 3:1 0.1% formic acid in H2O/MeOH v/v); 1H NMR 
(600 MHz, CD3OD) δ 8.07-8.02 (m, 2H), 7.75-7.69 (m, 1H), 7.62-7.56 (m, 2H), 5.18 (dd, J = 7.7, 
4.5, 1H), 3.17 (dp, J = 13.7, 6.9, 2H), 2.11-2.03 (m, 1H), 1.92 (dddd, J = 14.6, 12.1, 7.7, 4.7, 1H), 
1.81-1.70 (m, 1H), 1.68-1.57 (m, 1H); 13C NMR (150 MHz, CDCl3) δ 196.8, 158.7, 135.9, 134.7, 
130.4, 129.9, 56.2, 41.6, 29.6, 25.2; IR (thin film, cm-1) 3359, 3180, 2931, 1671, 1529, 1451, 1432; 
HRMS (ESI) m/z calculated for C12H19N4O
+ [M+H]+ 235.1553, found 235.1555. 
 
 
Tri-Boc protected arginine cyclopentyl ketone (3.S9): 
To a solution of tri-Boc-protected arginine Weinreb amide (3.S1, 50.0 mg, 0.0966 mmol, 1.0 
equiv) dissolved in THF (1.9 mL) was added a 2 M solution of cyclopentyl magnesium bromide 
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in diethyl ether (725 μL, 1.45 mmol, 15.0 equiv) at 0 °C. The reaction was heated at 45 °C and 
stirred for 2.5 h. The reaction was poured into 15 mL of 0.1 M HCl. The acidified aqueous phase 
was extracted with EtOAc (3x). The organic layers were combined, washed with brine, dried over 
Na2SO4, filtered, and evaporated under reduced pressure to afford an oil. The crude residue was 
purified by flash column chromatography (4:1 hexanes/EtOAc v/v) to afford 13.0 mg of the title 
compound (26% yield) as a colorless oil. Rf = 0.58 (2:1 hexanes/EtOAc v/v); 1H NMR (600 MHz, 
CDCl3) δ 11.47 (s, 1H), 8.32 (t, J = 5.5, 1H), 5.32 (d, J = 8.0, 1H), 4.43 (d, J = 7.3, 1H), 3.42 (td, 
J = 6.9, 5.3, 2H), 3.02 (p, J = 7.9, 1H), 1.95-1.88 (m, 2H), 1.84-1.71 (m, 3H), 1.71-1.60 (m, 4H), 
1.60-1.55 (m, 3H), 1.49 (s, 9H), 1.48 (s, 9H), 1.43 (s, 9H); 13C NMR (150 MHz, CDCl3) δ 212.1, 
163.7, 156.4, 155.5, 153.5, 83.3, 79.8, 79.4, 58.6, 48.3, 40.5, 30.7, 28.9, 28.9, 28.5, 28.4, 28.2, 
26.3, 26.3, 25.1; IR (thin film, cm-1) 3332, 2976, 2869, 1717, 1639, 1616, 1574, 1415; HRMS 
(ESI) m/z calculated for C26H47N4O7
+ [M+H]+ 527.3439, found 527.3443. 
 
 
(S)-1-(4-amino-5-cyclopentyl-5-oxopentyl)guanidine (3.42g): 
To a solution of tri-Boc protected arginine cyclopentyl ketone (3.S9, 13.0 mg, 0.0247 mmol, 1.0 
equiv) dissolved in DCM (0.7 mL) was added trifluoroacetic acid (TFA, 0.7 mL) at rt. The reaction 
was stirred for 4.3 h. After addition of dichloromethane (2.0 mL), the solution was evaporated 
under reduced pressure to afford 10.3 mg of the title compound as a bis-TFA salt with minor 
impurities (92% yield) as a colorless oil. Rf = 0.27 (RP18 TLC, 3:1 0.1% formic acid in H2O/MeOH 
v/v); 1H NMR (600 MHz, CD3OD) δ 4.29 (dd, J = 7.8, 4.1, 1H), 3.25 (td, J = 6.9, 5.5, 2H), 3.22-
3.17 (m, 1H), 2.13-2.02 (m, 2H), 1.90-1.80 (m, 3H), 1.76-1.69 (m, 3H), 1.68-1.61 (m, 4H); 13C 
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NMR (150 MHz, CD3OD)* δ 209.7, 158.8, 59.2, 48.2, 41.7, 31.9, 29.4, 27.7, 27.1, 27.1, 25.4; IR 
(thin film, cm-1) 3367, 3180, 2958, 2874, 1671; HRMS (ESI) m/z calculated for C11H23N4O
+ 
[M+H]+ 227.1866, found 227.1868. 
* The 13C signal of C-6 coalesced with methanol, as elucidated by HSQC. 
 
 
S-phenyl propanecarbothioate (3.37): 
To a suspension of anhydrous K2CO3 (502 mg, 3.63 mmol, 2.0 equiv) in dry EtOAc (9 mL) were 
added propionic anhydride (256 µL, 2.00 mmol, 1.1 equiv) and thiophenol (186 µL, 1.82 mmol, 
1.0 equiv). The reaction mixture stirred under N2 for 16 h. The reaction was quenched with 10 mL 
of water and extracted with EtOAc (3 x 10 mL). The combined organic layers were dried over 
Na2SO4, filtered and concentrated, affording 298 mg (99% yield) of the title compound as a clear 
colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.46 – 7.36 (m, 5H), 2.69 (q, J = 7.5 Hz, 2H), 1.23 (t, 
J = 7.5 Hz, 3H). All spectra obtained were consistent with literature values.75 
 
 
S-phenyl ethanecarbothioate (3.S10): 
To a suspension of anhydrous K2CO3 (500 mg, 3.6 mmol, 2.0 equiv) in dry EtOAc (9 mL) were 
added acetic anhydride (189 µL, 2.0 mmol, 1.1 equiv) and thiophenol (186 µL, 1.8 mmol, 1.0 
equiv). The reaction mixture stirred under N2 for 16 h. The reaction was quenched with 10 mL of 
water and extracted with EtOAc (3 x 10 mL). The combined organic layers were dried over 
Na2SO4, filtered and concentrated, affording 270 mg (98% yield) of the title compound as a clear 
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colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.42 (d, J = 0.8 Hz, 5H), 2.43 (d, J = 0.8 Hz, 3H). All 
spectra obtained were consistent with literature values.75 
 
 
S-phenyl butanecarbothioate (3.S11): 
To a suspension of anhydrous K2CO3 (155 mg, 1.12 mmol, 2.0 equiv) in dry EtOAc (5 mL) were 
added butyric anhydride (100 µL, 0.62 mmol, 1.1 equiv) and thiophenol (58 µL, 0.56 mmol, 1.0 
equiv). The reaction mixture stirred under N2 for 16 h. The reaction was quenched with 5 mL of 
water and extracted with EtOAc (3 x 5 mL). The combined organic layers were dried over Na2SO4, 
filtered and concentrated, affording 88 mg (87% yield) of the title compound as a clear colorless 
oil. 1H NMR (400 MHz, CDCl3) δ 7.41 (apparent s, 5H), 2.64 (t, J = 7.4 Hz, 2H), 1.75 (h, J = 7.4 
Hz, 2H), 1.00 (t, J = 7.4 Hz, 3H). All spectra were consistent with literature values.76 
 
 
S-phenyl hexanecarbothioate (3.S12): 
A solution of N-Ethyl-N′-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC, 118 mg, 
0.76  mmol, 1.0 equiv) and hexanoic acid (100 µL, 0.80 mmol, 1.05 equiv) in DCM (10 mL) was 
cooled on ice for 15 min. Thiophenol (78 µL, 0.76 mmol, 1.0 equiv) and 4-
(dimethylamino)pyridine (DMAP, 11 mg, 0.10 mmol, 0.13 equiv) were added to the cold solution, 
which was then allowed to warm to rt. The reaction mixture stirred under N2 for 18 h and was 
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quenched with EtOAc (10 mL) and sat. aq. NaHCO3 (20 mL). The quenched mixture was extracted 
with EtOAc (3 x 10 mL). The combined organic layers were washed with brine, dried over Na2SO4, 
filtered and concentrated under reduced pressure to an oil. The crude residue was purified by flash 
chromatography (2-20% gradient of DCM in hexanes) to afford 75 mg (47% yield) of the title 
compound as a colorless oil. Rf = 0.4 (20% DCM in hexanes). 1H NMR (600 MHz, CDCl3) δ 7.47 
– 7.35 (m, 4H), 2.65 (t, J = 7.4 Hz, 2H), 1.72 (p, J = 7.4 Hz, 2H), 1.41 – 1.28 (m, 4H), 0.91 (t, J = 
7.0 Hz, 3H). All spectra were consistent with literature values.77 
 
 
S-phenyl octanecarbothioate (3.S13): 
Thiophenol (513 µL, 5.0 mmol, 1.0 equiv) and triethylamine (697 µL, 5.0 mmol, 1.0 equiv) were 
dissolved in toluene. Octanoyl chloride (870 µL, 5.1 mmol, 1.02 equiv) was added dropwise over 
40 min, forming a white precipitate. The reaction mixture stirred for 10 min after the addition of 
the acyl chloride and then was quenched with sat. aq. NaHCO3 (15 mL). The organic layer was 
washed twice each with NaHCO3 and brine (10 mL), then dried over Na2SO4, filtered. The filtrate 
was concentrated under reduced pressure affording 1.13 g (97% yield) of the title compound as a 
viscous clear oil. 1H NMR (600 MHz, CDCl3) δ 7.41 (apparent s, 5H), 2.65 (t, J = 7.5 Hz, 2H), 
1.71 (p, J = 7.4 Hz, 2H), 1.42 – 1.22 (m, 8H), 0.89 (t, J = 6.8 Hz, 3H). All spectra obtained were 
consistent with literature values.78 
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S-phenyl 2-methylpropanecarbothioate (3.S14): 
To a suspension of anhydrous K2CO3 (155 mg, 1.12 mmol, 2.0 equiv) in dry EtOAc (5 mL) were 
added isobutyric anhydride (102 µL, 0.62 mmol, 1.1 equiv) and thiophenol (58 µL, 0.56 mmol, 
1.0 equiv). The reaction mixture stirred under N2 for 16 h. The reaction was quenched with 5 mL 
of water and extracted with EtOAc (3 x 5 mL). The combined organic layers were dried over 
Na2SO4, filtered and concentrated, affording 99 mg (99% yield) of the title compound as a clear 
colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.41 (s, 5H), 2.87 (hept, J = 6.9 Hz, 1H), 1.27 (d, J = 
6.9 Hz, 6H). All spectra obtained were consistent with literature values.77 
 
 
S-phenyl 3-methylbutanecarbothioate (3.S15): 
Thiophenol (513 µL, 5.0 mmol, 1.0 equiv) and triethylamine (697 µL, 5.0 mmol, 1.0 equiv) were 
dissolved in toluene. Isovaleryl chloride (622 µL, 5.1 mmol, 1.02 equiv) was added dropwise over 
40 min, forming a white precipitate. The reaction mixture stirred for 10 min after the addition of 
the acyl chloride and then was quenched with sat. aq. NaHCO3 (15 mL). The organic layer was 
washed twice each with NaHCO3 and brine (10 mL), then dried over Na2SO4, filtered. The filtrate 
was concentrated under reduced pressure affording 971 mg (99% yield) of the title compound as 
a viscous clear oil. 1H NMR (600 MHz, CDCl3) δ 7.41 (d, J = 1.7 Hz, 5H), 2.54 (d, J = 7.1 Hz, 
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2H), 2.22 (hept, J = 13.5, 6.7 Hz, 1H), 1.01 (d, J = 6.7 Hz, 6H). All spectra obtained were consistent 
with literature values.77 
 
 
S-phenyl benzothioate (3.S16): 
A solution of EDC (362 mg, 2.33 mmol, 1.0 equiv) and benzoic acid (300 mg, 2.45 mmol, 1.05 
equiv) in DCM (25 mL) was cooled on ice for 15 min. Thiophenol (240 µL, 2.33 mmol, 1.0 equiv) 
and DMAP (36 mg, 0.29 mmol, 0.13 equiv) were added to the cold solution, which was then 
allowed to warm to rt. The reaction mixture stirred under N2 for 18 h and was quenched with 
EtOAc (10 mL) and sat. aq. NaHCO3 (20 mL). The quenched mixture was extracted with EtOAc 
(3 x 20 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered 
and concentrated under reduced pressure to an oil. The crude residue was purified by flash 
chromatography (2-20% gradient of DCM in hexanes) to afford 249 mg (50% yield) of the title 
compound as yellow/pink crystals. Rf = 0.4 (15% EtOAc in hexanes). 1H NMR (600 MHz, CDCl3) 
δ 8.04 (dd, J = 8.1, 1.5 Hz, 2H), 7.61 (td, J = 7.4, 1.4 Hz, 1H), 7.55 – 7.43 (m, 7H). All spectra 
obtained were consistent with literature values.79 
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S-phenyl cyclopentanecarbothioate (3.S17): 
Synthesized according to a variation of a procedure by Hansen et al.57 To a solution of 
cyclopentane carboxylic acid (246 mg, 2.16 mmol, 1.0 equiv) and diphenyl disulfide (706 mg, 
3.23 mmol, 1.5 equiv) dissolved in DCM (10 mL) was added tributylphosphine (808 µL, 3.23 
mmol, 1.5 equiv) at 0 °C. The reaction warmed to rt and stirred for 3 h. The reaction was quenched 
by addition of sat. NaHCO3 and extracted with DCM. The combined organic layers were dried 
over Na2SO4, filtered, and evaporated under reduced pressure to an oil. The crude residue was 
purified by flash column chromatography (4:1 hexanes/DCM v/v) to afford 357 mg of the title 
compound (80% yield) as a colorless oil. Rf = 0.2 (4:1 hexanes/DCM). 1H NMR (400 MHz, 
CDCl3) δ 7.45 – 7.36 (m, 5H), 3.10 (p, J = 7.9 Hz, 1H), 2.04 – 1.78 (m, 4H), 1.81 – 1.65 (m, 2H), 
1.67 – 1.52 (m, 2H). All spectra obtained were consistent with literature values.80 
 
 
S-phenyl cyclohexanecarbothioate (3.S18): 
Synthesized according to a variation of a procedure by Hansen et al.57 To a solution of 
cyclohexanecarboxylic acid (247 mg, 2.16 mmol, 1.0 equiv) and diphenyl disulfide (706 mg, 3.23 
mmol, 1.5 equiv) dissolved in DCM (10 mL) was added tributylphosphine (808 µL, 3.23 mmol, 
1.5 equiv) at 0 °C. The reaction warmed to rt and stirred for 3 h. The reaction was quenched by 
addition of sat. NaHCO3 and extracted with DCM. The combined organic layers were dried over 
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Na2SO4, filtered, and evaporated under reduced pressure to an oil. The crude residue was purified 
by flash column chromatography (5-15% v/v gradient of DCM in hexanes) to afford 348 mg of 
the title compound (73% yield) as a colorless oil. Rf = 0.2. 1H NMR (400 MHz, CDCl3) δ 7.40 (s, 
5H), 2.61 (tt, J = 11.4, 3.5 Hz, 1H), 2.01 (ddt, J = 13.4, 3.3, 1.7 Hz, 2H), 1.82 (dt, J = 11.8, 3.1 Hz, 
2H), 1.68 (dtd, J = 10.5, 3.3, 1.5 Hz, 1H), 1.60 – 1.46 (m, 2H), 1.40 – 1.16 (m, 3H). All spectra 
obtained were consistent with literature values.79 
 
 
S-(pyridin-2-yl) propanethioate (3.S19): 
Synthesized according to a variation of a procedure by Hansen et al.57 To a solution of propionic 
acid (200 mg, 2.7 mmol, 1.0 equiv) and 2,2’-dipyridyldisulfide (892 mg, 4.04 mmol, 1.5 equiv) 
dissolved in DCM (25 mL) was added tributylphosphine (1.01 mL, 4.04 mmol, 1.5 equiv) at 0 °C. 
The reaction warmed to rt and stirred for 3 h. The reaction was quenched by addition of sat. 
NaHCO3 (20 mL) and extracted with DCM (3 x 15 mL). The combined organic layers were dried 
over Na2SO4, filtered, and evaporated under reduced pressure to an oil. The crude residue was 
purified by flash column chromatography (3-30% v/v gradient of EtOAc in hexanes) to afford 143 
mg of the title compound (32% yield) as a yellow oil. Rf = 0.3. 1H NMR (400 MHz, CDCl3) δ 
8.63 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 7.75 (td, J = 7.7, 1.9 Hz, 1H), 7.62 (d, J = 7.9 Hz, 1H), 7.30 
(ddd, J = 7.8, 4.9, 1.2 Hz, 1H), 2.73 (q, J = 7.5 Hz, 2H), 1.24 (t, J = 7.5 Hz, 4H). All spectra 
obtained were consistent with literature values.81 
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S-phenyl 2-aminoethanethioate (Boc-Gly-SPh, 3.S20): 
A solution of EDC (253 mg, 1.63 mmol, 1.0 equiv) and Boc-glycine (300 mg, 1.71 mmol, 1.05 
equiv) in DCM (20 mL) was cooled on ice for 15 min. Thiophenol (169 µL, 1.63 mmol, 1.0 equiv) 
and DMAP (12 mg, 0.11 mmol, 0.13 equiv) were added to the cold solution. The reaction warmed 
to rt, stirred for 16 hours under N2. The reaction was quenched by the addition of sat. aq. NaHCO3 
(20 mL) and extracted with DCM (3 x 15 mL). The combined organic layers were dried over 
Na2SO4, filtered and concentrated under reduced pressure to an oil. The crude residue was purified 
by flash chromatography (10-20% v/v gradient of EtOAc in hexanes) to afford 307 mg (70% yield) 
of the title compound as an off-white solid. Rf = 0.3. 1H NMR (400 MHz, CDCl3) δ 7.42 (s, 5H), 
5.11 (s, 1H), 4.15 (d, J = 6.1 Hz, 2H), 1.48 (s, 9H). All spectra obtained were consistent with 
literature values.82 
 
 
 
S-phenyl 2-aminoethanethioate hydrochloride (Gly-SPh, 3.S21): 
To a vial of thioester S3.20 (100 mg, 0.37 mmol) was added 2 mL of HCl in dioxane (4 M). The 
reaction mixture stirred for 2 h at rt. The liquids were removed under reduced pressure, affording 
76 mg (quantitative yield) of the title compound as an off-white solid. 1H NMR (400 MHz, 
CD3OD) δ 7.50 (s, 5H), 4.20 (s, 1H). All spectra obtained were consistent with literature values 82 
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S-(2-acetamidoethyl) propanethioate (propionyl-SNAC, 3.40) 
A solution of EDC (130 mg, 0.84 mmol, 1.0 equiv) and propionic acid (113 µL, 0.88 mmol, 1.05 
equiv) in DCM (8 mL) was cooled on ice for 15 min. N-acetylcysteamine (90 µL, 0.84 mmol, 1.0 
equiv, kindly donated by the group of Prof. David Sherman) and DMAP (12 mg, 0.11 mmol, 0.13 
equiv) were added to the cold solution, which was then allowed to warm to rt. The reaction stirred 
for 12 hours and was then quenched by the addition of CuSO4-impregnated silica (about 2 g). The 
slurry was filtered and extracted with a 1:1 v/v mixture of sat. aq. NaHCO3 and brine (3 x 10 mL) 
The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced 
pressure to a faintly blue oil. The crude residue was purified by flash chromatography (5% v/v 
MeOH in DCM) to afford 146 mg (99% yield) of the title compound as a yellow oil. Rf = 0.3 (5% 
MeOH in DCM). 1H NMR (400 MHz, CDCl3) 
1H NMR (400 MHz, CDCl3) δ 5.86 (s, 1H), 3.43 
(q, J = 6.2 Hz, 2H), 3.02 (t, J = 6.4 Hz, 2H), 2.60 (q, J = 7.5 Hz, 2H), 1.96 (s, 3H), 1.18 (t, J = 7.5 
Hz, 3H). All spectra obtained were consistent with literature values.83 
 
 
 
(R)-S-(2-(3-(2,4-dihydroxy-3,3-dimethylbutanamido)propanamido)ethyl) propanethioate 
(propionyl-pantetheine, 3.38):53 
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An approximately 1 M aqueous solution of D-pantethine (250 µL) was diluted in half with water. 
To the solution was added dithiothreitol (DTT, 60 mg, excess equiv), and the reaction mixture 
stirred under N2 for 2 h. The liquid was removed under reduced pressure and azeotropic toluene 
drying. The remaining clear residue was purified by flash chromatography (2-10% v/v MeOH in 
DCM, Rf = 0.2), affording 112 mg of D-pantetheine (3.32) as a clear viscous oil that was stored 
overnight under N2. 
The purified pantetheine was redissolved in degassed and N2-sparged water (10 mL). In a separate 
flask, propionyl-SPh (3.37, 87 mg, 1.3 equiv) was added to more degassed and sparged water (5 
mL), forming a film on top. NaCO3 (84 mg, 1.0 mmol, 2.5 equiv) was added in one portion to the 
aqueous mixture of 3.37, followed by dropwise addition of the pantetheine solution over 10 min. 
The reaction mixture stirred for 2 h under sparging N2 conditions. Enough NaCl to form a saturated 
solution was added to the reaction mixture, which was then extracted with THF (3 x 10 mL). The 
combined organic layers were dried over Na2SO4, filtered and concentrated under reduced 
pressure. The residue was purified over flash chromatography (2-10% v/v MeOH in DCM 
gradient), affording 106 mg (75% yield) of the title compound as a brown oil. Rf = 0.3 (10% MeOH 
in DCM). 1H NMR (600 MHz, CDCl3) δ 7.49 (t, J = 6.2 Hz, 1H), 6.79 (t, J = 5.8 Hz, 1H), 4.62 (s, 
1H), 4.05 (s, 1H), 3.97 (s, 1H), 3.52 (q, J = 6.5 Hz, 2H), 3.49 – 3.42 (m, 2H), 3.43 – 3.30 (m, 2H), 
3.03 – 2.92 (m, 2H), 2.57 (q, J = 7.5 Hz, 2H), 2.41 (t, J = 6.1 Hz, 2H), 1.15 (t, J = 7.5 Hz, 3H), 
0.96 (s, 3H), 0.89 (s, 3H); 13C NMR (150 MHz, CDCl3) δ 200.9, 174.1, 171.9, 77.5, 70.89, 39.7, 
39.4, 37.6, 35.8, 35.3, 28.3, 21.5, 20.6, 9.7; HRMS (ESI) m/z calculated for C14H26N2O5SNa
+ 
[M+Na]+ 337.1455, found 357.1463. 
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tert-butyl (S)-(1-(methoxy(methyl)amino)-1-oxopropan-2-yl)carbamate (3.S22) 
To a suspension of Boc-L-alanine (568 mg, 3.0 mmol, 1.0 equiv), N,O-dimethylhydroxyl-amine 
hydrochloride (265 mg, 3.3 mmol, 1.1 equiv), EDC (514 mg, 3.3 mmol, 1.1 equiv), HOBt (407 
mg, 3.0 mmol, 1.0 equiv) in DCM (12 mL) was added triethylamine (838 µL, 6.0 mmol, 2.0 equiv). 
The yellow reaction mixture stirred for 18 h at rt under N2. The reaction was quenched with sat. 
aq. NaHCO3 (20 mL) and extracted with DCM (3 x 20 mL). The combined organic layers were 
washed once with more brine (20 mL), dried over Na2SO4, filtered and concentrated under reduced 
pressure. The crude residue (487 mg, 70% yield) was used without further purification. 1H NMR 
(400 MHz, CDCl3) δ 4.71 – 4.52 (m, 1H), 3.73 (s, 3H), 3.16 (s, 3H), 1.39 (s, 9H), 1.32 – 1.24 (m, 
4H). All spectra obtained were consistent with literature values.84 
 
 
tert-butyl (S)-(3-oxopentan-2-yl)carbamate (3.S23) 
To a solution of Boc-protected alanine Weinreb amide (3.S22, 400 mg, 1.72 mmol, 1.0 equiv) 
dissolved in THF (86 mL) was added a 1 M solution of ZnCl2 in Et2O (172 µL, 0.17 mmol, 0.1 
equiv) and a 3 M solution of ethyl magnesium bromide in THF (8.6 mL, 25.8 mmol, 15.0 equiv) 
at 0 °C. The reaction was allowed to warm to rt and stirred for 4 h. The reaction was poured into 
100 mL of 0.1 M HCl. The acidified aqueous phase was extracted with EtOAc (2 x 20 mL). The 
organic layers were combined, washed with brine, dried over Na2SO4, filtered, and evaporated 
under reduced pressure to afford an oil. The crude residue was purified by flash column 
chromatography (4:1 hexanes/EtOAc v/v) to afford 163 mg of the title compound (47% yield) as 
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a yellow oil. 1H NMR (600 MHz, CDCl3) δ 5.29 (d, J = 6.3 Hz, 1H), 4.27 (t, J = 7.2 Hz, 1H), 2.53 
(dd, J = 17.9, 7.3 Hz, 1H), 2.44 (dd, J = 17.9, 7.3 Hz, 1H), 1.39 (s, 11H), 1.27 (d, J = 7.2 Hz, 4H), 
1.04 (t, J = 7.3 Hz, 4H); 13C NMR (150 MHz, CDCl3) δ 210.3, 155.3, 79.7, 54.9, 29.8, 28.4, 18.0, 
7.67. 
 
 
(S)-2-aminopentan-3-one (3.S24) 
To a solution of Boc-protected alanine ethyl ketone (3.S23, 101 mg, 0.50 mmol, 1.0 equiv) 
dissolved in DCM (1.7 mL) was added trifluoroacetic acid (TFA, 1.7 mL) at rt. The reaction was 
stirred for 2 h. The solvent was evaporated under reduced pressure to afford 46.7 mg of the title 
compound as a TFA salt (43% yield) as a colorless oil. 1H NMR (600 MHz, CDCl3) δ 5.29 (d, J = 
6.3 Hz, 1H), 4.27 (t, J = 7.2 Hz, 1H), 2.53 (dd, J = 17.9, 7.3 Hz, 1H), 2.44 (dd, J = 17.9, 7.3 Hz, 
1H), 1.39 (s, 11H), 1.27 (d, J = 7.2 Hz, 4H), 1.04 (t, J = 7.3 Hz, 4H); 13C NMR (150 MHz, CD3OD) 
δ 207.9, 55.6, 32.5, 15.74, 7.5; HRMS (ESI) m/z calculated for C5H12NO+ [M+H]+ 102.0913, 
found 102.0917. 
 
 
tert-butyl (S)-(1-(methoxy(methyl)amino)-4-methyl-1-oxopentan-2-yl)carbamate (3.S25) 
To a suspension of Boc-L-leucine hydrate (250 mg, 1.0 mmol, 1.0 equiv), N,O-dimethylhydroxyl-
amine hydrochloride (88 mg, 1.1 mmol, 1.1 equiv), EDC (171 mg, 1.1 mmol, 1.1 equiv), 
hydroxybenzotriazole (HOBt, 135 mg, 1.0 mmol, 1.0 equiv) in DCM (4 mL) was added 
diisopropylethyl amine (280 µL, 2.0 mmol, 2.0 equiv). The yellow reaction mixture stirred for 18 
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h at rt under N2. The reaction was quenched with sat. aq. NH4Cl (10 mL) and extracted with DCM 
(3 x 10 mL). The combined organic layers were washed once with more NH4Cl (10 mL), dried 
over Na2SO4, filtered and concentrated under reduced pressure. The crude residue (150 mg, 54% 
yield) was used without further purification. 1H NMR (400 MHz, CDCl3) δ 5.06 (d, J = 9.6 Hz, 
1H), 4.73 – 4.63 (m, 1H), 3.75 (s, 3H), 3.16 (s, 3H), 1.68 (dp, J = 13.1, 6.5 Hz, 1H), 1.39 (s, 9H), 
0.91 (dd, J = 14.4, 6.6 Hz, 6H). All spectra obtained were consistent with literature values.85 
 
 
tert-butyl (S)-(2-methyl-5-oxoheptan-4-yl)carbamate (3.S26) 
To a solution of tri-Boc-protected leucine Weinreb amide (3.S25, 120 mg, 0.44 mmol, 1.0 equiv) 
dissolved in THF (22 mL) was added a 1 M solution of ZnCl2 (44 µL, 0.04 mmol, 0.1 equiv) and 
a 3 M solution of ethyl magnesium bromide in diethyl ether (2.2 mL, 6.6 mmol, 15.0 equiv) at 0 
°C. The reaction was allowed to warm to rt and stirred for 4 h. The reaction was poured into 20 
mL of 0.1 M HCl. The acidified aqueous phase was extracted with EtOAc (3x). The organic layers 
were combined, washed with brine, dried over Na2SO4, filtered, and evaporated under reduced 
pressure to afford an oil. The crude residue was purified by flash column chromatography (10% 
v/v hexanes in EtOAc) to afford 83.0 mg of the title compound (69% yield) as a yellow oil. 1H 
NMR (400 MHz, CDCl3) δ 5.02 (d, J = 8.3 Hz, 1H), 4.31 (td, J = 9.1, 3.9 Hz, 1H), 2.63 – 2.37 (m, 
2H), 1.74 – 1.61 (m, 1H), 1.41 (s, 9H), 1.09 – 1.02 (m, 3H), 0.93 (dd, J = 17.7, 6.6 Hz, 6H). 
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(S)-4-amino-6-methylheptan-3-one (3.S27) 
To a solution of Boc-protected leucine ethyl ketone (3.S26, 70.0 mg, 0.29 mmol, 1.0 equiv) 
dissolved in DCM (2.0 mL) was added trifluoroacetic acid (TFA, 5.0 mL) at rt. The reaction was 
stirred for 2 h. The solvent was evaporated under reduced pressure to afford 26.9 mg of the title 
compound as a TFA salt (37% yield) as a colorless oil. 1H NMR (400 MHz, CD3OD) δ 4.13 (dd, 
J = 9.9, 3.2 Hz, 1H), 2.71 (dq, J = 18.4, 7.2 Hz, 1H), 2.56 (dq, J = 18.4, 7.2 Hz, 1H), 1.77 (qq, J = 
6.2, 3.5 Hz, 2H), 1.59 (t, J = 9.8 Hz, 1H), 1.10 (t, J = 7.2 Hz, 3H), 1.03 (dd, J = 10.2, 6.1 Hz, 6H); 
13C NMR (151 MHz, CD3OD) δ 207.9, 58.3, 39.9, 33.2, 25.7, 23.4, 21.4, 7.6; HRMS (ESI) m/z 
calculated for C8H18NO
+ [M+H]+ 144.1383, found 144.1387. 
 
 
tert-butyl (S)-(3-(1H-indol-3-yl)-1-(methoxy(methyl)amino)-1-oxopropan-2-yl)carbamate 
(3.S28) 
To a suspension of Boc-L-tryptophan (250 mg, 0.82 mmol, 1.0 equiv), N,O-dimethylhydroxyl-
amine hydrochloride (132 mg, 1.35 mmol, 1.65 equiv), EDC (189 mg, 0.99 mmol, 1.2 equiv), 
HOBt (134 mg, 0.99 mmol, 1.2 equiv) and DMAP (13 mg, 0.10 mmol, 0.13 equiv) in DCM (10 
mL) was added diisopropylethyl amine (859 µL, 4.9 mmol, 6.0 equiv). The yellow reaction 
mixture stirred for 18 h at rt under N2. The reaction was quenched with sat. aq. NH4Cl (10 mL) 
and extracted with DCM (3 x 10 mL). The combined organic layers were washed once with more 
NH4Cl (about 20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The 
crude residue was purified by flash chromatography (33-45% v/v gradient of EtOAc in hexanes) 
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to afford 150 mg (53% yield) of a clear oil. Rf = 0.2 (40% EtOAc in hexanes). 1H NMR (600 
MHz, cdcl3) δ 8.01 (s, 1H), 7.60 (d, J = 7.9 Hz, 1H), 7.34 (d, J = 8.1 Hz, 1H), 7.18 (t, J = 7.5 Hz, 
1H), 7.11 (t, J = 7.5 Hz, 1H), 7.06 (d, J = 2.3 Hz, 1H), 5.26 – 5.21 (m, 1H), 5.04 – 4.98 (m, 1H), 
3.65 (s, 3H), 3.26 – 3.19 (m, 1H), 3.15 (s, 3H), 1.40 (s, 9H). All spectra obtained were consistent 
with literature values.86 
 
 
 
tert-butyl (S)-(3-(1-(tert-butyldimethylsilyl)-1H-indol-3-yl)-1-(methoxy(methyl)amino)-1-
oxopropan-2-yl)carbamate (3.S29) 
A solution of Boc-protected tryptophan Weinreb amide (3.S28, 150 mg, 0.43 mmol, 1.0 equiv) in 
THF (3.5 mL) was cooled to -78 °C and stirred for 1 h with lithium hexamethyldisilazide (1.38 
mL of a 1 M solution in THF, 1.38 mmol, 3.2 equiv) under N2. Tert-butyldimethylsilyl chloride 
(78 mg, 0.52 mmol, 1.2 equiv) was added in one portion and the reaction mixture stirred for a 
further 2 h at -78 °C. After warming to rt, the reaction was quenched by the addition of sat. aq. 
NH4Cl (5 mL). The organic solvent was removed under reduced pressure, and the aqueous solution 
was extracted with EtOAc (3 x 10 mL). The combined organic layers were dried over Na2SO4, 
filtered and concentrated under reduced pressure. The crude residue was purified by flash 
chromatograph (30-40% v/v gradient of EtOAc in hexanes) to afford 157 mg (79% yield) of the 
title compound as a white foam. Rf = 0.3 (30% EtOAc in hexanes). 1H NMR (600 MHz, CDCl3) δ 
7.57 (d, J = 7.5 Hz, 1H), 7.45 (d, J = 7.9 Hz, 1H), 7.12 (p, J = 7.0 Hz, 2H), 7.00 (s, 1H), 5.21 (d, J = 8.7 
Hz, 1H), 5.01 (d, J = 8.2 Hz, 1H), 3.57 (s, 3H), 3.22 – 3.17 (m, 1H), 3.12 (s, 3H), 1.40 (s, 6H), 0.91 (s, 
9H), 0.57 (s, 6H). All spectra obtained were consistent with literature values.86 
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tert-butyl (S)-(1-(1-(tert-butyldimethylsilyl)-1H-indol-3-yl)-3-oxopentan-2-yl)carbamate 
(3.S30) 
To a solution of Boc- and TBS-protected amide (3.S29, 157 mg, 0.34 mmol, 1.0 equiv) in THF (3 
mL) cooled to 0 °C, was added ethyl magnesium bromide (340 µL of a 3 M solution in dimethyl 
ether, 1.02 mmol, 3.0 equiv) over 5 min. The reaction mixture stirred at 0 °C for 30 min, then 
warmed to rt over 1.5 h. The reaction was quenched by the addition of sat. aq. NH4Cl (about 5 
mL) and extracted with EtOAc (3 x 5 mL). The combined organic layers were dried over Na2SO4, 
filtered and concentrated under reduced pressure. The crude residue was purified by flash 
chromatography (10-20% v/v gradient of EtOAc in hexanes) to afford 114 mg (78% yield) of the 
title compound as an off-white solid. Rf = 0.5 (15% EtOAc in hexanes). 1H NMR (600 MHz, 
CDCl3) δ 7.60 (dd, J = 7.2, 1.5 Hz, 1H), 7.49 (d, J = 8.3 Hz, 1H), 7.21 – 7.09 (m, 2H), 6.95 (d, J 
= 2.9 Hz, 1H), 5.26 (d, J = 7.8 Hz, 1H), 4.65 (q, J = 6.8 Hz, 1H), 3.19 (dd, J = 6.3, 2.7 Hz, 2H), 
2.35 (pd, J = 9.9, 8.7, 3.8 Hz, 2H), 1.45 (s, 5H), 0.98 – 0.91 (m, 13H), 0.59 (t, J = 2.5 Hz, 7H); 13C 
NMR (150 MHz, CDCl3) δ 210.7, 155.4, 141.4, 130.9, 129.4, 121.2, 119.9, 118.9, 114.0, 112.5, 
79.7, 59.1, 34.3, 28.4, 28.1, 26.4, 19.5, 7.3, -3.9. 
 
 
tert-butyl (S)-(1-(1H-indol-3-yl)-3-oxopentan-2-yl)carbamate (3.S31) 
To a solution of Boc- and TBS-protected ketone (3.S30, 40 mg, 0.093 mmol, 1.0 equiv) in THF 
(1.8 mL) was added TBAF (464 µL of a 1 M solution, 0.46 mmol, 5.0 equiv). The reaction stirred 
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for 45 min and was quenched by the addition of sat. aq. NH4Cl (2 mL) and then extracted with 
EtOAc (3 x 5 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated 
under reduced pressure. The crude residue was purified by flash chromatography (25-35% v/v 
gradient of EtOAc in hexanes) to afford 23.7 mg (80% yield) of the title compound as a clear oil. 
Rf = 0.2 (20% EtOAc in hexanes).  1H NMR (600 MHz, CDCl3) δ 8.24 (d, J = 16.4 Hz, 1H), 7.59 
(d, J = 8.0 Hz, 1H), 7.35 (d, J = 8.1 Hz, 1H), 7.20 (t, J = 7.6 Hz, 1H), 7.13 (t, J = 7.5 Hz, 1H), 6.96 
(s, 1H), 5.25 (d, J = 7.5 Hz, 1H), 4.64 (q, J = 6.8 Hz, 1H), 3.21 (t, J = 5.4 Hz, 1H), 2.38 (q, J = 7.3 
Hz, 2H), 1.43 (s, 9H), 0.96 (t, J = 7.2 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 210.76, 155.50, 
136.25, 127.62, 122.72, 122.39, 119.82, 119.80, 118.94, 111.33, 110.50, 79.91, 77.37, 77.16, 
76.95, 59.47, 34.11, 28.47, 27.96, 7.49. 
 
 
 
(S)-2-amino-1-(1H-indol-3-yl)pentan-3-one (3.69) 
To a solution of Boc-protected tryptophan ethyl ketone (3.S31, 16.3 mg, 0.52 mmol, 1.0 equiv) 
dissolved in DCM (1.7 mL) was added trifluoroacetic acid (TFA, 1.7 mL) at rt. The reaction was 
stirred for 1 h. The solvent was evaporated under reduced pressure to afford 17.4 mg of the title 
compound as a TFA salt (quantitative yield) as a colorless oil. 1H NMR (600 MHz, CD3OD) δ 
7.60 (d, J = 7.9 Hz, 1H), 7.40 (d, J = 8.2 Hz, 1H), 7.19 (s, 1H), 7.15 (d, J = 8.1 Hz, 1H), 7.09 (t, J 
= 7.5 Hz, 1H), 4.43 (dd, J = 8.1, 6.5 Hz, 1H), 3.44 (dd, J = 14.9, 6.5 Hz, 1H), 3.21 (dd, J = 14.9, 
8.1 Hz, 1H), 2.52 (q, J = 7.2 Hz, 2H), 1.00 (t, J = 7.2 Hz, 3H); 13C NMR (151 MHz, CD3OD) δ 
207.9, 138.4, 128.3, 125.3, 123.1, 120.4, 118.9, 112.7, 107.9, 59.9, 34.5, 27.6, 7.4; HRMS (ESI) 
m/z calculated for C13H17N2O
+ [M+H]+ 217.1335, found 217.1339. 
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B. 1H and 13C NMR spectra of compounds 
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HSQC, highlighted peaks coalesced in 13CNMR  
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HSQC, highlighted peaks coalesced in 13CNMR 
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II. Cloning, protein expression and purification 
A. General information 
Escherichia coli cloning strains DH10B or DH5α (Invitrogen) were used for DNA propagation. 
Proteins were expressed in E. coli strains BL21(DE3) pRARE (customized for streptomycin and 
spectinomycin resistance by the University of Michigan Center for Structural Biology), BAP187 
or BAP1 previously transformed with pGro7 (Takara Bio) after transformation with genes 
subcloned into pET28b (Novagen) or pMCSG7 (provided by the University of Michigan Center 
for Structural Biology) plasmids. Cells were grown in either Luria-Bertani broth (LB) or Terrific 
broth (TB) supplemented with the corresponding antibiotics kanamycin (50 μg/mL), ampicillin 
(100 μg/mL), chloramphenicol (35 µg/mL) or spectinomycin (80 μg/mL) purchased from Gold 
Biotechnology. 
 
All primers were purchased from Integrated DNA Technologies. Phusion HF polymerase and DpnI 
restriction enzyme were purchased from New England BioLabs. Ligation-independent cloning 
(LIC)-qualified T4 DNA polymerase was purchased from EMD Millipore. QIAquick PCR 
purification, gel extraction and miniprep kits were purchased from Qiagen. HisPur nickel-
nitrilotriacetic acid (Ni-NTA) resin was purchased from Thermo Scientific. Proteins were 
concentrated using Amicon centrifugal filters purchased from EMD Millipore at 4,000 x g, 4 °C. 
PD-10 desalting columns were purchased from GE Healthcare. Protein samples were analyzed on 
Mini-PROTEAN TGX Gels (4-15%) from BioRad and visualized with Protein Ark Quick 
Coomassie Stain from Anatrace. Proteins were quantified with the Pierce 660 nm Assay Reagent 
from Thermo Scientific. 
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Purified maltose binding protein fusions of CoA biosynthetic proteins CoaA, CoaD and CoaE were 
kindly donated by Dr. Gregory Dodge of Prof. Janet Smith’s group at the University of Michigan. 
 
B. Sequence information 
pET28b-sxtA (Cylindrospermopsis raciborskii T3) was obtained from the laboratory of Prof. Brett 
Neilan (University of Newcastle). 
 
pET28b-sxtA ACP-AONS (Aphanizomenon gracile), pET28b-sxtA ACP-AONS (Aphanizomenon 
gracile), pET28b-sxtA ACP-AONS (Aphanizomenon gracile), were purchased from Twist 
Biosciences, with codons optimized for E. coli expression. 
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pMCSG7-C. raciborskii sxtA ACP-AONS genomic DNA sequence (Ala722-His1245) 
GenBank accession ABI75094.1; linkers and 6x-His tags are shown in red. The serine codon in 
bold was mutated to alanine in the ACP knockout (ACP(KO)-AONS) construct. 
atgcaccatcatcatcatcattcttctggtgtagatctgggtaccgagaacctgtacttccaatccaatgcgatgGC
AATTGGTTCATTGGTACCAAAAGCAACATCTGCAACTAAGGAAAACAAAACTGTAGCGGATCTCGTTAAAGAATGCA
TCTTAAAAGTAATGGGTTCCCAACGTCAGGCAGCCTACGCTCCACAACAAAAACTGCTGGATATGGGATTAGATTCT
TTAGATTTATTAGAACTGCAAACGCTCCTAGAGGAACGTTTAGGGATCAATCTGTCTGGAACGTTCTTTTTACAAAA
GAACACTCCAACTGCCATCATCACTTATTTCCAAAACCAAGTGGTACAAGAGAAACAATCTGATCTAGCTCCACCTG
TTGACTCAGCCAACGAAATCAACACTCTGGAAAACGTAGTTAACCAACAAAAAATTCCTCAAGTCACAAGAGTCGTC
ACAGAACAACAAGGTCGCAAGGTGCTAATTGACGGACATTGGGTGATAGACTTTGCTTCTTGCAACTATTTAGGTCT
TGACTTGCATCCAAAAGTTAAGGAAGCAATTCCACCAGCTTTGGATAAATGGGGCACACATCCAAGCTGGACTCGGC
TTGTTGCTTCCCCAGCAATTTATGAGGAATTGGAGGAAGAATTGTCCAAACTTTTAGGCGTACCTGATGTTTTAGTA
TTTCCAGCTGTAACACTGCTTCAGATAGGAATTTTACCACTATTAACTGGGAATAATGGTGTCATCTTTGGTGACAT
AGCTGCACATCGTTGTATTTATGAAGCGTGCTGTCTGGCTCAGCACAAAGGAGCCCAGTTCATCCAATATCGACATA
ATGATTTGAACGATTTAGCCGAAAAACTAGCAAAATATCCGCCTGAACAAGTAAAGATTATTGTCATTGATGGCGTG
TATTCCATGTCGGCAGATTTTCCCGATCTGCCAGCTTACGTGCATCTGGCAAAAGAGTACAATGCCTTAATTTACAT
GGATGATGCTCATGGTTTTGGCATTTTGGGCGAAAATCCCAGCAGCGATATGCCTTACGGTTACAAAGGAAACGGGA
TGGTGAATTATTTTGACCTGCGGTTTGCAGAGGATAATATCATCTATGTAGCTGGTTTGTCCAAAGCCTATTCTTCT
TACGCAGCATTCTTAACTTGTGGCGATCGCCGGATCAAAACCAACTTCCGCAACGCTTGGACTGCCATATTTTCTGG
TCCTTCTCCTGTTGCGAGTTTGGCAAGTGCCTTAGCCGGATTACAGGTGAATCGTCAGGAGGGGGAGCAGTTAAGAA
AACAAATTTATCACCTAACTCACAAATTGGTTACACAAGCAAGAGCCATTGGATTCGAAGTGGATAACTATGGTTAC
GTTCCCATCGTAGGCGTGTTAGTGGGAGATGCTCAACACATGATTGATGTGTGTCAACTCCTTTGGGAATATGGTAT
TTTAATTACTCCTGCTATTTTTCCAATCGTACCTTTAAATAAAAGTGCTTTAAGGTTTTCGATTACAGCCGCCAATA
CCGAAGAGGAGATAGACCAAGCAATTAAATCTCTCAAAGCAGTTTGGGATTTGCTACAAAAAAGGAAAGCTTTGCCT
TGTAAGCAGGAGGAAAACATACTCAAGCAT 
 
Translation 
MHHHHHHSSGVDLGTENLYFQSNAMAIGSLVPKATSATKENKTVADLVKECILKVMGSQRQAAYAPQQKLLDMGLDS
LDLLELQTLLEERLGINLSGTFFLQKNTPTAIITYFQNQVVQEKQSDLAPPVDSANEINTLENVVNQQKIPQVTRVV
TEQQGRKVLIDGHWVIDFASCNYLGLDLHPKVKEAIPPALDKWGTHPSWTRLVASPAIYEELEEELSKLLGVPDVLV
FPAVTLLQIGILPLLTGNNGVIFGDIAAHRCIYEACCLAQHKGAQFIQYRHNDLNDLAEKLAKYPPEQVKIIVIDGV
YSMSADFPDLPAYVHLAKEYNALIYMDDAHGFGILGENPSSDMPYGYKGNGMVNYFDLRFAEDNIIYVAGLSKAYSS
YAAFLTCGDRRIKTNFRNAWTAIFSGPSPVASLASALAGLQVNRQEGEQLRKQIYHLTHKLVTQARAIGFEVDNYGY
VPIVGVLVGDAQHMIDVCQLLWEYGILITPAIFPIVPLNKSALRFSITAANTEEEIDQAIKSLKAVWDLLQKRKALP
CKQEENILKH 
 
pMCSG7-C. raciborskii sxtA ACP genomic DNA sequence (Ala722-Gln815) 
atgcaccatcatcatcatcattcttctggtgtagatctgggtaccgagaacctgtacttccaatccaatgcgatgGC
AATTGGTTCATTGGTACCAAAAGCAACATCTGCAACTAAGGAAAACAAAACTGTAGCGGATCTCGTTAAAGAATGCA
TCTTAAAAGTAATGGGTTCCCAACGTCAGGCAGCCTACGCTCCACAACAAAAACTGCTGGATATGGGATTAGATTCT
TTAGATTTATTAGAACTGCAAACGCTCCTAGAGGAACGTTTAGGGATCAATCTGTCTGGAACGTTCTTTTTACAAAA
GAACACTCCAACTGCCATCATCACTTATTTCCAAAACCAAGTGGTACAA 
 
Translation 
MHHHHHHSSGVDLGTENLYFQSNAMAIGSLVPKATSATKENKTVADLVKECILKVMGSQRQAAYAPQQKLLDMGLDS
LDLLELQTLLEERLGINLSGTFFLQKNTPTAIITYFQNQVVQ 
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pET28b-A. gracile sxtA ACP-AONS E. coli-optimized DNA sequence (Ala735-His1234) 
GenBank accession LT549448.1; linkers and 6x-His tags are shown in red.  
atgggcagcagccatcatcatcatcatcacagcagcggcctggtgccgcgcggcagccatatggctagcatgactgg
tggacagcaaatgggtcgcggatccgaattcGCAACATCTGCGACTAAGGAGAACAAGACCGTAGCTGCCTTAGTCA
AAGAATGTGTGCTTAAAGTGATGGGCAGCCAGCGCGAGGCCGCTTATGCCCCTGAACAAAAATTGTTAGACATGGGG
TTAGATAGTTTAGACCTGTCTGAACTTCAGACTCTTTTGGAAAAACGTTTGGGCGTCAATCTTTCTGGGACTTTCTT
TTTTCAAAACAATACCCCCACTGCTATCATCACATACTTTCAGAACCAAGTTGTCCAAGAAAAGCAGAGTGATCTGG
CGAGCCCCGTGGACTTAGCTAATGAAATCAACACATTAGAAAATGTTGTCAATCAGCAGAAGATCCCTCAGGTTACG
CGCGTAGTGACTGAACAGCAAGGTCGTAAGGTCTTGATCGATGGCCACTGGGTGATTGACTTCGCCTCATGCAACTA
TTTAGGTTTAGACTTGCACCCCAAAGTGAAGGAGGCTATCCCCCCGGCTTTGGAGAAGTGGGGGGTCCATCCCTCTT
GGACACGTTTGGTGGCCAGCCCGGTAATCTATGAGGAATTAGAGGAGGAGTTAAGCAAACTGTTAGGAGTTCCCGAC
GTATTAGTTTTCCCAAGCGTCACATTACTTCAGATCGGGGTCTTGCCACTTCTGACAGGCTCGAACGGAGTTATTTT
AGGCGACATTGCTGCGCATCGTTGCATTTACGAGGCCTGCTGCCTGGCACAGCAGAAGGGCTCACAGTTTATCCAAT
ATCGCCACAATGACTTGAATGATTTAGCGGAGAAATTGGCAAAGTATCCACTGGAACAAGTCAAAATCATCGTCATT
GACGGAGTGTACTCTATGTCCGCCGACTTCCCAGACCTTCCGGCTTACGTCCGCCTGGCGAAGGAATACAATGCTTT
TATTTATATGGATGACGCGCACGGATTTGGTATTTTGGGTGAGAACCCGTCCTCCGATATGCCTTACGGATACAAAG
GTAATGGTATGGTGAATTATTTCGATCTTCAATTTGCCGAGGACAACATTATCTACGTCGCGGGGTTGTCTAAAGCC
TACAGTTCGTACGCCGCCTTTCTTACTTGCGGTGATCGTCAGATTAAGACCAATTTCCGTAATGCTTGGACTGCCAT
TTTCAGCGGTCCTAGCCCAGTGGCAAGCTTGGCATCAGCCTTGGCCGGCTTACAGGTTAATCGTCAGGAAGGAGAAC
AACTTCGCAAGCAAATCTACCACTTGACGCGCAAATTGGTGACCCAAGCTCGCGCCATTGGCTTCGAAGTGGACAAC
TACGGTTACGTTCCCATCGTTTCCGTCTTAGTCGGAGACGCGCAACACATGATTGACGTATGTCAGCTGCTGTGGGA
GTACGGCATTCTGATCACACCCGCTATTTTCCCAATTGTTCCACTTAATAAATCCGCGCTGCGCTTTTCTATCACAG
CTGCCAATACGGAAGAAGAGATTGACCAAGCCATCAAAGCATTGGAGGGGGTATGGGTCCTGCTTCAGAAAGAGAAG
gcggccgcactcgagcaccaccaccaccaccac 
 
Translation 
MGSSHHHHHHSSGLVPRGSHMASMTGGQQMGRGSEFATSATKENKTVAALVKECVLKVMGSQREAAYAPEQKLLDMG
LDSLDLSELQTLLEKRLGVNLSGTFFFQNNTPTAIITYFQNQVVQEKQSDLASPVDLANEINTLENVVNQQKIPQVT
RVVTEQQGRKVLIDGHWVIDFASCNYLGLDLHPKVKEAIPPALEKWGVHPSWTRLVASPVIYEELEEELSKLLGVPD
VLVFPSVTLLQIGVLPLLTGSNGVILGDIAAHRCIYEACCLAQQKGSQFIQYRHNDLNDLAEKLAKYPLEQVKIIVI
DGVYSMSADFPDLPAYVRLAKEYNAFIYMDDAHGFGILGENPSSDMPYGYKGNGMVNYFDLQFAEDNIIYVAGLSKA
YSSYAAFLTCGDRQIKTNFRNAWTAIFSGPSPVASLASALAGLQVNRQEGEQLRKQIYHLTRKLVTQARAIGFEVDN
YGYVPIVSVLVGDAQHMIDVCQLLWEYGILITPAIFPIVPLNKSALRFSITAANTEEEIDQAIKALEGVWVLLQKEK
AAALEHHHHHH 
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pET28b-D. circinale sxtA ACP-AONS E. coli-optimized DNA sequence (Ala735-His1234) 
GenBank accession DQ787201.1; linkers and 6x-His tags are shown in red.  
atgggcagcagccatcatcatcatcatcacagcagcggcctggtgccgcgcggcagccatatggctagcatgactgg
tggacagcaaatgggtcgcggatccgaattcGCTACAAAGGAAAATAAGACAGTAGCGGCTCTGGTCAAGGAGTGTG
TGCTTAAAGTCATGGGTTCCCAGCGTGAAGCTGCGTATGCCCCCGAACAAAAGCTGCTGGATATGGGCCTTGACTCC
CTTGACTTGAGTGAACTGCAGACTCTTTTAGAAAAACGCCTTGGGGTCAACCTTTCCGGTACATTTTTTTTCCAGAA
TAATACACCAACCGCAATTATCACATACTTTCAAAACCAGGTCGTACAAGAGAAGCAGAGTGACTTAGCGAGTCCCG
TTGACTTAGCGAACGAGATCAACACGTTAGAGAATGTCGTCAACCAGCAGAAAATCCCGCAAGTCACGCGTGTGGTA
ACTGAGCAACAAGGACGTAAAGTGTTAATTGACGGACATTGGGTCATTGACTTTGCGTCTTGTAATTATTTAGGACT
GGATTTGCATCCCAAGGTAAAAGAGGCGATTCCCCCAGCTCTTGAGAAGTGGGGGGTACATCCCAGTTGGACTCGTC
TGGTTGCCTCCCCAGTTATTTATGAAGAGTTGGAGGAAGAGTTGAGTAAGCTGCTGGGCGTTCCTGATGTATTAGTC
TTTCCTTCGGTGACTCTGTTGCAGATCGGTGTCTTGCCACTTTTGACGGGTAGCAACGGGGTAATTCTGGGGGATAT
TGCGGCCCATCGTTGCATCTACGAGGCCTGTTGCCTGGCTCAGCAGAAAGGGTCGCAGTTCATCCAGTACCGTCACA
ACGATTTAAATGACTTAGCCGAGAAACTTGCGAAGTACCCTCTTGAACAAGTCAAGATTATTGTGATCGACGGAGTG
TACTCTATGTCTGCGGACTTTCCAGACCTGCCGGCCTATGTTCGTTTGGCAAAAGAGTACAACGCTTTTATCTACAT
GGACGACGCACATGGTTTCGGGATCTTGGGAGAAAACCCCTCGTCAGATATGCCATACGGTTATAAAGGAAATGGTA
TGGTCAACTATTTCGACCTTCAATTCGCGGAGGACAATATCATTTATGTCGCTGGCTTATCGAAGGCATATTCCTCG
TATGCAGCATTTTTGACCTGCGGAGACCGCCAAATCAAGACAAACTTCCGCAACGCATGGACAGCTATCTTCTCCGG
TCCTTCGCCGGTAGCGTCTCTGGCATCGGCCTTAGCCGGTTTACAAGTGAATCGCCAAGAGGGCGAACAGTTGCGCA
AACAAATCTATCATCTTACTCGCAAATTGGTCACGCAGGCGCGCGCCATTGGATTCGAAGTAGACAACTATGGGTAT
GTCCCTATCGTGTCGGTGTTGGTAGGAGATGCCCAGCACATGATCGATGTGTGTCGCTTGCTTTGGGAATATGGCAT
CCTGATTACGCCAGCCATCTTTCCGATTGTTCCGCTGAATAAGTCTGCCTTACGTTTTTCCATCACTGCAGCAAATA
CGGAGGAAGAAATTGACCAAGCGATCAAGGCCTTAGAAGCTGTATGGGTCCTTTTACAGAAAGAAAAGgcggccgca
ctcgagcaccaccaccaccaccac 
 
Translation 
MGSSHHHHHHSSGLVPRGSHMASMTGGQQMGRGSEFATKENKTVAALVKECVLKVMGSQREAAYAPEQKLLDMGLDS
LDLSELQTLLEKRLGVNLSGTFFFQNNTPTAIITYFQNQVVQEKQSDLASPVDLANEINTLENVVNQQKIPQVTRVV
TEQQGRKVLIDGHWVIDFASCNYLGLDLHPKVKEAIPPALEKWGVHPSWTRLVASPVIYEELEEELSKLLGVPDVLV
FPSVTLLQIGVLPLLTGSNGVILGDIAAHRCIYEACCLAQQKGSQFIQYRHNDLNDLAEKLAKYPLEQVKIIVIDGV
YSMSADFPDLPAYVRLAKEYNAFIYMDDAHGFGILGENPSSDMPYGYKGNGMVNYFDLQFAEDNIIYVAGLSKAYSS
YAAFLTCGDRQIKTNFRNAWTAIFSGPSPVASLASALAGLQVNRQEGEQLRKQIYHLTRKLVTQARAIGFEVDNYGY
VPIVSVLVGDAQHMIDVCRLLWEYGILITPAIFPIVPLNKSALRFSITAANTEEEIDQAIKALEAVWVLLQKEKAAA
LEHHHHHH 
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pET28b-M. wollei sxtA ACP-AONS E. coli-optimized DNA sequence (Ala732-His1243) 
GenBank accession EU603711.1; linkers and 6x-His tags are shown in red.  
atgggcagcagccatcatcatcatcatcacagcagcggcctggtgccgcgcggcagccatatggctagcatgactgg
tggacagcaaatgggtcgcggatccgaattcGCTACCAAAGAGAACGAAACTGTAGCAGCGTTAGTAAAAGAGTGTT
TCTTGAAAGTTCTGGGATCGCAGCGTCAAGCAGCTTATGCGCCAAAGCAGAAATTGTTGGACATGGGCCTGGACAGC
CTTGACTTGCTTGAGCTGCAGACACTGCTTGAAGAGCGCCTTGGAGTGAGTCTGTCACGTACGTTCTTCTTGCAGAA
TAATACCCCCACAGCCATTATCACCTACTTCCAAACATATTTCCAGAATCAGGTAGTTCAAGAAAAGAAGTCCGATC
TGGCATCCCCCGTGGACTCCGCTAACGAAATTAATACCTTAGAGAATGTAGTGAACCAGCAAAAGATCCCTCAAGTT
ACCCGCGTTGTGACCGAACAGCAAGATCGCAAGGTTTTAATCGACGGCCATTGGGTGATCGATTTCGCCTCCTGCAA
TTACTTAGGATTAGACTTGCATCCCAAAGTCAAAGAGGCCATCCCCCCTGCGTTGGAAAAGTGGGGCGTACACCCAT
CTTGGACCCGCTTGGTAGCATCTCCAGCAATCTATGAGGAGCTGGAAGAGGAGCTTGCAAAACTTTTAGGGGTACCA
GACGTATTGTTGTTCCCATCCTTGACCTTACTGCAGATGGGGGTACTGCCCCTGCTGACCGGCAATAATGGAGTGAT
CTTCGGGGACATCTCCGCCCATCGCTGTATCTATGAGGCGTGCTGCTTAGCACAACATAAAGGAGCGCAATTCATTC
AGTACCGTCATAACGATCTGAATGACTTGGCGGCGAAATTGGCAAAATACCCGCTGGAACAAGTGAAGATCATCGCG
ATTGATGGGGTGTACAGCATGAGTGCTGACTTGCCAGACTTGCCCGCGTATGTCCGCTTAGCAAAACAGTATAATGC
TTTGATCTATATCGACGATGCTCATGGGTTCGGAATCCTTGGGGAAAATCCATCGAGTGATATGCCTTATGGATACA
AAGGAAACGGTATCGTAAATTATTTCGATCTTCGCTTCGCTGAAGACAACATCATTTACGTTGCTGGTCTTTCCAAA
GCCTACAGTTCATACGCAGCATTCGTTACTTGCGGAAATTCCCAAATCAAGACGCAGTTTCGTAACGCGTGGACCGC
CATTTTTTCTGGACCGTCACCAGTTGCATCGTTGGCAAGCGCCCTTGCTGGTCTTCAGGTCAATCGCCAAGAGGGGG
AGCAATTGCGTAAGCAGGTTTATTACTTAACGCATAAGTTAGTGACCCAGGCCCGCGCGATTGGTTTTGAAGTAGAC
AACTACTCATACGTGCCGATTGTCTCAGTACTTGTAGGGGACGCCCAGCATATCGTTGACGTCTGCCAGTTGTTATG
GGAATACGGAATTTTAATTACACCCGCGATTTTCCCTATTGTTCCGCTGAATAAAACCGCATTGCGTTTCAGCATTA
CCGCTGCGAACACCGAGGAGGAAATTGACCAAGCGATCAAAGCACTGGAGGCTGTATGGGACTTGCTGCAAAAGCGC
AAAGCCCTTTTATGTAAGgcggccgcactcgagcaccaccaccaccaccac 
 
Translation 
MGSSHHHHHHSSGLVPRGSHMASMTGGQQMGRGSEFATKENETVAALVKECFLKVLGSQRQAAYAPKQKLLDMGLDS
LDLLELQTLLEERLGVSLSRTFFLQNNTPTAIITYFQTYFQNQVVQEKKSDLASPVDSANEINTLENVVNQQKIPQV
TRVVTEQQDRKVLIDGHWVIDFASCNYLGLDLHPKVKEAIPPALEKWGVHPSWTRLVASPAIYEELEEELAKLLGVP
DVLLFPSLTLLQMGVLPLLTGNNGVIFGDISAHRCIYEACCLAQHKGAQFIQYRHNDLNDLAAKLAKYPLEQVKIIA
IDGVYSMSADLPDLPAYVRLAKQYNALIYIDDAHGFGILGENPSSDMPYGYKGNGIVNYFDLRFAEDNIIYVAGLSK
AYSSYAAFVTCGNSQIKTQFRNAWTAIFSGPSPVASLASALAGLQVNRQEGEQLRKQVYYLTHKLVTQARAIGFEVD
NYSYVPIVSVLVGDAQHIVDVCQLLWEYGILITPAIFPIVPLNKTALRFSITAANTEEEIDQAIKALEAVWDLLQKR
KALLCKAAALEHHHHHH 
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Table 3.S1. Primers used to generate constructs in this Chapter. 
Name Sequence 
Primers for SxtA(S773A) by site-directed mutagenesis of whole plasmids 
SxtA S773A forward 5’-
AAACTGCTGGATATGGGATTAGATGCGTTAGATTTATTAGAACTGCAAACG-
3’ 
SxtA S773A reverse 5’-
CGTTTGCAGTTCTAATAAATCTAACGCATCTAATCCCATATCCAGCAGTTT-
3’ 
Primers for ligation-independent cloning (LIC) 
SxtA ACP A722 LIC forward 5’-TACTTCCAATCCAATGCGATGGCAATTGGTTCATTGGTAC-3’ 
SxtA ACP Q815 LIC reverse 5’-TTATCCACTTCCAATGTTATTGTACCACTTGGTTTTGGAAA-3’ 
SxtA AONS H1245 LIC 
reverse 
5’-TACTTCCAATCCAATGCAATGCAAGAGAAACAATCTGATCT-3’ 
Primers for megaprimer PCR of whole plasmids (MEGAWHOP) 
MW SxtA AONS mega 
forward 
5’-CCAAACATATTTCCAGAATCAGGTAGTTC-3’ 
MW SxtA AONS mega reverse 5’-GTGCTCGAGTGCGGCCGC-3’ 
Overhangs for ligation-independent cloning are shown in boldface, mutations underlined 
 
C. raciborskii ACP knockout SxtA(S773A): pET28b-sxtA(S773A) was generated by site-
directed mutagenesis on pET28b-sxtA(wt). 50 μL PCR reaction mixtures contained 10 μL Phusion 
HF buffer, 2 ng/μL wt parent plasmid, 2 μM each of the S773A forward and reverse primers, 200 
μM each of dNTPs, 0.04 U/μL Phusion HF and 6% (v/v) DMSO. Amplification was accomplished 
with the following PCR procedure: 95 °C for 2:00, (95 °C 0:30, 60 °C 1:00, 68 °C 6:00) for 18 
cycles, with a final extension of 68 °C for 15:00. This was followed by a 10 μL digestion containing 
1 μL NEB CutSmart buffer, 8 μL of the PCR mixture and 20 units of DpnI. The reaction mixture 
was incubated at 37 °C for 3 h and transformed into chemically competent DH5α cells.  
 
C. raciborskii SxtA ACP: The excised domain was amplified from pET28b-sxtA(wt) in 50 μL 
reactions containing 10 μL Phusion HF buffer, 2 ng/μL parent plasmid, 2 μM each of forward and 
reverse LIC primers, 200 μM each of dNTPs, 0.04 U/μL Phusion HF. Excised domains were 
amplified according to the following PCR procedure: 95 °C 2:00, (95 °C 0:30, 46-50 °C 0:30, 72 
°C 0:45/kb) for 30 cycles, 72 °C 10:00. Inserts were purified by gel extraction and subcloned into 
pMCSG7 using standard LIC protocols.88 
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C. raciborskii ACP-AONS and ACP(KO)-AONS: The excised didomains were amplified from 
pET28b-sxtA (Cylindrospermopsis raciborskii T3) and pET28b-sxtA(S773A) in 50 μL reactions 
containing 10 μL Phusion HF buffer, 2 ng/μL parent plasmid, 2 μM each of forward and reverse 
LIC primers, 200 μM each of dNTPs, 0.04 U/μL Phusion HF. The didomain was amplified 
according to the following PCR procedure: 95 °C 2:00, (95 °C 0:30, 55 °C 1:00, 72 °C 2:00) for 
30 cycles, 72 °C 10:00. The insert was purified by gel extraction and subcloned into pMCSG7 
using standard LIC protocols.88 
 
Library generation by megaprimer PCR of whole plasmids (MEGAWHOP): The megaprimer 
was amplified from pET28b-sxtA (Microseira wollei) in 100 µL reactions containing 10 µL Taq 
buffer, 2 ng/µL parent plasmid, 1.5 µM each of forward and reverse MEGAWHOP primers, 20 
µM dGTP, 20 µM dATP, 100 µM dCTP, 100 µM dTTP, 0.2 U/µL Taq polymerase and 3 mM 
MgCl2. The AONS domain was amplified according to the following PCR procedure: 95 °C 2:00, 
(95 °C 0:20, 52 °C 0:30, 72 °C 1:30) for 30 cycles, 72 °C 10:00. The megaprimer was purified by 
gel extraction and then used to amplify whole plasmids in 50 µL reactions containing 10 μL 
Phusion HF buffer, 0.5 ng/μL parent plasmid, 10 ng/μL megaprimer, 200 μM each of dNTPs, 0.04 
U/μL Phusion HF polymerase. The following touchdown PCR procedure was followed: 68 °C 
5:00, 98 °C 2:00, (98 °C 0:30, 68-55 °C 1:00, 68 °C 5:30) for 30 cycles with the annealing 
temperature decreasing by 1 °C for each of the first thirteen cycles, 72 °C 15:00. This was followed 
by a 10 μL digestion containing 1 μL NEB CutSmart buffer, 8 μL of the PCR mixture and 20 units 
of DpnI for 3 h at 37 °C, and then ligation with 1,000 U T4 DNA ligase with an additional 1.2 μL 
of ligase buffer at 18 °C for 12 h. The reaction mixtures were then used to transform BAP1 pGro7 
E. coli.71 
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D. Protein overexpression and purification 
Overexpression of SxtA ACP(KO)-AONS: pMCSG7 plasmids containing the desired insert 
were transformed into pRARE-containing chemically competent BL21(DE3) E. coli cells. A single 
colony was picked to inoculate a 5 mL LB starter culture grown overnight at 37 °C, 200 rpm. The 
following day, 0.5 L TB media, supplemented with spectinomycin and ampicillin, was inoculated 
with the starter culture and incubated at 37 °C, 250 rpm until the OD600 reached 1.0. Cultures were 
equilibrated at 20 °C for 1 h. Expression was induced by addition of IPTG (final concentration 200 
μM). Cultures were incubated at 20 °C, 200 rpm for 18 h. 
 
Overexpression of holo-ACP and ACP-AONS for purification: pMCSG7 or pET28 plasmids 
containing intact ACP-AONS were transformed into BAP1 E. coli cells. A single colony was 
picked to inoculate a 10 mL LB starter culture grown overnight at 37 °C, 200 rpm. The following 
day, 1 L LB media was supplemented with ampicillin or kanamycin, inoculated with the starter 
cultures, and incubated at 37 °C, 200 rpm until the OD600 reached 0.6. The culture was cooled to 
rt and expression was induced by addition of IPTG (final concentration 100 μM). Cultures were 
incubated at 18 °C, 200 rpm for 18 h. 
 
Overexpression of ACP-AONS for whole-cell reactions: pMCSG7 or pET28 plasmids 
containing intact ACP-AONS were transformed into BAP1 pGro7 E. coli cells. A single colony 
was picked to inoculate a 5 mL LB starter culture grown overnight at 37 °C, 200 rpm. The 
following day, 0.5 L TB media was supplemented with chloramphenicol and either ampicillin or 
kanamycin, inoculated with the starter cultures, and incubated at 37 °C, 200 rpm until the OD600 
reached 0.6. Arabinose (final concentration 0.5 mg/mL) was added to induce chaperone expression 
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while the culture cooled to 18 °C. After one hour, ACP-AONS expression was induced by addition 
of IPTG (final concentration 200 μM). Cultures were incubated at 18 °C, 200 rpm for 18 h. Cells 
were separated into approx. 0.5 g chunks and stored at -80 °C. 
 
96-well plate expression of the ACP-AONS library: From an agar plate of SxtA ACP-AONS 
library members in BAP1 pGro7 E. coli, 94 colonies were picked to inoculate a 96-well plate. The 
95th well contained a parent wild-type colony and the 96th well an empty pET28b vector. Each well 
contained 600 μL LB media supplemented with kanamycin and chloramphenicol. The plate was 
covered and incubated overnight at 37 °C, 250 rpm. The following day, 50 μL of each starter 
culture was used to inoculate a second 96-well plate containing 1 mL of TB media per well. The 
plate was incubated for 4 h at 37 °C, 250 rpm. Arabinose (12 μL of 25 mg/mL for a final 
concentration of 0.5 mg/mL) was added to each well to induce chaperone expression, while the 
plate cooled over 1 h to 18 °C, still 250 rpm. Protein expression was then induced with the addition 
of IPTG (12 μL of 10 mM IPTG for a final concentration of 200 μM). Plates grew overnight at 18 
°C, 250 rpm. The following day, cells were pelleted by centrifuging the plates at 2,000 x g for 10 
min. The media was decanted, and cells were resuspended in the reaction buffer (see section III). 
 
Purification of all SxtA constructs: Cell pellets were resuspended in 4 mL of lysis buffer (1 mM 
PLP, 50 mM HEPES, 300 mM NaCl, 10 mM imidazole, and 10% v/v glycerol at pH 8.0) with per 
gram of wet cell mass. PLP was not added to holo-ACP cell pellets. Protease inhibitors pepstatin 
A (1 μg/mL), benzamidine hydrochloride (15 μg/mL), and PMSF (1 mM) were added to the 
resuspension mixture before incubation at 4 °C for 20 min with gentle shaking. Cells were lysed 
by sonication (3 s on, 6 s off, 5 min total). Insoluble material was removed by centrifugation 
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(30,000 x g for 30 min at 4 °C). The clarified lysate was incubated with gentle shaking along with 
1-2 mL of nickel-NTA resin for 1 h at 4 °C and poured into a column. The resin-bound protein 
was washed with 25 mL wash buffer (50 mM HEPES, 300 mM NaCl, 25 mM imidazole, 10% v/v 
glycerol, pH 8.0). The desired protein was eluted with 6 mL elution buffer (50 mM HEPES, 300 
mM NaCl, 300 mM imidazole, 10% v/v glyercol, pH 8.0). The eluted protein was concentrated 
using 3 – 50 kDa centrifugal cutoff filters and exchanged into storage buffer (50 mM HEPES, 200 
mM NaCl, 10% v/v glycerol, pH 7.4) using a PD-10 column. The desalted protein was 
concentrated further using 50 kDa centrifugal cutoff filters, aliquoted, flash frozen in liquid 
nitrogen and stored at -80 °C.  
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Table 3.S2. SxtA protein constructs and molecular weights with intact initial Met. 
Construct name Plasmid Expression line Calculated molecular 
weight (Da) 
CR SxtA holo-ACP pMCSG7 BAP1 13,533.2 
CR SxtA ACP(KO)-AONS pMCSG7 BL21(DE3) pRARE 60,974.0 
CR SxtA ACP-AONS pMCSG7 BAP1 61,314.1 
AG SxtA ACP-AONS pET28b BAP1 61,205.6 
DC SxtA ACP-AONS pET28b BAP1 60,988.5 
MW SxtA ACP-AONS pET28b BAP1 62,041.7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.S1. Denatured SDS-PAGE protein gels. 
Proteins of interest are highlighted in red. 
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III. Enzymatic reactions 
 
A. General information 
 
CoASH, butyryl-, isobutyryl-, isovaleryl-, octanoyl- and benzoyl-CoA were purchased from 
Sigma-Aldrich. Acetyl-, malonyl-, propionyl-, methylmalonyl-, and hexanoyl-CoA were obtained 
from CoALA Biosciences. S-adenosyl methionine was purchased as the tosyl salt from Carbosynth 
and prepared as a 50 mM aqueous solution immediately before use. Synthesized substrates and 
product standards were prepared as 50 mM stock solutions in DMSO. Electrospray liquid 
chromatography-mass spectrometry (LC-MS) analysis was performed on an Agilent G6545A 
quadrupole-time of flight mass spectrometer in positive mode with an Agilent 1290 UPLC system 
or an Agilent 6320 time of flight mass spectrometer with an Agilent 1290 Infinity II UPLC system. 
Solvent A = water with 0.1% formic acid. Solvent B = 95% acetonitrile, 5% water and 0.1% formic 
acid. MS data were analyzed using the Agilent Qualitative Mass Hunter software. 
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Table 3.S3. Acyl-ACP masses. 
Species Calculated intact 
protein mass (Da) 
Observed mass 
(Da)a 
Calculated Ppant 
ejection89 
fragment (m/z) 
Observed Ppant 
ejection mass 
(m/z) 
Apo-ACP 13,193.1 13,193.2 N/A N/A 
Holo-ACP 
 
13,533.2 13,533.2 261.13 261.13 
Acetyl-ACP 
 
13,575.2 13,575.4 303.14 303.14 
Propionyl-ACP 
 
13,589.2 13,589.5 317.15 317.15 
n-Butyryl-ACP 
 
13,603.2 13,603.4 331.17 331.17 
n-Hexanoyl-ACP 
 
13,631.3 13631.9 359.20 359.20 
n-Octanoyl-ACP 
 
13,659.3 ND 387.23 ND 
Isobutryl-ACP 
 
13,603.2 13,603.4 331.17 331.17 
Isovaleryl-ACP 
 
13,617.3 13,617.8 345.18 345.18 
Benzoyl-ACP 
 
13,637.2 13,637.9 365.15 365.15 
Cyclopentanoyl-ACP 
 
13,629.3 13,629.4 357.18 357.18 
Cyclohexanoyl-ACP 
 
13,643.3 ND 371.20 ND 
Gly-ACP
 
13,590.2 13,590.1 318.15 318.15 
ND: not detected. All masses are based on C. raciborskii SxtA holo-ACP. aMinor species resulting from loss of the 
initial Met residue were occasionally observed. 
 
  
 217 
 
B. Reactions and data 
 
Preparation of propionyl-ACP (3.39): 1.5 mM propionyl-SPh (3.37), 300 µM holo-ACP from 
C. raciborskii SxtA in 50 mM HEPES pH 7.4, 150 mM NaCl and 10% v/v glycerol were combined 
(total volume 1 mL) and incubated at 30 °C for 2 h. The reaction mixture was loaded onto a PD-
10 desalting column for exchange into storage buffer (50 mM HEPES, 200 mM NaCl, 10% v/v 
glycerol, pH 7.4). The desalted protein was concentrated further using 10 kDa centrifugal cutoff 
filters, aliquoted, flash frozen in liquid nitrogen and stored at -80 °C. The loading levels were 
analyzed by intact protein MS (about 80%) and the final protein concentration was measured by 
the Pierce 660 assay. LC-MS analysis: column = Phenomenex Aeris 3.6 μm WIDEPORE C4 2.1 
x 50 mm; method = 5% B at 0.5 mL/min for 2 min, followed by a linear gradient to 100% B over 
4 min, 100% B for 2 min, followed by a 0.1 min linear gradient to 5% B and 1.9 min equilibration 
at 5% B (total time 10 min). tR = 4.1 min. The relative abundance of ejected Ppant ions for holo-
and propionyl-ACP were used to calculate the fraction of each ACP species.89 
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Thiol comparison (Figure 3.7): 
With thiols thiophenol (SPh), 2-thiopyridine, N-acetylcysteamine (SNAC), pantetheine, 
phosphopantetheine (Ppant), 3’-dephospho-CoA, CoA and holo-ACP. 
CoA biosynthesis. 250 μM propionyl-pantetheine (3.38), 2 mM Arg, 8 mM ATP, 0.2 mg/mL CoaA 
(to generate Ppant, see 3.32 in Figure 3.6), 0.2 mg/mL CoaD (to generate 3’-dephospho-CoA), and 
0.2 mg/mL CoaE (for CoA) in 50 mM HEPES pH 7.4, 150 mM NaCl, 10 mM MgCl2 and 0.5 mM 
MnCl2 (total volume 42 μL) were combined and incubated at 30 °C for 3 h. For condensation 
reactions without pantetheine or the CoA biosynthetic intermediates, the volume of pantetheine 
and CoaADE was replaced with water. After 3 h, 21 μL aliquots were removed to check CoA 
biosynthesis progress and the reactions were quenched by the addition of 4 μL water and then 
diluting 5x with MeOH. Precipitate was pelleted at 12,000 x g for 20 min. The supernatant was 
transferred to sample vials for LC-MS analysis: column = Waters XBridge C18 3.5 µm , 2.1 x 150 
mm; solvent A = water with 0.1% v/v formic acid, solvent B = methanol with 0.1% v/v formic 
acid; method = 10% B at 0.2 mL/min for 2 min, followed by a linear gradient to 90% B over 15 
min, then a gradient to 90% over 1 min (total time 18 min). tR (3.38): 11.52 min; tR (propionyl-
phosphopantetheine): 10.19 min; tR (propionyl-3’-dephospho-CoA): 9.24 min. The CoA thioester 
peak was not detected, although all intermediate peaks were also no longer present. 
Condensation: To the remaining 21 μL were added the remaining propionyl thioesters (SPh, 
SNAC, 2-thiopyridine, ACP) and 8 μM ACP(KO)-AONS for a total volume of 25 μL. The 
condensation reactions were incubated at 30 °C for an additional 4 h and then quenched by diluting 
5x with acetonitrile. The supernatant was diluted 20x with the LC-MS analysis mixture for a final 
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ratio of 5% quenched reaction, 2.5% of aqueous 10 μg/mL 15N Arg·HCl (Cambridge Isotope 
Laboratories), 46% acetonitrile, 46.5% of 1% formic acid in water (e.g., 10 μL of quenched 
reaction, 5 μL of 10 μg/mL 15N Arg·HCl, 92 μL acetonitrile, 93 μL of 1% formic acid in water for 
a total volume of 200 μL). Samples were analyzed by LC-MS: column = Waters Acquity 1.7 µm 
UPLC BEH HILIC 2.1 x 100 mm column; method = 85% B at 0.3 mL/min for 2 min, followed by 
a linear gradient to 75% B at 0.4 mL/min over 3 min and a second linear gradient to 60% B over 
0.5 min, 60% B for 1 min and then 6.5 min re-equilibration at 85% B at 0.3 mL/min (total time 15 
min). tR (3.8): 1.94 min; tR (
15N Arg): 4.0 min. Yields were calculated by comparing the areas 
under the curve of the product extracted ion chromatograms to the 15N Arg internal standard and 
compared to a standard curve of ketone 3.8. Reactions were run in duplicate 
 
 
Comparison of thiophenol and SNAC acyl donors and SxtA ACP in cis or trans with AONS 
(Figure 3.8): 2 mM propionyl thioesters, 4 mM 2-vinylpyridine, 2 mM Arg, 8 µM C. raciborskii 
ACP(KO)-AONS or ACP-AONS, 8 or 50 µM holo-ACP in 50 mM HEPES pH 7.4, 150 mM NaCl, 
1 mM MgCl2, 0.5 mM MnCl2 (total volume 25 μL) were combined and incubated at 30 °C for 4 
h. Reactions were quenched by diluting 5x with acetonitrile. Precipitate was pelleted at 12,000 x 
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g for 20 min. The supernatant was diluted 20x with the LC-MS analysis mixture for a final ratio 
of 5% quenched reaction, 2.5% of aqueous 10 μg/mL 15N Arg·HCl (Cambridge Isotope 
Laboratories), 46% acetonitrile, 46.5% of 1% formic acid in water (e.g., 10 μL of quenched 
reaction, 5 μL of 10 μg/mL 15N Arg·HCl, 92 μL acetonitrile, 93 μL of 1% formic acid in water for 
a total volume of 200 μL). Samples were analyzed by LC-MS: column = Waters Acquity 1.7 μm 
UPLC BEH HILIC 2.1 x 100 mm column; method = 85% B at 0.3 mL/min for 2 min, followed by 
a linear gradient to 75% B at 0.4 mL/min over 3 min and a second linear gradient to 60% B over 
0.5 min, 60% B for 1 min and then 6.5 min re-equilibration at 85% B at 0.3 mL/min (total time 15 
min). tR (3.8): 1.94 min; tR (
15N Arg): 4.0 min. Yields were calculated by comparing the areas 
under the curve of the product extracted ion chromatograms to the 15N Arg internal standard and 
compared to a standard curve of ketone 3.8. Reactions were run in duplicate. 
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Figure 3.S2. Comparison of conversion to ketone 3.8 with different acyl donors. 
The other conditions for 2-thiopyridine were not tested. 
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AONS-mediated condensation of arginine and acyl-CoAs (Table 3.2): 500 μM acyl-CoA, 2 
mM Arg, 8 μM C. raciborskii ACP(KO)-AONS in 50 mM HEPES pH 7.4, 150 mM NaCl, 1 mM 
MgCl2, 0.5 mM MnCl2 (total volume 25 μL) were combined and incubated at 30 °C for 2 h. 
Reactions were quenched by diluting 5x with acetonitrile. Precipitate was pelleted at 12,000 x g 
for 20 min. The supernatant was diluted 20x with the LC-MS analysis mixture for a final ratio of 
5% quenched reaction, 2.5% of aqueous 10 μg/mL 15N Arg·HCl (Cambridge Isotope 
Laboratories), 46% acetonitrile, 46.5% of 1% formic acid in water (e.g., 10 μL of quenched 
reaction, 5 μL of 10 μg/mL 15N Arg·HCl, 92 μL acetonitrile, 93 μL of 1% formic acid in water for 
a total volume of 200 μL). Samples were analyzed by LC-MS: column = Waters Acquity 1.7 μm 
UPLC BEH HILIC 2.1 x 100 mm column; method = 85% B at 0.3 mL/min for 2 min, followed by 
a linear gradient to 75% B at 0.4 mL/min over 3 min and a second linear gradient to 60% B over 
0.5 min, 60% B for 1 min and then 6.5 min re-equilibration at 85% B at 0.3 mL/min (total time 15 
min). tR (
15N Arg): 4.0 min. See Supplementary Table 3.S4 for product tR values. Yields were 
calculated by comparing the areas under the curve of the product extracted ion chromatograms to 
the 15N Arg internal standard and normalized to the propionyl-CoA reaction (Table S4, entry 2). 
Reactions were run in triplicate. 
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ACP-AONS-mediated condensation of arginine-based ketones, with acyl-thiophenol donors 
(Table 3.3): 1 mM acyl-SPh and 10 μM C. raciborskii ACP-AONS in 50 mM HEPES pH 7.4, 
150 mM NaCl, 1 mM MgCl2, 0.5 mM MnCl2 (total volume 25 μL) were combined and incubated 
at 30 °C for 4 h. Reactions were quenched by diluting 5x with acetonitrile. Precipitate was pelleted 
at 12,000 x g for 20 min. The supernatant was diluted 20x with the LC-MS analysis mixture for a 
final ratio of 5% quenched reaction, 2.5% of aqueous 10 μg/mL 15N Arg·HCl (Cambridge Isotope 
Laboratories), 46% acetonitrile, 46.5% of 1% formic acid in water (e.g., 10 μL of quenched 
reaction, 5 μL of 10 μg/mL 15N Arg·HCl, 92 μL acetonitrile, 93 μL of 1% formic acid in water for 
a total volume of 200 μL). Samples were analyzed by LC-MS: column = Waters Acquity 1.7 μm 
UPLC BEH HILIC 2.1 x 100 mm column; method = 85% B at 0.3 mL/min for 2 min, followed by 
a linear gradient to 75% B at 0.4 mL/min over 3 min and a second linear gradient to 60% B over 
0.5 min, 60% B for 1 min and then 6.5 min re-equilibration at 85% B at 0.3 mL/min (total time 15 
min). tR (
15N Arg): 4.0 min. See Supplementary Table 3.S4 for product tR values. Yields were 
calculated by comparing the areas under the curve of the product extracted ion chromatograms to 
the 15N Arg internal standard and normalized to the propionyl-CoA reaction (Table 3.2, entry 2). 
Reactions were run in duplicate. 
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Loading: 1 mM acyl-SPh and 50 µM C. raciborskii SxtA holo-ACP in 50 mM HEPES pH 7.4, 
150 mM NaCl, 1 mM MgCl2, 0.5 mM MnCl2 (total volume 25 μL) were combined and incubated 
at 30 °C for 1.5 h. The reactions were diluted to 4 µM ACP with 1% formic acid in water and 
transferred to sample vials for intact protein MS analysis: column = Phenomenex Aeris 3.6 μm 
WIDEPORE C4 2.1 x 50 mm; method = 5% B at 0.5 mL/min for 2 min, followed by a linear 
gradient to 100% B over 4 min, 100% B for 2 min, followed by a 0.1 min linear gradient to 5% B 
and 1.9 min equilibration at 5% B (total time 10 min). tR = 4.1-4.2 min. The relative abundance of 
ejected Ppant ions for holo- and acyl-ACP were used to calculate the fraction of loaded ACP.  
 
 
pH screen of nonenzymatic transthioesterification (Figure 3.9A): 1 mM acyl-SPh, 50 µM C. 
raciborskii holo-ACP and 4 mM Arg in 50 mM HEPES, 150 mM NaCl, 1 mM MgCl2, 0.5 mM 
MnCl2 (total volume 25 μL) were combined and incubated at 30 °C for 2 h. The pH ranged from 
6.6 to 8.6, in 0.4 unit increments. The reactions were diluted to 4 µM ACP with 1% formic acid in 
water and transferred to sample vials for intact protein MS analysis: column = Phenomenex Aeris 
3.6 μm WIDEPORE C4 2.1 x 50 mm; method = 5% B at 0.5 mL/min for 2 min, followed by a 
linear gradient to 100% B over 4 min, 100% B for 2 min, followed by a 0.1 min linear gradient to 
5% B and 1.9 min equilibration at 5% B (total time 10 min). tR = 4.1-4.2 min. The relative 
abundance of ejected Ppant ions for holo-and acyl-ACP were used to calculate the fraction of 
loaded ACP.  
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pH screen of AONS-mediated condensation (Figure 3.9B): 1 mM acyl-SPh, 4 mM Arg, and 10 
µM C. raciborskii ACP-AONS in 50 mM HEPES, 150 mM NaCl, 1 mM MgCl2, 0.5 mM MnCl2 
(total volume 25 μL) were combined and incubated at 30 °C for 4 h. The pH ranged from 6.6 to 
8.6, in 0.2 unit increments. Reactions were quenched by diluting 5x with methanol. Precipitate was 
pelleted at 12,000 x g for 20 min. The supernatant was diluted 20x with the LC-MS analysis 
mixture for a final ratio of 5% quenched reaction, 2.5% of aqueous 10 μg/mL 15N Arg·HCl 
(Cambridge Isotope Laboratories), 46% acetonitrile, 46.5% of 1% formic acid in water (e.g., 10 
μL of quenched reaction, 5 μL of 10 μg/mL 15N Arg·HCl, 92 μL acetonitrile, 93 μL of 1% formic 
acid in water for a total volume of 200 μL). Samples were analyzed by LC-MS: column = Waters 
Acquity 1.7 μm UPLC BEH HILIC 2.1 x 100 mm column; method = 85% B at 0.3 mL/min for 2 
min, followed by a linear gradient to 75% B at 0.4 mL/min over 3 min and a second linear gradient 
to 60% B over 0.5 min, 60% B for 1 min and then 6.5 min re-equilibration at 85% B at 0.3 mL/min 
(total time 15 min). tR (
15N Arg): 4.0 min. See Table 3.S4 for product tR values. Yields were 
calculated by comparing the areas under the curve of the product extracted ion chromatograms to 
the 15N Arg internal standard. Reactions were run in duplicate. 
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AONS-mediated condensation to identify the limiting reagent (Figure 3.10): 1 mM propionyl-
SPh (3.37), 4 mM Arg, 10 µM C. raciborskii ACP-AONS in 50 mM HEPES pH 7.0, 150 mM 
NaCl, 1 mM MgCl2, 0.5 mM MnCl2 (total volume 25 μL) were combined and incubated at 30 °C 
for 4 h. Additional components: 1 mM propionyl-SPh, 50 µM holo-ACP, 10 µM ACP-AONS, 10 
µM ACP(KO)-AONS or buffer were added for a final volume of 35 µL. The reactions incubated 
at 30 °C for 14 more hours. Reactions were quenched by diluting 5x with methanol. Precipitate 
was pelleted at 12,000 x g for 20 min. The supernatant was diluted 20x with the LC-MS analysis 
mixture for a final ratio of 5% quenched reaction, 2.5% of aqueous 10 μg/mL 15N Arg·HCl 
(Cambridge Isotope Laboratories), 46% acetonitrile, 46.5% of 1% formic acid in water (e.g., 10 
μL of quenched reaction, 5 μL of 10 μg/mL 15N Arg·HCl, 92 μL acetonitrile, 93 μL of 1% formic 
acid in water for a total volume of 200 μL). Samples were analyzed by LC-MS: column = Waters 
Acquity 1.7 μm UPLC BEH HILIC 2.1 x 100 mm column; method = 85% B at 0.3 mL/min for 2 
min, followed by a linear gradient to 75% B at 0.4 mL/min over 3 min and a second linear gradient 
to 60% B over 0.5 min, 60% B for 1 min and then 6.5 min re-equilibration at 85% B at 0.3 mL/min 
(total time 15 min). tR (3.8): 1.94 min; tR (
15N Arg): 4.0 min. Yields were calculated by comparing 
the areas under the curve of the product extracted ion chromatograms to the 15N Arg internal 
standard and compared to a standard curve of ketone 3.8. Reactions were run in duplicate. 
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AONS-mediated condensation with both arginine enantiomers (Figure 3.11): 1 mM 
propionyl-panthetheine (3.38), 4 mM D- or L-arginine, 10 µM M. wollei ACP-AONS in 50 mM 
HEPES pH 7.0 and 150 mM NaCl (total volume) were combined and incubated at 30 °C for 18 h. 
At various timepoints, 10 µL aliquots were removed and quenched by diluting 5x with methanol. 
Precipitate was pelleted at 12,000 x g for 20 min. The supernatant was diluted 20x with the LC-
MS analysis mixture for a final ratio of 5% quenched reaction, 2.5% of aqueous 10 μg/mL 15N 
Arg·HCl (Cambridge Isotope Laboratories), 46% acetonitrile, 46.5% of 1% formic acid in water 
(e.g., 10 μL of quenched reaction, 5 μL of 10 μg/mL 15N Arg·HCl, 92 μL acetonitrile, 93 μL of 
1% formic acid in water for a total volume of 200 μL). Samples were analyzed by LC-MS: column 
= Waters Acquity 1.7 μm UPLC BEH HILIC 2.1 x 100 mm column; method = 85% B at 0.3 
mL/min for 2 min, followed by a linear gradient to 75% B at 0.4 mL/min over 3 min and a second 
linear gradient to 60% B over 0.5 min, 60% B for 1 min and then 6.5 min re-equilibration at 85% 
B at 0.3 mL/min (total time 15 min). tR (3.8): 1.94 min; tR (
15N Arg): 4.0 min. Yields were 
calculated by comparing the areas under the curve of the product extracted ion chromatograms to 
the 15N Arg internal standard and compared to a standard curve of ketone 3.8. Reactions were run 
in duplicate. The inconsistent values at early timepoints were likely due to evaporation of the 
quenched mixtures before LC-MS analysis. 
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Deuterium incorporation into SxtA product ketone 3.8 (Figure 3.14A): 2 mM ketone 3.8, 50 
mM HEPES pH 7.0, 150 mM NaCl in D2O were combined for a total volume of 25 µL and 
incubated at 30 °C for 18 h. The reaction was quenched by diluting 5x with methanol. Precipitate 
was pelleted at 12,000 x g for 20 min. The supernatant was diluted 20x with the LC-MS analysis 
mixture for a final ratio of 5% quenched reaction, 46% acetonitrile, 49% of 1% formic acid in 
water (e.g., 10 μL of quenched reaction, 92 μL acetonitrile, 98 μL of 1% formic acid in water for 
a total volume of 200 μL). Samples were analyzed by LC-MS: column = Waters Acquity 1.7 μm 
UPLC BEH HILIC 2.1 x 100 mm column; method = 85% B at 0.3 mL/min for 2 min, followed by 
a linear gradient to 75% B at 0.4 mL/min over 3 min and a second linear gradient to 60% B over 
0.5 min, 60% B for 1 min and then 6.5 min re-equilibration at 85% B at 0.3 mL/min (total time 15 
min). tR (3.8): 1.94 min. The reactions were run in duplicate. 
Chromatograms were extracted for the monoisotopic mass, m+1, m+2, m+3 (1-3 heavy atoms) for 
z = 1, and integrated. The natural abundances of heavy atom isotopologs (13C, 15N as calculated by 
enviPat https://www.envipat.eawag.ch/index.php) were subtracted from the m+1 and m+2 
integration values before calculating the fraction of deuterated ketone. 
 
 
Comparison of condensation mediated by different SxtA ACP-AONS homologs (Figure 
3.15): 1 mM propionyl-SPh (3.37), 4 mM Arg, 10 µM ACP-AONS homologs (four total) in 50 
mM HEPES pH 7.0, 150 mM NaCl, 1 mM MgCl2, 0.5 mM MnCl2 (total volume 25 μL) were 
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combined and incubated at 30 °C for 4 h. Reactions were quenched by diluting 5x with methanol. 
Precipitate was pelleted at 12,000 x g for 20 min. The supernatant was diluted 20x with the LC-
MS analysis mixture for a final ratio of 5% quenched reaction, 2.5% of aqueous 10 μg/mL 15N 
Arg·HCl (Cambridge Isotope Laboratories), 46% acetonitrile, 46.5% of 1% formic acid in water 
(e.g., 10 μL of quenched reaction, 5 μL of 10 μg/mL 15N Arg·HCl, 92 μL acetonitrile, 93 μL of 
1% formic acid in water for a total volume of 200 μL). Samples were analyzed by LC-MS: column 
= Waters Acquity 1.7 μm UPLC BEH HILIC 2.1 x 100 mm column; method = 85% B at 0.3 
mL/min for 2 min, followed by a linear gradient to 75% B at 0.4 mL/min over 3 min and a second 
linear gradient to 60% B over 0.5 min, 60% B for 1 min and then 6.5 min re-equilibration at 85% 
B at 0.3 mL/min (total time 15 min). tR (3.8): 1.94 min; tR (
15N Arg): 4.0 min. Yields were 
calculated by comparing the areas under the curve of the product extracted ion chromatograms to 
the 15N Arg internal standard and compared to a standard curve of ketone 3.8. Reactions were run 
in duplicate. 
 
 
Amino acid substrate screen with ACP-AONS homologs (Figure 3.16): 1 mM propionyl-SPh 
(3.37), 4 mM L-amino acids (twenty-four total), 10 µM ACP-AONS homologs (four total) in 50 
mM HEPES pH 7.0, 150 mM NaCl, 1 mM MgCl2, 0.5 mM MnCl2 (total volume 25 μL) were 
combined and incubated at 30 °C for 18 h. Reactions were quenched by diluting 5x with methanol. 
Precipitate was pelleted at 12,000 x g for 20 min. The supernatant was diluted 20x with the LC-
MS analysis mixture for a final ratio of 5% quenched reaction, 2.5% of aqueous 10 μg/mL 15N 
Arg·HCl (Cambridge Isotope Laboratories), 46% acetonitrile, 46.5% of 1% formic acid in water 
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(e.g., 10 μL of quenched reaction, 5 μL of 10 μg/mL 15N Arg·HCl, 92 μL acetonitrile, 93 μL of 
1% formic acid in water for a total volume of 200 μL). Samples were analyzed by LC-MS: column 
= Waters Acquity 1.7 μm UPLC BEH HILIC 2.1 x 100 mm column; method = 85% B at 0.3 
mL/min for 2 min, followed by a linear gradient to 75% B at 0.4 mL/min over 3 min and a second 
linear gradient to 60% B over 0.5 min, 60% B for 1 min and then 6.5 min re-equilibration at 85% 
B at 0.3 mL/min (total time 15 min). tR (3.8): 1.94 min; tR (
15N Arg): 4.0 min. Yields were 
calculated by comparing the areas under the curve of the product extracted ion chromatograms to 
the 15N Arg internal standard. 
 
 
Acyl group substrate screen with ACP-AONS homologs (Figure 3.17): 1 mM acyl-SPh and 10 
μM ACP-AONS homologs (four total) in 50 mM HEPES pH 7.0, 150 mM NaCl, 1 mM MgCl2, 
0.5 mM MnCl2 (total volume 25 μL) were combined and incubated at 30 °C for 4 h. Reactions 
were quenched by diluting 5x with methanol. Precipitate was pelleted at 12,000 x g for 20 min. 
The supernatant was diluted 20x with the LC-MS analysis mixture for a final ratio of 5% quenched 
reaction, 2.5% of aqueous 10 μg/mL 15N Arg·HCl (Cambridge Isotope Laboratories), 46% 
acetonitrile, 46.5% of 1% formic acid in water (e.g., 10 μL of quenched reaction, 5 μL of 10 μg/mL 
15N Arg·HCl, 92 μL acetonitrile, 93 μL of 1% formic acid in water for a total volume of 200 μL). 
Samples were analyzed by LC-MS: column = Waters Acquity 1.7 μm UPLC BEH HILIC 2.1 x 
100 mm column; method = 85% B at 0.3 mL/min for 2 min, followed by a linear gradient to 75% 
B at 0.4 mL/min over 3 min and a second linear gradient to 60% B over 0.5 min, 60% B for 1 min 
and then 6.5 min re-equilibration at 85% B at 0.3 mL/min (total time 15 min). tR (
15N Arg): 4.0 
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min. See Supplementary Table 3.S5 for product tR values. Yields were calculated by comparing 
the areas under the curve of the product extracted ion chromatograms to the 15N Arg internal 
standard. Reactions were run in duplicate. The glycyl substrate 3.S20 was not tested. 
 
 
Crude format comparisons (C. raciborskii) and homolog whole-cell reaction comparison 
(Figure 3.19): 
Crude formats, with BAP1 (Figure 3.18A): Cell pellets of BAP1 E. coli expressing C. raciborskii 
SxtA ACP-AONS (600 mg) were resuspended in 3 mL of storage buffer (50 mM HEPES, 200 
mM NaCl, 10% v/v glyercol, pH 7.4) to make a 200 mg/mL suspension. The suspension was 
separated into a 1 mL and 2 mL portion, the latter of which was lysed by sonication (10 s on, 20 s 
off, 30 s total). The lysate was separated further into 2 x 1 mL portions; one portion was clarified 
by pelleting the debris 17,000 x g for 10 min at 4 °C. The biocatalytic reactions contained 1 mM 
propionyl-SPh (3.37), 4 mM Arg, 45 mg/mL of resuspended whole cells or crude lysate, or 90 
mg/mL of clarified lysate in 50 mM HEPES pH 7.4, 150 mM NaCl, 1 mM MgCl2, 0.5 mM MnCl2, 
and 0.1 mM PLP (total volume 100 µL). The reactions were incubated at 30 °C for 18 h and 
quenched by diluting 5x with acetonitrile. 
Crude formats, with BAP1 pGro7 (Figure 3.18A): Cell pellets of BAP1 pGro7 E. coli expressing 
C. raciborskii SxtA ACP-AONS (400 mg) were resuspended in 2 mL of storage buffer to make a 
200 mg/mL suspension. The suspension was separated into 2 x 1 mL, one of which was lysed by 
sonication (10 s on, 20 s off, 30 s total). The biocatalytic reactions contained 1 mM propionyl-SPh 
(3.37), 4 mM Arg, 10% v/v of organic solvents (MeOH, DMSO or THF), 45 mg/mL of 
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resuspended whole cells or crude lysate in 50 mM HEPES pH 7.0, 150 mM NaCl, 1 mM MgCl2, 
0.5 mM MnCl2, and 0.1 mM PLP (total volume 400 µL). The reactions were stirred at 30 °C for 
18 h and quenched by diluting 5x with methanol. A crude lysate and in vitro reaction containing 
10 µM of purified C. raciborskii ACP-AONS had comparable amounts of biocatalyst (Figure 
3.18C). 
Whole-cell reactions with ACP-AONS homologs (Figure 3.18B): Cell pellets of BAP1 and BAP1 
pGro7 E. coli expressing SxtA ACP-AONS homologs (200 mg each) were resuspended in 1 mL 
of storage buffer. The biocatalytic reactions contained 1 mM propionyl-SPh (3.37), 4 mM Arg, 
10% v/v of organic solvents (MeOH, DMSO or THF), 45 mg/mL of resuspended whole cells or 
crude lysate in 50 mM HEPES pH 7.0, 150 mM NaCl, 1 mM MgCl2, 0.5 mM MnCl2, and 0.1 mM 
PLP (total volume 400 µL). The reactions were stirred at 30 °C for 18 h and quenched by diluting 
5x with methanol. 
Analysis: Precipitate from quenched reactions was pelleted at 12,000 x g for 20 min. The 
supernatant was diluted 20x with the LC-MS analysis mixture for a final ratio of 5% quenched 
reaction, 2.5% of aqueous 10 μg/mL 15N Arg·HCl (Cambridge Isotope Laboratories), 46% 
acetonitrile, 46.5% of 1% formic acid in water (e.g., 10 μL of quenched reaction, 5 μL of 10 μg/mL 
15N Arg·HCl, 92 μL acetonitrile, 93 μL of 1% formic acid in water for a total volume of 200 μL). 
Samples were analyzed by LC-MS: column = Waters Acquity 1.7 μm UPLC BEH HILIC 2.1 x 
100 mm column; method = 85% B at 0.3 mL/min for 2 min, followed by a linear gradient to 75% 
B at 0.4 mL/min over 3 min and a second linear gradient to 60% B over 0.5 min, 60% B for 1 min 
and then 6.5 min re-equilibration at 85% B at 0.3 mL/min (total time 15 min). tR (3.8): 1.94 min; 
tR (
15N Arg): 4.0 min. Yields were calculated by comparing the areas under the curve of the product 
extracted ion chromatograms to the 15N Arg internal standard. 
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Whole-cell library screening of M. wollei ACP-AONS variants (Figure 3.20): Cell pellets in 
96-well plates were resuspended in the reaction solution containing 1 mM thioester 3.37, 8 mM 
tryptophan, 50 mM HEPES pH 7.0 and 150 mM NaCl (final volume 250 µL per well). Plates were 
covered and incubated at 30 °C, 250 rpm for 18 h. Reactions were quenched by diluting 2x with 
MeOH with 0.5% v/v formic acid. Precipitate from quenched reactions was pelleted at 2,000 x g 
for 10 min. From each well 200 µL was sterile filtered through a 0.2 µm 96-well plate filter for 
droplet microfluidic MS analysis by Prof. Robert Kennedy’s group. 
Droplet Generation from Multi-well Plate (MWP)  
Oil-segmented sample droplets were generated by sampling from a MWP. Quenched reaction 
samples were transferred from their original plate to a droplet making plate. The edges of the 
droplet making plate were built-up to 3 mm height using epoxy to hold oil over the wells. Samples 
were pulled into a 150 µm i.d. x 360 µm o.d Teflon tube (IDEX Health and Science, Oak Harbor, 
WA) connected to a Hamilton 25 µL gastight syringe (Reno, NV) mounted on a PHD 2000 
Programmable syringe pump (Harvard Apparatus, Holliston, TX). Both the syringe and Teflon 
tube were prefilled with perfluorodecalin (PFD, 95% purity, Acros Organics, NJ) prior to droplet 
generation. A computer controlled XYZ-positioner (built in-house from XSlide assemblies, 
Velmex Inc., Bloomfield, NY) was used to move the inlet of the Teflon tube from sample to sample 
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while the syringe was withdrawing at 1.2 µL/min. Quenched reaction droplets with 45 nL volume 
were segmented by 50 nL oil to make a droplet train. Each train began with calibration droplets 
containing simulated 1 % conversion samples.  
MS Analysis  
Teflon tubing containing droplets was threaded through a CE-MS ESI Source equipped with 
coaxial sheath-flow (Agilent Technologies, Santa Clara, CA). Sheath and droplet flows were drive 
by Fusion 400 syringe pumps (Chemyx, Stafford, TX) at 25 µL/min and 5 µL/min respectively. 
Sheath buffer contained 50/50 methanol/water with 0.5% formic acid. ESI-MS analysis was 
performed on an Agilent 6410 triple quadrupole mass spectrometer (Agilent Technologies, Santa 
Clara, CA) operated in multiple reaction monitoring (MRM) mode using the parameters in 
Table**. ESI potential was set to 2500 V, nebulizer gas to 12 psi, and drying gas from MS source 
was 10 L/min at 275 °C.  
Table 3.S4. Analysis of whole-cell reactions by droplet MS 
Analyte m/z transition  Dwell time (ms) Fragmentor (V) Collision energy 
(v) 
Tryptophan (3.68) 205 → 188 150 135 15 
Ketone pdt (3.69) 217 → 130 150 120 15 
 
 
Figure 3.S3. Droplet MS of calibration droplets and potential hits of active tryptophan 
variants. 
Data courtesy of LeeAnne Wang. Left: the 1% standard is equivalent to 1% conversion (10 µM) 
to ketone 3.69. Right: re-injections of the three potential hits. 
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Table 3.S5. Arginine-based ketone products from reactions catalyzed by the AONS domain. 
Entry R = Thioester substrate Product 
tR of product 
(min) 
1 Me acetyl-CoA or -SPh 
 
2.35 
2 Et propionyl-CoA or -SPh 
 
1.94 
3 Pr butyryl-CoA or -SPh 
 
1.62 
4 n-pentyl hexanoyl-CoA or -SPh 
 
1.24 
5 n-heptyl octanoyl-CoA or -SPh 
 
1.13 
6 iPr isobutyryl-CoA or -SPh 
 
1.67 
7 iBu isovaleryl-CoA or -SPh 
 
1.42 
8 Ph benzoyl-CoA or -SPh 
 
1.67 
9 cyclopentyl 3.S17 
 
1.58 
10 cyclohexyla 3.S18 
 
1.41 
aThe authentic standard for this product has not been synthesized. 
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Figure 3.S4. Extracted ion chromatograms of expected arginine ketone product masses 
(blue) and product standards (gray) for SxtA’s native product (3.8) and shunt product (3.9).  
A representative standard curve of ketone 3.8 used to calculate reaction conversions for AONS-
mediated reactions is on the bottom left. Standard curves were not constructed for the other 
products, so the relative yields are compared through the ratios of area under the curves of expected 
product divided by the area of the internal standard, 15N Arg.
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Figure 3.S5. Extracted ion chromatograms of expected arginine ketone product masses 
(blue) and product standards (gray). 
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Table 3.S6. Ethyl ketone products from reactions catalyzed by the AONS domain. 
Entry Amino acid Product tR of product (min) 
1 Arginine 
 
1.94 
2 Canavanine 
 
2.14 
3 Histidinea 
 
2.63 
4 Glycinea 
 
1.41 
5 Alanine 
 
1.32 
6 Leucine 
 
1.14 
7 Serinea 
 
1.56 
8 Tryptophan 
 
1.11 
aThese products have not been verified with synthetic standards. 
 
 
 
 
 
  
Figure 3.S6. Extracted ion chromatograms of expected ethyl ketone products masses (blue) and 
product standards (gray). 
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Chapter 4: SxtA AONS-Mediated Deuterium Labeling 
 
Reprinted (adapted) with permission from “Biocatalytic, Stereoselective Deuteration of α-
Amino Acids and Methyl Esters”. Chun, S. W.; Narayan, A. R. H. ACS Catal. 2020, 10, 7413-
7418. Copyright © 2020, American Chemical Society. 
Summary 
α-2H amino acids are valuable precursors toward labeled pharmaceutical agents and tools for 
studying biological systems; however, these molecules are costly to purchase and challenging to 
synthesize in a site- and stereoselective manner. Here, we show that an α-oxoamine synthase that 
evolved for saxitoxin biosynthesis, SxtA AONS, can produce a range of α-2H amino acids and 
esters site- and stereoselectively using D2O as the deuterium source. Additionally, we demonstrate 
the utility of this operationally simple reaction on preparative scale in the stereoselective 
chemoenzymatic synthesis of a deuterated analog of safinamide, a drug used to treat Parkinson’s 
disease. Having established that SxtA AONS can generate its nucleophilic quinonoid intermediate 
in the absence of a thioester partner, we will also be able to harness this biocatalyst for the 
formation of other amino acid derivatives. 
 
4.1 Introduction 
During our studies in the SxtA AONS-mediated synthesis of non-native α-amino ketones, we 
also considered whether this enzyme could elaborate α-amino acids into α-tetra-substituted 
derivatives (see 4.4, Figure 4.1). These products would arise from the key nucleophilic quinonoid 
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intermediate 4.2 adding to other classes of electrophiles rather than thioesters. Whether some other 
factor is required to trigger deprotonation of the external aldimine intermediate 4.1 in SxtA AONS 
to generate 4.2 was unknown. 
For numerous members of the α-oxoamine synthase (AOS) family, deprotonation does not 
proceed until the thioester substrate was added to the reaction solution.1–4 In reactions with SxtA 
AONS, the presence of compatible thioesters would result in mixture of competing α-amino ketone 
and tetra-substituted products. However, there are reports of three homologs, Bacillus sphaericus 
BioF and aminolevulinic acid synthase (ALAS) from Rhodobacter sphaeroides and Mus 
musculus,5–7 forming quinonoid I with only amino acid present. Other BioF2 and ALAS4 homologs 
also belong to the “thioester required” group, and this property also is not apparently predicted by 
the primary amino acid sequence alone. 
In the mid and late 1900s, it was debated whether the step following amino acid-PLP imine 
formation is deprotonation or decarboxylation. The existence of the non-decarboxylating 2-amino-
3-ketobutyric acid CoA ligase (KBL, see Chapter 3.1) in the AOS protein family, and multiple 
Figure 4.1. SxtA AONS-catalyzed diversification of α-amino acids through quinonoid 
intermediate I. 
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isotope labeling experiments summarized in Figure 4.2 strongly support that the step following 
amino acid binding in the AOS mechanism is indeed deprotonation.2,5,6,8,9 Figure 4.2B depicts the  
 
Figure 4.2. Isotopic labeling experiments to determine the mechanism of AOS enzymes. 
(A) Reactions with HemA or aminolevulinic acid synthase (ALAS). (B) reactions with BioF. 
 
 
results of the initial experiments aimed at ascertaining to which group SxtA AONS belongs, 
“thioester required”, or “thioester-less” deprotonation. Microseira wollei SxtA AONS and L-Arg 
(4.19) were incubated overnight in D2O-exchanged buffer and analyzed by MS (Figure 4.3). 
Approximately 18% of the arginine population now showed a mass of 1 Da higher than the 
substrate, indicating the replacement of one non-exchangeable hydrogen with a deuterium atom. 
This placed M. wollei SxtA AONS (as well as the C. raciborskii AONS homolog in our possession) 
in the “thioester-less” group, which would allow us to pursue the formation of tetra-substituted 
amino acid derivatives (see 4.4, Figure 4.1). This result prompted the exploration of SxtA AONS-
mediated α-deuteration as a synthetically useful reaction. 
Deuterated compounds are important tools in fundamental research and commercial endeavors 
including drug discovery and development.10–13 Deuterated drugs are often metabolized more 
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slowly than the analogous protio-compounds due to the kinetic isotope effect, affording longer 
half-lives and allowing for lower doses.14 The first deuterated drug candidate fludalanine (4.22,  
 
Figure 4.3. α-deuteration of L-Arg by SxtA AONS in deuterated buffer in the absence of a 
thioester partner. 
 
 
see Figure 4.4) was initially tested in the late 1970s as a mixture with cycloserine for inhibition 
of bacterial alanine racemase.15 For clinical trials, 4.22 was synthesized on gram-scale in four 
synthetic steps and one chiral resolution step.16 The deuterated analog was metabolized 2-3 times 
more slowly than the protio-compound, but eventually failed trials due to buildup of a toxic 
downstream metabolite.10,17 Scientists have continued developing deuterated bioactive 
compounds, with the FDA also recognizing the potential benefits of deuterated pharmaceutical 
agents. The first deuterated analog of an existing drug, deutetrabenazine (4.23), was approved in 
2017 for its doubled half-life over tetrabenazine.18 
 
Figure 4.4. Historical pharmaceutical candidates and products containing deuterium. 
 
 
The value of deuterated compounds creates a demand for methods to selectively introduce 
isotopic labels into available building blocks. For example, α-2H amino acids are potential 
pharmaceutical precursors,19 can be incorporated into proteins to improve NMR signal,20 and are 
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tools to probe protein and natural product metabolism.21,22 Despite the value of these molecules, 
synthetic access is challenging, with difficulties in achieving site- and stereoselectivity in the  
 
Figure 4.5. Preparations of deuterated compounds and amino acids. 
(A) Classical methods for synthesizing α-deuterated amino acids are lengthy (left). Recent 
chemical methods starting from the corresponding protio-amino acids vary in activity (right). (B) 
Potential biocatalytic deuteration by three classes of PLP-dependent enzymes. 
 
deuterium incorporation step. Established methods toward α-2H amino acids follow multi-step 
routes where protecting groups and chiral auxiliaries are required (see 4.24 to 4.3, Figure 4.5A), 
accounting for the hundred-fold higher cost for enantioenriched α-2H-amino acids relative to their 
protio- counterparts.23–25 Recent approaches offer more efficient access by targeting deuterated 
compounds directly from the corresponding unlabeled acids (see 4.25 to 4.3, Figure 4.5A). 
Although these methods provide high-levels of deuterium incorporation, they often fall short in 
achieving site- and stereoselectivity on a wide array of substrates.26,27 
A biocatalytic approach to the transformation of protio-amino acids to α-deuterated analogs 
offers several potential advantages, including precise stereoselectivity, the elimination of 
protecting groups, and mild, sustainable reaction conditions.28 Deuterium sources such as D2 and 
D2O are economical and available in bulk.
29 Any of the pyridoxal phosphate (PLP)-dependent 
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subclasses that begin with the deprotonation of the α-carbon could potentially be a biocatalyst for 
deuterium incorporation.30,31 In contrast to PLP-dependent transaminases and racemases, which 
catalyze deuterated amino acid formation with some substrate flexibility but rarely have control 
over site- and stereoselectivity (Figure 4.5B).32,33 α-oxoamine synthases (AOS) have been shown 
to install a deuterium atom at the α-position of select amino acids stereoselectively. For example, 
in mechanistic studies of AOS proteins BioF and serine palmitoyltransferase (SPT), incubation in 
D2O led to α-deuteration of their native substrates L-Ala and L-Ser, respectively.3,5 The deuterated 
products retained the L- configuration. 
 
Figure 4.6. SxtA AONS mediates α-deuterium incorporation on a wide range of substrates. 
 
 
After demonstrating that SxtA AONS accepts multiple structurally unrelated α-amino acid 
substrates in addition to its native L-arginine for conversion into α-amino ketones (see Chapter 
3.3), we reasoned that those seven non-native acids and perhaps others would also be substrates 
for α-deuteration. Here, we show that SxtA AONS is indeed an effective catalyst for α-deuteration 
of select L-amino acids and a broad panel of α-amino ester substrates (Figure 4.6). These deuterated 
building blocks can be generated on preparative-scale and employed in multi-step synthesis as we 
have demonstrated in the synthesis of a deuterated form of the Parkinson’s drug, safinamide.34,35 
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4.2 Deuterium Incorporation into Arg-Based Compounds 
Of the two methods to detect the presence of a quinonoid intermediate, UV-vis spectroscopy 
or isotopic labeling, we selected the latter as for its relative ease of interpretation. The 
spectroscopic details of SxtA AONS are discussed in Chapter 5.3. Our activity test consisted of 
incubating enzyme and an amino acid in deuterated buffer followed by MS analysis. 
 
Figure 4.7. Initial experiments of SxtA ACP-AONS in D2O. 
SxtA AONS incorporates deuterium into the native amino acid substrate L-Arg (4.19) at low levels, 
and at near theoretical maximum levels of the native ketone product (4.31). 
 
Several factors were considered prior to and during the analysis. Enzymatic reactions were 
quenched with a protio rather than deuterated (i.e., CH3OH instead of CD3OD) organic solvent to 
ensure that all exchangeable hydrogens were protons, and that any change in the exact mass was 
due to the formation of a new C–D bond, not heteroatom–D. Additionally, all ordinary protio- 
compound samples will contain isotopologs of the monoisotopic mass due to the presence of 
naturally occurring heavy isotopes such as 13C, 15N, and 34S. For example, in arginine, an 
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isotopolog with one 13C atom (176.1223 Da) is predicted to occur at 6.5% abundance than that of 
the monoisotopic mass (175.1190 Da). The difference in exact mass between a 13C and 2H 
isotopolog (176.1252 Da) is 0.0029 Da, too small to be resolved on our TOF and Q-TOF MS 
instruments. Therefore, these calculated abundances of heavy isotopologs were subtracted from 
the isotopic distributions to correct for naturally occurring heavy isotopes and compared to no-
enzyme negative controls in D2O and H2O. 
Initial experiments with M. wollei SxtA ACP-AONS and 4 mM L-Arg (L-4.19) incubated in 
deuterated buffer (78:22 v/v D2O to H2O) showed 18% deuterium incorporation after overnight 
incubation, equivalent to at least 36 deuteration turnovers (Figure 4.7). A positive control 
condensation reaction also containing propionyl-pantetheine (4.29) in addition to enzyme and L-
Arg resulted in 94 µM (9.4% conversion or <5 turnovers) of the native ketone product 4.31. 
However, 76% of the ketone formed had incorporation of at least one deuterium atom (4.30). In a 
separate reaction containing enzyme and 1 mM of the synthetic standard of 4.31, the total 
deuterium incorporation into the ketone was also 77%. This is equivalent to at least 154 enzyme 
deuteration turnovers, indicating that SxtA AONS may be more active in deprotonation and 
protonation than condensation. When the volumetric fraction of D2O was raised to >99:1 by 
preparing the buffers directly in D2O and pre-equilibrating the enzyme, the deuterium 
incorporation in 4 mM L-Arg increased from 18% to 37% (about 74 turnovers).  
Taken together, these data indicate that M. wollei SxtA AONS falls in the “thioester-less 
deprotonation” group of AOS enzymes. Because the protio-substrates and the deuterated products 
are in equilibrium with each other, the theoretical maximum deuterium incorporation is 
approximately equal to the D2O:H2O ratio. Any possible equilibrium isotope effects were not 
measured.36 
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The SxtA AONS product ketone 4.31 is also a better compound for AONS-mediated deuterium 
incorporation than the native amino acid substrate, L-Arg (L-4.19). One contributing factor may 
be the pKa of the alpha carbon, which is several units lower in an α-amino ketone than an α-amino 
acid.5,37 In a negative control reaction lacking enzyme, 78% D2O conditions tested above afforded 
8% of ketone 4.30 (at a starting concentration of 1 mM) with deuterium incorporation, while no 
nonenzymatic deuterium incorporation into L-Arg was detected. A second consideration may be 
that the binding of the ketone better induces a protein conformational change that favors 
deprotonation and formation of quinonoid intermediates.2,37 
 
Figure 4.8. Deuteration of arginine-related substrates. 
(A) α-deuterated compound formation. (B) Potential mechanisms of proton/deuterium transfers in 
SxtA AONS. (C) Timecourse of α-deuteration by mass spectrometry. (D) Comparison of 
deuterium incorporation and enantiomeric composition when starting with L-Arg-OMe (blue) or 
D-Arg-OMe (red). 
 
After discovering that the standalone domain SxtA AONS is sufficient to accomplish 
deuterium incorporation, we conducted all further experiments with SxtA AONS rather than the 
SxtA ACP-AONS didomain. To compare the approximate rates of deuterium incorporation in 
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these arginine-based compounds, we conducted time course experiments with both arginine (4.19) 
and arginine methyl ester enantiomers38 (4.32, all at 4 mM) and the product standard (4.31, at 2 
mM) in >99% D2O buffer. Under these conditions, approximately 20% of the L-acid had one 
deuterium atom incorporated as determined by LC-MS analysis (Figure 4.8C, black line). Whereas 
deuterium labeling was moderate for L-Arg, both ketone 4.31 and its structural mimic L-Arg-OMe 
reached maximum theoretical deuteration within 15 minutes (100 and 200 turnovers, respectively). 
Interestingly, substrates deuterated at a low level by SxtA AONS were readily transformed into 
compounds that were efficiently deuterated through esterification to the corresponding methyl 
ester (see D-Arg vs. D-Arg-OMe). Minor deuterium incorporation into the acids and esters was 
observed in controls lacking active enzyme, while the lower pKa of ketone 4.31 led to 15% 
nonenzymatic deuteration.5 
The site of deuterium incorporation was confirmed to be the α-carbon of L-Arg-OMe (L-4.32). 
In a phosphate-buffered reaction monitored by 1H NMR, the α-proton triplet signal at 4.09 ppm 
disappeared over 45 min, demonstrating complete replacement by deuterium (Figure 4.9). No 
decrease in the beta proton signals was observed, even at extended timepoints indicating a higher 
level of site-selectivity for SxtA AONS compared with deuteration mediated by other PLP-
dependent enzymes.32,39,40 The exception to this site-selectivity was observed only with ketone 
4.31, which possesses additional acidic protons alpha to the carbonyl group.5 No more than a single 
deuterium atom was incorporated into non-glycine-based amino acid and methyl ester-based 
substrates. 
As SxtA AONS deuterates both enantiomers of Arg-OMe, we next investigated the 
configuration of the deuterated products (4.33). In prior studies of AOS proteins, the catalytic 
lysine residue (Lys1083 in M. wollei SxtA) is proposed to stereospecifically mediate both the 
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initial deprotonation of the L-amino acid substrate and the subsequent reprotonation of the α-
position to generate L- products (Figure 4.8B, blue arrows).41,42 Notably, this residue is located on 
the si face of PLP in all published AOS crystal structures.43–47 On the basis of this general 
mechanism, the deprotonation and deuteration of D-Arg-OMe (D-32) is unexpected, but consistent 
with our previous observation that D-Arg is also converted to ketone 4.31 at low levels with 
unknown stereochemistry (see Chapter 3.2). Ongoing structural studies in collaboration with Prof. 
Janet Smith’s group aim to distinguish if SxtA AONS accommodates different binding modes48 
for each Arg-OMe enantiomer or if an alternative active site residue or water can serve as a base49 
to account for activity on D-configured substrates (Figure 4.8B, red arrows, and Figure 4.S29). 
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Figure 4.9. 1H NMR of L-Arg-OMe incubated with AONS over 3 h, confirming exchange of the α-proton (labeled b) to deuterium. 
Peaks present between 3.7-3.5 ppm are attributed to glycerol from the enzyme storage buffer. The integration of the beta protons (labeled 
c) remained at 2.0 throughout the experiment. 
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To determine the degree of stereocontrol exhibited by SxtA AONS, 20 mM of each Arg-OMe 
enantiomer was separately incubated with 20 µM SxtA AONS (1000 turnovers for full 
conversion). The resulting material was assessed for deuterium labeling and enantiopurity at 
various timepoints. In situ Fmoc protection after quenching the enzymatic reaction conveniently 
lowered the polarity of the α-amino esters and provided a UV-active chromophore that could be 
monitored. Analysis of Fmoc-derivatized compounds by chiral supercritical fluid chromatography 
(SFC) provided the enantiopurity of each product (see Table 4.S6). For L-Arg-OMe, complete 
deuterium incorporation and a high degree of retention of the L- configuration was observed at 45 
min, with slight enantio-erosion to 90:10 L to D occurring by 18 h (Figure 4.8D, blue lines). At this 
higher substrate concentration, D-Arg-OMe reached 89% deuteration (red lines, 890 turnovers). 
The rate of enantio-erosion was faster than that of the L-enantiomer, ending at a 38:62 L to D 
enantiomeric ratio after 18 h. For both enantiomers of ester 4.32, the retention of the original 
configuration does not track directly with the deuteration level, nor is the reprotonation step 
observed to be completely stereoselective. The reprotonation step for L-Arg-OMe is generally 
stereoretentive to afford primarily the deuterated L-isomer. The putative reprotonation step with a 
D-Arg-OMe substrate is less selective, producing significant quantities of L-product. The 
mechanism of deprotonation and reprotonation remains unclear in the absence of a SxtA AONS 
crystal structure. 
 
4.3 Deuterium Incorporation into Other Substrates 
We next evaluated the substrate promiscuity of SxtA AONS for deuterium incorporation. We 
anticipated that the other seven substrates for condensation (Gly, Ala, Leu, Ser, Trp, His, 
canavanine, see Chapter 3.3) would also be deuterated, as they must be deprotonated first in order 
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to form ketones. We screened twenty-four α-amino acids in total consisting of nineteen 
proteinogenic acids and five arginine-related acids (Figure 4.10A). 
 
Figure 4.10. Deuterium incorporation at the alpha position of amino acids and their methyl 
esters.  
(A) Deuterium incorporation into 4 mM of L-substrates after overnight incubation with SxtA 
AONS in D2O. (B) Total stereoretention of 20 mM of the original methyl ester substrate 
configuration at the time of highest deuterium incorporation (see Section 4.6 Experimental for full 
data set). 
 
In line with our initial studies with L-Arg (L-4.19) at 4 mM, most of these amino acids, 
including the structurally similar substrates L-ornithine, L-Lys and L-homoarginine, showed no or 
deuteration incorporation (Figure 4.10A, blue). Although some polar substrates demonstrated 
modest levels of deuterium incorporation, only two substrates were >90% deuterated, L-His and 
the Arg-mimic L-canavanine. The remaining five condensation substrates (Gly, Ala, Leu, Ser, Trp) 
were deuterated in low to modest levels. Based on our previous observation that esterification of 
Arg free acids to the corresponding methyl esters significantly increased both the rate and levels 
of deuterium incorporation (Figure 4.8C), we next assessed the corresponding methyl esters of the 
entire substrate panel (Figure 4.10A, gray). Most of these substrates were commercially available 
or accessible through synthesis in 1-2 steps. Gratifyingly, every L-methyl ester evaluated was 
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labeled to some extent with deuterium, and a majority (twenty side chains) were >90% labeled 
upon overnight incubation. The lowest-converting substrates were those with acidic side chains, 
as well as the polar ester L-Cys-OMe, and the aliphatic substrate L-Leu-OMe. Esterification 
slightly decreased the deuterium incorporation of Asp-based compounds, whereas L-Cys-OMe had 
significantly lower deuterium incorporation, likely due to the high levels of disulfide formation. 
Several D-methyl esters were also deuterated, but with no apparent correlation between the side 
chain and incorporation level (see Figure 4.S4). Thus, for SxtA AONS, a significantly greater 
breadth of methyl esters was deuterated compared to the analogous panel of amino acid substrates. 
The increased activity on methyl ester substrates may be due to the lower pKa of the α-proton,41,50,51 
higher structural similarity to the ethyl ketone product 4.31, or both. 
To assess the stereocontrol in SxtA AONS-catalyzed deuteration of non-arginine esters, we 
resolved the stereoisomers of compounds possessing fifteen different side chains by chiral SFC 
(Figure 4.10B). In reactions with L-methyl esters (black dots), the L- configuration was retained, 
with many substrates affording both high deuterium incorporation and retention of the original 
configuration at the alpha position. L-Tyr-OMe was the only L-substrate observed to have relatively 
low stereoretention (41:59 D/L er). There is no significant correlation between the steric bulk or 
class of side chain and level of deuterium incorporation. For D-esters (red dots), deuterium 
incorporation varied widely from <1% in select aliphatic side chains (e.g., D-Val-OMe, see Table 
4.S8 for full data set) to 94% for D-Arg-OMe. The mixtures of stereoisomers resulting from D-
substrates are approximately halfway between full stereoretention and stereoinversion to L for 
every molecule processed. Thus, after deprotonation of a D-substrate and formation of a putative 
quinonoid intermediate, the reprotonation step appears to be non-selective (see Figure 4.8B). A 
racemic mixture of deuterated ester was also observed when SxtA AONS was replaced with free 
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PLP in nonenzymatic reactions; however, only low amounts of deuteration occur in the absence 
of enzyme (see Table 4.S2 for full data set).52,53 For the achiral ester Gly-OMe, approximately 5% 
of the product mixture showed incorporation of two deuterium atoms. The remaining 95% of 
singly deuterated isotopomers could not be separated in our hands by chiral SFC analysis to 
determine enantioenrichment. 
 
Condensation to Ethyl Ketones from Methyl Esters 
The α-deuteration screen in Figure 4.10 demonstrated that seventeen of the amino acids that 
bind to the PLP cofactor of SxtA AONS and were deprotonated to form the first quinonoid 
intermediate (see 4.2, Figure 4.6), the next step on-pathway to α-amino ketone formation. 
However, only ketones derived from eight of those seventeen acids (Arg, Gly, Ala, Leu, Ser, Trp, 
His, canavanine, see Chapter 3.3) were detected. Because all twenty-four of the methyl ester 
substrates screened bound and were deprotonated to generate deuterated products, the esters might 
also be converted to α-amino ketones or α-tetra-substituted compounds (Figure 4.11). 
 
Figure 4.11. Potential ethyl ketone or α-tetra-substituted amino acid derivative formation 
from the corresponding methyl esters. 
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α-amino methyl esters and propionyl-pantetheine (4.29) were incubated with SxtA ACP-
AONS and analyzed for formation of ethyl ketones (4.38) and α-tetra-substituted compounds by 
LC-MS. Only the same eight ketones were detected, but not quantified due to low overall 
conversion. We did not observe unhydrolyzed or undecarboxylated ketones (4.39 and 4.40). The 
esterification from α-amino acids to their corresponding methyl esters induced SxtA AONS to 
deprotonate all substrates, but the modification was not sufficient to continue to the addition of the 
propionyl group. Perhaps intermediate 4.36 more closely resembles quinonoid II, formed by 
deprotonation of PLP-ethyl ketone complexes (see 2.36 in Figure 2.7) rather than quinonoid I (see 
4.2 in Figure 4.1). Formation of a diketone product from addition of another acyl group to the 
native product 4.31 has not previously been detected, and therefore, the protein conformation of 
quinonoid 4.36 may not be conducive to acyl addition. There may be another contributing factor 
in the ketone formation mechanism controlling the progression toward 4.38. Spectroscopic studies 
of SxtA to identify some possible factors are detailed in Chapter 5.3. 
 
Other AOS Enzymes 
 
Figure 4.12. The native reactions of ALAS (A) and SPT (B). 
 
 
We obtained two other AOS enzymes, R. sphaeroides ALAS and Sphingomonas wittichii 
serine palmitoyltransferase (SPT), which natively catalyze the reactions in Figure 4.12. The 
proteins were also screened for their ability to deuterate the α-position of α-amino acids. For ALAS 
(Figure 4.13, left), low deuterium incorporation was detected in a few amino acids (Met, Thr, Gln). 
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We observed modest incorporation into two substrates, Asn and Ser, and the remaining side chains 
had very minor activity. The native substrate Gly could not be detected on the Q-TOF MS 
instrument to confirm that R. sphaeroides ALAS also belongs to the group of AOS enzymes that 
deprotonates α-amino acids in the absence of its thioester substrate succinyl-CoA (4.6). Due to the 
acidic succinyl group added in the native condensation reaction (see 4.7, Figure 4.12A), it was 
difficult to easily synthesize ester structural mimics to screen for increased deuteration activity as 
we did for SxtA AONS. 
SPT’s palmitoyl (C16) substrate is also aliphatic like SxtA AONS’ propionyl group (see 4.43 
and 4.44, Figure 4.12B), so we screened the enzyme with both α-amino acids and their 
corresponding methyl esters (Figure 4.13, right). For the acids, side chains of similar size and 
polarity to the native Ser substrate (Cys, Met, Asn, Thr) were deuterated in modest to good 
amounts. Esterification generally increased incorporation, with significant improvement in 
deuterium levels in substrates like Gly-OMe and Ala-OMe. However, the gains in deuteration were 
not nearly as dramatic across the entire panel of SPT substrates as in the case for SxtA AONS. The 
lower pKa of the α-amino ester compared to the acid may have contributed to the higher SPT 
activity, but we speculate that the rest of the acyl chain is also involved in shifting the protein’s 
conformation to one favoring deprotonation. 
We also intend to test α-amino myristyl esters (C14), closer structural mimics to the SPT 
product 4.44 as well. Even if this esterification does increase the deuteration, myristyl esters are 
more difficult to handle and prepare. The myristic alcohol used for esterification is a solid at room 
temperature and insoluble in water, whereas many of the methyl ester substrates in Figure 4.10 
were synthesized neat in methanol. Therefore, we elected to use SxtA AONS over ALAS and SPT 
for preparative-scale reactions due to its higher activity and broader substrate scope. 
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Figure 4.13. Deuterium incorporation into α-amino acids and methyl esters, catalyzed by 
AOS proteins ALAS and SPT. 
 
 
4.4 Chemoenzymatic Synthesis of Deuterated Safinamide and Alanine 
With evidence that SxtA AONS performs over a thousand turnovers, we sought to test the 
scalability of this transformation. As an initial target, we selected the Parkinson’s drug, safinamide, 
which can be synthesized from an L-Ala-OMe precursor.34,35,54  
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Figure 4.14. Deuterium incorporation into increasing concentrations of L-Ala-OMe. 
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We first maximized the substrate concentration, testing up to 50 mM ester and selected 40 mM 
for the best compromise between total deuterium incorporation and reaction volume (Figure 4.14). 
A 200-mg preparative scale deuteration reaction was conducted in 40 mL of D2O, requiring nearly 
40 mg of SxtA AONS, a quantity easily purified from 0.5 L of E. coli culture (Figure 4.15). 
Although high levels of hydrolysis of methyl esters to acids in phosphate buffer were previously 
observed, we conducted the scale-up in phosphate to minimize co-purification with HEPES. The 
HEPES buffer has a similar Rf by thin-layer chromatography to Ala-OMe (4.44) and is highly 
soluble in methanol, the organic solvent used to quench the enzymatic reaction and redissolve the 
ester for chromatography. We recovered 60% of the ester (4.45) from the deuteration reaction after 
purification by flash column chromatography with >99% deuterium incorporation and 96% ee. 
This deuterated building block was elaborated over three steps according to an established route 
to safinamide to deliver deutero-safinamide (4.47) with 96% final deuterium incorporation (Figure 
4.15).54 
To determine the final enantioenrichment, we also synthesized both protio-enantiomers of 
safinamide from D- and L-Ala-OMe. Although the primary amino group of Ala is now secondary 
in safinamide, both isomers proved to be too polar to be resolved by SFC. Literature on quality 
control of commercial-grade safinamide suggests that the drug compound, as well as the other very 
polar side chains we could not resolve by SFC in Figure 4.10, should be analyzed by ligand-
exchange chromatography instead.55,56 Assuming racemic reprotonation after deuterium loss 
throughout the safinamide synthesis, however, we estimate the final ee to be 93%. 
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Figure 4.15. Synthesis of deutero-safinamide (4.47) and L-[2-2H]alanine (4.48). 
 
 
Deuterated ester 4.45 was also easily saponified with LiOH to α-deuterated alanine 4.48, 
maintaining 97% of the α-deuterium label, an example of a building block useful in protein 
synthesis or other coupling reactions.57,58 
 
4.5 Conclusions 
We have demonstrated that SxtA AONS, a PLP-dependent enzyme that natively transforms an 
amino acid into an α-amino ketone, can be repurposed to install deuterium atoms site-selectively 
at the α-carbon of amino acids and amino esters. The presence of thioesters is not required for 
deuteration to occur. The method is particularly robust on a broad range of methyl ester substrates 
affording α-deuterated products under mild conditions. Even among promiscuous PLP-dependent 
amino acid-derivatizing enzymes, such as the broad-specificity racemases, SxtA AONS’ ability to 
accommodate such a wide range of substrates that vary in structure and stereochemical 
configuration is unprecedented. The overall stereoselectivity of the C–D bond-forming step varies 
according to the side chain of α-amino methyl esters but in general, SxtA AONS exhibits high 
stereoselectivity with L-substrates, affording deuterated products with high levels of stereocontrol 
to generate products with the L- configuration. Finally, the utility and scalability of this one-step, 
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protecting group-free, biocatalytic method was applied to the chemoenzymatic synthesis of 
deuterium-labeled safinamide. 
We anticipate that this method can easily be applied to the syntheses of other deuterated or 
tritiated products. Additionally, for substrates that are close to the line of full stereoinversion in 
Figure 4.10B (e.g., D-Ala-OMe, D-Met-OMe), SxtA AONS or its variants may potentially be 
leveraged for dynamic kinetic resolution. Furthermore, Ikushiro and coworkers have demonstrated 
that AOS enzymes in the “thioester required deprotonation” category can be used as biocatalysts 
for deuterium incorporation. Although deuterium incorporation occurred extremely slowly in L-
Ser (t1/2 = 103 ± 6 h) for Sphingomonas paucimobilis SPT, the rate was enhanced (t1/2 = 0.75 ± 
0.03 h) in the presence of nonhydrolyzable and unreactive thioether 4.49 (Figure 4.15), which 
mimics the structure of the native thioester substrate, palmitoyl-CoA (see 4.42, Figure 4.12). 
Similarly, for SxtA AONS, binding of a pantetheine or CoA thioethers such as 4.51 could cause 
the desired protein conformational change to accelerate deuteration. New directions in biocatalytic 
α-deuteration mediated by wild-type SxtA AONS and the libraries currently being developed for 
α-amino ketone and α-tetra-substituted amino acid derivative synthesis will continue to be 
explored. 
 
Figure 4.16. α-deuteration in a “thioester required” AOS enzyme by addition of a thioether 
that mimics the structure of the native thioester partner substrate. 
See Ikushiro et al. 3 
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The data from these deuterium incorporation experiments indicate that SxtA AONS can bind 
the majority of our L-amino acid substrate panel and deprotonate all twenty-four α-protons if the 
acid is esterified. However, only seven of the non-native side chains continue to be processed to 
α-amino ketones, so there must be multiple factors controlling possible conformational changes 
for deprotonation to the quinonoid intermediate and then addition to the thioester. The following 
Chapter will discuss our efforts to identify the residues and interactions responsible for SxtA 
AONS conformational changes. 
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4.6 Experimental 
I. Chemical synthesis 
A. General information 
All reagents were used as received unless otherwise noted. Reactions were carried out under a 
nitrogen atmosphere using standard Schlenck techniques unless otherwise noted. Solvents were 
degassed and dried over aluminum columns on an MBraun solvent system (Inert Corporation, 
Model PS-00-3). Reactions were monitored by thin layer chromatography using Machery-Nagel 
60 F254 precoated silica TLC plates (0.25 mm) or Merck Silica Gel 60 RP-18 WF-254S precoated 
silica TLC plates (0.25 mm) which were visualized using UV, ninhydrin, p-anisaldehyde, cerium 
ammonium molybdate, 2,4-dinitrophenylhydrazine, or bromocresol green stain. Flash column 
chromatography was performed using Machery-Nagel 60 μm (230-400 mesh) silica gel. All 
compounds purified by flash column chromatography were sufficiently pure for use in further 
experiments unless otherwise indicated. Preparative-scale high performance liquid 
chromatography was carried out on a Waters 1525 Binary HPLC pump equipped with a Waters 
2489 UV detector using a Phenomenex Kinetex 5 µm C18, 21.2 x 150 mm column. Solvent A = 
water with 0.1% v/v formic acid; solvent B = acetonitrile with 0.1% v/v formic acid. 1H and 13C 
NMR spectra were obtained in CDCl3, CD3OD or D2O at rt (25 °C), unless otherwise noted, on 
Varian 400 MHz or Varian 600 MHz spectrometers. Chemical shifts of 1H NMR spectra were 
recorded in parts per million (ppm) on the δ scale referenced to residual solvent peaks. Electrospray 
ionization liquid chromatography-mass spectrometry (LC-MS) analysis was performed on an 
Agilent G6545A quadrupole-time of flight mass spectrometer in positive mode with an Agilent 
1290 UPLC system, or an Agilent 6320 time of flight mass spectrometer with an Agilent 1290 
Infinity II UPLC system. Solvent A = water with 0.1% formic acid. Solvent B = 95% acetonitrile, 
5% water and 0.1% formic acid. MS data were analyzed using the Agilent Qualitative Mass Hunter 
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software. Chiral separation was performed on the Waters Investigator supercritical fluid 
chromatography (SFC) system. SFC data were analyzed using the Waters ChromScope Software. 
 
B. Compound synthesis 
General procedure for direct esterification of unprotected amino acids 
 
The amino acid (2.2 mmol, 1.0 equiv) was suspended in methanol (2.5 mL) in a 20 mL vial. 
Thionyl chloride (180 µL, 2.4 mmol, 1.1 equiv) was added dropwise to the suspension on ice, 
resulting in dissolution of the amino acid. The vial was then capped, and the reaction mixture 
stirred at 65 °C for 2.5 h. Diethyl ether (5 mL) was added. The reaction mixture was concentrated 
under reduced pressure and diluted with more ether (5 mL) repeatedly to remove residual acid 
until a foam or solid formed. 
 
 
L-homoarginine methyl ester dihydrochloride (L-homoArg-OMe, L-4.S1): The general 
procedure afforded 610 mg of the title compound as a gray foam (quantitative yield). 1H NMR 
(600 MHz, D2O) δ 4.15 (t, J = 6.4 Hz, 1H), 3.83 (s, 3H), 3.19 (t, J = 6.9 Hz, 2H), 2.05 – 1.87 (m, 
2H), 1.67 – 1.59 (m, 2H), 1.55 – 1.35 (m, 2H). All spectra obtained were consistent with literature 
values.59 
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L-canavanine methyl ester dihydrochloride (L-4.S2): The general procedure afforded 96 mg of 
the title compound as an off-white foam (quantitative yield from 100 mg of L-canavanine sulfate). 
1H NMR (600 MHz, D2O) δ 4.31 (t, J = 6.6 Hz, 1H), 4.20 – 4.08 (m, 2H), 3.85 (s, 3H), 2.44 – 
2.27 (m, 2H). All spectra obtained were consistent with literature values.60 
 
 
D-lysine methyl ester dihydrochloride (D-4.S3): The general procedure afforded 520 mg of the 
title compound as a pale-yellow powder (quantitative yield). 1H NMR (600 MHz, D2O) δ 4.15 (t, 
J = 6.5 Hz, 1H), 3.83 (s, 3H), 2.99 (t, J = 7.8 Hz, 2H), 2.08 – 1.87 (m, 2H), 1.70 (p, J = 7.8 Hz, 
2H), 1.59 – 1.39 (m, 2H). All spectra obtained were consistent with literature values.61  
 
 
D-ornithine methyl ester dihydrochloride (D-4.S4): The general procedure afforded 480 mg of 
the title compound as a yellow powder (99% yield). 1H NMR (600 MHz, D2O) δ 4.19 (t, J = 6.5 
Hz, 1H), 3.85 (s, 3H), 3.04 (t, J = 7.7 Hz, 2H), 2.14 – 1.93 (m, 2H), 1.92 – 1.70 (m, 2H). All spectra 
obtained were consistent with literature values.62 
 
 
D-allo-threonine methyl ester hydrochloride (D-4.S5): The general procedure afforded 377 mg 
of the title compound as white needle crystals (quantitative yield). 1H NMR (600 MHz, CD3OD) 
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δ 4.25 (qd, J = 6.6, 3.6 Hz, 1H), 4.07 (d, J = 3.5 Hz, 1H), 3.85 (s, 3H), 1.26 (d, J = 6.6 Hz, 3H). 
All spectra obtained were consistent with literature values.63 
 
 
D-allo-isoleucine methyl ester hydrochloride (D-4.S6): The general procedure afforded 400 mg 
of the title compound as a white foam (99% yield). 1H NMR (600 MHz, D2O) δ 4.12 (d, J = 3.9 
Hz, 1H), 3.83 (s, 3H), 2.18 – 2.09 (m, 1H), 1.54 – 1.41 (m, 1H), 1.37 – 1.22 (m, 1H), 0.96 (d, J = 
7.1 Hz, 3H), 0.93 (t, J = 7.4 Hz, 3H). All spectra obtained were consistent with literature values.64 
 
 
L-citrulline methyl ester hydrochloride (L-4.S7): The general procedure afforded 500 mg of the 
title compound as an off-white foam (quantitative yield). 1H NMR (600 MHz, D2O) δ 4.15 (t, J = 
6.4 Hz, 1H), 3.82 (s, 3H), 3.12 (td, J = 6.7, 3.0 Hz, 2H), 2.03 – 1.85 (m, 2H), 1.68 – 1.47 (m, 2H). 
All spectra obtained were consistent with literature values.65 
 
 
D-citrulline methyl ester hydrochloride (D-4.S7): The general procedure afforded 498 mg of the 
title compound as an off-white foam (99% yield). 1H NMR (600 MHz, D2O) δ 4.15 (t, J = 6.4 Hz, 
1H), 3.82 (s, 3H), 3.12 (td, J = 6.7, 3.0 Hz, 2H), 2.02 – 1.85 (m, 2H), 1.66 – 1.46 (m, 2H). All 
spectra obtained were consistent with literature values.65 
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General procedure for esterification and Boc-deprotection of substrates with amide-containing 
side chains (Asn, Gln). Adapted from Kuttan et al.66 
 
Boc-protected amino acid (2.6 mmol, 1.0 equiv) was resuspended in methanol (5.0 mL) in a 20 
mL vial. Cerium ammonium nitrate (1.5 g, 2.6 mmol, 1.0 equiv) was added to the resuspension 
and the vial was sealed. The reaction stirred at 65 °C for 24 h, turning from a deep red suspension 
to a yellow solution overnight. Solvent was removed under reduced pressure and the crude residue 
was purified by flash chromatography (10% methanol v/v in dichloromethane). 
 
 
L-asparagine methyl ester (L-4.S8): The general procedure afforded 411 mg of the title 
compound as off-white needle-shaped crystals (99% yield). Rf = 0.1 (10% v/v methanol in 
dichloromethane). 1H NMR (600 MHz, D2O) δ 4.40 (dd, J = 6.1, 4.5 Hz, 1H), 3.83 (s, 3H), 3.08 
(dd, J = 17.4, 6.1 Hz, 1H), 3.01 (dd, J = 17.4, 4.5 Hz, 1H). All spectra obtained were consistent 
with literature values.67 
 
 
D-asparagine methyl ester (D-4.S8): The general procedure afforded 225 mg of the title 
compound as off-white needle-shaped crystals (54% yield). Rf = 0.1 (10% v/v methanol in 
dichloromethane). 1H NMR (600 MHz, D2O) δ 4.41 (dd, J = 6.0, 4.5 Hz, 1H), 3.83 (s, 2H), 3.09 
(dd, J = 17.4, 6.0 Hz, 1H), 3.01 (dd, J = 17.4, 4.5 Hz, 1H). All spectra obtained were consistent 
with literature values.67 
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L-glutamine methyl ester (L-4.S9): The general procedure afforded 223 mg of the title compound 
as off-white needle-shaped crystals (50% yield). Rf = 0.1 (10% v/v methanol in dichloromethane).
 
1H NMR (600 MHz, D2O) δ 4.17 (t, J = 6.7 Hz, 1H), 3.83 (s, 3H), 2.57 – 2.45 (m, 2H), 2.29 – 
2.15 (m, 2H). All spectra obtained were consistent with literature values.68  
 
 
D-glutamine methyl ester (D-4.S9): The general procedure afforded 353 mg of the title compound 
as off-white needle crystals (79% yield). Rf = 0.1 (10% v/v methanol in dichloromethane). 1H 
NMR (600 MHz, D2O) δ 4.17 (t, J = 6.7 Hz, 1H), 3.83 (s, 3H), 2.57 – 2.44 (m, 2H), 2.29 – 2.14 
(m, 2H). All spectra obtained were consistent with literature values.68 
 
 
D-glutamic acid α-methyl ester (D-4.S10): A round-bottomed flask was charged N-Cbz-D-
glutamic acid alpha-methyl ester (200 mg, 0.68 mmol), 10 wt% Pd/C (50 mg) and methanol (10 
mL). The flask was sparged with N2 for 20 min then equipped with an H2-filled balloon and 
sparged again for 15 min. The reaction was stirred under an H2 atmosphere for 24 h. The reaction 
mixture was filtered through celite and concentrated to afford 106 mg of the title compound as a 
white powder (97% yield). 1H NMR (600 MHz, D2O) δ 4.14 (t, J = 6.4 Hz, 1H), 3.82 (s, 3H), 2.37 
(td, J = 7.3, 2.6 Hz, 2H), 2.23 – 2.06 (m, 2H). All spectra obtained were consistent with the 
commercially available L-glutamic acid α-methyl ester.69 
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Tri-Boc-protected D-homoarginine (D-4.S12): procedure adapted from Tsuchiya et al.70 D-lysine 
hydrochloride (66 mg, 0.36 mmol, 1.0 equiv) and anhydrous copper carbonate (160 mg, 0.72 
mmol, 2.0 equiv) were resuspended in 2.5 mL of water in a 20 mL vial equipped with a stir bar. 
The vial was sealed and the reaction mixture heated at 100 °C for 1 h. The cooled reaction mixture 
was then filtered to remove the insoluble copper salt. The blue filtrate was concentrated to a residue 
in a 10 mL round bottom flask equipped with a stir bar and resuspended in 350 µL of dioxane and 
717 µL of formamide. 4.S11 (110 mg, 0.36 mmol, 1.0 equiv) and iPr2NEt (150 µL, 0.83 mmol, 
2.3 equiv) were added to the resuspension, which stirred overnight under N2 at rt. The following 
day, the clear blue solution was diluted with EtOAc (5 mL) and brine (10 mL), and extracted with 
EtOAc (3 x 15 mL). The homoarginine intermediate was not especially soluble in EtOAc, so the 
combined organic layers were not dried, but concentrated slowly down to a pale blue powder in a 
25 mL round bottom flask. To the flask was added acetone (5 mL), water (1 mL), EDTA·2Na (88 
mg, 0.24 mmol, 0.66 equiv), NaHCO3 (93 mg, 1.1 mmol, 3.0 equiv) and Boc anhydride (180 mg, 
0.83 mmol, 2.3 equiv), resulting in an opaque blue viscous resuspension that stirred vigorously 
overnight under N2 at rt. After 16 h, the reaction mixture had become biphasic—a clear organic 
layer on top and a clear blue aqueous lower layer. The mixture was diluted with brine (5 mL) and 
extracted with EtOAc (3 x 15 mL). The combined organic layers were dried over Na2SO4, filtered 
and concentrated to a pale green residue. Flash chromatography (5% v/v methanol in 
dichloromethane) afforded 106 mg (60% yield over three steps) of the title compound as a clear 
residue. Rf = 0.3. 1H NMR (600 MHz, CD3OD) δ 4.07 (dd, J = 9.2, 4.6 Hz, 1H), 3.37 (dt, J = 7.1, 
2.7 Hz, 2H), 1.85 (m, 2H), 1.72 – 1.56 (m, 4H), 1.54 – 1.51 (m, 9H), 1.47 (m, 9H), 1.45 (m, 9H); 
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13C NMR (150 MHz, CD3OD) δ 164.4, 164.3, 158.1, 157.5, 154.1, 84.4, 80.4 (2 carbons), 49.9, 
41.6, 32.6, 29.8, 28.8, 28.6, 28.3, 24.2; HRMS (ESI) m/z calcd for C22H41N4O8
+ [M+H]+ 489.2919 
m/z, found 489.2922. All spectra obtained were consistent with literature values.71 
 
 
D-homoarginine methyl ester dihydrochloride (D-4.S1): The general procedure for direct 
esterification of unprotected amino acids afforded 35 mg (quantitative yield) of the title compound 
from tri-Boc-protected D-homoarginine D-S12 (43 mg) obtained as a reddish-brown residue. 1H 
NMR (600 MHz, D2O) δ 4.14 (t, J = 6.4 Hz, 1H), 3.83 (s, 3H), 3.18 (t, J = 6.9 Hz, 2H), 2.03 – 
1.86 (m, 2H), 1.65 – 1.58 (m, 2H), 1.55 – 1.28 (m, 2H). All spectra obtained were consistent with 
literature values.59 
 
 
L-[2-2H]alanine (4.48): L-[2-2H]alanine methyl ester 4.35 (20 mg, 0.19 mmol, 1.0 equiv) as a 1 
M solution in methanol, and LiOH (9 mg, 0.38 mmol, 2.0 equiv) as a 1 M solution in water were 
combined and stirred in a 4 mL vial at rt for 30 min (monitored by TLC, 10% v/v methanol in 
dichloromethane, starting material Rf = 0.2). The solvent was then removed under reduced 
pressure, affording a white powder (21 mg as a mixture of lithium salts). Rf = 0. 1H NMR (400 
MHz, D2O) δ 1.20 (s, 3H); 13C NMR (150 MHz, D2O) δ 185.3, 51.7 (t, J = 21 Hz), 20.9; HRMS 
(ESI) m/z calcd for C3H7DNO2 [M+H]
+ 91.0612 m/z, found 91.0616 (97.6% deuterium 
incorporation).72 
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Deuterated safinamide and the (R)-enantiomer were synthesized according to a procedure modified 
from Du et al.54 
 
4-((3-fluorobenzyl)oxy)benzaldehyde (4.S13): To a flame-dried 25 mL flask equipped with a stir 
bar were added 1-(chloromethyl)-3-fluorobenzene (1.2 mL, 9.6 mmol, 1.2 equiv), 4-
hydroxybenzaldehyde (0.98 g, 8.0 mmol, 1.0 equiv), anhydrous potassium carbonate (1.1 g, 8.0 
mmol, 1.0 equiv), potassium iodide (0.13 mg, 0.8 mmol, 0.1 equiv) and anhydrous ethanol (12 
mL). The reaction mixture refluxed at 85 °C for 6 h, and then partially concentrated to a slurry. 
The slurry was diluted with brine and extracted with EtOAc. The combined organic layers were 
washed with sat. aq. sodium thiosulfate to remove excess iodide, then dried over Na2SO4, filtered 
and concentrated. Flash chromatography on silica gel (25% v/v EtOAc in hexanes) afforded 1.68 
g (91% yield) of the title compound as an off-white solid. Rf = 0.3. 1H NMR (400 MHz, CDCl3) 
δ 9.90 (s, 1H), 7.89 – 7.81 (m, 2H), 7.37 (td, J = 7.9, 5.8 Hz, 1H), 7.22 – 7.13 (m, 2H), 7.06 (dd, J 
= 8.2, 6.4 Hz, 3H), 5.15 (s, 2H). All spectra obtained were consistent with literature values.73 
 
 
Methyl (4-((3-fluorobenzyl)oxy)benzyl)-L-alaninate ((S)- 4.S14): To a flame-dried 10 mL flask 
equipped with a stir bar were added aldehyde 4.S13 (166 mg, 0.72 mmol, 1.0 equiv), L-alanine 
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methyl ester hydrochloride (100 mg, 0.72 mmol, 1.0 equiv), Na2SO4 (36 mg, 0.25 mmol, 0.35 
equiv), and anhydrous methanol (0.9 mL). NEt3 was added dropwise and the reaction stirred under 
N2 at rt for 2 h. The reaction mixture was then filtered to remove solids. NaBH4 (28 mg, 0.72 
mmol, 1.0 equiv) was added in two portions to the filtrate, which bubbled and then formed a white 
suspension overnight. The following day, the reaction mixture was concentrated slightly under 
reduced pressure, diluted with brine (5 mL) and extracted with toluene (3 x 15 mL). The combined 
organic layers were dried over Na2SO4, filtered and concentrated. The residue was purified by 
flash chromatography on silica gel (50% v/v EtOAc in hexanes), affording 200 mg (86% yield) of 
the title compound as a clear oil. Rf = 0.3. 1H NMR (600 MHz, CD3OD) δ 7.37 (td, J = 8.0, 5.8 
Hz, 1H), 7.28 – 7.20 (m, 3H), 7.17 (d, J = 9.5, 1H), 7.06 – 6.99 (m, 1H), 6.98 – 6.90 (m, 2H), 5.09 
(s, 2H), 3.70 (s, 3H), 3.68 (d, J = 12.6 Hz, 1H), 3.60 (d, J = 12.6 Hz, 1H), 3.36 (q, J = 7.0 Hz, 1H), 
1.29 (d, J = 7.0 Hz, 3H). All spectra obtained were consistent with literature values.54 
 
 
Methyl (4-((3-fluorobenzyl)oxy)benzyl)-D-alaninate ((R)- 4.S14): The above procedure 
afforded 123 mg (54% yield) of the title compound as a clear oil from 100 mg of D-alanine methyl 
ester hydrochloride.1H NMR (600 MHz, CD3OD) δ 7.33 (td, J = 7.9, 5.8 Hz, 1H), 7.26 – 7.22 (m, 
2H), 7.20 (d, J = 7.6 Hz, 1H), 7.14 (d, J = 9.9 Hz, 1H), 7.00 (td, J = 8.6, 2.7 Hz, 1H), 6.94 – 6.90 
(m, 2H), 5.03 (s, 2H), 3.67 (overlapping singlet and doublet, J = 14.7 Hz, 4H), 3.59 (d, J = 12.6 
Hz, 1H), 3.37 (q, J = 7.0 Hz, 1H), 1.28 (d, J = 7.0 Hz, 3H); 13C NMR (150 MHz, CD3OD) δ 176.5, 
164.3 (d, J = 245 Hz), 159.2, 141.6 (d, J = 7 Hz), 132.4, 131.3 (d, J = 8 Hz), 131.0, 124.0 (d, J = 
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3 Hz), 115.9, 115.4 (d, J = 21 Hz), 115.0 (d, J = 22 Hz), 69.9, 56.4, 52.4, 51.8, 18.5; HRMS (ESI) 
m/z calcd for C18H21FNO2 [M+H]
+ 318.1500 m/z, found 318.1503. 
 
 
Methyl (4-((3-fluorobenzyl)oxy)benzyl)-L-alaninate-2-d (4.46): The above procedure afforded 
34 mg (58% yield) of the title compound as a clear oil from 20 mg (0.19 mmol) of 4.45. 1H NMR 
(600 MHz, CD3OD) δ 7.36 (td, J = 7.9, 5.8 Hz, 1H), 7.29 – 7.20 (m, 3H), 7.16 (dt, J = 9.9, 2.1 Hz, 
1H), 7.02 (td, J = 8.6, 2.6 Hz, 1H), 6.97 – 6.91 (m, 2H), 5.07 (s, 2H), 3.69 (s, 3H), 3.67 (d, J = 
12.6 Hz, 1H), 3.58 (d, J = 12.6 Hz, 1H), 1.27 (s, 3H); 13C NMR (150 MHz, CD3OD) δ 176.8, 
164.4 (d, J = 245 Hz), 159.3, 141.7 (d, J = 7 Hz), 132.7, 131.3 (d, J = 8 Hz), 131.0, 124.0 (d, J = 
3 Hz), 115.9, 115.4 (d, J = 21 Hz), 115.0 (d, J = 22 Hz), 70.0, 56.1 (t, J = 21 Hz), 52.4, 51.9, 18.5; 
HRMS (ESI) m/z calcd for C18H20DFNO2 [M+H]
+ 319.1563 m/z, found 319.1568 (96% deuterium 
incorporation). 
 
 
(S)-safinamide, methanesulfonate salt ((S)- 4.S15): To a 20 mL vial equipped with a stir bar was 
added ester (S)-4.S14 (150 mg, 0.46 mmol, 1.0 equiv) and 2 mL of concentrated aqueous ammonia. 
The vial was sealed and heated at 55 °C overnight. After 16 h, a white resuspension had formed. 
The reaction mixture was concentrated to a white powder (140 mg) under reduced pressure, 50 mg 
of which was purified by preparative high-performance liquid chromatography. Solvent A = water 
with 0.1% formic acid. Solvent B = acetonitrile with 0.1% formic acid; method = 5% B at 10 
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mL/min for 1 min, followed by a linear gradient to 70% B over 7 min, and a second linear gradient 
to 100% B over 7 min, 100% B for 1 min, a linear gradient to 5% B over 1 min and then 1 min re-
equilibration at 5% B (total time 18 min). The desired amide product eluted at 7.7 min, partially 
separated from a major side product (RT = 8.5 min) that appears to be the carboxylic acid. Relevant 
fractions were combined and concentrated to a white powder (35 mg). To the powder was added 
5 mL of isopropanol, and the mixture was heated to 45 °C. Methanesulfonic acid (7.6 µL, 0.12 
mmol, 1.0 equiv) was added to the reaction mixture, which was cooled slowly to rt to precipitate 
the product salt. The suspension was concentrated, affording 41 mg (approx. 70% of the amount 
chromatographed) of the title compound as a white powder. 1H NMR (600 MHz, CD3OD) δ 7.46 
– 7.41 (m, 2H), 7.38 (td, J = 8.0, 5.8 Hz, 1H), 7.24 (dt, J = 7.6, 1.3 Hz, 1H), 7.17 (dt, J = 9.8, 2.1 
Hz, 1H), 7.10 – 7.05 (m, 2H), 7.03 (td, J = 8.5, 2.4 Hz, 1H), 5.14 (s, 2H), 4.11 (s, 2H), 3.95 (q, J 
= 7.0 Hz, 1H), 2.71 (s, 3H), 1.55 (d, J = 7.0 Hz, 3H). All spectra obtained were consistent with 
literature values.55 
 
 
(R)-safinamide, methanesulfonate salt ((R)- 4.S15): The above procedure afforded 17 mg of the 
title compound as a white powder from starting from 50 mg of (R)-4.S14 (27% over 2 steps). 1H 
NMR (600 MHz, CD3OD) δ 7.45 – 7.41 (m, 2H), 7.38 (td, J = 8.0, 5.8 Hz, 1H), 7.25 (dt, J = 7.7, 
1.3 Hz, 1H), 7.17 (dt, J = 9.8, 2.1 Hz, 1H), 7.10 – 7.06 (m, 2H), 7.03 (td, J = 8.4, 2.3 Hz, 1H), 5.15 
(s, 2H), 4.11 (s, 2H), 3.93 (q, J = 7.0 Hz, 1H), 2.71 (s, 3H), 1.55 (d, J = 7.0 Hz, 3H); 13C NMR 
(150 MHz, CD3OD) δ 172.4, 164.4 (d, J = 245 Hz), 160.9, 141.3 (d, J = 7 Hz), 132.8, 131.4 (d, J 
= 8 Hz), 124.6, 124.1 (d, J = 3 Hz), 116.6, 115.6 (d, J = 21 Hz), 115.0 (d, J = 22 Hz), 70.0, 56.4, 
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50.5, 39.5, 16.9; HRMS (ESI) m/z calcd for C17H20FN2O2 [M+H]
+ 303.1503 m/z, found 303.1512. 
All spectra obtained were consistent with literature values.55 
 
 
Deuterated safinamide, methanesulfonate salt (4.47): The above procedure afforded 13 mg 
(32% yield over 2 steps) of the title compound as a white powder from 32 mg (0.10 mmol) of 4.46. 
1H NMR (600 MHz, CD3OD) δ 7.45 – 7.41 (m, 2H), 7.38 (td, J = 8.0, 5.8 Hz, 1H), 7.26 – 7.23 
(m, 1H), 7.17 (dt, J = 9.8, 2.1 Hz, 1H), 7.10 – 7.06 (m, 2H), 7.06 – 7.01 (m, 1H), 5.15 (s, 2H), 4.10 
(s, 2H), 2.71 (s, 3H), 1.54 (s, 3H); 13C NMR (150 MHz, CD3OD) δ 172.3, 164.4 (d, J = 245 Hz), 
160.9, 141.3 (d, J = 7 Hz), 132.8, 131.4 (d, J = 8 Hz), 124.6, 124.1 (d, J = 3 Hz), 116.6, 115.6 (d, 
J = 21 Hz), 115.0 (d, J = 22 Hz), 70.0, 56.1 (t, J = 21 Hz), 50.4, 39.5, 16.8; HRMS (ESI) m/z calcd 
for C17H19DFN2O2 [M+H]
+ 304.1566 m/z, found 304.1565 (95.8% deuterium incorporation). Due 
to the polarity of safinamide, the final ee could not be determined by SFC. 
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II. Cloning, protein expression and purification 
A. General information 
Escherichia coli cloning strain DH5α (Invitrogen) was used for DNA propagation. Protein was 
expressed in E. coli strains BL21(DE3) (New England BioLabs) after transformation with 
MW_sxtA_AONS subcloned into pMCSG7K (provided by the University of Michigan Center for 
Structural Biology) plasmids. Cells were grown in Luria Bertani (LB) or Terrific broth (TB) with 
4% v/v glycerol supplemented with kanamycin (50 µg/mL) purchased from Gold Biotechnology. 
 
A pET28b plasmid containing Swit_SPT was purchased from Twist Biosciences. 
 
Primers were purchased from Integrated DNA Technologies. DpnI restriction enzyme was 
purchased from New England BioLabs. Ligation-independent cloning (LIC)-qualified T4 DNA 
polymerase was purchased from EMD Millipore. QIAquick PCR purification, gel extraction and 
miniprep kits were purchased from Qiagen. HisPur nickel-nitrilotriacetic acid (Ni-NTA) resin was 
purchased from Thermo Scientific. Proteins were concentrated using Amicon centrifugal filters 
purchased from EMD Millipore at 4,000 x g, 4 °C. PD-10 desalting columns were purchased from 
GE Healthcare. Protein samples were analyzed on Mini-PROTEAN TGX Gels (4-15%) from 
BioRad and visualized with Protein Ark Quick Coomassie Stain from Anatrace. Proteins were 
quantified with the Pierce 660 nm Assay Reagent from Thermo Scientific. 
 
  
 281 
 
B. Sequence information 
pMCSG7K Microseira wollei sxtA AONS E. coli-optimized sequence. GenBank accession 
ACG63826.1; linkers and the 6x-His tag are shown in bold. 
atgcaccatcatcatcatcattcttctggtgtagatctgggtaccgagaacctgtacttccaatccaatgcaGAAAA
GCAGAGTGATCTGGCGAGCCCCGTGGACTTAGCTAATGAAATCAACACATTAGAAAATGTTGTCAATCAGCAGAAGA
TCCCTCAGGTTACGCGCGTAGTGACTGAACAGCAAGGTCGTAAGGTCTTGATCGATGGCCACTGGGTGATTGACTTC
GCCTCATGCAACTATTTAGGTTTAGACTTGCACCCCAAAGTGAAGGAGGCTATCCCCCCGGCTTTGGAGAAGTGGGG
GGTCCATCCCTCTTGGACACGTTTGGTGGCCAGCCCGGTAATCTATGAGGAATTAGAGGAGGAGTTAAGCAAACTGT
TAGGAGTTCCCGACGTATTAGTTTTCCCAAGCGTCACATTACTTCAGATCGGGGTCTTGCCACTTCTGACAGGCTCG
AACGGAGTTATTTTAGGCGACATTGCTGCGCATCGTTGCATTTACGAGGCCTGCTGCCTGGCACAGCAGAAGGGCTC
ACAGTTTATCCAATATCGCCACAATGACTTGAATGATTTAGCGGAGAAATTGGCAAAGTATCCACTGGAACAAGTCA
AAATCATCGTCATTGACGGAGTGTACTCTATGTCCGCCGACTTCCCAGACCTTCCGGCTTACGTCCGCCTGGCGAAG
GAATACAATGCTTTTATTTATATGGATGACGCGCACGGATTTGGTATTTTGGGTGAGAACCCGTCCTCCGATATGCC
TTACGGATACAAAGGTAATGGTATGGTGAATTATTTCGATCTTCAATTTGCCGAGGACAACATTATCTACGTCGCGG
GGTTGTCTAAAGCCTACAGTTCGTACGCCGCCTTTCTTACTTGCGGTGATCGTCAGATTAAGACCAATTTCCGTAAT
GCTTGGACTGCCATTTTCAGCGGTCCTAGCCCAGTGGCAAGCTTGGCATCAGCCTTGGCCGGCTTACAGGTTAATCG
TCAGGAAGGAGAACAACTTCGCAAGCAAATCTACCACTTGACGCGCAAATTGGTGACCCAAGCTCGCGCCATTGGCT
TCGAAGTGGACAACTACGGTTACGTTCCCATCGTTTCCGTCTTAGTCGGAGACGCGCAACACATGATTGACGTATGT
CAGCTGCTGTGGGAGTACGGCATTCTGATCACACCCGCTATTTTCCCAATTGTTCCACTTAATAAATCCGCGCTGCG
CTTTTCTATCACAGCTGCCAATACGGAAGAAGAGATTGACCAAGCCATCAAAGCATTGGAGGGGGTATGGGTCCTGC
TTCAGAAAGAGAAGcattag 
 
Translation: linkers and the 6x-His tag are shown in bold. 
MHHHHHHSSGVDLGTENLYFQSNAEKKSDLASPVDSANEINTLENVVNQQKIPQVTRVVTEQQDRKVLIDGHWVIDF
ASCNYLGLDLHPKVKEAIPPALEKWGVHPSWTRLVASPAIYEELEEELAKLLGVPDVLLFPSLTLLQMGVLPLLTGN
NGVIFGDISAHRCIYEACCLAQHKGAQFIQYRHNDLNDLAAKLAKYPLEQVKIIAIDGVYSMSADLPDLPAYVRLAK
QYNALIYIDDAHGFGILGENPSSDMPYGYKGNGIVNYFDLRFAEDNIIYVAGLSKAYSSYAAFVTCGNSQIKTQFRN
AWTAIFSGPSPVASLASALAGLQVNRQEGEQLRKQVYYLTHKLVTQARAIGFEVDNYSYVPIVSVLVGDAQHIVDVC
QLLWEYGILITPAIFPIVPLNKTALRFSITAANTEEEIDQAIKALEAVWDLLQKRKALLCKH* 
 
Primers used: overhangs for ligation-independent cloning are shown in boldface. The reverse 
primer encodes an extra His residue at the C terminus as an error in the primer design (underlined). 
MW_AONS_LIC_fwd – 5’-TACTTCCAATCCAATGCAGAAAAGAAGTCCGATCTGGC-3’ 
MW_AONS_LIC_rev – 5’-TTATCCACTTCCAATGCTAATGCTTACATAAAAGGGCTTTGCG-3’ 
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pMCSG7 Rhodobacter capsulatus hemA (aminolevulinic acid synthase, ALAS) E. coli-optimized 
sequence. GenBank accession ADE85192.1; linkers and the 6x-His tag are shown in bold. 
atgcaccatcatcatcatcattcttctggtgtagatctgggtaccgagaacctgtacttccaatccaatgcaatgGA
TTACAACTTGGCATTAGATAAAGCCATCCAAAAGTTGCATGACGAAGGCCGCTATCGTACCTTCATCGACATTGAGC
GTGAAAAAGGAGCTTTTCCTAAAGCGCAGTGGAATCGTCCCGATGGAGGGAAACAAGACATCACTGTCTGGTGCGGC
AACGATTATTTGGGCATGGGTCAACACCCTGTGGTCCTTGCCGCCATGCACGAGGCCTTAGAGGCCGTCGGAGCTGG
GTCTGGAGGCACACGCAACATTAGTGGCACGACCGCATATCATCGTCGTCTTGAGGCAGAAATTGCCGATTTGCACG
GGAAGGAGGCAGCTTTGGTCTTCTCGTCTGCTTACATTGCGAATGATGCGACGCTGAGCACGTTACGTGTCCTTTTT
CCAGGGCTTATCATTTATAGTGACTCATTGAATCATGCGTCTATGATCGAAGGGATCAAGCGTAATGCAGGGCCGAA
ACGCATCTTCCGTCACAACGACGTTGCTCACCTTCGTGAATTGATTGCGGCAGATGACCCGGCGGCCCCAAAATTAA
TTGCGTTTGAGTCCGTTTACAGTATGGATGGCGATTTCGGACCTATTAAGGAGATCTGCGATATTGCGGACGAGTTT
GGTGCCCTTACATACATCGATGAAGTACATGCAGTAGGGATGTACGGCCCTCGCGGTGCAGGAGTCGCGGAGCGCGA
TGGGCTGATGCACCGTATCGACATCTTCAATGGAACCTTGGCGAAAGCATACGGCGTATTCGGCGGCTATATTGCTG
CTTCGGCGAAAATGGTGGATGCCGTTCGTTCCTATGCGCCGGGGTTTATTTTCTCAACTTCGCTTCCGCCTGCGATC
GCTGCTGGAGCCCAAGCGTCTATCGCGTTTTTGAAAACCGCCGAAGGACAGAAATTACGCGACGCGCAACAAATGCA
CGCAAAGGTCCTGAAAATGCGCCTTAAAGCCCTTGGGATGCCCATCATTGATCACGGATCCCATATTGTGCCTGTCG
TAATCGGGGATCCCGTGCACACTAAAGCCGTGAGCGATATGTTGCTTTCGGATTATGGGGTTTATGTCCAACCAATC
AACTTTCCCACGGTCCCACGCGGAACGGAGCGTCTTCGCTTTACCCCGAGCCCTGTCCATGACTTAAAGCAGATTGA
CGGGTTGGTGCACGCCATGGATCTTCTTTGGGCTCGTTGTGCACTTAATCGTGCAGAAGCCTCGGCT 
 
Translation: linkers and the 6x-His tag are shown in bold. 
MHHHHHHSSGVDLGTENLYFQSNAMDYNLALDKAIQKLHDEGRYRTFIDIEREKGAFPKAQWNRPDGGKQDITVWCG
NDYLGMGQHPVVLAAMHEALEAVGAGSGGTRNISGTTAYHRRLEAEIADLHGEAALVFSSAYIANDATLSTLRVLFP
GLIIYSDSLNHASMIEGIKRNAGPKRIFRHNDVAHLRELIAADDPAAPKLIAFESVYSMDGDFGPIKEICDIADEFG
ALTYIDEVHAVGMYGPRGAGVAERDGLMHRIDIFNGTLAKAYGVFGGYIAASAKMVDAVRSYAPGFIFSTSLPPAIA
AGAQASIAFLKTAEGQKLRDAQQMHAKVLKMRLKALGMPIIDHGSHIVPVVIGDPVHTKAVSDMLLSDYGVYVQPIN
FPTVPRGTERLRFTPSPVHDLKQIDGLVHAMDLLWARCALNRAEASA 
 
Primers used: overhangs for ligation-independent cloning are shown in boldface. 
RC_hemA_LIC_fwd – 5’-TACTTCCAATCCAATGCAGATTACAACTTGGCATTAGATAAAG-3’ 
RC_hemA_LIC_rev – 5’-TTATCCACTTCCAATGCTAAGCCGAGGCTTCTGCACG-3’ 
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pET28b Sphingomonas wittichii serine palmitoyltransferase E. coli-optimized sequence. GenBank 
accession ABQ70245.1; linkers and the 6x-His tag are shown in bold. 
atgggcagcagccatcatcatcatcatcacagcagcggcctggtgccgcgcggcagccatatggctagcatgactgg
tggacagcaaatgggtcgcggatccgaattcgagctcATGGCCGATTTGCTTAGCAAATTTGATCCTTTAATCGCCG
AGCGCGAGGCATTGCTTGCGACCGGCGTACGTGACCCGTACGCAATTGTTATGGACAAAGTGCTTTCGCCAACAGAA
GCCATGATTAATGGTCGTAAGACAATCTTGCTTGGTACGTATAATTACATGGGTATGACTTTCGATCCAGACGTGAT
TGCCGCCGGCAAGCAGGCGCTTGATGAATTTGGATCAGGAACAACAGGCTCCCGTGTCCTTAATGGAACTTATCAAG
GGCACAAAGCCTGCGAGGACGCACTGAAAGAGTTCTATGGAACAGAGCACGCTATCGTTTTCTCCACCGGATACCAG
GCTAACCTGGGTATGATCAGCACTCTGGCCGGTAAAGGTGACTATATCATTTTGGATGCCGACTCGCACGCCTCCAT
CTACGACGGTTGTTGGTTGGGAGACGCGGAGATCGTACGCTTCCGTCACAACAGTGTGGAGGACTTAGATAAGCGTT
TGGGTCGCCTTCCAGCCGAGGCCGGCAAATTAGTTGTTTTGGAGGGTGTCTACTCAATGATGGGCGACATCGCTCCC
CTGCAGGAGATGGTTGCAGTCTCAAAAAAACATGGGGCCATGATCTTAGTTGACGAAGCGCATGGGATGGGATTCTT
CGGGGAGCACGGTCGTGGTGTATTCGAAGAAGCAGGGGTAGAGGCAGACGTTGACTTCGTCGTTGGCACCTTTTCTA
AGTCAGTAGGGACGGTTGGTGGCTTCTGTGTGTCAAATCATCCCAAATTCGAAGTCCTTCGCTTGGTCTGCCGCCCT
TACGTCTTTACCGCATCATTGCCACCCAGCGTGGTAGCTACCGCGGCTACCAGCATCCGCAAGCTGATGCACGCAGG
CGACAAGCGCGCGCACTTATGGAAGAATAGTCGTCGTCTTCACCAAGGGTTGCGTGACATGGGCTACAAGTTGGGAA
CGGAGACAGCACAGTCTGCAATCATCGCTGTGATTTTGACGGACATGGCGCAGGCAGTAGCACTGTGGCAAGGGTTG
CTTGAGGCTGGGCTTTATGTAAATACGGCACGTCCGCCTGCTACGCCCGCCGGGATGTTCCTTTTGCGCTGCTCGTT
ATGTGCAGAACATAGTGATGAGCAAGTAGAGCAAATCCTGGGCATGTTTGAGTCGGCAGGGCGTGCTACGGGAGTAA
TTCCCAAGCTTgcggccgcactcgagcaccaccaccaccaccac 
 
 
Translation: linkers and the 6x-His tag are shown in bold. 
MGSSHHHHHHSSGLVPRGSHMASMTGGQQMGRGSEFELMADLLSKFDPLIAEREALLATGVRDPYAIVMDKVLSPTE
AMINGRKTILLGTYNYMGMTFDPDVIAAGKQALDEFGSGTTGSRVLNGTYQGHKACEDALKEFYGTEHAIVFSTGYQ
ANLGMISTLAGKGDYIILDADSHASIYDGCWLGDAEIVRFRHNSVEDLDKRLGRLPAEAGKLVVLEGVYSMMGDIAP
LQEMVAVSKKHGAMILVDEAHGMGFFGEHGRGVFEEAGVEADVDFVVGTFSKSVGTVGGFCVSNHPKFEVLRLVCRP
YVFTASLPPSVVATAATSIRKLMHAGDKRAHLWKNSRRLHQGLRDMGYKLGTETAQSAIIAVILTDMAQAVALWQGL
LEAGLYVNTARPPATPAGMFLLRCSLCAEHSDEQVEQILGMFESAGRATGVIPKLAAALEHHHHHH 
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C. Cloning 
M. wollei sxtA ACP-AONS didomain (residues Ala722-Lys1243) as an E. coli-optimized sequence 
were ordered from Twist Biosciences subcloned into a pET28b plasmid (pET28b-MW_sxtA_ACP-
AONS). The AONS domain (residues Glu822-Lys1243) was amplified in a 50 µL PCR reaction 
containing 10 μL Phusion HF buffer, 2 ng/μL parent plasmid, 2 μM each of forward and reverse 
LIC primers, 200 μM each of dNTPs, 0.04 U/μL Phusion HF. The didomain was amplified 
according to the following PCR procedure: 95 °C 2:00, (95 °C 0:30, 55 °C 1:00, 60 °C 2:00) for 
30 cycles, 72 °C 10:00. The insert was purified by gel extraction and subcloned into pMCSG7K 
(custom plasmid provided by the University of Michigan Life Sciences Institute Center for 
Structural Biology) using standard LIC protocols,74 resulting in pMCSG7K-MW_sxtA_AONS. 
 
R. capsulatus hemA was obtained as an E. coli-optimized gene fragment from IDT and was 
amplified in a 50 µL PCR reaction containing 10 μL Phusion HF buffer, 0.8 ng/μL gene fragment, 
2 μM each of forward and reverse LIC primers, 200 μM each of dNTPs, 0.04 U/μL Phusion HF. 
The didomain was amplified according to the following PCR procedure: 95 °C 2:00, (95 °C 0:30, 
64 °C 0:45, 60 °C 1:30) for 25 cycles, 72 °C 10:00. The insert was purified by gel extraction and 
subcloned into pMCSG7 (provided by the University of Michigan Life Sciences Institute Center 
for Structural Biology) using standard LIC protocols,74 resulting in pMCSG7-RC_hemA. 
 
Correct insertion was confirmed by Sanger sequencing at the University of Michigan DNA 
Sequencing Core. 
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D. Protein overexpression and purification 
Chemically competent BL21(DE3) cells were transformed with pMCSG7K-MW_sxtA_AONS. A 
single colony was picked to inoculate a 5 mL LB starter culture containing 50 µg/mL kanamycin 
and was incubated overnight at 37 °C, 200 rpm. The following day, 0.5 L TB media containing 50 
µg/mL kanamycin was inoculated with the starter culture and incubated at 37 °C, 250 rpm until 
the OD600 reached 1.0. Cultures were equilibrated at 20 °C for 1 h prior to induction by addition 
of isopropyl-β-D-thiogalactopyranoside (IPTG, final concentration 200 μM). Cultures were 
incubated at 20 °C, 200 rpm for 18 h. 
Harvested cell pellets were resuspended in approx. 4 mL of lysis buffer (50 mM HEPES, 300 mM 
NaCl, 10 mM imidazole, 1 mM PLP, 10% v/v glycerol, pH 8.0) per gram of wet pellet. The 
resuspended mixture was lysed by sonication (3 s on, 6 s off, 4:00 total). Insoluble material was 
removed by centrifugation (30,000 x g for 30 min at 4 °C). The clarified lysate was incubated with 
gentle shaking along with 2 mL of nickel-NTA resin for 1 h at 4 °C and poured into a column. The 
resin-bound protein was washed with 25 mL wash buffer (50 mM HEPES, 300 mM NaCl, 25 mM 
imidazole, 10% (v/v) glycerol, pH 8.0). The desired protein was eluted with 6 mL elution buffer 
(50 mM HEPES, 300 mM NaCl, 300 mM imidazole, 10% (v/v) glycerol, pH 8.0). The eluted 
protein was concentrated using 30 kDa centrifugal cutoff filters and exchanged into storage buffer 
(50 mM HEPES, 200 mM NaCl, pH 7.4) using a PD-10 column. The desalted protein was 
concentrated further using 30 kDa centrifugal cutoff filters, aliquoted, flash frozen in liquid 
nitrogen and stored at -80 °C. The typical yield was ~80 mg protein per half liter of TB culture. 
 
HemA was expressed and isolated following same procedure but with the following buffers: lysis 
buffer contained 50 mM Tris-HCl, 300 mM NaCl, 10 mM imidazole, 1 mM TCEP, 1 mM PLP, 
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10% v/v glycerol, pH 8.0; wash elution buffer contained 50 mM Tris-HCl, 300 mM NaCl, 25 mM 
imidazole, 1 mM TCEP, 10% v/v glycerol, pH 8.0; buffer contained 50 mM Tris-HCl, 300 mM 
NaCl, 300 mM imidazole, 1 mM TCEP, 10% v/v glycerol, pH 8.0; storage buffer contained 50 
mM HEPES, 200 mM NaCl, 10% v/v glycerol, pH 7.4. 
 
SPT was expressed and isolated following same procedure but with the following buffers: lysis 
buffer contained 20 mM potassium phosphate, 150 mM NaCl, 10 mM imidazole, 1 mM PLP, 10% 
v/v glycerol, pH 7.5; wash buffer contained 20 mM potassium phosphate, 150 mM NaCl, 40 mM 
imidazole, 10% v/v glycerol, pH 7.5; elution buffer contained 20 mM potassium phosphate, 150 
mM NaCl, 300 mM imidazole, 10% v/v glycerol, pH 7.5; storage buffer contained 50 mM HEPES, 
200 mM NaCl, 10% v/v glycerol, pH 7.4. 
 
   
Figure 4.S1. Denatured SDS-PAGE protein gel of SxtA AONS, SPT and HemA (ALAS). 
Left: expected mass of recombinant M. wollei SxtA AONS = 49,641 Da. Right: lanes 2 and 3, 
expected mass of S. wittichii SPT = 48,549 Da; lane 4: expected mass of R. capsulatus HemA = 
46,984 Da. 
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III. Enzymatic reactions 
A. General information 
Deuterium oxide was purchased from Cambridge Isotopes. Deuterated solutions were prepared by 
lyophilization on a Labconco FreeZone 2.5 L Freeze Dry System. 
 
B. Preparation of deuterium-equilibrated solutions 
Preparation of deuterated buffers 
Reaction buffer was initially prepared in H2O as a 10x concentrate (500 mM HEPES or potassium 
phosphate, 1.5 M NaCl, pH 7.0) and lyophilized. The remaining powder was resuspended in D2O 
and lyophilized a second time. This powder was redissolved in D2O to make a 10x stock solution. 
 
Preparation of deuterium-equilibrated protein 
The 10x D2O-equilibrated buffer above was diluted to the 1x working concentration (50 mM 
HEPES or phosphate, 150 mM NaCl) with additional D2O. Protein aliquots of SxtA AONS were 
thawed and diluted with the 1x buffer, and then concentrated in 30 kDa MWCO centrifugal filters. 
The dilution/concentration cycle was repeated 3x total to exchange the protein into deuterated 
buffer. Protein concentration was measured again by the Pierce 660 assay and proteins were then 
used in assays on the same day. 
 
Preparation of deuterium-equilibrated substrates 
α-amino acids and their corresponding α-methyl esters were dissolved in D2O to make 100 mM 
solutions. Less soluble acid substrates (Cys, Asp, Glu, Trp, Tyr) were prepared at 50 mM instead. 
The solutions were lyophilized, and the resulting powders or residues were redissolved in D2O. 
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C. Enzymatic reaction procedures and data 
 
Deuterium incorporation assays for mass spectrometry only (Figures 4.7, 4.8C, 4.10A, 13) 
Buffer (50 mM HEPES, 150 mM NaCl diluted from 10x concentration above), 4 mM amino 
acid or methyl ester and 20 µM SxtA AONS in D2O were combined for a total volume of 25 µL 
and incubated at 30 °C for 18 h. For PLP-only nonenzymatic control reactions, SxtA AONS was 
replaced with 20 µM PLP, and the substrate concentration varied between 4 and 20 mM (see Table 
4.S2). For the timecourse reactions (Figure 4.8C), the total volume of the analytical-scale reactions 
was 100 µL. At every timepoint (1, 5, 10, 15, 20, 30, 60 and 120 min), 10 µL of the reaction 
mixture was withdrawn. In all cases, the enzymatic reactions were quenched with 4 volumes of 
MeOH. Precipitate was pelleted at 12,000 x g for 20 min. The supernatant was diluted 20x with 
acetonitrile and 1% formic acid in water for a final concentration of 4 µM substrate. The final 
ratios (v/v) for analysis were 5% quenched reaction, 49% of 1% formic acid in water and 45% 
acetonitrile. For reactions with higher concentrations of substrates, reaction aliquots were 
quenched as above but diluted further to a final substrate concentration of 4 µM such that the final 
LC-MS sample mixture was 50% aqueous and 50% organic by volume. Samples were analyzed 
by LC-MS: column = Waters Acquity 1.7 μm UPLC BEH Amide HILIC 2.1 x 100 mm; method 
= 85% B at 0.3 mL/min for 2 min, followed by a linear gradient to 75% B at 0.4 mL/min over 3 
min and a second linear gradient to 60% B over 0.5 min, 60% B for 1 min and then 5.5 min re-
equilibration at 85% B at 0.3 mL/min (total time 12 min). See Table 4.S1 for the retention times 
of each amino acid and methyl ester substrate tested. 
For early reactions with D2O <99%, the stock buffer, substrate and protein solutions were used as 
normally prepared in H2O and the remaining volume was filled with D2O. Following reports that 
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blue light decreased the pKa of amino acid-PLP complexes,75 we also attempted to irradiate 
translucent 96-well plate containing SxtA AONS and amino acids in D2O with a blue Kessil lamp 
(450 nm). The irradiation suppressed almost all enzymatic activity. 
Reaction with C. raciborskii SxtA ACP-AONS: Buffer (50 mM HEPES, 150 mM NaCl, 1 mM 
MgCl2, 0.5 mM MnCl2), 4 mM L-Arg and 10 µM SxtA ACP-AONS in D2O were combined for a 
total volume of 25 µL and incubated at 30 °C for 18 h (76% v/v D2O). Deuterium incorporation: 
37%. Positive control with 1 mM propionyl-SPh: 81% deuteration. 
Reactions with HemA/ALAS were performed with 50 mM HEPES pH 7.4, 150 mM NaCl, 1 mM 
MgCl2, 4 mM L-Arg and 20 µM HemA in D2O in a total volume of 25 µL and incubated at 30 °C 
for 18 h (76% v/v D2O). 
Reactions with SPT were performed with 20 mM potassium phosphate pH 7.4, 150 mM NaCl, 1 
mM MgCl2, 4 mM amino acids and 20 µM SPT in D2O in a total volume of 25 µL and incubated 
at 30 °C for 18 h (81% v/v D2O). 
 
 
Recovery of deuterated L-Ala-OMe (4.45) on preparative scale (Figure 4.15) 
Buffer (50 mM potassium phosphate, 150 mM NaCl diluted from 10x concentration above), 40 
mM L-alanine methyl ester hydrochloride (4.44, 223 mg) and 20 µM SxtA AONS in D2O were 
combined for a total volume of 40 mL and incubated at 30 °C for 8 h. The reaction was quenched 
by the addition of 160 mL of MeOH. Precipitate was pelleted at 5,000 x g for 20 min. The 
supernatant was concentrated to a white powder under reduced pressure. Ester 4.39 was dissolved 
in 4 mL of methanol and purified by flash chromatography on silica gel (10% v/v methanol in 
dichloromethane). The deuterated ester was isolated as the free base (98 mg, 60% recovery), with 
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99.2% deuterium incorporation. Rf = 0.2. 1H NMR (600 MHz, CD3OD) δ 3.83 (s, 3H), 1.51 (s, 
3H); 13C NMR (150 MHz, CD3OD) δ 172.1, 53.6, 49.7 (t, J = 21 Hz), 16.5; HRMS (ESI) m/z 
calcd for C18H20DFNO2 [M+H]
+ 105.0769 m/z, found 105.0773 (99.2% deuterium incorporation). 
97.3% ee. 
 
1H NMR observation of deuterium incorporation into L-Arg-OMe (L-4.32, Figure 4.9) 
Buffer (50 mM phosphate and 150 mM NaCl diluted from the 10x concentrated stock described 
above) and 20 mM L-Arg-OMe (L-4.32) were combined in D2O in a microcentrifugue tube (450 
µL final volume with enzyme). Upon addition of 20 µM SxtA AONS, the reaction mixture was 
immediately pipetted into an NMR tube and inserted into the NMR instrument (600 MHz) for 
observation. See Fig 4.9 for spectra. 
 
 
Biosynthesis of α-amino ketones from α-amino methyl esters (Figure 4.11) 
4 mM α-amino Me esters, 1 mM propionyl-pantetheine (4.27), and 20 µM M. wollei SxtA ACP-
AONS were combined for a total reaction volume of 25 µL. The reactions were incubated at 30 
°C for 18 h. Reactions were quenched by diluting 5x with methanol. Precipitate was pelleted at 
12,000 x g for 20 min. The supernatant was diluted 20x with acetonitrile, 1% formic acid, and 
aqueous 10 μg/mL 15N Arg·HCl. The final ratios (v/v) for analysis were 5% quenched reaction, 
2.5% of aqueous 10 μg/mL 15N Arg·HCl (Cambridge Isotope Laboratories), 46% acetonitrile, 
46.5% of 1% formic acid in water (e.g., 10 μL of quenched reaction, 5 μL of 10 μg/mL 15N 
Arg·HCl, 92 μL acetonitrile, 93 μL of 1% formic acid in water for a total volume of 200 μL). 
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Samples were analyzed by LC-MS: column = Waters Acquity 1.7 μm UPLC BEH Amide HILIC 
2.1 x 100 mm column; method = 85% B at 0.3 mL/min for 2 min, followed by a linear gradient to 
75% B at 0.4 mL/min over 3 min and a second linear gradient to 60% B over 0.5 min, 60% B for 
1 min and then 6.5 min re-equilibration at 85% B at 0.3 mL/min (total time 15 min). tR (
15N Arg): 
4.0 min. Ratios were calculated by comparing the areas under the curve of the extracted ion 
chromatograms. The overall ketone yield was not calculated. Reactions were run in duplicate. 
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Table 4.S1. Summary of retention times of amino acid and methyl ester substrates by LC-
MS 
Side chain Retention time of acid (min) Retention time of methyl ester (min) 
Gly 3.0 1.5 
Ala 2.6 1.4 
Val 2.0 1.1 
Leu 1.6 1.1 
Ile 1.7 (D-allo: 1.8 min) 1.1 (D-allo: 1.2) 
Nle 1.6 1.1 
Cys 2.8 1.1 
Met 2.0 1.1 
Asn 3.8a 1.8 
Gln 3.6a 1.7 
Ser 3.7 1.7 
Thr 3.2 (D-allo: 3.3) 1.5 (D-allo: 1.7) 
Phe 1.7 1.1 
Tyr 2.1 1.2 
Trp 1.5 1.1 
His 4.4 2.8 
Lys 4.4 2.8 
Orn 4.6 3.0b 
Arg 4.3 2.5 
Canavanine 4.3 2.7 
Homoarginine 4.0 2.4 
Citrulline 3.7 1.9 
Asp 3.4 1.8 
Glu 3.0 1.5 
aThe masses corresponding to the free acids were only detected in reactions with the methyl esters substrates and not 
in reactions with the amino acid substrates.  bA portion also appears as the cyclized adduct. 
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Deuterium incorporation into arginine ketone standards 
Buffer (50 mM potassium phosphate, 150 mM NaCl diluted from 10x concentration above), 2 mM 
synthetic ketone standards (synthesized by Dr. Meagan Hinze, see Chapter 3.4) and 20 µM SxtA 
AONS in D2O were combined for a total volume of 25 µL (96% v/v) and incubated at 30 °C for 2 
h. The enzymatic reactions were quenched with 4 volumes of MeOH. Precipitate was pelleted at 
12,000 x g for 20 min. The supernatant was diluted 20x with acetonitrile and 1% formic acid in 
water. Samples were analyzed by LC-MS: column = Waters Acquity 1.7 μm UPLC BEH Amide 
HILIC 2.1 x 100 mm; method = 85% B at 0.3 mL/min for 2 min, followed by a linear gradient to 
75% B at 0.4 mL/min over 3 min and a second linear gradient to 60% B over 0.5 min, 60% B for 
1 min and then 5.5 min re-equilibration at 85% B at 0.3 mL/min (total time 12 min). 
Because of the additional acidic α-protons on the ketones, they may be deuterated more than 
once. 
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Figure 4.S2. High deuterium incorporation into synthetic arginine-based ketones. 
 294 
 
Table 4.S2. Deuterium incorporation into amino acid and methyl ester substrates (4 mM vs. 
20 mM) 
 4 mM 20 mM 
Side chain L- amino 
acid 
L- methyl ester D- methyl 
ester 
L- methyl 
ester 
D-methyl 
ester 
PLP only with 
D- Me esters 
Gly 11.8% ± 0.6 98.2% ± 0.3 N/A 99.7% ± 0.1 N/A 6.2% ± 0.1 
Ala 18.8% ± 1.3 97.9% ± 0.1 17.0% ± 1.8 99.6% ± 0.1 14.0% ± 0.1 1.0% ± 0.1 
Val 11.9% ± 0.6 97.3% ± 0.5 2.7% ± 0.1 99.6% ± 0.1 0.7% ± 0.1 0.5% ± 0.1 
Leu 8.1% ± 1.3 67.7% ± 0.1 21.1% ± 1.4 22.6% ± 2.1 11.2% ± 0.2 0.8% ± 0.1 
Ile 4.5% ± 0.3 97.4% ± 0.4 1.5% ± 0.1 98.4% ± 0.1 0.4% ± 0.1 0.7% ± 0.1 
Nle 35.0% ± 0.1 97.9% ± 0.1 26.8% ± 0.3 96.8% ± 0.4 26.3% ± 0.1 1.1% ± 0.1 
Cys 85.3% ± 0.2 37.2% ± 2.0 6.2% ± 0.6 2.6% ± 0.1 1.5% ± 0.1 5.7% ± 0.1a 
Met 23.9% ± 0.2 97.9% ± 0.1 45.8% 0.3 39.0% ± 0.1 18.3% ± 0.2 1.0% ± 0.1 
Asn ND 94.4% ± 0.5 68.6% ± 0.4 94.4% ± 1.0 48.6% ± 3.1 11.9% ± 0.7 
Gln ND 97.5% ± 0.1 6.3% ± 0.7 71.3% ± 0.2 3.8% ± 0.4 2.8% ± 0.7 
Ser 37.2% ± 0.6 97.7% ± 0.4 68.2% ± 0.8 99.6% ± 0.1 61.7% ± 0.5 3.1% ± 0.1 
Thr 64.3% ± 0.1 98.2% ± 0.1 98.2% ± 0.1 99.6% ± 0.1 5.0% ± 0.5 1.9% ± 0.1 
Phe 11.6% ± 0.3 97.4% ± 0.5 82.2% ± 0.7 69.2% ± 0.1 38.4% ± 0.5 7.1% ± 0.1 
Tyr 14.2% ± 0.5 98.7% ± 0.1 98.5% ± 0.1 99.8% ± 0.1 92.3% ± 0.4 2.6% ± 0.1 
Trp 12.6% ± 1.1 97.7% ± 0.1 54.0% ± 0.3 99.7%b 22.6% ± 0.1 0.2% ± 0.1 
His 97.3% ± 1.2 96.2% ± 0.7 71.3% ± 0.8 0% 0% 7.0% ± 0.2a 
Lys 0% 98.0% ± 0.1 4.8% ± 0.1 85.8% ± 2.5 0% 4.6% ± 0.1a 
Orn 0% 94.4% ± 0.1 8.9% ± 0.1 7.0%b 0% 3.6% ± 0.4a 
Arg 37.4% ± 0.7 98.4% ± 0.3 97.3% ± 0.7 99.6% ± 0.1 94.3% ± 0.6 3.0% ± 0.1a 
Canavanine 97.9% ± 0.1 96.7% ± 0.1 N/A 99.3% ± 0.1 N/A N/A 
Homoarg. 0.6% ± 0.1 97.6% ± 0.3 26.6% ± 3.1 97.4% ± 0.4 1.4%b 2.3% ± 0.2a 
Citrulline 0% 96.5% ± 0.6 11.9% ± 0.1 0% 0% 3.6% ± 0.1a 
Asp 40.7% ± 2.8 36.9% ± 0.3 1.2% ± 0.1 22.7% ± 0.3 0.2% ± 0.1 1.7% ± 0.1 
Glu 0% 27.2% ± 0.3 3.9% ± 0.7 14.5% ± 0.1 2.2% ± 0.1 12.7% ± 0.1 
aUsed 4 mM ester substrate. bOne sample was analyzed. 
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Table 4.S3. Deuterium incorporation in nonenzymatic control reactions after 18 h (omitted 
from Figure 4.8C) 
Substrate Additive Deuterium incorporation 
L-Arg (L-4.19) 20 µM PLP 1.2% ± 0.1 
L-Arg (L-4.19) none 0.9% ± 0.1 
L-Arg-OMe (L-4.32) 20 µM PLP 9.3% ± 0.1 
L-Arg-OMe (L-4.32) none 0.7% ± 0.1 
Product ketone standard 4.31 20 µM PLP 42.9% ± 0.3 
Product ketone standard 4.31 none 28.9% ± 0.1 
 
Chromatograms were extracted for the monoisotopic mass, m+1 and m+2 (one and two heavy 
atoms, respectively) for z = 1, and integrated. The natural abundances of heavy atom isotopologs 
(13C, 15N, 34S, as calculated by enviPat https://www.envipat.eawag.ch/index.php) were subtracted 
from the m+1 and m+2 integration values before calculating the fraction of deuterated amino acid 
or methyl ester. A small level of nonenzymatic deuterium incorporated was observed in a few 
substrates, which were subtracted from the enzymatic reaction totals. For methyl ester samples, 
the acids resulting from hydrolyzed esters were not included in the deuteration calculation. 
Deuterium incorporation values listed above are the average of two samples. 
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Figure 4.S3. Plots of α-deuteration after esterification of L substrates at 4 mM after overnight 
incubation (see Table 4.S2). 
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Figure 4.S4. SxtA AONS-mediated deuterium incorporation in D-amino methyl esters only, 
overnight incubation (see Table 4.S2).  
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D. Determination of enantioenrichment 
The amine groups of amino acid and methyl ester substrates were Fmoc-protected prior to chiral 
supercritical fluid chromatography analysis. 
 
Preparation of enantiopure and racemic standards for supercritical fluid chromatography 
Adapted from Zhou et al.76 Buffer (50 mM HEPES pH 7.0, 150 mM NaCl), 20 mM total methyl 
ester, and 0-40 mM NaOH (an equimolar amount to neutralize HCl salts originating from the stock 
solutions, e.g., L-Arg-OMe·2HCl, see Table 4.S4) were combined for a total volume of 50 µL. 
This buffer solution was diluted with 100 µL of MeCN and basified slightly with 50 µL of borate 
buffer (40 mM, pH 9.2), and then derivatized with 50 µL of an Fmoc-Cl solution (80 mM in 
acetonitrile). After 15 min at rt, reactions were centrifuged at 10,000 x g for 10 min and 200 µL of 
the supernatant was transferred to sample vials for SFC analysis. 
 
Table 4.S4 Example derivatization for the Arg-OMe racemic standard 
Stock solution Volume 
1 M HEPES buffer pH 7.0 5 µL 
3 M NaCl 5 µL 
100 mM L-Arg-OMe·2HCl 10 µL 
100 mM D-Arg-OMe·2HCl 10 µL 
1 M NaOH 4 µL 
water 16 µL 
MeCN 100 µL 
40 mM borate buffer pH 9.2 50 µL 
80 mM Fmoc-Cl in MeCN 50 µL 
Total volume 250 µL 
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Deuterium incorporation for methyl ester substrates and preparation of reaction mixtures 
for SFC and MS (Figures 4.8D and 4.10B) 
Enzymatic reactions in duplicate were performed with 50 mM HEPES original pH 7, 150 mM 
NaCl, 4 or 20 mM methyl ester (varies by substrate, see Table 4.S8), and 20 µM SxtA AONS in 
D2O (final volume scaled by the number of desired timepoints). For every timepoint sample, 100 
µL (for SFC analysis) and 10 µL (for LC-MS analysis) aliquots were removed and stopped by 
flash freezing in liquid nitrogen. Thawed aliquots for LC-MS analysis were prepared as described 
above in subsection “Deuterium incorporation assays for mass spectrometry only”. Thawed SFC 
aliquots were quenched with 4 volumes of MeOH and precipitate was pelleted at 12,000 x g for 
20 min. The supernatant was transferred to a glass test tube and all liquids were removed under 
reduced pressure. The residues were redissolved in water and NaOH to neutralize any HCl salts 
for a total volume of 50 µL. This buffer solution was diluted with 100 µL of MeCN and basified 
slightly with 50 µL of borate buffer (40 mM, pH 9.2), and then derivatized with 50 µL of an 80 
mM Fmoc-Cl solution in acetonitrile. After 15 min at rt, reactions were centrifuged at 10,000 x g 
for 10 min and 200 µL of the supernatant was transferred to sample vials for SFC analysis. 
For reactions at 4 mM substrate concentration (Orn), the supernatant was diluted 1:1 v/v with 
MeOH before transferring to sample vials. 
 
Table 4.S5. Example SFC preparation for a racemic Arg-OMe reaction originally with 20 
mM total methyl esters 
Stock solution Volume 
Quenched reaction residue - 
1 M NaOH 4 µL 
water 46 µL 
MeCN 100 µL 
40 mM borate buffer pH 9.2 50 µL 
80 mM Fmoc-Cl in MeCN 50 µL 
Total volume 250 µL 
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Chiral separation by SFC: Co-solvent = MeOH with 0.5% v/v formic acid. Column = Daicel 
CHIRALCEL 5 µm OD-H 1.6 x 250 mm. Isomers were separated with the isocratic methods listed 
in Table 4.S7. Residual Fmoc-Cl, hydrolyzed Fmoc-OH and derivatized HEPES were also visible 
in some methods. The UV signal of Fmoc derivatives was monitored at 262 nm. Safinamide 
samples were monitored at 228 nm but could not be resolved. Deuterium incorporation and er/dr 
values in Table 4.S8 are an average of two samples. Background activity seen in the nonenzymatic 
negative controls and contaminants in single stereoisomer standards were subtracted.  
 
Table 4.S6. Deuterium incorporation and stereoretention in Figure 4.8D 
Time L-Arg-OMe D-Arg-OMe Racemic Arg-OMe 
 Deuterium Stereoretention Deuterium Stereoretention Deuterium er (D:L) 
0 min 0% 100% 0% 100% 0% 50:50 
5 min 42.3% 98.8% - - - - 
10 min 60.4% 98.8% - - - - 
15 min 74.3% 98.6% - - 43.5% 49:51 
30 min 93.1% 98.5% - - 55.9% 49:51 
45 min 96.5% 94.7% - - 61.2% 47:53 
1 h 97.1% 97.2% 31.6% 96.3% 65.1% 47:53 
2 h 97.1% 94.9% 52.8% 79.8% 75.4% 44:56 
3 h - - 66.0% 81.0% 80.9% 44:56 
4 h - - 72.1% 77.5% 83.1% 43:57 
5 h - - 77.9% 73.2% 85.1% 44:56 
6 h 96.8% 90.8% 81.6% 69.9% 86.2% 43:57 
18 h 96.6% 90.1% 88.9% 61.8% 87.7% 43:57 
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Table 4.S7. Separation conditions and retention times of α-amino methyl esters by SFCa 
Side chain Cosolvent 
concentration 
tR Fmoc-OH 
(min) 
tR D isomer 
(min) 
tR L isomer 
(min) 
Notes: 
Gly N/A N/A N/A N/A The configuration of singly 
deuterated species cannot be 
determined on this 
instrument. 
Ala 15% 6.4 5.8 8.3  
Val 15% 6.4 4.4 5.3  
Leu 15% 6.4 4.7 5.3  
Ile 15% 6.4 4.5 5.2  
Nle 12% 8.4 7.0 8.4 See footnote b 
Cys 25% 3.7 5.0 6.4 See footnote c 
Met 25% 3.7 4.6 5.2  
Asn 25% 3.7 6.5 7.8  
Gln 30% 3.1 5.2 5.8  
Ser 30% 3.7 4.3 6.0  
Thr 10% 10.2 16.0 17.4  
Phe 25% 3.7 5.8 7.3  
Tyr 30% 3.1 5.3 6.9  
Trp 35% 2.7 10.9 11.7  
His - - - - See footnote d 
Lys - - - - See footnote d 
Orn 40% 2.7 5.1 8.4  
Arg 31% 3.0 4.1 5.3  
Canavanine - - - - See footnote d 
Homoarginine - - - - See footnote d 
Citrulline - - - - See footnote d 
Asp - - - - See footnote d 
Glu - - - - See footnote d 
Safinamide - N/A - - See footnote d 
aAt 25% cosolvent and above, a blank MeOH injection is required between each sample to clear derivatized HEPES. 
bThe L isomer and Fmoc-OH co-elute, so only 0.5 equiv of Fmoc-Cl was added to the derivatization reaction. The 
ratios may still be skewed, so these data points were not included in Figure 4.10B. cRequired the addition of 100 mM 
TCEP to the sample mixture to reduce the cystine disulfides back to cysteine methyl ester. dThe most polar side chains 
and safinamide could not be separated by SFC. 
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Table 4.S8. Enantiomeric and diastereomeric ratios at the time of highest deuterium 
incorporation in Figure 4.10B 
Side chain L ester 
deuterium 
incorporation 
L ester 
stereoretention 
Time (h) D ester 
deuterium 
incorporation 
D ester 
stereoretention 
Time (h) 
Glycine 99.7% N/A 18a N/A N/A N/A 
Alanine 99.6% 99.3% 4a 14.0% 88.6% 18a 
Valine 99.5% 99.7% 8a 0.7% 100% 18a 
Leucine 22.6% 98.2% 18a 11.2% 92.4% 18a 
Isoleucine 98.4% 100% 4a 0.4% 100% 18a 
Norleucine 96.8% 99%c 18a 26.3% 88.3%c 18a 
Cysteine 2.6% 98.3% 8a 1.5% 100% 18a 
Methionine 39.0% 99.5% 18a 18.3% 81.5% 18a 
Asparagine 94.5% 97.5% 8a 48.6% 75.8% 18a 
Glutamine 71.3% 100% 8a 3.8% 100% 18a 
Serine 99.6% 90.4% 8a 61.7% 66.6% 18a 
Threonine 99.6%  98.6% 18a 5.0% 97.3% 18a 
Phenylalanine 69.2% 98.4% 18a 38.4% 76% 18a 
Tyrosine 99.8% 59.3% 8a 92.3% 47% 18a 
Tryptophan 99.7% 98.4% 8a 22.6% 86.9% 18a 
Histidine 97.9% - 18b 71.4% - 18b 
Lysine 85.8% - 18a 4.8% - 18b 
Ornithine 94.4% 99.5% 18b 8.5% 89.4% 18b 
Arginine 99.6% 96% 1a 94.3% 43.8% 18a 
Canavanine 99.3% - 2a N/A - N/A 
Homoarginine 97.4% - 6a 17.2% - 18b 
Citrulline 96.5% - 18b 11.9% - 18b 
Aspartic acid 22.8% - 18a 0.2% - 18a 
Glutamic acid 14.5% - 18a 2.2% - 18a 
The enantiomers of safinamide, and the most acidic and basic side chains could not be resolved well by SFC. a20 mM 
ester. b4 mM ester. cValues may be skewed by the co-elution of the Fmoc-OH and L-Nle-OMe. These were omitted 
from Figure 4.10B but are included in Figure 4.S5 and Figure 4.S6 below. 
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Figure 4.S5. Plot of endpoint deuterium incorporation vs. stereoretention in Table 4.S8. 
Norleucine and cysteine data are included. 
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Figure 4.S6. Expansions of crowded clusters of Figure 4.S5. 
Top left corner of Figure 4.S5 (left). Top right corner of Figure 4.S5 (right).  
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IV. NMR spectra and SFC traces 
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Expansion of 57-48 ppm showing C–D 1:1:1 triplet signal of carbon b 
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Expansion of 57-48 ppm showing C–D 1:1:1 triplet signal and a small amount of C–H 
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Expansion of 57-48 ppm showing C–D 1:1:1 triplet signal 
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Expansion of 57-48 ppm showing C–D 1:1:1 triplet signal and a small amount of C–H 
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SFC traces 
A 
Racemic mixture of Ala-OMe 
 
 
 
 
 
 
 
 
 
 
 
 
 
L-Ala-OMe incubated with SxtA AONS in D2O 
 
 
 
 
 
  
Peak # Ret. Time Compound Area (%) 
1 5.8 D-Ala-OMe 27.3874 
2 6.3 Fmoc-OH N/A 
3 8.2 L-Ala-OMe 26.9739 
Peak # Ret. Time Compound Area (%) 
1 5.8 D-Ala-OMe 0.5916 
3 8.2 L-Ala-OMe 99.4084 
Fmoc-OH 
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D-Ala-OMe incubated with SxtA AONS in D2O 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Preparative-scale L-Ala-OMe incubated with SxtA AONS in D2O and recovered 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Peak # Ret. Time Compound Area (%) 
1 5.8 D-Ala-OMe 47.5593 
3 8.2 L-Ala-OMe 6.0548 
Peak # Ret. Time Compound Area (%) 
1 5.9 D-Ala-OMe 1.3352 
3 8.4 L-Ala-OMe 98.6648 
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Figure 4.S7. Spectra of alanine and alanine methyl esters. 
(A) PDA traces of Fmoc-protected DL-alanine methyl ester from commercial standards, and protected ester after incubation with SxtA 
AONS (CHIRALCEL OD-H, 15% MeOH with 0.5% formic acid, 3.5 mL/min); (B) representative mass spectra. 
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A 
Racemic mixture of Val-OMe 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
L-Val-OMe incubated with SxtA AONS in D2O 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Peak # Ret. Time Compound Area (%) 
1 4.4 D-Val-OMe 26.1644 
2 5.3 L-Val-OMe 73.8365 
Peak # Ret. Time Compound Area (%) 
1 4.4 D-Val-OMe 0.2611 
2 5.3 L-Val-OMe 99.7389 
Fmoc-OH 
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D-Val-OMe incubated with SxtA AONS in D2O 
 
 
 
 
 
 
 
 
 
  
Peak # Ret. Time Compound Area (%) 
1 4.4 D-Val-OMe 100 
2 5.3 L-Val-OMe 0 
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Figure 4.S8. Spectra of valine methyl esters. 
(A) PDA traces of Fmoc-protected DL-valine methyl ester from commercial standards, and protected ester after incubation with SxtA 
AONS (CHIRALCEL OD-H, 15% MeOH with 0.5% formic acid, 3.5 mL/min); (B) representative mass spectra.  
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A 
Racemic mixture of Leu-OMe 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
L-Leu-OMe incubated with SxtA AONS in D2O 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Peak # Ret. Time Compound Area (%) 
1 4.7 D-Leu-OMe 33.3945 
2 5.3 L-Leu-OMe 33.4817 
Peak # Ret. Time Compound Area (%) 
1 4.7 D-Leu-OMe 1.9266 
2 5.3 L-Leu-OMe 98.0734 
Fmoc-OH 
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D-Leu-OMe incubated with SxtA AONS in D2O 
 
 
 
 
 
 
 
 
 
 
 
 
  
Peak # Ret. Time Compound Area (%) 
1 4.7 D-Leu-OMe 92.3778 
2 5.3 L-Leu-OMe 7.6222 
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Figure 4.S9. Spectra of leucine methyl esters. 
(A) PDA traces of Fmoc-protected DL-leucine methyl ester from commercial standards, and protected ester after incubation with SxtA 
AONS (CHIRALCEL OD-H, 15% MeOH with 0.5% formic acid, 3.5 mL/min); (B) representative mass spectra. 
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A 
Diastereomeric mixture of L-Ile-OMe and D-allo-Ile-OMe 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
L-Ile-OMe incubated with SxtA AONS in D2O 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Peak # Ret. Time Compound Area (%) 
1 4.5 D-allo-Ile-OMe 52.5066 
2 5.2 L-Ile-OMe 47.4934 
Peak # Ret. Time Compound Area (%) 
1 4.5 D-allo-Ile-OMe N/A 
2 5.2 L-Ile-OMe 100 
Fmoc-OH 
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D-allo-Ile-OMe incubated with SxtA AONS in D2O 
 
 
 
 
 
 
 
 
 
 
 
  
Peak # Ret. Time Compound Area (%) 
1 4.5 D-allo-Ile-OMe 95.1717 
2 5.15 contaminant 4.8283 
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Figure 4.S10. Spectra of Ile methyl esters. 
(A) PDA traces of Fmoc-protected diastereomeric isoleucine methyl esters from commercial and synthetic standards, and protected ester 
after incubation with SxtA AONS (CHIRALCEL OD-H, 15% MeOH with 0.5% formic acid, 3.5 mL/min); (B) representative mass 
spectra. 
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A 
Racemic mixture of Nle-OMe 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
L-Nle-OMe incubated with SxtA AONS in D2O 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Peak # Ret. Time Compound Area (%) 
1 7.0 D-Nle-OMe 48.9639 
2 8.5 L-Nle-OMe/ 
Fmoc-OH 
51.0361 
Peak # Ret. Time Compound Area (%) 
1 7.0 D-Nle-OMe 0.9902 
2 8.4 L-Nle-OMe/ 
Fmoc-OH 
99.0098 
Fmoc-OH 
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D-Nle-OMe incubated with SxtA AONS in D2O 
 
 
 
 
 
 
 
 
 
 
 
 
 
Due to the overlap of Fmoc-OH and L-norleucine methyl ester, these data are not included in Figure 4.10B. 
  
Peak # Ret. Time Compound Area (%) 
1 7.0 D-Nle-OMe 86.1412 
2 8.4 L-Nle-OMe/ 
Fmoc-OH 
13.8588 
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Figure 4.S11. Spectra of norleucine methyl esters. 
(A) PDA traces of Fmoc-protected DL-norleucine methyl ester from commercial standards, and protected ester after incubation with 
SxtA AONS (CHIRALCEL OD-H, 12% MeOH with 0.5% formic acid, 3.5 mL/min); (B) representative mass spectra. 
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A 
Racemic mixture of Cys-OMe 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
L-Cys-OMe incubated with SxtA AONS in D2O 
 
 
 
 
 
 
 
 
(no Cys-OMe peaks could be seen 
until the addition of 100 mM TCEP) 
 
 
 
  
Peak # Ret. Time Compound Area (%) 
1 4.9 D-Cys-OMe w/ 
contaminant 
48.5631 
2 6.4 L-Cys-OMe 51.4369 
Peak # Ret. Time Compound Area (%) 
1 5.0 D-Cys-OMe w/ 
contaminant in 
negative control 
5.5179 
2 6.4 L-Cys-OMe 94.4821 
Fmoc-OH 
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D-Cys-OMe incubated with SxtA AONS in D2O 
 
 
 
 
 
 
 
 
(no Cys-OMe peaks could be seen 
until the addition of 100 mM TCEP) 
 
 
 
 
 
 
 
  
Peak # Ret. Time Compound Area (%) 
1 4.9 D-Cys-OMe 96.8949 
2 6.5 L-Cys-OMe 
present in 
standard 
3.0151 
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Figure 4.S12. Spectra of cysteine methyl esters. 
(A) PDA traces of Fmoc-protected DL-cysteine methyl ester from commercial standards, and protected ester after incubation with SxtA 
AONS (CHIRALCEL OD-H, 25% MeOH with 0.5% formic acid, 3.5 mL/min); (B) representative mass spectra. 
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A 
Racemic mixture of Met-OMe 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
L-Met-OMe incubated with SxtA AONS in D2O 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Peak # Ret. Time Compound Area (%) 
1 4.6 D-Met-OMe 58.1468 
2 5.2 L-Met-OMe 41.8532 
Peak # Ret. Time Compound Area (%) 
1 4.5 D-Met-OMe 
present in 
standard 
5.7735 
2 5.2 L-Met-OMe 94.2265 
Fmoc-OH 
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D-Met-OMe incubated with SxtA AONS in D2O 
 
 
 
 
 
  
Peak # Ret. Time Compound Area (%) 
1 4.6 D-Met-OMe 81.3321 
2 5.2 some L-Met-
OMe present 
in standard 
18.6679 
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Figure 4.S13. Spectra of methionine methyl esters. 
(A) PDA traces of Fmoc-protected DL-methionine methyl ester from commercial standards, and protected ester after incubation with 
SxtA AONS (CHIRALCEL OD-H, 25% MeOH with 0.5% formic acid, 3.5 mL/min); (B) representative mass spectra. 
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A 
Racemic mixture of Asn-OMe 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
L-Asn-OMe incubated with SxtA AONS in D2O 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Peak # Ret. Time Compound Area (%) 
1 6.5 D-Asn-OMe 59.2012 
2 7.8 L-Asn-OMe 40.7988 
Peak # Ret. Time Compound Area (%) 
1 6.6 D-Asn-OMe 3.0832 
2 7.8 L-Asn-OMe 96.9168 
Fmoc-OH 
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D-Asn-OMe incubated with SxtA AONS in D2O 
 
 
 
 
  
Peak # Ret. Time Compound Area (%) 
1 6.6 D-Asn-OMe 72.7943 
2 7.8 L-Asn-OMe 27.2057 
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Figure 4.S14. Spectra of asparagine methyl esters. 
(A) PDA traces of Fmoc-protected DL-asparagine methyl ester from synthetic standards, and protected ester after incubation with SxtA 
AONS (CHIRALCEL OD-H, 25% MeOH with 0.5% formic acid, 3.5 mL/min); (B) representative mass spectra. 
  
 348 
 
A 
Racemic mixture of Gln-OMe 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
L-Gln-OMe incubated with SxtA AONS in D2O 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Peak # Ret. Time Compound Area (%) 
1 5.2 D-Gln-OMe 28.0295 
2 5.8 L-Gln-OMe 71.9705 
Peak # Ret. Time Compound Area (%) 
1 5.3 D-Gln-OMe 1.5301 
2 5.8 L-Gln-OMe 98.4699 
Fmoc-OH 
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D-Gln-OMe incubated with SxtA AONS in D2O 
 
 
 
 
 
 
 
 
 
 
 
  
Peak # Ret. Time Compound Area (%) 
1 5.2 D-Gln-OMe 97.6724 
2 5.8 L-Gln-OMe 2.3276 
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Figure 4.S15. Spectra of glutamine methyl esters. 
(A) PDA traces of Fmoc-protected DL-glutamine methyl ester from synthetic standards, and protected ester after incubation with SxtA 
AONS (CHIRALCEL OD-H, 30% MeOH with 0.5% formic acid, 3.5 mL/min); (B) representative mass spectra. 
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A 
Racemic mixture of Ser-OMe 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
L-Ser-OMe incubated with SxtA AONS in D2O 
 
 
 
 
 
 
 
 
 
 
 
 
  
Peak # Ret. Time Compound Area (%) 
1 4.3 D-Ser-OMe 48.126 
2 6.0 L-Ser-OMe 51.874 
Peak # Ret. Time Compound Area (%) 
1 4.3 D-Ser-OMe 9.2886 
2 6.0 L-Ser-OMe 90.7114 
Fmoc-OH 
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D-Ser-OMe incubated with SxtA AONS in D2O 
 
 
 
 
 
 
 
 
 
 
  
Peak # Ret. Time Compound Area (%) 
1 4.3 D-Ser-OMe 66.4427 
2 6.0 L-Ser-OMe 33.5573 
 353 
 
B 
119.0 120.0 121.0 122.0 123.0 124.0
0
4×10 5
8×10 5
1.2×10 6
1.6×10 6
L-Ser-OMe, no enzyme
Mass (m/z)
C
o
u
n
ts
120.0664
1
2
0
.1
6
6
121.0702
119.0 120.0 121.0 122.0 123.0 124.0
0
4×10 5
8×10 5
1.2×10 6
1.6×10 6
L-Ser-OMe with SxtA AONS
Mass (m/z)
C
o
u
n
ts
121.0727
1
2
1
.1
7
3
1
122.0752
 
 
 
 
 
 
 
Figure 4.S16. Spectra of serine methyl esters. 
(A) PDA traces of Fmoc-protected DL-serine methyl ester from commercial standards, and protected ester after incubation with SxtA 
AONS (CHIRALCEL OD-H, 30% MeOH with 0.5% formic acid, 3.5 mL/min); (B) representative mass spectra. 
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A 
Diastereomeric mixture of L-Thr-OMe and D-allo-Thr-OMe 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
L-Thr-OMe incubated with SxtA AONS in D2O 
 
 
 
 
 
 
 
 
 
 
 
 
  
Peak # Ret. Time Compound Area (%) 
1 16.1 D-allo-Thr-OMe 52.2747 
2 17.5 L-Thr-OMe 47.7253 
Peak # Ret. Time Compound Area (%) 
1 16.1 D-allo-Thr-OMe 1.3838 
2 17.5 L-Thr-OMe 98.6162 
Fmoc-OH 
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D-allo-Thr-OMe incubated with SxtA AONS in D2O 
 
 
 
 
 
 
 
 
 
 
  
Peak # Ret. Time Compound Area (%) 
1 16.1 D-allo-Thr-OMe 97.7578 
2 17.4 L-Thr-OMe 2.2422 
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Figure 4.S17. Spectra of threonine methyl esters.  
(A) PDA traces of Fmoc-protected diastereomeric mixture of L-threonine methyl ester and D-allo-Thr-OMe derivatized from commercial 
and synthetic standards, and protected ester after incubation with SxtA AONS (CHIRALCEL OD-H, 10% MeOH with 0.5% formic 
acid, 3.5 mL/min); (B) representative mass spectra. 
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A 
Racemic mixture of Phe-OMe 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
L-Phe-OMe incubated with SxtA AONS in D2O 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Peak # Ret. Time Compound Area (%) 
1 5.8 D-Phe-OMe 56.7128 
2 7.3 L-Phe-OMe 43.2872 
Peak # Ret. Time Compound Area (%) 
1 5.8 D-Phe-OMe 1.5733 
2 7.3 L-Phe-OMe 98.4267 
Fmoc-OH 
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D-Phe-OMe incubated with SxtA AONS in D2O 
 
 
 
 
 
 
 
 
 
 
  
Peak # Ret. Time Compound Area (%) 
1 5.8 D-Phe-OMe 76.762 
2 7.3 L-Phe-OMe w/ 
some observed 
in negative 
control 
23.238 
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Figure 4.S18. Spectra of phenylalanine methyl esters. 
(A) PDA traces of Fmoc-protected DL-phenylalanine methyl ester from commercial or synthetic standards, and protected ester after 
incubation with SxtA AONS (CHIRALCEL OD-H, 25% MeOH with 0.5% formic acid, 3.5 mL/min); (B) representative mass spectra. 
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A 
Racemic mixture of Tyr-OMe 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
L-Tyr-OMe incubated with SxtA AONS in D2O 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Peak # Ret. Time Compound Area (%) 
1 5.4 D-Tyr-OMe 52.2381 
2 6.9 L-Tyr-OMe 47.7619 
Peak # Ret. Time Compound Area (%) 
1 5.3 D-Tyr-OMe 40.7262 
2 6.9 L-Tyr-OMe 59.2738 
Fmoc-OH 
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D-Tyr-OMe incubated with SxtA AONS in D2O 
 
 
 
 
 
 
 
 
 
  
Peak # Ret. Time Compound Area (%) 
1 5.3 D-Tyr-OMe 47.1282 
2 6.9 L-Tyr-OMe 52.8718 
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Figure 4.S19. Spectra of tyrosine methyl esters. 
(A) PDA traces of Fmoc-protected r DL-tyrosine methyl ester from commercial standards, and protected ester after incubation with SxtA 
AONS (CHIRALCEL OD-H, 30% MeOH with 0.5% formic acid, 3.5 mL/min); (B) representative mass spectra. 
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A 
Racemic mixture of Trp-OMe 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
L-Trp-OMe incubated with SxtA AONS in D2O 
 
 
 
 
 
 
 
 
 
 
 
 
  
Peak # Ret. Time Compound Area (%) 
1 10.9 D-Trp-OMe 48.5944 
2 11.8 L-Trp-OMe 51.4057 
Peak # Ret. Time Compound Area (%) 
1 10.9 D-Trp-OMe 0.354 
2 11.8 L-Trp-OMe 99.646 
Fmoc-OH 
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D-Trp-OMe incubated with SxtA AONS in D2O 
 
 
 
 
 
 
 
 
 
 
 
  
Peak # Ret. Time Compound Area (%) 
1 10.9 D-Trp-OMe 86.0366 
2 11.8 L-Trp-OMe 13.9634 
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Figure 4.S20. Spectra of tryptophan methyl esters. 
(A) PDA traces of Fmoc-protected DL-tryptophan methyl ester from commercial standards, and protected ester after incubation with 
SxtA AONS (CHIRALCEL OD-H, 35% MeOH with 0.5% formic acid, 3.5 mL/min); (B) representative mass spectra. 
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A 
Racemic mixture of Orn-OMe 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
L-Orn-OMe incubated with SxtA AONS in D2O 
 
 
 
 
 
 
 
 
 
 
 
 
  
Peak # Ret. Time Compound Area (%) 
1 5.1 D-Orn-OMe 51.2342 
2 8.4 L-Orn-OMe 48.7658 
Peak # Ret. Time Compound Area (%) 
1 5.1 D-Orn-OMe w/ 
some observed 
in negative 
control 
1.0266 
2 8.2 L-Orn-OMe 98.9774 
Fmoc-OH 
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D-Orn-OMe incubated with SxtA AONS in D2O 
 
 
 
 
 
 
 
 
 
 
 
  
Peak # Ret. Time Compound Area (%) 
1 5.1 D-Orn-OMe w/ 
some observed 
in negative 
control 
89.4086 
2 8.2 L-Orn-OMe 10.5914 
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Figure 4.S21. Spectra of ornithine methyl esters. 
(A) PDA traces of Fmoc-protected DL-ornithine methyl ester from commercial and synthetic standards, and protected ester after 
incubation with SxtA AONS (CHIRALCEL OD-H, 40% MeOH with 0.5% formic acid, 3.5 mL/min); (B) representative mass spectra. 
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A 
Racemic mixture of Arg-OMe 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
L-Arg-OMe incubated with SxtA AONS in D2O 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Peak # Ret. Time Compound Area (%) 
1 3.7 D-Arg-OMe 49.6511 
2 4.6 L-Arg-OMe 50.3489 
Peak # Ret. Time Compound Area (%) 
1 4.3 D-Arg-OMe 3.8931 
2 4.6 L-Arg-OMe 96.1069 
Fmoc-OH 
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D-Arg-OMe incubated with SxtA AONS in D2O 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Buffer optimization 
 
Peak # Ret. Time Compound Area (%) 
1 3.7 D-Arg-OMe 44.151 
2 4.6 L-Arg-OMe 55.849 
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The retention time of D-Arg-OMe shifts later as its relative concentration decreases, while the retention time of L-Arg-OMe remains the 
same. 
  
 372 
 
B 
188.0 189.0 190.0 191.0 192.0 193.0
0
4×10 5
8×10 5
1.2×10 6
L-Arg-OMe, no enzyme
Mass (m/z)
C
o
u
n
ts
189.1331
1
8
9
.2
5
8
3
190.1359
191.1375
188.0 189.0 190.0 191.0 192.0 193.0
0
4×10 5
8×10 5
1.2×10 6
L-Arg-OMe with SxtA AONS
Mass (m/z)
C
o
u
n
ts
189.1342
1
9
0
.2
6
7
9
190.1422
191.1445
 
 
 
 
 
 
 
 
Figure 4.S22. Spectra of arginine methyl esters. 
(A) PDA traces of Fmoc-protected DL-arginine methyl ester from commercial standards, and protected ester after incubation with 
SxtA AONS (CHIRALCEL OD-H, 31% MeOH with 0.5% formic acid, 3.5 mL/min); (B) representative mass spectra. 
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Figure 4.S23. Representative mass spectra of basic α-amino methyl esters (His and Lys) that 
could not be resolved by SFC 
Negative controls (left) and enzymatic reactions with SxtA AONS (right). 
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Figure 4.S24. Representative mass spectra of basic α-amino methyl esters (canavanine and 
citrulline) that could not be resolved by SFC 
Negative controls (left) and enzymatic reactions with SxtA AONS (right). 
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Figure 4.S25. Representative mass spectra of homoarginine methyl esters and Gly-OMe that 
could not be resolved by SFC. 
Negative controls (left) and enzymatic reactions with SxtA AONS (right). About 5% of Gly-OMe 
showed incorporation of two deuterium atoms.  
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Figure 4.S26. Representative mass spectra of acidic α-amino methyl esters (aspartic and 
glutamic acids) that could not be resolved by SFC 
Negative controls (left) and enzymatic reactions with SxtA AONS (right). 
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Figure 4.S27. Representative mass spectra of the SxtA product ketone 4.31. 
Nonenzymatic negative control and enzymatic reactions with SxtA AONS. At extended 
timepoints, ketones with more than one deuterium atom incorporated were detected due the 
additional acidic protons.5 
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Figure 4.S28. Mass spectra of the safinamide methyl ester precursors 4.S14 and 4.46, and 
safinamide free bases 4.S15 and 4.47. 
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V. Proposed mechanisms 
The stereochemistry problem we encountered in this Chapter is the related the one observed in 
Chapter 3 with D-Arg as a condensation substrate. In α-oxoamine synthase (AOS) proteins, the 
catalytic lysine residue is proposed to stereospecifically mediate the initial deprotonation of the 
amino acid substrate and the final reprotonation of the alpha position in product ketones. This 
residue is located on the si face of PLP in all published AOS crystal structures, which would result 
in no deuteration of D-Arg-OMe if it were to proceed through the same mechanism as the L-
enantiomer. However, other PLP-dependent enzymes that have both L- and D-amino acid 
substrates are known: the stereoinverting D-phenylglycine aminotransferase uses alternate binding 
mode that flips the orientation of the carboxylate group and side chain to place the alpha protons 
of the D- and L-substrates on the same face as the catalytic lysine,48 while amino acid racemases 
have a tyrosine residue on the face opposite to lysine to deprotonate both stereoisomers.49 It is 
unclear if SxtA AONS utilizes either of these mechanisms or another alternative, and if the 
mechanism may change with different substrates. 
 
 
Figure 4.S29. Proposed mechanisms of deprotonation in multiple PLP-dependent enzymes: 
alternate binding modes or two bases on opposite PLP faces. 
 
Some members of the AOS family are reported to require binding of the thioester partner substrate 
before deprotonation of the external aldimine I intermediate.3 The binding of the thioester is 
proposed rotate the α-proton to be deprotonated by the lysine residue.42,77 Gratifyingly, the 
 380 
 
deuterium incorporation occurred here in the absence of any thioesters that would lead to a mixture 
of deuterated amino acids and α-amino ketones. Transaminases are reported to deuterate the beta 
carbons of their substrates,32 and could generate up to one turnover of undesired α-ketoacid 
products, which we did not observe with SxtA AONS. Racemases would produce a racemic 
mixture of products, which is similar to what we saw with D-esters, whereas L-substrates were 
generally highly stereoretentive. 
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Chapter 5: Structural and Spectroscopic Characterization of SxtA 
 
Sarah Ackenhusen, Dr. Meredith Skiba and Yongtong Shero Lao contributed to experiments in this 
Chapter. 
Summary 
After reporting the native function of the SxtA, we have worked to develop the individual 
partner enzyme domains for productive enzymatic reactions on non-native substrates. Finer 
mechanistic details of the SxtA MT and AONS reactions that may resolve previously observed 
limitations in reactivity have yet to be elucidated. Here, we discuss structural and spectroscopic 
studies of these two catalytic domains. SxtA MT was found to be a metal-dependent 
methyltransferase but employs Mn2+ for monomethylation of malonyl-ACP compared to 
dimethylation of the same substrate by other GNAT-associated MTs, AprA and GphF MTL. With 
a homology structure of SxtA MT, we sought to identify the origin of these activity differences. 
We have not observed SxtA MT-catalyzed dimethylation. Additionally, we conducted 
spectroscopic studies on SxtA AONS to identify potential rate-determining or unproductive steps 
that limit the enzyme's activity. Spectroscopic changes in the presence of the native substrate, 
product and some compatible thiols were observed, and key intermediate species were detected. 
The residues for productive protein-small molecule interactions and conformational changes have 
not been identified yet. These results will be used to improve SxtA AONS' biocatalytic potential 
in the transformation of α-amino acids to α-amino ketones, α-deuterated amino acids and tetra-
substituted amino acid derivatives. 
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5.1 Introduction 
After probing the reactivity patterns of SxtA domains Chapters 3 and 4, we are also interested 
in the structural features of its domains and inter-domain protein-protein interactions that dictate 
its functions (Figure 5.1). Further understanding of the mechanisms of SxtA domains could 
contribute to future improvement of the individual domains or the entire SxtA module to make 
more robust and promiscuous biocatalysts. Of particular interest are the SxtA MT and AONS 
domains, which belong to subsets of larger protein classes, methyltransferases and PLP-dependent 
enzymes. The general properties of these protein families have been reviewed elsewhere,1,2 but 
much less is known about the structural and mechanistic details of both GNAT-associated MTs 
(MTLs) like SxtA MT and α-oxoamine synthases (AOS). 
 
Figure 5.1. The catalytic cycle of the SxtA module leading to formation of the native and 
shunt ketone products. 
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Many of the experiments discussed in this Chapter were designed with the assistance and input 
of Prof. Janet L. Smith’s group at the University of Michigan. Smith lab members Dr. Meredith 
Skiba and later Yongtong Shero Lao had already been studying other GNAT-associated MTs for 
years when we began investigating SxtA in late 2016 and agreed to collaborate on structural studies 
of SxtA MT and AONS domains. 
Chapter 5 presents our efforts to understand finer mechanistic details of SxtA MT and AONS. 
For SxtA MT, this was based on a sequence alignment and a homology model. We do not have 
additional structural data of SxtA AONS, so we summarize our spectroscopic studies to detect 
potential intermediates in the catalytic cycle. 
 
5.2 SxtA MT Structure and Mutagenesis 
We first observed unusual SxtA MT activity during experiments to characterize the C. 
raciborskii SxtA module (see Chapter 2.3). The preliminary reactions containing SxtA module, 
malonyl-CoA, SAM and arginine omitted the MnCl2 salt. When the reaction mixture was analyzed 
by LC-MS, we observed a 13:87 distribution of the two ketone products 5.7 and 5.8 (Table 5.1, 
entry 1). Since 87% of the ketone formed had bypassed the MT domain, we speculated at the time 
that it was simply a very slow-acting domain. Under these conditions, malonyl-CoA (5.2) was the 
only CoA substrate that showed that the MT domain had been active, suggesting that malonyl-
CoA was the SxtA starter unit and malonyl-ACP the MT substrate.3 
Dr. Meredith Skiba also arrived at the same answer from an X-ray crystal structure of AprA 
MTL, an MT adjacent to an inactive GNAT domain from the apratoxin A biosynthetic pathway 
(48% sequence identity to SxtA MT-GNAT).4,5 The apo structure of AprA MTL (PDB: 6B39) is 
structurally related to two MTs which methylate the α-carbon of 1,3-dicarbonyl substrates (see 
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5.9, Figure 5.2),6,7 and a third enzyme, MppJ, an Fe3+-dependent C-MT that methylates its substrate 
(5.11) adjacent to a 1,2-dicarbonyl moiety.8 Both carbonyl groups were engaged in interactions 
with the metal center in MppJ; the analogy of this in AprA MTL and SxtA MT is malonyl-CoA/-
ACP coordinated to a metal ion. 
 
Table 5.1. Metal salt screen of SxtA-catalyzed ketone formation 
 
Entry Metal Salts % Native Product (5.7) % Shunt Product (5.8) 
1 MgCl2 only 13 87 
2 No MgCl2 8 92 
3 MgCl2 and Fe(NH4)2(SO4)2 12 88 
4 MgCl2 and MnCl2 41 59 
5 MgCl2 and CoCl2 4 96 
 
When Fe(NH4)2(SO4)2 salts were added to reactions with AprA MTL, mono- and dimethylation 
of malonyl-ACP was observed.4 However, the addition of iron salts to reactions with the SxtA 
module had no effect on the ratio of full length (5.7) to truncated (5.8) ketone products (Table 5.1, 
entry 3). In a screen of other metal salts, only the addition of MnCl2 increased the MT activity to 
a 41:59 ratio of 5.7 to 5.8 (entry 4). No dimethylated product (i.e., an isopropyl ketone) was 
observed. This indicates that the SxtA module is isolated from E. coli with some metal already 
bound in the MT domain, but without full incorporation. The identity of the specific metal and the 
occupancy level has not yet been confirmed by inductively coupled plasma mass spectrometry 
(ICP-MS). Acetyl-CoA/-ACP (see 5.14), which had previously been proposed as the SxtA MT 
substrate9 lacks the second carbonyl group for bidentate binding to metal center and the truncated 
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ketone 5.8 resulting from an acetyl substrate appears to be an in vitro shunt product only. There 
was no indication that the metal centers are redox-active; rather, they are likely acting as Lewis 
acids to lower the pKa at the site of methylation in the substrates.
8 
 
Figure 5.2. The activity of C-methyltransferases most closely structurally related to SxtA 
MT.  
CurJ MT,6 PksCT7 MT, MppJ,8 AprA MTL, GphF MTL
4 and SxtA MT3 methylate adjacent to two 
carbonyl groups. 
 
 
To identify the metal-binding residues, we aligned the primary sequences and generated a 
homology model of SxtA MT-GNAT relative to AprA MTL (PDB: 6B3B).
4 Whereas the Fe3+ in 
MppJ was coordinated by two His residues and two water molecules (see 5.15, Figure 5.3)8 and 
AprA MTL by His369, His456 and Gln461 (5.16), the metal ligands in SxtA MT appear to be 
His372, Gln459 and Gln464 (Figures 5.3 and 5.4). In addition, the Fe-dependent AprA MTL and 
a related enzyme, GphF MTL, dimethylate malonyl-ACP in their native pathways,
5,10 while SxtA 
MT with manganese added only monomethylates. However, there was no obvious explanation in 
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the SxtA MT homology model that would account for the difference in reactivity and or differences 
in the mechanism of methylation. 
 
Figure 5.3. Ligands of metal-dependent C-methyltransferases. 
Red spheres represent water ligands. MppJ PDB: 4KIB;8 AprA PDB: 6B3B.4 
 
 
 
Figure 5.4. Cartoon structure of the SxtA MT homology model. 
The SxtA model was based upon AprA (PDB: 6B3B). Potential key residues are labeled. Some 
residues were omitted for clarity. M: metal ion (Mn2+ in the AprA structure and we propose this is 
also the metal used by SxtA MT). 
 
 
We had previously proposed that SxtA MT employs a two-electron mechanism because the 
methylation occurs at an acidic carbon adjacent to two carbonyls. Because the homology model 
lacks common features of radical enzymes, we anticipate still that SxtA MT catalyzes a two-
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electron methylation. With an estimated pKa of approximately 1511 that is further decreased by 
coordination to Mn2+, malonyl-ACP could be enolized by a base either above or below the 
substrate in either the keto or enol forms (see 5.18, Figure 5.5). The base may be another residue 
or a coordinated water molecule. In either case, nucleophilic attack by the enolate intermediate on 
SAM would result in (S)-methylmalonyl-ACP (5.20). In this configuration, the methyl group is 
above the metal ion (Figure 5.4), so a second enolization to generate dimethylmalonyl-ACP in 
AprA/GphF MTL must be initiated from the bottom face. The second planar enolate intermediate 
can attack a second SAM molecule above the metal center. 
 
Figure 5.5. Proposed dimethylation mechanism of malonyl-ACP. 
 
 
In order to investigate if dimethylation can be achieved in SxtA MT as in AprA/GphF MTL, a 
series of SxtA MT-GNAT variants was generated. To slow GNAT-catalyzed decarboxylation of 
malonyl- to acetyl-ACP and allow more time for the MT domain to operate, we first substituted 
T637 for valine. In addition, Gln459, a metal-coordinating residue, was replaced with His to more 
closely resemble the AprA MTL active site. One potential base for malonyl-ACP deprotonation in 
the SxtA MT active site is Ser247, which suppressed most second methylation activity when 
substituted with Ala in AprA MTL (S245A).
4 A third target was Phe458, which is located below 
the malonyl substrate. This is equivalent to Tyr455 in AprA MTL, which could function as the base 
for the second deprotonation event. AprA Y455F also had limited dimethylation activity like 
S245A.4 
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Figure 5.6. Intact protein activity assay of SxtA MT-GNAT activity. 
 
 
SxtA MT-GNAT variants were incubated with malonyl-ACP for 3 h, and then the mixtures 
were analyzed by intact protein MS to determine the distribution of acetyl-, malonyl, 
methylmalonyl- and propionyl-ACP (Figure 5.6). Changing any of the metal-chelating residues 
significantly affected the methylation activity: SxtA MT-GNAT Q464A and SxtA H372A (see 
Chapter 2) did not produce methylmalonyl- or propionyl-ACP, and attenuated methylation activity 
was observed in experiments with SxtA MT-GNAT Q459A/T637V (Figure 5.7). MT-GNAT 
Q459H/T637V, substitutions intended to match AprA MTL, attained only 64% methylation 
compared to 78% methylation in the T637V control reaction. Exchanging the manganese salt for 
other common metals in additional reactions with SxtA MT-GNAT Q459H/T637V with did not 
lead to demethylated products (Figure 5.8). We observed protein precipitation in reactions with 
some divalent metals (Ni, Co, Cu, Zn). Reactions starting from a racemic mixture of 
methylmalonyl-ACP (5.4) were also not methylated a second time. Taken together, these data 
suggest that only changing the metal and coordinating ligands in SxtA MT is not sufficient to 
duplicate the dimethylation activity of AprA/GphF MTL.  
Reactions with the variants containing substitutions to the residue which could be acting as a 
base in the deprotonation of malonyl-ACP, SxtA MT S247A/T637V and F458Y/T637V were very 
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similar to the T637V control (Figure 5.7, bottom). Methylation was not abolished in the 
S247A/T637V variant and no dimethylation was detected with the F458Y/T637V variant. These 
results indicate that Ser247A and Phe458 may not be directly involved in the current 
monomethylation in SxtA MT. A triple variant, SxtA MT-GNAT F458Y/Q459H/T637V to most 
closely mimic the AprA MTL active site was expressed but was removed with the insoluble fraction 
during purification, so this variant could not be screened. In total, the deprotonation of malonyl-
ACP appears to be mediated by residues that we have not found. The possibility that the base may 
be a water molecule coordinated by unidentified residues has also not been excluded. 
Throughout time course reactions with AprA MTL, the Smith lab observed nearly identical 
fractions of methylmalonyl- and dimethylmalonyl-ACP (5.4 and 5.13) and no buildup of a pool of 
methylmalonyl-ACP.4 This suggested that both methylation reactions occur after MTL binds 
malonyl-ACP rather than dissociation of methylmalonyl-ACP and a later second methylation 
event, and was supported by SAM and acyl-ACP binding at opposite ends of the AprA MTL active 
site. It is not yet known in SxtA MT if the SAH byproduct can similarly be exchanged for a second 
molecule of SAM while methylmalonyl-ACP is still associated. The active site volume of SxtA 
MT is also not known, so it may be possible that interactions between the SxtA MT active site and 
methylmalonyl-ACP disfavor binding of the bulkier dimethylmalonyl-ACP. 
The results from experiments with SxtA MT-GNAT variants indicate that the structural basis 
of the different levels of methylation between SxtA MT and AprA/GphF MTL is the sum of many 
differences from the metal ion identity, metal-coordinating residues, bases and other unidentified 
factors that may be outside of the first coordination sphere. 
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Figure 5.7. Methylation and decarboxylation activity of MT-GNAT variants with mutations 
in metal-coordinating residues and potential bases to deprotonate malonyl- or 
methylmalonyl-ACP. 
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Figure 5.8. Metal salt screen with SxtA MT-GNAT Q459H/T637V. 
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5.3 UV-Vis Spectroscopy of SxtA AONS 
Due to the PLP chromophore, SxtA AONS and some of the PLP-amino acid or PLP-ketone 
intermediates can be detected by UV-Vis spectroscopy.2 For these studies, we elected to use the 
M. wollei homolog of SxtA AONS based on its high expression levels and cleanest protein 
purification. 
 
Figure 5.9. Proposed catalytic cycle of SxtA AONS with experimentally determined 
maximum absorbances of intermediate species. 
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In its internal aldimine resting state, the PLP-Lys complex in AOS enzymes is in equilibrium 
between two tautomers: the enolimine intermediate (5.23, Figure 5.9) favored by nonpolar 
environments that absorbs at approximately 330 nm, and the ketoenamine tautomer (5.24) that is 
reported to dominate in polar environments and which absorbs in the 430 nm region.12 As the 
amino acid substrate is titrated in, the population ketoenamine tautomer of the external aldimine I 
intermediate increases in AOS proteins, as we observed with serine palmitoyltransferase (SPT) 
and L-Ser (Figure 5.10).13–17 This tautomer further lowers the pKa of the alpha proton and is 
proposed to be the more active state.18 
To observe the tautomeric distribution changes of SxtA AONS with after L-Arg biding, we 
obtained spectra of the enzyme without substrate and monitored the changes as the amino acid was 
added. Without substrate present, SxtA AONS is distributed between the enolimine and 
ketoenamine species (335 and 425 nm, respectively, Figure 5.10), but addition of L-Arg caused 
the absorbance at 326 nm to increase and flatten at 425 nm, and the enzymatic solution turned 
from yellow to clear. Although we have determined that quinonoid intermediate I (5.27) does form, 
as indicated by productive deuteration of various substrates (see Chapter 4.2), a new peak at 
approximately 500 nm corresponding to a quinonoid species has not been observed. Quinonoid 
5.27 may be too transient to be seen by UV-Vis, even at higher pH. Spectra were unchanged by 
the later addition of propionyl-pantetheine (5.32), a thioester accepted by SxtA AONS to form the 
native ketone product 5.7.  
There was little change to the spectra when other substrates, such as D-Arg or L-Arg-OMe, 
were titrated into the enzyme solutions at pH 7. At basic pH in the presence of L-Arg-OMe, a small 
peak at 484 nm was observed, which we attribute to quinoinoid I. Additionally, in the presence of 
propionyl thioester 5.32, a new peak was observed at 454 nm, likely corresponding to the tetra-
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substituted intermediate 5.33, which cannot decarboxylate until the ester group spontaneously 
hydrolyzes to a carboxylic acid (Figure 5.11).19 
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Figure 5.10. UV-Vis spectroscopy of SPT and SxtA AONS under multiple conditions. 
SPT: serine palmitoyltransferase. 
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Figure 5.11. Formation of the tetra-substituted PLP-complex from L-Arg-OMe on pathway 
to the native product. 
 
 
When the synthetic standard of ketone 5.7 was added, a second quinonoid (5.29) appeared at 
500 nm, in addition to a small shoulder around 464 nm which may be the second external 
intermediate (5.30). The enzymatic solution turned from yellow to orange to reflect the new 
maximum absorbance. As the pH increased, the 500 nm quinonoid II peak also grew dramatically. 
Through spectroscopy of more exact titration and pH shifts, the Kd of the product ketone and pKa 
of the ketone-PLP complex can be experimentally calculated. From the procedures of Ferreira and 
coworkers, we roughly estimate a low micromolar Kd and a pKa between 8-9 for ketone 5.7.
20 
 
 
 
 
 
 
 
Figure 5.12. Shifting the equilibrium of PLP tautomers in the presence of thiols and 
thioesters. 
Spectra courtesy of Sarah Ackenhusen. 
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In data obtained by Sarah Ackenhusen, addition of propionyl-CoA and CoASH without L-Arg 
present shifted the equilibrium of the resting state tautomers toward the active ketoenamine 
species. The Kd of L-Arg was also determined to be 0.9 mM, similar to the values for other AOS 
enzymes.20–22 
These spectroscopic experiments contribute more to our understanding of SxtA AONS. The 
resting state of the enzyme shows the expected equilibrium between two tautomers (335 and 425 
nm, respectively). In contrast to well-studied AOS enzymes, when the native amino acid substrate, 
L-Arg, binds, the less active enolimine species (326 nm) became the major peak in SxtA AONS. 
This pattern is the opposite of what has been observed in other reported AOS studies and suggests 
that the active site is now more neutral after binding of the positively charged Arg.18 Binding of 
the bulkier thiols and thioesters (e.g., CoASH and propionyl-CoA) shifts the equilibrium back 
toward the more acidic ketoenamine tautomer (also 425 nm, see Figure 5.12) to favor 
deprotonation and formation of the quinonoid intermediate (484 nm, 5.27). This species is too 
short-lived to be observed with an L-Arg substrate but can still form in the absence of a thiol or 
thioester in solution. After addition of the propionyl group and decarboxylation (5.28 to 5.30, 
Figure 5.9), quinonoid II (500 nm) may be reprotonated, and the final ketone product displaced. 
Because ketone 5.7 likely binds much more tightly to SxtA AONS than L-Arg (Figures 5.10 and 
5.12), the rate-limiting step in the AONS catalytic cycle may be product release, as suggested by 
Ferreira and coworkers.20,23,24 Basic reaction conditions favor quinonoid II over external aldimine 
II, which may elucidate why we previously observed a decline in overall SxtA AONS activity as 
the pH increased (Chapter 3.2). 
We attempted to test for product inhibition by incubating SxtA AONS with unlabeled synthetic 
ketone 5.7 then adding 15N-arginine and propionyl thioester 5.32 to synthesize labeled ketone 
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(Figure 5.13). The quantification was highly variable due to the storage of quenched samples, and 
the total ketone present did not converge on one value. The possible inhibition to explain the 
relatively short AONS condensation lifetime was not very dramatic. It may be a combination of 
factors, not limited to product inhibition that leads to a cessation of AONS condensation activity 
in under 4 h. 
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Figure 5.13. Biosynthesis of 15N-labeled ketone with unlabeled synthetic product spiked in. 
The addition of synthetic standard 5.7 ranged from 0-250 µM. 
 
 
To improve SxtA AONS as a biocatalyst for formation of amino acid derivatives, we may 
engineer the active site to favor the currently minor but more active ketoenamine tautomer by 
introducing more polar side chains. Additionally, some interactions between the enzyme and the 
acyl group of the thioester partner substrate/product ketones could be disrupted to weaken the 
binding of ketones and promote product dissociation. 
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5.4 Conclusions 
We elucidated SxtA’s native function previously within saxitoxin biosynthesis and then 
proceeded to probe possible non-native activities of two partner enzyme domains, MT and AONS. 
Specifically, for the MT domain, we investigated the possibility of introducing dimethylation 
activity, and for SxtA AONS, improvement as a general biocatalyst for the modification of amino 
acids. 
We had deduced the starter unit of SxtA and the substrate of the MT domain from activity tests 
of a panel of acyl-CoAs and matching the final module products, ketones 5.7 and 5.8 to synthetic 
standards. Our suspicions were confirmed by structural data of AprA MTL from Dr. Meredith 
Skiba and coworkers showing that GNAT-associated MTs like SxtA MT are metal dependent. 
Mn2+ was the only metal that increased SxtA MT activity, improving the ratio of native to shunt 
product from 13:87 to 45:55. Attempts to determine the exact residues responsible for the 
deprotonation and thus the difference between the monomethylation activity of SxtA and 
dimethylation by AprA/GphF MTL have not been fruitful. We may make a more informed 
evaluation of MT mechanism is when a complete crystal structure is obtained. 
Although we have observed that SxtA AONS catalyzes many non-native reactions in α-amino 
ketone generation, a short enzyme lifetime (<4 h) has hampered efforts to run preparative-scale 
reactions. Employing the corresponding methyl esters of the amino acids (Chapter 4.3) may have 
caused a conformational change that allowed all esters to be deprotonated and form quinonoid 
intermediates (Figure 5.14). However, in condensation reactions consisting of SxtA AONS, 
propionyl-panthetheine and Me esters, we did not observe the formation of new ketone products. 
It is possible that these reactions are stalled at the tetra-substituted intermediate 5.33. Due to the 
known hydrolysis of Me esters to carboxylic acids within AOS active sites (i.e. 5.33 to 5.28),19 it 
is more likely there was no acyl addition to quinonoid 5.36 in Figure 5.14. We previously 
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suggested that quinonoid 5.36 may be more similar to quinonoid II (5.29), to which we have never 
observed the second addition of an acyl group to generate a diketone product. However, the 
spectroscopic studies in Chapter 5.3 show that quinonoids 5.29 (maximum absorbance at 500 nm) 
and 5.36 (484 nm) are spectroscopically distinct. From the binding studies in this Chapter 
demonstrating that propionyl-CoA but not -pantetheine (5.32) shifts the equilibrium toward the 
more active enzyme state, it is also possible that 5.32 was not enough to also cause a 
conformational change where the acyl group can add to quinonoids 5.27 or 5.36 at neutral pH. 
 
Figure 5.14. SxtA AONS-catalyzed transformation of a panel of α-amino acids and their 
methyl esters to α-amino ketones. 
 
 
Based on our results with SxtA and its domains, future work will strive to identify the residues 
that govern the selectivity of binding different amino acid side chains and interactions between 
Ppant/CoA/holo-ACP and SxtA AONS. These studies may uncover the enzyme conformational 
changes to allow formation of PLP-tetra-substituted species such as 5.33 and their released 
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products. On the pathway to α-amino ketones, favorable decarboxylation of 5.28 leads to the 
second quinonoid 5.29, and we will also work to increase the enzyme turnover by weakening the 
enzyme-ketone binding for product release. Potential product inhibition can also be addressed by 
designing enzymatic cascades to remove ketone 5.7 and raise overall flux. We anticipate that these 
studies will contribute to the improvement of SxtA AONS as a biocatalyst for preparative-scale 
synthesis of α-amino ketones, more broadly, for the modification of α-amino acids. 
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5.5 Experimental 
I. Chemical synthesis 
 
Synthetic ketone products 5.7, 5.8 were synthesized according to the procedures described in 
Chapter 2. Propionyl-pantetheine (5.32) and other arginine-based ketones were synthesized 
according to the procedures described in Chapter 3. Compounds were stored as 50 mM stock 
solutions in DMSO. 
 
II. Cloning, protein expression and purification 
A. General information 
Escherichia coli cloning strain DH5α (Invitrogen) was used for DNA propagation. Protein was 
expressed in E. coli strains BL21(DE3) (New England BioLabs) or BAP1 after transformation 
with the appropriate plasmids. Cells were grown in Luria Bertani (LB) or Terrific broth (TB) with 
4% v/v glycerol supplemented with kanamycin (50 µg/mL) or ampicillin (100 µg/mL) purchased 
from Gold Biotechnology. 
 
Primers were purchased from Integrated DNA Technologies. DpnI restriction enzyme was 
purchased from New England BioLabs. Ligation-independent cloning (LIC)-qualified T4 DNA 
polymerase was purchased from EMD Millipore. QIAquick PCR purification, gel extraction and 
miniprep kits were purchased from Qiagen. HisPur nickel-nitrilotriacetic acid (Ni-NTA) resin was 
purchased from Thermo Scientific. Proteins were concentrated using Amicon centrifugal filters 
purchased from EMD Millipore at 4,000 x g, 4 °C. PD-10 desalting columns were purchased from 
GE Healthcare. Protein samples were analyzed on Mini-PROTEAN TGX Gels (4-15%) from 
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BioRad and visualized with Protein Ark Quick Coomassie Stain from Anatrace. Proteins were 
quantified with the Pierce 660 nm Assay Reagent from Thermo Scientific. 
 
pET28b-sxtA from C. raciborskii was obtained from the laboratory of Prof. Brett Neilan 
(University of Newcastle) and expressed and purified as described in Chapter 2. pMCSG7-
sxtA_ACP, pMCSG7-sxtA_MT-GNAT, pMCSG7-sxtA(T637V) from C. raciborskii were 
subcloned as described in Chapter 2. pMCSG7K-sxtA_AONS from M. wollei was subcloned, 
expressed and purified with pET28b-SPT as described in Chapter 4. 
pET24b-sfp was kindly donated by the lab of Professor David Sherman at the University of 
Michigan, and expressed and purified as described in Chapter 2. 
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B. Sequence information 
pMCSG7 C. raciborskii sxtA MT-GNAT (Met1-Ser721), gDNA sequence. GenBank accession 
ABI75094.1; linkers and the 6x-His tag are shown in bold. 
atgcaccatcatcatcatcattcttctggtgtagatctgggtaccgagaacctgtacttccaatccaatgcaATGTT
ACAAAAGATTAATCGTTATACTCACGGCTTTGTGGCGGTTCCCGTTATTCTTGCGTGTCGAGAAAAAGGTGTTTTTG
AATTACTCGCCGATGAAAGTCCTCTCTCTTTAAACCAAATGGTGGAACATCTGGGAGCTAACAGCGGACATTTTCAA
GTTGCTTTGAGGATGCTCGAGTCTTTACATTGGCTTTCCCGAAATAAGGAGCTTAAATACTCTCTAACCGCAGAAGC
AGCGATTCACAACAAAATTTCGGAAGACATTCTTCAATTGTACAACCTACCAATTCAGTCTTATTTAGAAGGGAAAC
AAGGAAATTTGCTGGGAAGATGGATTGAGCGTTCTTGCCAATTGTGGAACCTGGACAATCCCCTAATGGCAGATTTT
TTAGATGGATTACTGGTCATCCCACTCCTGCTGGCACTGCACAAACACAACTTGCTTGCAGATTCGGAGGACAAACC
TTTGCTCTCCTCATTAAGCTCAACAGTGCAAGAAGAGTTGGGTAAGTTATTTCTCCACCTTGGCTGGGCTGACCTTA
CAGCAGGTCGTTTGACCATAACCGAACTTGGTCGATTTATGGGAGAGCGAGCCTTGAATACAGCCATAGTGGCGTCC
TACACTCCTATGTTGTCCCGCATTCATGATGTATTGTTTGGCAATTGTCTCTCCGTATTCCAAAGAGATGCTTCCGG
TCACGAAAGGCACATTGATCGCACCCTTAACGTGATCGGGAGTGGATTTCAACACCAGAAATATTTTGCCGATTTAG
AAGAAAGTATCCTCTCAGTATTCAATCAGTTGCCATTAGAAGAACAACCCAAATACATTACTGACATGGGGTGTGGC
GATGGAACTCTCCTGAAACGAGTCTGGGAAACCATTCAATTTAAGTCTGCTAGGGGAAAAGCACTCGAACAGTATCC
CCTGCGTCTTATAGGTGTAGATTATAACGAAGCTTCTTTAAAAGCTACCACACGCACCCTTGCTAGCCTTCCCCACT
TAGTTTTACAGGGAGATATTGGGAACCCAGAACAAATGGTGCGTTCTTTAGAAGCTCATGGCATTCATGATCCCGAA
AATATCCTGCACATCCGTTCGTTCCTCGACCATGATCGTCTCTTTATTCCTCCTCAGAAAAGAAACGAATTGAAAGA
ACGTGCTCACTTACCTTACCAATCAGTCTGTGTCGATGATCAAGGAGAGCTTATTCCTCCTCATGTTATGGTGCAAA
GTTTGGTGGAACACTTAGAAAGATGGTCTCAAGTGGTCAATAAACACGGTTTAATGATTTTGGAGGTCCATTGTTTG
GAACCAAGGGTAGTCTATCAGTTTTTAGACAAAAGCGAAAACTTACATTTCGATGCGTTTCAGGGATTTTCTCAGCA
GTATCTTGTGGAAGCTGAGGTTTTTCTCATGTCTGCTGCACAAGTAGGTCTATTTCCAAAACTAGAGCTTTCTAAAA
GATACCCAAAAACATTTCCTTTTACTCGCATTACGCTTAATTACTTCGAGAAAAGACCTTACAAAATTAGTCATGCC
TATTTGTCAGATTTACCTGCCTTAGTTGACTTGGAGGTCAAGTGTTGGCCAGAAAATTTACGGGCATCTACTCATGA
AATTCGGCGAAGACTTGAGCTAAACCCGCAAGGTAATTTAGTGCTGATTATAGAAGATCAAATTATTGGTGCGATTT
ATTCCCAAACAATTACCAGCACTGAGGCATTAGAGAATGTAAAATATGCGCAAGTGCCGACGTTACATACTCCCCAA
GGGTCAGTTATTCAACTGCTCGCACTAAATATTCTACCTGAGTTTCAGGCGCGGGGGTTAGGAAATGAATTGCGGGA
CTTTATGCTTTACTACTGTACCCTGAAAGGCGGCATTGAGAGCGTGGTGGGTGTAACTCGCTGTCGAAATTATGTCA
ATTATTCCCAAATGCCGATGATGGAGTATTTAAAGCTACACAATGAGCAACGACAGCTTCTGGATCCAATTGTGGGT
TTCCATGTGTCGGGAGGAGCCGAAATTAGGGGAATTATTGCTAATTATCGTCCGGAAGATACAGATAATCTCGGCAT
GGGTATTTTGATTGAATATAACCTGCGCGACAGTGCTTTGCACTCGCCTGGTGATCGCAAAGGACCGTATATTAACT
CA 
 
Translation: 
MHHHHHHSSGVDLGTENLYFQSNAMLQKINRYTHGFVAVPVILACREKGVFELLADESPLSLNQMVEHLGANSGHFQ
VALRMLESLHWLSRNKELKYSLTAEAAIHNKISEDILQLYNLPIQSYLEGKQGNLLGRWIERSCQLWNLDNPLMADF
LDGLLVIPLLLALHKHNLLADSEDKPLLSSLSSTVQEELGKLFLHLGWADLTAGRLTITELGRFMGERALNTAIVAS
YTPMLSRIHDVLFGNCLSVFQRDASGHERHIDRTLNVIGSGFQHQKYFADLEESILSVFNQLPLEEQPKYITDMGCG
DGTLLKRVWETIQFKSARGKALEQYPLRLIGVDYNEASLKATTRTLASLPHLVLQGDIGNPEQMVRSLEAHGIHDPE
NILHIRSFLDHDRLFIPPQKRNELKERAHLPYQSVCVDDQGELIPPHVMVQSLVEHLERWSQVVNKHGLMILEVHCL
EPRVVYQFLDKSENLHFDAFQGFSQQYLVEAEVFLMSAAQVGLFPKLELSKRYPKTFPFTRITLNYFEKRPYKISHA
YLSDLPALVDLEVKCWPENLRASTHEIRRRLELNPQGNLVLIIEDQIIGAIYSQTITSTEALENVKYAQVPTLHTPQ
GSVIQLLALNILPEFQARGLGNELRDFMLYYCTLKGGIESVVGVTRCRNYVNYSQMPMMEYLKLHNEQRQLLDPIVG
FHVSGGAEIRGIIANYRPEDTDNLGMGILIEYNLRDSALHSPGDRKGPYINS  
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pMCSG7-C. raciborskii sxtA ACP genomic DNA sequence (Ala722-Gln815) 
atgcaccatcatcatcatcattcttctggtgtagatctgggtaccgagaacctgtacttccaatccaatgcgatgGC
AATTGGTTCATTGGTACCAAAAGCAACATCTGCAACTAAGGAAAACAAAACTGTAGCGGATCTCGTTAAAGAATGCA
TCTTAAAAGTAATGGGTTCCCAACGTCAGGCAGCCTACGCTCCACAACAAAAACTGCTGGATATGGGATTAGATTCT
TTAGATTTATTAGAACTGCAAACGCTCCTAGAGGAACGTTTAGGGATCAATCTGTCTGGAACGTTCTTTTTACAAAA
GAACACTCCAACTGCCATCATCACTTATTTCCAAAACCAAGTGGTACAA 
 
Translation 
MHHHHHHSSGVDLGTENLYFQSNAMAIGSLVPKATSATKENKTVADLVKECILKVMGSQRQAAYAPQQKLLDMGLDS
LDLLELQTLLEERLGINLSGTFFLQKNTPTAIITYFQNQVVQ 
 
 
 
pMCSG7K Microseira wollei sxtA AONS E. coli-optimized sequence 
GenBank accession ACG63826.1; linkers and the 6x-His tag are shown in bold. 
atgcaccatcatcatcatcattcttctggtgtagatctgggtaccgagaacctgtacttccaatccaatgcaGAAAA
GCAGAGTGATCTGGCGAGCCCCGTGGACTTAGCTAATGAAATCAACACATTAGAAAATGTTGTCAATCAGCAGAAGA
TCCCTCAGGTTACGCGCGTAGTGACTGAACAGCAAGGTCGTAAGGTCTTGATCGATGGCCACTGGGTGATTGACTTC
GCCTCATGCAACTATTTAGGTTTAGACTTGCACCCCAAAGTGAAGGAGGCTATCCCCCCGGCTTTGGAGAAGTGGGG
GGTCCATCCCTCTTGGACACGTTTGGTGGCCAGCCCGGTAATCTATGAGGAATTAGAGGAGGAGTTAAGCAAACTGT
TAGGAGTTCCCGACGTATTAGTTTTCCCAAGCGTCACATTACTTCAGATCGGGGTCTTGCCACTTCTGACAGGCTCG
AACGGAGTTATTTTAGGCGACATTGCTGCGCATCGTTGCATTTACGAGGCCTGCTGCCTGGCACAGCAGAAGGGCTC
ACAGTTTATCCAATATCGCCACAATGACTTGAATGATTTAGCGGAGAAATTGGCAAAGTATCCACTGGAACAAGTCA
AAATCATCGTCATTGACGGAGTGTACTCTATGTCCGCCGACTTCCCAGACCTTCCGGCTTACGTCCGCCTGGCGAAG
GAATACAATGCTTTTATTTATATGGATGACGCGCACGGATTTGGTATTTTGGGTGAGAACCCGTCCTCCGATATGCC
TTACGGATACAAAGGTAATGGTATGGTGAATTATTTCGATCTTCAATTTGCCGAGGACAACATTATCTACGTCGCGG
GGTTGTCTAAAGCCTACAGTTCGTACGCCGCCTTTCTTACTTGCGGTGATCGTCAGATTAAGACCAATTTCCGTAAT
GCTTGGACTGCCATTTTCAGCGGTCCTAGCCCAGTGGCAAGCTTGGCATCAGCCTTGGCCGGCTTACAGGTTAATCG
TCAGGAAGGAGAACAACTTCGCAAGCAAATCTACCACTTGACGCGCAAATTGGTGACCCAAGCTCGCGCCATTGGCT
TCGAAGTGGACAACTACGGTTACGTTCCCATCGTTTCCGTCTTAGTCGGAGACGCGCAACACATGATTGACGTATGT
CAGCTGCTGTGGGAGTACGGCATTCTGATCACACCCGCTATTTTCCCAATTGTTCCACTTAATAAATCCGCGCTGCG
CTTTTCTATCACAGCTGCCAATACGGAAGAAGAGATTGACCAAGCCATCAAAGCATTGGAGGGGGTATGGGTCCTGC
TTCAGAAAGAGAAGcattag 
 
Translation: linkers and the 6x-His tag are shown in bold. There is an extra His residue at the C-
terminus, added as a mistake in the primer design. 
MHHHHHHSSGVDLGTENLYFQSNAEKKSDLASPVDSANEINTLENVVNQQKIPQVTRVVTEQQDRKVLIDGHWVIDF
ASCNYLGLDLHPKVKEAIPPALEKWGVHPSWTRLVASPAIYEELEEELAKLLGVPDVLLFPSLTLLQMGVLPLLTGN
NGVIFGDISAHRCIYEACCLAQHKGAQFIQYRHNDLNDLAAKLAKYPLEQVKIIAIDGVYSMSADLPDLPAYVRLAK
QYNALIYIDDAHGFGILGENPSSDMPYGYKGNGIVNYFDLRFAEDNIIYVAGLSKAYSSYAAFVTCGNSQIKTQFRN
AWTAIFSGPSPVASLASALAGLQVNRQEGEQLRKQVYYLTHKLVTQARAIGFEVDNYSYVPIVSVLVGDAQHIVDVC
QLLWEYGILITPAIFPIVPLNKTALRFSITAANTEEEIDQAIKALEAVWDLLQKRKALLCKH* 
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Figure 6.S1. Sequence alignment of SxtA MT-GNAT (1-721) and AprA MTL-ΨGNAT (1-
629). 
Overall sequence identity is 48%. Sequences were aligned with Clustal Omega 
(https://www.ebi.ac.uk/Tools/msa/clustalo/) and displayed in JalView. The metal-binding residues 
are boxed in red and starred. 
 
  
* 
* * 
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C. Cloning 
Table 5.S1. Primers used to generate constructs in this Chapter. 
Name Sequence 
Primers for site-directed mutagenesis of whole plasmids 
SxtA S247A 5’-
CACATTGATCGCACCCTTAACGTGATCGGGGCTGGATTTCAACACCAGAAATA 
TTT-3’ 
SxtA F458Y 5’-GACAAAAGCGAAAACTTACATTTCGATGCGTATCAGGGATTTTCTCAG 
SxtA Q459H 5’-AAAAGCGAAAACTTACATTTCGATGCGTTTCACGGATTTTCTCAGCAG-3’ 
SxtA Q459A 5’-AAAAGCGAAAACTTACATTTCGATGCGTTTGCGGGATTTTCTCAGCAG-3’ 
SxtA F458Y/Q459H 5’-
GACAAAAGCGAAAACTTACATTTCGATGCGTATCACGGATTTTCTCAGCAG-3’ 
SxtA Q464A 5’-
CATTTCGATGCGTTTCAGGGATTTTCTCAGGCGTATCTTGTGGAAGCTGAGG -
3’ 
Primers for ligation-independent cloning (LIC) 
SxtA MT M1 LIC forward 5’-TACTTCCAATCCAATGCAATGTTACAAAAGATTAATCG-3’ 
SxtA GNAT S721 LIC 
reverse 
5’-TTATCCACTTCCAATGCTATGAGTTAATATACGGTCCTT-3’ 
Mutations are highlighted in red. LIC handles in bold. 
 
SxtA MT-GNAT T637V: The excised didomain was amplified from pMCSG7-sxtA(T637V) (see 
Chapter 2) in a 50 μL reaction containing 10 μL Phusion HF buffer, 2 ng/μL parent plasmid, 2 μM 
each of forward and reverse LIC primers, 200 μM each of dNTPs, 0.04 U/μL Phusion HF. Excised 
domains were amplified according to the following PCR procedure: 95 °C 2:00, (95 °C 0:30, 50 
°C 0:30, 72 °C 0:45/kb) for 30 cycles, 72 °C 10:00. The insert was purified by gel extraction and 
subcloned into pMCSG7 using standard LIC protocols.25  
 
Other SxtA MT-GNAT variants: pMCSG7-sxtA_MT-GNAT variants were generated by site-
directed mutagenesis of pMCSG7-sxtA_MT-GNAT(wt) or pMCSG7-sxtA_MT-GNAT(T637V). 
50 μL PCR reaction mixtures contained 10 μL Phusion HF buffer, 2 ng/μL wt parent plasmid, 2 
μM each of the S773A forward and reverse primers, 200 μM each of dNTPs, 0.04 U/μL Phusion 
HF and 6% (v/v) DMSO. Amplification was accomplished with the following PCR procedure: 95 
°C for 2:00, (95 °C 0:30, 48-60 °C 1:00, 68 °C 4:00) for 18 cycles, with a final extension of 68 °C 
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for 10:00. This was followed by a 10 μL digestion containing 1 μL NEB CutSmart buffer, 8 μL of 
the PCR mixture and 20 units of DpnI. The reaction mixture was incubated at 37 °C for 3 h and 
transformed into chemically competent DH5α cells. Colonies containing the correct mutation(s) 
were verified by Sanger sequencing. 
 
D. Protein overexpression and purification 
Overexpression of all proteins (SxtA MT-GNAT variants, apo-ACP, and AONS): pMCSG7 
or pMCSG7K plasmids containing the desired insert were transformed into chemically competent 
BL21(DE3) E. coli cells. A single colony was picked to inoculate a 5 mL LB starter culture grown 
overnight at 37 °C, 200 rpm. The following day, 0.5 L TB media supplemented with either 
kanamycin or ampicillin, was inoculated with the starter culture and incubated at 37 °C, 250 rpm 
until the OD600 reached 1.0. For apo-ACP, the media was also supplemented with a trace metals 
mixture (final concentrations: 50 μM FeCl3, 20 μM CaCl2, 10 μM MnCl2, 10 μM ZnCl2, 2 μM 
CoCl2, 2 μM CuCl2, 2 μM NiCl2, 2 μM Na2MoO4, 2 μM Na2SeO3, 2 μM B(OH)3). Cultures were 
equilibrated at 20 °C for 1 h. Expression was induced by addition of IPTG (final concentration 200 
μM). Cultures were incubated at 20 °C, 200 rpm for 18 h. 
 
Purification of all proteins: Cell pellets were resuspended in 4 mL of lysis buffer (50 mM 
HEPES, 300 mM NaCl, 10 mM imidazole, and 10% (v/v) glycerol at pH 8.0) per gram of wet cell 
mass. For SxtA AONS, 1 mM PLP was added to the lysis buffer. Cells were lysed by sonication 
(3 s on, 6 s off, 5 min total). Insoluble material was removed by centrifugation (30,000 x g for 30 
min at 4 °C). The clarified lysate was incubated with gentle shaking along with 1-2 mL of nickel-
NTA resin for 1 h at 4 °C and poured into a column. The resin-bound protein was washed with 25 
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mL wash buffer (50 mM HEPES, 300 mM NaCl, 25 mM imidazole, 10% (v/v) glycerol, pH 8.0). 
The desired protein was eluted with 6 mL elution buffer (50 mM HEPES, 300 mM NaCl, 300 mM 
imidazole, 10% (v/v) glyercol, pH 8.0). The eluted protein was concentrated using 3 – 50 kDa 
centrifugal cutoff filters and exchanged into storage buffer (50 mM HEPES, 200 mM NaCl, 10% 
(v/v) glycerol, pH 7.4) using a PD-10 column. The desalted protein was concentrated further using 
10 – 50 kDa centrifugal cutoff filters, aliquoted, flash frozen in liquid nitrogen and stored at -80 
°C. 
  
Figure 5.S2. Denatured SDS-PAGE protein gels of new constructs used in this Chapter. 
SxtA MT-GNAT molecular weight with intact Met1: 84,167.6 Da. Each set of four lanes per 
construct shows the crude lysate, insoluble material, soluble fraction and isolated protein from left 
to right. 
 
III. Enzymatic reactions 
A. General information 
CoASH, propionyl-CoA and malonyl-CoA were purchased from CoALA Biosciences. S-adenosyl 
methionine was purchased as the tosyl salt from Carbosynth and prepared as a 50 mM aqueous 
solution immediately before use. Electrospray liquid chromatography-mass spectrometry (LC-
MS) analysis was performed on an Agilent G6545A quadrupole-time of flight mass spectrometer 
in positive mode with an Agilent 1290 UPLC system. Solvent A = water with 0.1% formic acid. 
Solvent B = 95% acetonitrile, 5% water and 0.1% formic acid. MS data were analyzed using the 
Agilent Qualitative Mass Hunter software. Intact proteins were deconvoluted with the maximum 
 415 
 
entropy algorithm. Absorbance spectra of SxtA AONS were obtained on a Shimadzu UV-2501 PC 
spectrophotometer over a range of 300-550 nm. Malonyl- and methylmalonyl-ACP were prepared 
as described in Chapter 2. 
 
 
Metal screen of the SxtA module: 250 μM acyl-CoA, 1 mM SAM, 2 mM Arg, 10 μM SxtA in 
50 mM HEPES pH 7.4, 150 mM NaCl, 1 mM MgCl2, 0.5 mM other metal salts (total volume 25 
μL) were combined and incubated at 30 °C for 2 h. Reactions were quenched by diluting 5x with 
acetonitrile. Precipitate was pelleted at 12,000 x g for 20 min. The supernatant was diluted 20x 
with acetonitrile, 1% formic acid, and aqueous 10 μg/mL 15N Arg·HCl. The final ratios (v/v) for 
analysis were 5% quenched reaction, 2.5% of aqueous 10 μg/mL 15N Arg·HCl (Cambridge Isotope 
Laboratories), 46% acetonitrile, 46.5% of 1% formic acid in water (e.g., 10 μL of quenched 
reaction, 5 μL of 10 μg/mL 15N Arg·HCl, 92 μL acetonitrile, 93 μL of 1% formic acid in water for 
a total volume of 200 μL). Samples were analyzed by LC-MS: column = Waters Acquity 1.7 μm 
UPLC BEH Amide HILIC 2.1 x 100 mm column; method = 85% B at 0.3 mL/min for 2 min, 
followed by a linear gradient to 75% B at 0.4 mL/min over 3 min and a second linear gradient to 
60% B over 0.5 min, 60% B for 1 min and then 6.5 min re-equilibration at 85% B at 0.3 mL/min 
(total time 15 min). tR (5.7): 1.94 min; tR (5.8): 2.35 min; tR (
15N Arg): 4.0 min. Ratios were 
calculated by comparing the areas under the curve of the extracted ion chromatograms. The overall 
ketone yield was not calculated. Reactions were run in duplicate. 
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Salts tested: Fe(NH4)2(SO4)2, MnCl2, NiCl2, CoCl2, CuCl2, CaCl2, Na2MoO4, ZnCl2. Mn
2+ was the 
only salt to show significant improvement over the MgCl2 only control. Fe
3+, Ca2+ and Mo6+ were 
unchanged from the control, while the remaining salts caused varying levels of precipitation.   
 
 
Methylation of malonyl-ACP: 100 μM malonyl-ACP and 15 μM MT-GNAT variant in 50 mM 
HEPES pH 7.4, 150 mM NaCl, 1 mM MgCl2, 0.5 mM MnCl2 (or other metal salt), and 1 mM SAM 
were combined for a total volume of 35 μL and incubated at 30 °C for 3 h. At 15, 30, 45, 60, 120, 
and 180 min, 5 μL aliquots were removed and quenched by diluting 12.5x with 1% formic acid in 
water. Samples were analyzed using a Ppant ejection assay of intact proteins.26 LC-MS analysis: 
column = Phenomenex Aeris 3.6 μm WIDEPORE C4 2.1 x 50 mm; method = 5% B at 0.5 mL/min 
for 2 min, followed by a linear gradient to 100% B over 4 min, 100% B for 2 min, followed by a 
0.1 min linear gradient to 5% B and 1.9 min equilibration at 5% B (total time 10 min). tR = 4.1 
min. The relative abundance of ejected Ppant ions for acetyl-, malonyl-, propionyl- and 
methylmalonyl-ACP were used to calculate the fraction of each acyl-ACP species. They hydrolysis 
product holo-ACP was excluded from the methylation analysis. No dimethylation to 
dimethylmalonyl-ACP was observed. 
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Salts tested: Fe(NH4)2(SO4)2, MnCl2, NiCl2, CoCl2, CuCl2, CaCl2, Na2MoO4, ZnCl2. Like the full 
module reactions, Ni2+, Co2+ Cu2+ and Zn2+ salts caused varying levels of precipitation, 
diminishing MT-GNAT activity.   
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Figure 5.S3. Total methylation of malonyl-ACP, the sum of methylmalonyl- and propionyl-ACP 
population fractions, plotted per timepoint. 
Mutations in metal-coordinating residues and deprotonation candidates (top) and metal salt screen 
with SxtA MT-GNAT Q459H/T637V. 
 
UV-Vis spectroscopy of serine palmitoyltransferase (SPT): 20 µM of SPT and 0-10 mM of 
serine in 20 mM potassium phosphate pH 7.4 and 150 mM NaCl were combined for a total volume 
of 100 µL in a clear 96-well plate. The reactions equilibrated for 10 min at rt before spectroscopic 
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readings. Absorbance spectra were acquired from 300–550 nm, with the buffer only background 
spectra subtracted to obtain the traces in Figure 5.11. 
 
UV-Vis spectroscopy of SxtA AONS: All reactions contained 20 µM of M. wollei SxtA AONS 
in 50 mM HEPES buffer with 150 mM NaCl for a total volume of 100 µL in a clear 96-well plate. 
The reactions equilibrated for 10 min at rt before spectroscopic readings. Absorbance spectra were 
acquired from 300–550 nm, with the buffer only background spectra subtracted to obtain the traces 
in Figure 5.10. 
Arginine and arginine methyl ester titration: 0-10 mM at pH 7.0. 
L-Arg-OMe at high pH: 4 mM methyl ester, with HEPES buffer at pH 7.5, 8.0, 8.2, 8.4 and 8.6. 
After initial readings, 1 mM propionyl-pantetheine (5.32) was added, and the spectra collected 
again after 10 min of equilibration. 
Titration of the native product (5.7): 0-2 mM at pH 7.0. 
pH screen of ketone 5.7: 1 mM of synthetic ketone 5.7 ranging from pH 6.6 to 8.6. 
Kd of L-Arg and thiol/thioesters shifts in the absence of arginine (Figure 5.12): these data were 
collected by Sarah Ackenhusen. At pH 7.0, arginine was titrated in small increments, and peak 
changes at 326 and 425 nm were monitored to calculate the Kd. In Figure 5.12, the concentration 
of propionyl-pantetheine (5.32), propionyl-CoA and CoASH was 1 mM. 
 
UV-Vis spectroscopy of arginine-based synthetic ketones: 20 µM of SxtA AONS and 1 mM 
ketones (as synthesized in Chapters 2 and 3) in 50 mM HEPES buffer, pH 7.0 or 8.0 and 150 mM 
NaCl were combined for a total volume of 100 µL in a clear 96-well plate. The reactions 
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equilibrated for 10 min at rt before spectroscopic readings. Absorbance spectra were acquired from 
300–550 nm, with the buffer only background spectra subtracted to obtain the data in Figure 5.S4. 
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Figure 5.S4. SxtA AONS mixed with synthetic ketone product standards. 
Top: UV-Vis absorbance spectra. Bottom: the ketone addition caused the enzymatic solutions to 
shift from pale yellow (bottom right) to orange and red (top rows). The addition of L-Arg to SxtA 
AONS caused solutions to turn clear (not shown). 
 
 
 
Product inhibition of SxtA AONS: 2 mM of 15N-labeled arginine (5.34, purchased from 
Cambridge Isotopes), 0-250 µM of synthetic ketone 5.7, 1 mM propionyl-panthetheine (5.32) and 
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20 µM M. wollei SxtA ACP-AONS (see Chapter 4) in 50 mM HEPES pH 7.0, 150 NaCl were 
combined for a total reaction volume of 100 µL and incubated at 30 αC. For reactions with 0, 50 
or 100 µM of synthetic product doped in, additional DMSO was added (2.5 2.0 or 1.5 µL, 
respectively) to maintain a constant volume of DMSO across all reactions. At 0.5, 1, 2, 3, 4, 5, 6 
and 18 h, 10 µL of reaction was removed and quenched in 40 µL of methanol in a 96-well plate. 
Precipitation in the quenched reaction mixtures was pelleted by centrifugation of the plate at 2000 
x g for 10 min and then filtering the supernatant through a 0.2 µM sterile filtration plate. 10 µL of 
the flow-through was added to a solution of 93 µL of acetonitrile, 95 µL of 1% v/v formic acid in 
water and 2 µL of 200 µM of tryptophan. Samples were analyzed by LC-MS: column = Waters 
Acquity 1.7 μm UPLC BEH Amide HILIC 2.1 x 100 mm column; method = 85% B at 0.3 mL/min 
for 2 min, followed by a linear gradient to 75% B at 0.4 mL/min over 3 min and a second linear 
gradient to 60% B over 0.5 min, 60% B for 1 min and then 6.5 min re-equilibration at 85% B at 
0.3 mL/min (total time 15 min). tR (5.7, 5.35): 1.94 min; tR (Trp): 1.55 min. The amount of labeled 
product formed was calculated by comparing the areas under the curve of the extracted ion 
chromatograms of 5.35 to the internal 5.7 standards. 
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Figure 5.S5. Comparison of new 15N-labeled ketone formed to the total product. 
The error bars were not shown in Figure 5.13, but their large magnitude suggests inconsistent 
ketone synthesis, obscuring more detailed product inhibition analysis. 
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Chapter 6: Synthesis of chiral amines with type II oxidase AnaB 
 
Summary 
Nearly 40% of bioactive pharmaceutical compounds contain a chiral amine motif, but efficient 
chemo- and stereoselective preparations of these compounds remains challenging. Extensively 
functionalized amines, including the cyclic amines, are found in NRPS pathways but are also 
relatively expensive to utilize in chemoenzymatic reactions. We identified a highly reactive CP-
bound intermediate generated by the oxidase AnaB in anatoxin-a biosynthesis that could be 
harnessed for the preparation of chiral cyclic amines. The released small molecule products could 
serve as a building block to more complex bioactive scaffolds but cannot be efficiently or 
economically generated with stoichiometric carrier protein AnaD. Here, a four-step carrier protein-
partner enzyme catalytic cycle is developed to load an amine substrate, oxidize to an iminium ion 
by AnaB, add an exogenous nucleophile stereoselectively and offload product in a self-contained 
cycle that allows for the use of catalytic quantities of CP. Although we identified complementary 
loading and offloading cycles and a nucleophile and confirmed AnaB activity, the complete one-
pot cycle is stalled by the formation of an overoxidized side product. Future development of this 
platform will be aimed at limiting the undesired overoxidation and optimizing preparative-scale 
chemoenzymatic reactions to isolate small molecule products in synthetically relevant quantities. 
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6.1 Introduction 
Although we initially selected the polyketide-like synthase SxtA to develop a seemingly self-
contained unit with its own loading and offloading, our proposed carrier protein-partner enzyme 
platforms are not limited to type I cis-acting systems. We have also investigated standalone 
enzymes from another secondary metabolite biosynthetic pathway to develop catalytic cycles 
where all enzymes are acting in trans.  
 
Anatoxin-a (6.1) and naturally produced analogs (6.2-6.4) are potent toxins produced by 
several genera of cyanobacteria, including Anabaena flos-aquae (Figure 6.1A). Like saxitoxin, it 
is a component of algal blooms, and first discovered after poisoning cattle and dogs in Canada who 
drank contaminated water in the 1960s.1 The toxin was first isolated in 1977 and reported with to 
possess a bicyclic structure.2 Aronstam and Witkop then reported in 1981 that anatoxin-a binds 
irreversibly to neuronal- and muscle-type nicotinic acetylcholine receptors (nAChRs).3 With toxin 
bound to nAChRs, the associated sodium channels initially open to release Na+ ions, and then 
eventually desensitize to block additional ion flow, resulting in respiratory paralysis and death.3 
Figure 6.1. The natural product anatoxin-a. 
(A) The parent toxin and some common derivatives. (B) Feeding studies with anatoxin-a 
producers by Hemscheidt and Ploux. 
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The similarly named molecule anatoxin-a(S) (now known as guanitoxin) has the same mechanism 
of action,4 but the two compounds are structurally unrelated. Anatoxin-a is much less toxic than 
saxitoxin (LD50 of 200-250 µg/kg vs. approx. 8.3 ng/kg of STX)
5,6 by intraperitoneal injection in 
mice, but a toxic dose of anatoxin-a is fatal in under 30 min, earning it the nickname very fast 
death factor.1  
 
From feeding experiments of labeled acetic acid and glutamic acid in the mid-1990s, 
Hemscheidt and coworkers proposed that the bridging bicyclic core of anatoxin-a was 
biosynthesized from glutamic acid (6.6), proline or ornithine and the remainder of the molecule by 
a polyketide synthase (Figure 6.1B).7 By 2009, Ploux and coworkers had identified a polyketide 
synthase and nonribosomal peptide synthetase biosynthetic gene cluster unique to anatoxin-a-
producing strains, named ana.8 Further feeding studies indicated that the starter unit of the 
anatoxin-a biosynthetic pathway is L-proline (6.7), like other pyrrolidine- or pyrrole-containing 
natural products.9,10 The Ploux group has demonstrated that L-Pro is adenylated by AnaC, and 
loaded onto the peptidyl carrier protein (PCP) AnaD (see 6.10, Figure 6.2).10 The subsequent two-
Figure 6.2. Initiation of anatoxin-a biosynthesis and oxidation Pro-AnaD by the flavin-
dependent oxidase AnaB and elaboration into a chiral amine with a second stereocenter. 
ACP 6.12 is an acyl carrier protein with a fatty acyl chain bound and protected with the three 
α-helices. PDB: 2FAE. 
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electron oxidation of 6.10 is performed by the flavin-adenine dinucleotide (FAD)-dependent 
oxidase AnaB.11 The product, iminium ion 6.11, contains an electrophilic carbon center that we 
envision leveraging for the synthesis of chiral cyclic amines in an artificial CP-PE catalytic cycle. 
The iminium ion species 6.11 is highly reactive and could potentially be functionalized by a 
nucleophile. In addition, because CPs may protect reactive cargo in a chiral environment within 
their helices (see 6.12),12 the nucleophilic addition could be stereoselective (6.14), forming a cyclic 
amine with two stereocenters. 
Chiral amines are a ubiquitous motif in pharmaceutical compounds, represented in about 40% 
of products on the market in 2014.13 Like the preparation and modification of amino acids, chiral 
amine synthesis often faces challenges in protecting group manipulation, stereoselectivity, and 
chiral resolution, among others.14 We envisioned developing the AnaD-AnaB pair to oxidize 
proline-related heterocycles and the subsequent nucleophilic addition step as a biocatalytic 
platform to synthesize chiral amines. However, this would require building loading and offloading 
steps into the total catalytic cycle; two potential routes with differing loading methods are outlined 
in Figure 6.3. 
The apo catalytic cycle (Figure 6.3A) starts with the inactive apo form of AnaD. A 
promiscuous phosphopantetheinyl transferase (PPTase) transfers both Ppant and substrate to apo-
AnaD (6.16) from coenzyme A (CoA) thioesters. The substrate may then be oxidized up to the 
iminium ion 6.11 and attacked by a nucleophile to form 6.13. Acyl carrier protein hydrolase 
(AcpH) closes the cycle by cleaving off the Ppant-product thioester 6.19. To reduce the cost of 
forming Pro-CoA (6.17), we also can start from a precursor pantetheine (Pant) thioester 6.18 and 
build up to CoA through the CoA biosynthetic enzymes CoaADE.15 Alternatively, in a catalytic 
cycle starting from holo-AnaD (6.9, Figure 6.3B), activated substrates are loaded diffusively by 
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nonenzymatic transthioesterification.16 Following oxidation by AnaB and nucleophilic addition, 
the product acid 6.14 is cleaved from AnaD by a type II thioesterase (TEII). Steps were verified 
separately before successively combination into the full four-step process. 
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Figure 6.3. Generating significant quantities of chiral amines by AnaB and nucleophiles also requires the development of a 
platform to utilize the carrier protein AnaD in catalytic amounts as well. 
Potential catalytic cycles can begin with either apo- or holo-AnaD. PPTase: phosphopantetheinyl transferase; TEII: type II thioesterase; 
ATP: adenosine triphosphate.
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6.2 Loading and Offloading 
From Apo-AnaD 
The two proposed catalytic cycles use two different paired loading and offloading methods. 
For the apo cycle (Figure 6.3A), both steps were envisioned to be enzymatic. We used the 
promiscuous PPTase Sfp from Bacillus subtilis, which natively primes apo- to holo-PCPs in 
surfactin biosynthesism as the catalyst for the loading step.17 CoaADE, two kinases (CoaAE) and 
one adenylyltransferase (CoaD) are three enzymes from coenzyme A biosynthesis, and have been 
shown to transform an extremely wide range of pantetheinyl derivatives into CoA compounds 
using 3 ATP molecules.15,18 We synthesized Pro and phenylalanine aminoacyl-CoA thioesters as 
the substrate for Sfp, and two precursors, Pro- and Phe-pantetheine (see 6.21 and 6.22, Figure 
6.4A) for CoA biosynthesis. 
 
 
Plasmids containing anaD and anaB from the anatoxin-a producing strain Oscillatoria PCC 
6506 were obtained from Olivier Ploux at the French National Centre for Scientific Research.9,10 
Figure 6.4. Enzymatic loading and offloading reactions for the apo catalytic cycle. 
(A) CoA biosynthesis from pantetheine thioesters, followed by priming/loading catalyzed by 
Sfp. (B) AcpH from P. fluorescens converts its native substrate holo-AcpP to apo but is inactive 
with AnaD. 
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Although AnaD expressed well in BL21(DE3) and BAP1 strains of E. coli,19 the apo-PCP 
precipitated in the low salt storage buffer, rendering quantification difficult. Fortunately, the 
precipitated protein re-solubilized in enzymatic reactions to prime and load substrates. By contrast, 
holo-AnaD was soluble in all conditions used. 
Incubation of apo-AnaD and Sfp with synthetic and biosynthetically produced Pro-CoA (6.16) 
or Phe-CoA (6.23) and analysis by intact protein mass spectrometry showed the expected mass of 
aminoacyl-AnaD (6.10 and 6.24, Figure 6.4A). For Pro, the major product was holo-AnaD, an 
observation also noted by the Ploux lab.10 We propose that the hydrolysis of Pro is primarily an 
artifact of ionization, as proline and other secondary amines are known to be especially reactive in 
the gas phase.20 
To regenerate apo-AnaD, we obtained the genes for AcpH from Pseudomonas aeruginosa and 
Psueodomonas fluorescens.21–23 Endogenously, AcpH is a phosphodiesterase that cleaves the 
Ppant cofactor from holo-AcpP, the acyl carrier protein of fatty acid biosynthesis in primary 
metabolism, to apo-AcpP (Figure 6.4B).21 This apparently nonessential protein has been reported 
to aggregate easily,21,23 but active AcpH has also been demonstrated to operate on AcpP with 
substrates bound and non-native CPs.18 P. fluorescens is reported to be both the more stable and 
promiscuous homolog.23 We first expressed the two AcpH homologs from P. aeruginosa (Pa) and 
P. fluorescenes (Pf). The former was inactive in our hands, while Pf_AcpH was also not active 
when expressed under the T7 promoter in DE3 strains. With assistance of Dr. Gregory Dodge of 
Prof. Janet Smith’s group at the University of Michigan, Pf_acpH was placed under control of the 
Trc24 promoter. The new recombinant protein successfully converted E. coli holo-AcpP 
completely to apoprotein and Ppant (6.27) but had no activity on holo-AnaD. Sequence alignment 
of AcpP and AnaD shows only 36% identity between the two proteins; it was not unexpected that 
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Pf_AcpH and AnaD are incompatible. Considering the difficulty in obtaining active Pf_AcpH, we 
then turned our attention to the holo catalytic cycle, which also uses catalytic amounts of Ppant. 
 
From Holo-AnaD 
The second catalytic cycle starts from holo-CP and utilizes a paired offloading mechanism to 
return to the same species. We propose a nonenzymatic loading step to bypass the native loading 
gatekeeper AnaC10 and additionally, eliminate the use of ATP. However, our aminoacyl donor 
substrates still require activation to thioesters before undergoing nonenzymatic 
transthioesterification with the Ppant cofactor of holo-AnaD. For this purpose, we synthesized the 
thiophenol (-SPh) and N-acetylcysteamine (-SNAC) thioesters of L-Pro and L-Phe (Figure 6.5). 
The thiophenol esters oxidized the holo-AnaD, forming a disulfide adduct (6.30, +108 Da) rather 
than aminoacyl-AnaD species. The SNAC thioesters afforded the expected aminoacyl-AnaD after 
incubation at 28 °C for 1-3 h. We have determined that the resulting free HSNAC causes 
significant amounts of hydrolysis back to holo-AnaD, so 2-vinylpyridine was added to scavenge 
the thiol.16 Due to the structural similarity of HSNAC and Ppant, the scavenger forms an adduct 
with AnaD as well (6.34), and was not used in later experiments.  
This second catalytic cycle regenerates holo-AnaD by TEIIs. Unlike type I thioesters that 
cleave finished PKS/NRPS products at the end of a pathway, the type II enzymes cleave stalled 
unproductive intermediates from CPs to restart biosynthesis.25 Four TEIIs from NRPS pathways 
were expressed and purified, including AnaA, the putative TEII of the anatoxin-a pathway.8,26–28 
Pro- and Phe-loaded AnaD (by any of the above methods) was incubated with TEII for 2 h at 28 
°C (Table 6.1). Although all four TEIIs showed some activity, TycF was generally the most active 
for both substrates and was chosen for further studies. SNAC thioesters are also hydrolyzed, 
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potentially diminishing the overall yield by prematurely cleaving and deactivating the aminoacyl 
donor before loading onto AnaD, but the Walsh lab has reported that CP-bound thioesters are  
 
 
favored over SNAC thioesters.26 Activity toward all substrates appears to slow dramatically after 
2 h, for unknown reasons, never reaching complete hydrolysis. Three additional genes of TEIIs 
(grsT, pltG and srfAD) from NRPS pathways have been obtained and will be expressed and 
assessed for activity.29–31 With the loading and offloading steps for the holo catalytic cycle 
established, we then began combining steps of our artificial catalytic cycle in one pot. 
  
Figure 6.5. Diffusive loading of holo-AnaD by thiophenol and SNAC esters. 
(A) Thiophenol esters oxidize the carrier protein itself. No aminoacyl-AnaD was observed. (B) 
SNAC thioesters transfer aminoacyl groups for incomplete loading. Adding 2-vinylpyridine as 
a thiol scavenger also inactivated holo-ACP. 
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Table 6.1. Hydrolysis of Pro and Phe aminoacyl groups from AnaD 
 
 
 
 
 
 
 
 
 
 
 
6.3 Multi-Step Catalytic Cycles 
Of the known flavin-dependent Pro-PCP oxidases and dehydrogenases, AnaB is the only 
enzyme that performs a two-electron oxidation, while PltE,32 PigA,33 CloN5 and CouN534 catalyze 
four-electron oxidations to aromatic pyrrole species which are planar and no longer highly 
electrophilic. Ploux and coworkers have proposed a mechanism for AnaB-catalyzed oxidation of 
Pro-AnaD 6.10, beginning with the α-deprotonation by Glu244, followed by hydride transfer to 
the FAD cofactor (Figure 6.6, top). A Glu244-assisted rearrangement affords the product with the 
unsaturation between N1 and C5. The reduced AnaB returns to the oxidized state with molecular 
oxygen, releasing a molecule of hydrogen peroxide.11 Additionally, the iminium ion is proposed 
to be maintained throughout extension by PKS modules AnaEF until cyclization by AnaJ (Figure 
6.6, bottom).35 
 
Entry Thioesterase 
Fraction of holo-AnaD (6.9) 
From 6.10 (Pro) From 6.24 (Phe) 
1 None (0 h) 48 30 
2 None (2 h) 70 37 
3 AnaA 76 50 
4 TycF 78 79 
5 RedJ 82 61 
6 RifR 78 50 
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AnaB was incubated with free proline and proline thioesters (pantetheine, CoA, SNAC), but 
no oxidation was observed by MS. When AnaD-bound substrate (6.10) was treated with AnaB, 
the mass of 6.10 decreased by 2 Da after a short incubation with AnaB, corresponding to the 
structure of 6.11 (Figure 6.7). A 4 Da loss was also seen at extended times, indicating that a second 
undesired oxidation to pyrrole 6.43 is occurring. It is not yet clear whether this overoxidation is 
enzymatic or spontaneous but could be examined in an O2-free single turnover oxidation reaction 
consisting of Pro-AnaD 6.10 and AnaB. Both oxidation products were confirmed by the MS/MS 
Ppant ejection assay.36 
 
Figure 6.6. Proposed mechanism of AnaB to generate the first iminium intermediate, then 
elongation and cyclization into the final product anatoxin-a. 
 435 
 
 
 
KCN, indole or nitromethane were also added after loading to act as a nucleophile, attacking 
intermediate 6.11 before the second oxidation could occur. Only a small amount of a species 
corresponding to cyanide addition (6.44) was detected. 
With all four of the processes successful operating in isolation, two steps (loading and 
offloading) were then combined in one pot (Table 6.2) to demonstrate substrate flux throughout 
the system. AnaD pre-loaded with Pro (6.10) was incubated with TycF to offload AnaD, and Phe-
SNAC (6.32) to load a second substrate (Table 6.2). Background hydrolysis to holo-AnaD (6.9) 
by the buffer or HSNAC occurred in all runs, as measured by intact protein MS (entry 2). Because 
of incomplete Pro loading, some Phe-loaded AnaD (6.24) was observed in the absence of TEII 
(entry 4). In the presence of both TycF and thioester 6.32, there was increased conversion of 6.10 
to holo-AnaD but less Phe loading, likely due to additional TycF-catalyzed hydrolysis (entry 5). 
The same pattern of reactivity was observed when pre-loaded 6.24 was incubated with TycF and 
Pro-SNAC (6.32). 
 
Figure 6.7. AnaB-catalyzed oxidation of Pro-AnaD to pyrrolinium and pyrrole species. 
The initial AnaB product (6.12) could be intercepted by nucleophilic addition before the second 
oxidation reaction that erodes all stereoinformation and renders the substrates inactive. 
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Table 6.2. Substrate exchange from Pro- to Phe-AnaD 
 
Entry Time TycF Phe-SNAC Pro (6.10) Holo (6.9) Phe (6.24) 
1 0 min - - 52% 48% 0% 
2 30 min - - 47 53 0 
3 30 min + - 34 66 0 
4 30 min - + 32 28 40 
5 30 min + + 27 39 34 
 
 
After confirming that loading and offloading were possible in one pot, three consecutive steps 
(loading, oxidation and offloading) were investigated (Figure 6.8). Small molecule analysis by 
LC-MS showed hydrolyzed proline (6.7) and the growth of a peak corresponding to the mass of 
acid 6.45, but not hydroxylated proline 6.46 or acid 6.47. Analysis of the intact proteins showed 
the accumulation of side product 6.43, which we attribute to TycF having limited activity towards 
pyrroles bound to AnaD. Varying the pH or amounts of TycF or AnaB did not significantly 
improve the relative yield of the desired product 6.45. 
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A complete one-pot four-step cycle (Figure 6.19) containing AnaD, AnaB, aminoacyl donor 
Pro-SNAC and the nucleophile KCN was incubated. By intact protein MS, a new peak and ejected 
fragment corresponding to 6.44 appeared after 1 h, but also diminished over extended time. When 
the small molecules were analyzed we saw none of the desired acid 6.47, only 6.45 from premature 
cleavage. The nitrile Pro derivatives 6.44 and 6.47 may be unstable, so we can only confirm three 
of four processes currently. Although the side product 6.43 accumulated more slowly here than in 
the three-step cycle, we propose that the TycF-catalyzed cleavage to close the catalytic cycles is 
the main bottleneck to AnaD turnover. We will continue to study the kinetics of our catalytic cycle 
with new nucleophiles and TEIIs, and the effects of adjusting the amount of each component. 
Figure 6.8. The basic three-step catalytic cycle consisting of substrate loading, oxidation 
by AnaB and product cleavage by TycF. 
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Because the CP-PE platform also provides a method to evaluate AnaB’s substrate scope, we 
have begun screening some unnatural substrates (Figure 6.10). Increasing the ring size to 6 (6.48) 
abolished AnaB activity. Unexpectedly, D-Pro (D-6.10), was oxidized in the three-step catalytic 
cycle, and a mass corresponding to 6.11 appeared, but with unknown configuration at C2. The 
crystal structure of AnaB shows the possible catalytically active His125 residue opposite the 
known active Glu244,37 so mutagenesis efforts are in progress to generate E244A and H125A 
variants to determine their catalytic importance and identify other relevant residues.  
 
Figure 6.9. The preliminary four-step holo catalytic cycle in one pot to load Pro onto 
AnaD, AnaB-catalyzed oxidation, cyanide addition and cleavage by TycF only completed 
three of four steps. 
Overoxidation to the pyrrole species 6.43 was still faster than nucleophilic addition. 
 439 
 
 
6.4 Conclusions 
Despite their ubiquity in pharmaceutical and fine chemical products, chiral cyclic amines 
present a major synthetic challenge. The biosynthesis of natural products in Nature provides the 
bases and inspiration for the development of new chemoenzymatic strategies. We designed a 
biocatalytic platform centered on the oxidation of a prolyl-AnaD species by the partner enzyme 
AnaB to the iminium intermediate 6.11, that then can be attacked by exogenous nucleophiles to 
generate a second chiral center. In order to use AnaD catalytically, we also added loading and 
offloading steps to recycle the PCP. In the first catalytic cycle, apo-AnaD could be primed and 
loaded, but we could not regenerate the apo state with a phosphodiesterase originally intended for 
fatty acid synthase carrier proteins. In the second catalytic cycle, holo-AnaD was diffusively 
loaded by synthetic acyl donors and potential products were hydrolyzed by thioesterases, 
successfully closing the catalytic cycle. In addition, we observed AnaB-catalyzed oxidation and 
small amounts of cyanide addition to the iminium ion product. 
However, we are not able to perform the complete four-step cycle in the same pot efficiently. 
This is primarily due to the overoxidation of 6.11 to a pyrrole species (6.43), which is stable and 
can no longer be attacked by cyanide or other water-compatible electrophiles, or even cleaved to 
Figure 6.10. Reactivity of AnaB with non-native substrates.  
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restart the catalytic cycle (Figure 6.11). Thus, our process is stalled by the pyrrole side product and 
future efforts to develop AnaB as a viable biocatalyst must focus on preventing formation of 6.43. 
 
 
Additional AnaB homologs from other anatoxin-a-producers can be tested to identify a protein 
that mediates the second oxidation reaction more slowly (if an enzymatic process). Regardless of 
whether the overoxidation is AnaB-catalyzed or spontaneous, more nucleophiles will be screened 
to discover a reagent that can trap the iminium intermediate more rapidly. Once the complete four-
step catalytic cycle (Figure 6.11) has been demonstrated on the native Pro substrate, we will turn 
our attention to increasing the overall catalytic efficiency. This will likely focus on tuning the 
enzymatic activity of AnaB and TycF or other TEIIs by directed evolution. 
The strategies investigated here to efficently utilize a PE that is absolutely CP-dependent (in 
situ substrate generation, nonenzymatic loading from inexpensive aminoacyl donors in 
combination with multiple offloading methods) provide preliminary groundwork for the 
Figure 6.11. The final holo catalytic platform built in this Chapter. 
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development of other artificial CP-PE biocatalytic platforms. The products of these catalytic cycles 
will not just be restricted to amino acid-based modifications or amines in NRPS systems, but also 
to other synthetically valuable scaffolds found in PKS and hybrid systems. With screening of many 
other CP-PE combinations and directed evolution, we anticipate that increasingly more PEs will 
soon be leveraged for their synthetic potential.  
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6.5 Experimental 
I. Chemical synthesis 
A. General information 
All reagents were used as received unless otherwise noted. Reactions were carried out under a 
nitrogen atmosphere using standard Schlenck techniques unless otherwise noted. Solvents were 
degassed and dried over aluminum columns on an MBraun solvent system (Inert Corporation, 
Model PS-00-3). Reactions were monitored by thin layer chromatography using Machery-Nagel 
60 F254 precoated silica TLC plates (0.25 mm) or Merck Silica Gel 60 RP-18 WF-254S precoated 
silica TLC plates (0.25 mm) which were visualized using UV, ninhydrin, p-anisaldehyde, cerium 
ammonium molybdate, 2,4-dinitrophenylhydrazine, or bromocresol green stain. Flash column 
chromatography was performed using Machery-Nagel 60 μm (230-400 mesh) silica gel. All 
compounds purified by flash column chromatography were sufficiently pure for use in further 
experiments unless otherwise indicated. 1H and 13C NMR spectra were obtained in CDCl3 or 
CD3OD at rt (25 °C), unless otherwise noted, on Varian 400 MHz or Varian 600 MHz 
spectrometers. Chemical shifts of 1H NMR spectra were recorded in parts per million (ppm) on 
the δ scale referenced to residual solvent peaks. Electrospray ionization liquid chromatography-
mass spectrometry (LC-MS) analysis was performed on an Agilent G6545A quadrupole-time of 
flight mass spectrometer in positive mode with an Agilent 1290 UPLC system. Solvent A = water 
with 0.1% formic acid. Solvent B = 95% acetonitrile, 5% water and 0.1% formic acid. MS data 
were analyzed using the Agilent Qualitative Mass Hunter software. 
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B. Compound synthesis 
 
D-pantetheine (6.S1) was prepared according to the procedure described in Chapter 3. 
 
HSNAC (6.S2), and Phe-SPh (6.29),38 and were kindly provided by the lab of Prof. David 
Sherman.  
 
General procedure for the coupling of Boc-protected amino acids to D-pantetheine or 
HSNAC39 
 
A 1 M solution of 6.S1 (187 mg, 0.67 mmol, 1.0 equiv) or HSNAC (72 µL, 0.67 mmol, 1.0 equiv) 
in dry DCM (6 mL) in a round bottomed flask was cooled to 0 °C in an ice bath. In a separate pear-
shaped flask, Boc-protected amino acid (0.71 mmol, 1.05 equiv), EDC·HCl (129 mg, 0.67 mmol, 
1.0 equiv) and DMAP (10 mg, 0.08 mmol, 0.13 equiv) were dissolved in 6 mL of DCM, and then 
transferred to the round bottomed flask via cannula. The ice bath was removed, and the reaction 
stirred overnight at rt under N2. Solvent was removed under reduced pressure and the crude residue 
was purified by flash chromatography. 
 
 
tert-butyl (S)-2-(((2-(3-((R)-2,4-dihydroxy-3,3-dimethylbutanamido)propanamido)ethyl)-
thio) carbonyl)pyrrolidine-1-carboxylate [Boc-Pro-Pant] (6.S3). The above procedure afforded 
198 mg (86%) of the title compound as a clear syrup. Purified by flash chromatography (2-10% 
 444 
 
gradient of MeOH in DCM). Rf = 0.3 (10% MeOH in DCM). 1H NMR (600 MHz, CD3OD) δ 4.43 
(dt, J = 9.4, 5.2 Hz, 1H), 3.93 (s, 1H), 3.56 – 3.47 (m, 6H), 3.36 (q, J = 6.7 Hz, 2H), 3.05 (t, J = 
6.6 Hz, 2H), 2.48 – 2.43 (m, 2H), 2.39 – 2.23 (m, 1H), 2.07 – 1.91 (m, 3H), 1.52 (s, 4H), 1.45 (s, 
5H), 0.96 (s, 9H); 1H NMR (400 MHz, CDCl3) (approximately 2:1 ratio of rotamers) δ 7.70 – 7.53 
(br s, 1H), 6.98 – 6.67 (m, 1H), 4.06 – 4.00 (m, 1H), 3.67 – 3.54 (m, 2H), 3.54 – 3.49 (m, 2H), 
3.45 – 3.34 (m, 2H), 3.16-2.94 (m, 2H), 2.51-2.40 (m, 2H), 2.25 – 2.14 (m, 1H), 2.05 –1.84 (m, 3 
H), 1.5 –1.39 (s, 9H), 1.09 – 0.90 (s, 6H); 13C NMR (150 MHz, CD3OD) δ 203.1, 176.0, 173.7, 
81.9, 70.3, 67.6, 47.7, 40.3, 36.3, 32.5, 31.7, 28.6, 24.3, 21.3, 20.9; HRMS (ESI) calcd for 
C21H38N3O7S [M+H]
+ m/z 476.2425, found 476.2424. 
 
 
tert-butyl (S)-2-(((2-(3-((R)-2,4-dihydroxy-3,3-dimethylbutanamido)propanamido)ethyl)-
thio) carbonyl)piperidine-1-carboxylate (6.S4). The above procedure afforded 189 mg (39%) of 
the title compound as a clear syrup. Purified by flash chromatography (2-10% gradient of MeOH 
in DCM). Rf = 0.25 (10% MeOH in DCM). 1H NMR (400 MHz, CD3OD) δ 4.02 (dd, J = 16.0, 
4.0 Hz,1H), 3.89 (s, 1H), 3.55 – 3.34 (m, 8H), 3.11 – 2.98 (m, 2H), 2.60 (t, J = 6.9 Hz, 1H), 2.42 
(q, J = 6.7, 5.8 Hz, 2H), 2.37 – 2.25 (m, 1H), 1.65 (d, J = 11.6 Hz, 3H), 1.49 (d, 5H), 1.47 (s, 4H), 
1.42 – 1.23 (m, 1H), 0.92 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 201.6, 174.0, 171.9, 110.2, 93.3, 
81.1, 70.9, 50.9, 42.6, 39.6, 39.4, 36.0, 35.2, 28.5, 26.4, 24.7, 24.64, 21.8, 20.6; HRMS (ESI) calcd 
for C22H40N3O7S [M+H]
+ m/z 490.2581, found 490.2587. 
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S-(2-(3-((R)-2,4-dihydroxy-3,3-dimethylbutanamido)propanamido)ethyl) (S)-2-((tert-
butoxycarbonyl)amino)-3-phenylpropanethioate (6.S5) [Boc-Phe-Pant]: The above procedure 
afforded 141 mg (40%) of the title compound as a clear syrup. Purified by flash chromatography 
(2-10% gradient of MeOH in DCM). Rf = 0.3 (10% MeOH in DCM). 1H NMR (600 MHz, CDCl3, 
mixture of rotamers) δ 7.64 – 7.44 (m, 2H), 7.31 – 7.05 (m, 5H), 6.99 (s, 1H), 5.41 – 5.14 (m, 1H), 
4.57 – 4.42 (m, 1H), 3.98 (s, 1H), 3.51 (p, J = 6.3 Hz, 3H), 3.49 – 3.39 (m, 4H), 3.36 (q, J = 7.1 
Hz, 2H), 3.04 – 2.90 (m, J = 9.9, 7.9 Hz, 2H), 2.61 (p, J = 7.1 Hz, 2H), 2.42 (dt, J = 30.2, 6.0 Hz, 
2H), 1.42 – 1.22 (m, 9H), 0.94 (d, J = 7.5 Hz, 3H), 0.89 (s, 3H); 13C NMR (150 MHz, CDCl3) δ 
201.73, 174.30, 171.96, 155.61, 155.51, 129.48, 129.30, 128.76, 128.52, 127.21, 77.37, 77.16, 
76.95, 70.65, 65.91, 61.57, 42.68, 42.65, 39.40, 39.36, 38.01, 35.81, 35.45, 28.36, 24.33, 21.46, 
21.29, 20.64, 15.30. 
 
 
tert-butyl (S)-2-(((2-acetamidoethyl)thio)carbonyl)pyrrolidine-1-carboxylate (6.S7) [Boc-
Pro-SNAC]: The above procedure afforded 610 mg (83% yield) of the title compound as an off-
white powder. Purified by flash chromatography (5% MeOH in DCM). Rf = 0.5 (10% MeOH in 
DCM). 1H NMR (400 MHz, CDCl3, mixture of rotamers) δ 6.09 (s, 1H), 4.43 (dd, J = 8.8, 3.1 Hz, 
1H), 3.61 – 3.31 (m, 4H), 3.11 – 2.95 (m, 2H), 2.29 – 2.13 (m, 1H), 2.04 – 1.83 (m, 6H), 1.47 (s, 
9H). 
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tert-butyl (R)-2-(((2-acetamidoethyl)thio)carbonyl)pyrrolidine-1-carboxylate (6.S8) [Boc-D--
Pro-SNAC]: The above procedure afforded 14 mg (5% yield) of the title compound as an off-
white powder. Purified by flash chromatography (5% MeOH in DCM). Rf = 0.5 (10% MeOH in 
DCM). 1H NMR (400 MHz, CDCl3, mixture of rotamers) δ δ 5.95 (s, 1H), 4.39 (ddd, J = 29.1, 
8.8, 3.3 Hz, 1H), 3.41 (overlapping m and q, J = 6.2 Hz, 4H), 3.01 (t, J = 6.4 Hz, 2H), 2.34 (s, 3H), 
1.96 (s, 4H), 1.49 – 1.11 (m, 9H). 
 
 
S-(2-acetamidoethyl) 1H-pyrrole-2-carbothioate (6.S9): Used the unprotected acid. The above 
procedure afforded 582mg (57% yield) as a light-green solid. Purified by flash chromatography 
(2% MeOH in DCM). Rf = 0.3 (5% MeOH in DCM). 1H NMR (400 MHz, CDCl3) δ 9.29 (s, 1H), 
7.04 (tt, J = 3.7, 1.7 Hz, 2H), 6.29 (dt, J = 3.7, 2.5 Hz, 1H), 6.05 (s, 1H), 3.52 (q, J = 6.0 Hz, 2H), 
3.19 (dd, J = 6.8, 5.7 Hz, 2H), 1.97 (s, 3H). All spectra obtained matched literature values.40 
 
General procedure for the deprotection of Boc-protected thioesters 
 
To a 1-dram vial containing Boc-protected aminoacyl thioesters was added excess HCl (4 M in 
dioxane). The reaction mixture stirred sealed for 2 h, before concentrating and washing 3x with 
hexanes. Products were isolated as hydrochloride salts and stored as 100 mM solutions in DMSO 
at -20 °C until further use. 
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S-(2-(3-((R)-2,4-dihydroxy-3,3-dimethylbutanamido) propanamido)ethyl) (S)-pyrrolidine-2-
carbothioate, hydrochloride salt [Pro-Pant] (6.21). The above procedure afforded 38 mg 
(100%) of the title compound as a white paste. Rf = 0 (10% MeOH in DCM). 1H NMR (600 MHz, 
CD3OD) δ 4.66 (q, J = 5.9, 4.1 Hz, 1H), 4.15 (s, 1H), 3.49 – 3.37 (m, 6H), 2.63 (t, J = 6.5 Hz, 2H), 
2.54 – 2.41 (m, 2H), 2.17 – 2.03 (m, 4H), 1.16 (s, 3H), 1.00 (s, 3H); 13C NMR (150 MHz, CD3OD) 
δ 196.8, 179.2, 172.4, 7.15, 76.5, 67.2, 49.8, 49.4, 49.2, 49.1, 49.0, 48.8, 48.7, 48.5, 47.1, 41.7, 
39.5, 37.1, 32.8, 30.7, 29.7, 24.5, 22.7, 19.2; HRMS (ESI) calcd for C16H30N3O5S [M+H]
+ m/z 
376.1901, found 376.1904. 
 
 
S-(2-(3-((R)-2,4-dihydroxy-3,3-dimethylbutanamido) propanamido)ethyl) (S)-piperidine-2-
carbothioate, hydrochloride salt (6.S10): The above procedure afforded 49 mg (100%) of the 
title compound as a white paste. Rf = 0 (10% MeOH in DCM). 1H NMR (600 MHz, CD3OD) δ 4.29 
(dd, J = 11.2, 3.7 Hz, 1H), 4.16 (s, 1H), 3.43 (t, J = 6.2 Hz, 8H), 2.64 (t, J = 6.5 Hz, 2H), 2.47 – 2.30 (m, 
2H), 1.98 – 1.69 (m, 6H), 1.18 (s, 3H), 1.01 (s, 3H); 13C NMR (150 MHz, CD3OD) δ 197.6, 179.2, 172.4, 
77.1, 76.5, 64.5, 49.8, 45.3, 41.7, 39.6, 32.8, 29.3, 28.8, 22.8, 19.2; HRMS (ESI) calcd for 
C17H32N3O5S [M+H]
+ m/z 390.2057, found 390.2063. 
 
 448 
 
 
Tert-butyl (S)-2-((phenylthio)carbonyl)pyrrolidine-1-carboxylate [Boc-Pro-SPh] (6.S11).41 A 
solution of Boc-amino acid (1.0 equiv) and diphenyl disulfide (1.5 equiv) in DCM (40x) was 
cooled to 0 °C in an ice bath. Tributylphosphine (1.5 equiv) was added dropwise over 5 min. The 
reaction mixture stirred under N2 for 1 h until completion, as visualized by TLC. The reaction was 
quenched with sat. aq. NaHCO3 and extracted 3x with DCM. The combined organic layers were 
dried over Na2SO4, filtered and concentrated. The crude residue was purified by flash 
chromatography. Rf = 0.25 (10% EtOAc in hexanes). The crude mixture was purified by column 
chromatography using in 10% EtOAc in hexanes. Isolated 0.59 g (82%) as a white crystalline 
solid. 1H NMR (600 MHz, CDCl3) (approximately 2:1 mixture of rotamers) δ 7.48 – 7.35 (m, 5H), 
4.59 – 4.43 (dd, J = 8.8, 3.6 Hz, 1H), 3.68 – 3.41 (m, 2H), 2.34 – 1.90 (m, 4H), 1.53 – 1.47 (s, 9H); 
13C NMR (150 MHz, CDCl3) δ 200.8, 154.0, 134.6, 129.4, 129.3, 127.7, 80.8, 66.3, 46.8, 31.7, 
28.6, 23.7. All spectra obtained were consistent with literature values.42 
 
 
S-phenyl (S)-pyrrolidine-2-carbothioate hydrochloride salt [Pro-SPh(·HCl)] (6.28): The 
deprotection procedure afforded 79 mg (100%) of the title compound from 100 mg of substrate as 
a white paste. 1H NMR (CD3OD, 600 MHz) δ 7.70 – 7.32 (m, 5H), 4.82 – 4.78 (m, 1H), 3.39 (ddt, 
J = 11.6, 7.3, 3.6 Hz, 2H), 2.56 (dddd, J = 13.3, 8.5, 7.6, 5.9 Hz, 1H), 2.22 (dq, J = 13.1, 7.6 Hz, 
1H), 2.17 – 2.04 (m, 2H); 13C NMR (CD3OD, 150 MHz) δ 195.4, 136.0, 131.5, 130.8, 126.45, 
67.1, 47.31, 30.8, 24.8; HRMS (ESI) calcd for C11H13NOS [M+H]
+ m/z 208.0791, found 208.0790. 
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S-(2-acetamidoethyl) (R)-pyrrolidine-2-carbothioate (6.S12) [D-Pro-SNAC]: The deprotection 
procedure afforded 11 mg (quantitative yield) of the title compound from 14 mg of substrate as an 
off-white powder. 1H NMR (400 MHz, CD3OD) δ 4.64 (t, J = 7.7 Hz, 1H), 3.78 – 3.55 (m, 1H), 
3.42 (td, J = 6.6, 3.8 Hz, 1H), 3.34 (t, J = 6.7 Hz, 2H), 3.26 – 3.10 (m, 1H), 3.01 (t, J = 6.7 Hz, 
2H), 2.55 – 2.45 (m, 1H), 2.33 (s, 3H), 2.21 – 2.03 (m, 2H). 
 
 
 
 
Prolyl-coenzyme A [Pro-CoA] (6.16): Aminoacyl thioester (1.9 mg, 0.0076 mmol, 3.0 equiv) 
and coenzyme A, trilithium salt (2.0 mg, 0.0025 mmol, 1.0 equiv ) were dissolved in 2.0 mL 50 
mM phosphate buffer, pH 8.5 in a 1 dram vial. The reaction mixture stirred sealed for 30 min and 
was filtered through a 0.2 µm syringe filter and washed with 0.2 mL of MeOH for purification by 
preparative HPLC in one injection (Beckman Coulter 126 Solvent Module/166 detector at 260 nm; 
Phenomenex Luna C18(2) column, 250 x 22 mm, 5 µm particle size; the flow rate was 8 mL/min, 
solvent A was 100 mM ammonium formate lowered to pH 5 with formic acid and solvent B was 
acetonitrile). Product was eluted using a method of 10 min at 5% B, linear gradient to 95% B over 
20 min, 9 min at 95% B, linear gradient to 5% B over 1 min, hold for 15 min at 5% B. Relevant 
fractions were pooled and concentrated to remove acetonitrile and then lyophilized. Purified 
aminoacyl-CoA compounds were stored as 1 mM solutions in water at -20 °C until further use. tR 
= 21 min. Isolated 3 mg (quantitative) as a white powder. HRMS (ESI) calcd for C26H44N8O17P3S 
[M+H]+ m/z 865.1752, found 865.1724. 
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Phe-CoA (6.23): The above procedure afforded 1.2 mg (52%) of the title compound as a white 
powder. tR = 24 min. HRMS (ESI) calcd for C30H46N8O17P3S [M+H]
+ m/z 915.1909, found 
915.1907. 
 
 
The following compounds were synthesized by Joshua Pyser: 
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C. 1H and 13C NMR spectra of compounds 
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II. Cloning, protein expression and purification 
A. General information 
Escherichia coli cloning strain DH5α (Invitrogen) was used for DNA propagation. Protein was 
expressed in E. coli strains BL21, BL21(DE3) (New England BioLabs) or BAP1 after 
transformation with relevant plasmids. Cells were grown in Luria Bertani (LB) or Terrific broth 
(TB) with 4% v/v glycerol supplemented with kanamycin (50 µg/mL) purchased from Gold 
Biotechnology. 
 
Primers were purchased from Integrated DNA Technologies and subcloned into various ligation-
independent cloning (LIC) vectors. DpnI restriction enzyme was purchased from New England 
BioLabs. LIC-qualified T4 DNA polymerase was purchased from EMD Millipore. QIAquick PCR 
purification, gel extraction and miniprep kits were purchased from Qiagen. HisPur nickel-
nitrilotriacetic acid (Ni-NTA) resin was purchased from Thermo Scientific. Proteins were 
concentrated using Amicon centrifugal filters purchased from EMD Millipore at 4,000 x g, 4 °C. 
PD-10 desalting columns were purchased from GE Healthcare. Protein samples were analyzed on 
Mini-PROTEAN TGX Gels (4-15%) from BioRad and visualized with Protein Ark Quick 
Coomassie Stain from Anatrace. Proteins were quantified with the Pierce 660 nm Assay Reagent 
from Thermo Scientific. 
 
B. Sequence information 
A pET28a plasmids containing anaB and anaD were obtained from the lab of Prof. Olivier Ploux 
at the French National Centre for Scientific Research, and were purified according to the published 
procedures.9,10 Plasmids containing maltose binding protein fusions of coaA, coaD and coaE were 
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obtained from the lab of Prof. Michael Burkart of the University of California in San Diego. 
pET22b-PaAcpH was also obtained from the lab of Michael Burkart and was expressed and 
purified according to a published procedure.18 Plasmids containing rifR and redJ were obtained 
from the laboratory of Prof. Janet Smith at the University of Michigan, and were expressed and 
purified according to published procedures.27,28 A pET24b vector encoding the gene for the 
promiscuous phosphopantetheinyl-transferase Sfp (Bacillus subtilis)17 was kindly donated by the 
group of Prof. David Sherman (University of Michigan Life Sciences Institute) and was expressed 
and purified according to the procedure in Chapter 2. 
anaA from Oscillatoria PCC 6506 and tycF from Brevibacillus brevis subcloned into pET151 
plasmids were purchased from Integrated DNA Technologies. Gene fragment of P. fluorescens 
Pf_AcpH and thioestersases GrsT, PltG and SrfAD (not used yet) were purchased from IDT. 
 
Table 6.S1. Proteins used in this Chapter 
Protein name Source organism GenBank accession 
AnaD Oscillatoria PCC 6506 CBN59194.1 
AnaB Oscillatoria PCC 6506 CBN59192.1 
AcpP E. coli AAA23740.1 
Pa_AcpH Pseudomonas aeruginosa CEI16732.1 
Pf_AcpH Pseudomonas fluorescens KIR20923.1 
AnaA Oscillatoria PCC 6506 CBN59190.1 
RedJ Streptomyces coelicolor ATCC A3(2) AL939125.1 
RifR Amycolatopsis mediterranei AF040570.3 
TycF Brevibacillus brevis AP008955.1 
GrsT Aneurinibacillus migulanus AAA58717.1 
PltG Pseudomonas fluorescens Pf-5 AAY92065.1 
SrfAD Bacillus subtilis CAA49819.1 
Sfp Bacillus subtilis BAA09125.1 
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Pf_AcpH E. coli-optimized gene fragment: 
ATGAACTATCTGGCACATCTGCATCTGGGTGGTCAGCTGCCTGCACAGCTGCTGGGTAGCCTGTATGGTGATTTTGT
TAAAGGTCGTCTGCAGGGTCAGTTTAGTCCGCAGATTGAAGCAGCAATTCAGCTGCATCGTAGCATTGATCGTTTTA
CCGATAGCCATCCGCTGGTTGGTGAAGCACTGAGCCGTTTTAGCCAGACCCGTCGTCGTTATGCAGGTATTGTTCTG
GATGTGTTTTTTGATCATTGTCTGGCACGTGATTGGGCACTGTATGCAGATCAGCCGCTGGAACGTTTTACCAGCCA
TGTTTATCAGGTTCTGGCAGCAGAACCGGCACTGCCTGGTCGTCTGGCACAGATTGCACCGTATATGGCAGCCGATG
ATTGGCTGGGTAGTTATCGTGAATTTGCAGTTATGGAACAGGTTCTGCGTGGTATTAGCCGTCGTCTGACCCAGCCG
GAAGAACTGGGTTATGCAATGCAAGAACTGCGTGTTCTGTATGAACCGCTGAGCGAAGATTTTCGTCTGTTTTATCC
GGAACTGCAGGCATTCGCACTGCAGTTTTAA 
 
Translation: 
MNYLAHLHLGGQLPAQLLGSLYGDFVKGRLQGQFSPQIEAAIQLHRSIDRFTDSHPLVGEALSRFSQTRRRYAGIVL
DVFFDHCLARDWALYADQPLERFTSHVYQVLAAEPALPGRLAQIAPYMAADDWLGSYREFAVMEQVLRGISRRLTQP
EELGYAMQELRVLYEPLSEDFRLFYPELQAFALQF* 
 
For cloning into pMCSG7, pMCSG9 and pMocr (LIC overhangs in bold): 
PfAcpH LIC fwd1 5’-tacttccaatccaatgcaAACTATCTGGCACATCTGCATCTGGG-3’ 
PfAcpH LIC rev1 5’-ttatccacttccaatgttaAAACTGCAGTGCGAATGCCTG-3’ 
 
The LIC insert was amplified in a 50 μL reaction containing 10 μL Xtreme buffer, 1 µM gene 
fragment, 3 μM each of forward and reverse LIC primers, 200 μM each of dNTPs, 0.04 U/μL KOD 
Xtreme Hot Start polymerase (Millipore). Excised domains were amplified according to the 
following PCR procedure: 94 °C 2:00, (98 °C 0:10, 68 °C 1:00) for 39 cycles, 68 °C 5:00. The 
insert was purified by gel extraction and subcloned into pMCSG7, pMCSG9 and pMocr using 
standard LIC protocols.43  
 
Pf_AcpH was subcloned into pTRC9 by Dr. Gregory Dodge to produce an MBP-fused protein. 
  Figure 6.S1. SDS-PAGE gel of the Pf_AcpH-MBP fusion protein (expected MW: 65 kDa). 
Image courtesy of Dr. Gregory Dodge. 
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C. Protein expression and purification 
Overexpression of CoaADE: ampicillin-resistant plasmids containing the gene of interest were 
transformed into chemically competent BL21(DE3) E. coli cells. A single colony was picked to 
inoculate a 5 mL LB starter culture supplemented with ampicillin (100 µg/mL) grown overnight 
at 37 °C, 200 rpm. The following day, 0.5 L TB media supplemented with ampicillin, was 
inoculated with the starter culture and incubated at 37 °C, 250 rpm until the OD600 reached 1.0. 
Cultures were equilibrated at 20 °C for 1 h. Expression was induced by addition of IPTG (final 
concentration 200 μM). Cultures were incubated at 20 °C, 200 rpm for 18 h. 
 
Overexpression of AnaA and TycF: plasmids containing the gene of interest were transformed 
into chemically competent BL21(DE3) (holo-AnaD: BAP1) E. coli cells. A single colony was 
picked to inoculate a 5 mL LB starter culture grown overnight at 37 °C, 200 rpm. The following 
day, 1 L LB media supplemented with either kanamycin or ampicillin, was inoculated with the 
starter culture and incubated at 37 °C, 250 rpm until the OD600 reached 0.6. For apo-ACP, the 
media was also supplemented with a trace metals mixture (final concentrations: 50 μM FeCl3, 20 
μM CaCl2, 10 μM MnCl2, 10 μM ZnCl2, 2 μM CoCl2, 2 μM CuCl2, 2 μM NiCl2, 2 μM Na2MoO4, 
2 μM Na2SeO3, 2 μM B(OH)3). Cultures were cooled to rt. Expression was induced by addition of 
IPTG (final concentration 200 μM). Cultures were incubated at 20 °C, 200 rpm for 18 h. AnaB 
was grown at 25 °C for 18 h instead of 20 °C. 
 
Purification of CoaADE: Cell pellets were resuspended in 4 mL of lysis buffer (100 mM Tris-
HCl, 500 mM NaCl, and 0.1 mM DTT at pH 7.9) per gram of wet cell mass and incubated with 
lysozyme and DNase (Promega) on ice for 1 h. Cells were lysed by sonication (3 s on, 6 s off, 5 
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min total). Insoluble material was removed by centrifugation (17,000 x g for 30 min at 4 °C). The 
clarified lysate was incubated with gentle shaking along with 5 mL of amylose resin for 1 h at 4 
°C and poured into a column. The resin-bound protein was washed with 25 mL lysis buffer and 
eluted with 16 mL elution buffer (10 mM Tris-HCl, 500 mM NaCl, 0.1 mM DTT, 10 mM maltose, 
pH 7.9). The eluted protein was concentrated using 3 – 50 kDa centrifugal cutoff filters and 
dialyzed overnight into lysis buffer. The final protein was concentrated further using 50 kDa 
centrifugal cutoff filters, aliquoted, flash frozen in liquid nitrogen and stored at -80 °C. 
 
Purification of AnaA and TycF: Cell pellets were resuspended in 4 mL of lysis buffer (50 mM 
Tris-HCl, 300 mM NaCl, 10 mM imidazole, and 10% (v/v) glycerol at pH 7.4) per gram of wet 
cell mass. Cells were lysed by sonication (3 s on, 6 s off, 3 min total). Insoluble material was 
removed by centrifugation (30,000 x g for 30 min at 4 °C). The clarified lysate was incubated with 
gentle shaking along with 1 mL of nickel-NTA resin for 1 h at 4 °C and poured into a column. The 
resin-bound protein was washed with 25 mL wash buffer (50 mM Tris-HCl, 300 mM NaCl, 25 
mM imidazole, 10% (v/v) glycerol, pH 7.4). The desired protein was eluted with 4 mL elution 
buffer ((50 mM Tris-HCl, 300 mM NaCl, 300 mM imidazole, and 10% (v/v) glycerol at pH 7.4The 
eluted protein was concentrated using 30 kDa centrifugal cutoff filters and exchanged into storage 
buffer (50 mM Tris-HCl and 10% (v/v) glycerol at pH 7.4) using a PD-10 column. The desalted 
protein was concentrated further using 30 kDa centrifugal cutoff filters, aliquoted, flash frozen in 
liquid nitrogen and stored at -80 °C. 
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III. Enzymatic reactions and data 
A. General information 
Electrospray liquid chromatography-mass spectrometry (LC-MS) analysis was performed on an 
Agilent G6545A quadrupole-time of flight mass spectrometer in positive mode with an Agilent 
1290 UPLC system. Solvent A = water with 0.1% formic acid. Solvent B = 95% acetonitrile, 5% 
water and 0.1% formic acid. MS data were analyzed using the Agilent Qualitative Mass Hunter 
software. Intact proteins were deconvoluted with the maximum entropy algorithm. 
 
Recombinant holo-AcpP from E. coli was prepared by Dr. Gregory Dodge. 
Species Calculated 
protein mass 
(Da)a 
Observed mass 
(Da) 
Calculated Ppant 
ejection fragment 
(m/z) 
Observed Ppant 
ejection mass 
(m/z)b 
Apo-AnaD 13,809.8 13,810.2 N/A N/A 
Holo-AnaD 
 
14,149.9 14,150.4 261.13 261.13 
Pro-AnaD 
 
14,247 14,247 358.18 358.18 
Pyrroline 
 
14,245 14,245 356.16 356.15 
Pyrrole 
 
14,243 14,243 354.15 354.15 
Phe-AnaD 
 
14,297 14,297 408.20 408.20 
Thiophenol disulfide 
 
14,258 14,258 369.13 - 
2-vinylpyridine adduct 
 
14,241 14,241 352.17 352.17 
Cyanide adduct 
 
14,272 ND 383.18 383.18 
aAll constructs from pET28 were observed to lose their initial Met. This also allowed for significant formation of 
gluconoylated adducts44 (+178 Da when deconvoluted) that did not appear to affect protein function and were factored 
into all calculations of PCP species breakdowns. bThe Ppant ejection assay was not run for all experiments. 
 
 
 467 
 
 
Enzymatic loading of apo-AnaD (Figure 6.4A) 
Directly from aminoacyl-CoA: 50 µM apo-AnaD, 200 µM Pro- or Phe-pantetheine, 10 µM Sfp, in 
50 mM Tris-HCl pH 7.5 and 10 mM MgCl2 were combined (total volume 50 µL) and incubated at 
37 °C for 1 h. 
With CoA biosynthesis: 50 µM apo-AnaD, 200 µM Pro- or Phe-CoA, 800 µM ATP, 0.2 mg/mL 
CoaA, 0.2 mg/mL CoaD, 0.2 mg/mL CoaE, 10 µM Sfp in 50 mM Tris-HCl pH 7.5 and 10 mM 
MgCl2 were combined (total volume 50 µL) and incubated at 37 °C for 1 h. 
In both cases, reactions were quenched by diluting 10x with 1% v/v of formic acid in water, and 
pelleting any precipitation by centrifuging at 10,000 x g, 4 °C for 10 min. The supernatant was 
transferred to sample vials for LC-MS analysis: column = Phenomenex Aeris 3.6 μm WIDEPORE 
C4 2.1 x 50 mm; method = 5% B at 0.5 mL/min for 2 min, followed by a linear gradient to 100% 
B over 4 min, 100% B for 2 min, followed by a 0.1 min linear gradient to 5% B and 1.9 min 
equilibration at 5% B (total time 10 min). tR = 4.4 min. The relative abundance of the deconvoluted 
protein species were used to calculate the fraction of holo-, Pro- and Phe-AnaD present. 
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Conversion of holo-CPs to apo (Figure 6.4B): 50 µM holo-AnaD or AcpP and 2 µM Pf_AcpH 
in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 12.5 mM MgCl2, 1 mM MnCl2, and 10% v/v glycerol 
were combined (total volume 50 µL) and incubated at 37 °C for 16 h. Reactions were quenched 
by diluting 10x with 1% v/v of formic acid in water, and pelleting any precipitation by centrifuging 
at 10,000 x g, 4 °C for 10 min. The supernatant was transferred to sample vials for LC-MS analysis: 
column = Phenomenex Aeris 3.6 μm WIDEPORE C4 2.1 x 50 mm; method = 5% B at 0.5 mL/min 
for 2 min, followed by a linear gradient to 100% B over 4 min, 100% B for 2 min, followed by a 
0.1 min linear gradient to 5% B and 1.9 min equilibration at 5% B (total time 10 min). tR (AcpP) 
= 4.1 min. The relative abundance of the deconvoluted protein species were used to calculate the 
fraction of holo- and apo-CP. 
 
Holo-AcpP was completely converted, but we observed no activity on holo-AnaD. 
 
 
Figure 6.S2. Sequence alignment of AnaD and AcpP. 
Sequences were aligned by MUSCLE (https://www.ebi.ac.uk/Tools/msa/muscle/) and colored in 
JalView. 
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Diffusive loading of holo-AnaD (Figure 6.5): 50 µM holo-AnaD, 1 mM aminoacyl-SNAC or -
SPh, in 50 mM potassium phosphate pH 6.8 were combined (total volume 50 µL) and incubated 
at 28 °C for 1-3 h. The total loading was calculated by comparing the area of deconvoluted protein 
peaks after intact protein MS. 2-vinylpyridine (8 mM) formed unproductive adducts with holo-
AnaD (61% of all CP present after 4 h) and was omitted from later reactions. 
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Figure 6.S3. Deconvoluted protein spectra of holo-AnaD incubated with aminoacyl-SNAC 
thioesters. 
 
 
 
Hydrolysis of aminoacyl groups from AnaD (Table 6.1): 50 µM AnaD (mixture of holo and 
aminoacyl) and 2 µM thioesterase in 50 mM potassium phosphate pH 6.8 were combined (total 
volume 50 µL) and incubated at 28 °C for 1-3 h. The total hydrolysis was calculated by comparing 
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the area of deconvoluted protein peaks after intact protein MS. HSNAC-accelerated hydrolysis 
was measured by adding 1 mM HSNAC to reactions. 
Hydrolysis of aminoacyl-SNACs: 1 mM Pro- or Phe-SNAC and 2 µM TycF in 50 mM potassium 
phosphate pH 6.8 were combined (total volume 100 µL) and incubated at 28 °C for 4 h. After 
every hour, 25 µL was removed and quenched in 75 µL of MeOH. Precipitate was pelleted by 
centrifuging at 10,000 x g for 10 min. The supernatant was transferred to sample vials for LC-MS 
analysis: column = Waters Acquity 1.7 µm UPLC BEH C18 column, 2.1 mm x 50 mm; method = 
5% B at 0.5 mL/min for 30 s, followed by a linear gradient to 100% B over 3 min, 100% B for 1 
min, followed by a 0.1 min linear gradient to 5% B and 0.4 min equilibration at 5% B (total time 
5 min). Minor hydrolysis was observed in the no-enzyme negative controls. 
Pro-SNAC: 6% total hydrolysis after 4 h 
Phe-SNAC: 20% total hydrolysis after 4 h 
 
 
AnaB-catalyzed oxidation of Pro-AnaD (Figure 6.7): 50 µM Pro-AnaD (mixture of holo and 
Pro) and 2 µM AnaB in 50 mM potassium phosphate pH 6.8 were combined (total volume 75 µL) 
and incubated at 28 °C for 1.5 h. Every 30 min, 25 µL aliquots were removed and quenched by 
diluting 10x in 1% v/v formic acid in water. The oxidation was calculated by comparing the 
intensity of the ejected Ppant ions. Because of the small mass changes, the deconvoluted protein 
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peak appeared to be a mixture of the three species, with the molecular weight becoming closer to 
the pyrrole mass over time. 
On free small molecules: other substrates tested included L-Pro, Pro-SNAC, Pro-pantetheine, Pro-
phosphopantetheine (via CoaA) and Pro-CoA (via CoaADE). No oxidation was observed by small 
molecule MS. For pantetheine and larger molecules: column = Waters XBridge C18 3.5 µm , 2.1 
x 150 mm; solvent A = water with 0.1% v/v formic acid, solvent B = methanol with 0.1% v/v 
formic acid; method = 10% B at 0.2 mL/min for 2 min, followed by a linear gradient to 90% B 
over 15 min, then a gradient to 90% over 1 min (total time 18 min). tR (Pro-pantetheine) = 8.2 min; 
tR (Pro-phosphopantetheine) = 5.2 min; tR (3’-dephospho-Pro-CoA) = 5.9 min. 
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Figure 6.S4. Deconvoluted protein spectra of Pro-AnaD incubated with AnaB. 
 
 
 
AnaB-catalyzed oxidation with nucleophilic addition: 50 µM Pro-AnaD (mixture of holo and 
Pro), 1 mM potassium cyanide and 1.5 µM AnaB in 50 mM potassium phosphate pH 6.8 were 
combined (total volume 50 µL) and incubated at 28 °C for 2 h. Every hour, 25 µL aliquots were 
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removed and quenched by diluting 10x in 1% v/v formic acid in water. The oxidation and 
nucleophilic addition were observed by comparing the intensity of the ejected Ppant ions. 
 
 
 
Figure 6.S5. Ejected ions of the AnaB oxidation reaction with and without KCN present. 
A new peak is present in the KCN reaction matching the mass of a cyanide addition ejected ion. 
While this peak did not grow over time, it also did not appear to be oxidized a second time by 
AnaB. 
 
 
One-pot offloading and loading (Table 6.2): 50 µM Pro-AnaD (mixture of holo and Pro), 1 mM 
Phe-SNAC and 2 µM TycF in 50 mM potassium phosphate pH 6.8 were combined (total volume 
With KCN 
No KCN 
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100 µL) and incubated at 28 °C for 1.5 h. Every hour, 25 µL aliquots were removed and quenched 
by diluting 10x in 1% v/v formic acid in water. The distribution of aminoacyl and holo species 
was calculated by comparing the area of deconvoluted protein peaks after intact protein MS. 
 
 
One-pot loading, oxidation and offloading (Figure 6.8): 50 µM holo-AnaD, 1 mM Pro-SNAC, 
1.5 µM AnaB, 2 µM TycF and a 50 µM phenylalanine internal standard in 50 mM potassium 
phosphate pH 6.8 were combined (total volume 200 µL) and incubated at 28 °C for 4 h. Every 
hour, 50 µL aliquots were removed and quenched by diluting 10x in 1% v/v formic acid in water. 
Precipitation was pelleted by centrifuging 10,000 x g for 10 min. Half of the supernantant was 
transferred to sample vials for intact protein MS. The distribution of aminoacyl and holo species 
was calculated by comparing the area of deconvoluted protein peaks after intact protein MS. The 
other half was filtered through a 3 kDa molecular cutoff filter (Millipore) and the flow-through 
analyzed by small molecule LC-MS: column = Waters Acquity 1.7 µm UPLC BEH C18 column, 
2.1 mm x 50 mm; method = 5% B at 0.5 mL/min for 30 s, followed by a linear gradient to 100% 
B over 3 min, 100% B for 1 min, followed by a 0.1 min linear gradient to 5% B and 0.4 min 
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equilibration at 5% B (total time 5 min). tR (6.45) = 0.9 min; tR (phenylalanine) = 1.2 min. The 
area of the extracted ion chromatograms of acid 6.45 vs. phenylalanine were compared.45 
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Figure 6.S6. Extracted ion chromatograms of the pyrrolinium acid product relative to the 
internal standard. 
 
Pro-AnaD and AnaB were also incubated for 2 h for complete conversion to the pyrrole 6.44 before 
addition of TycF. There was no cleavage to regenerate holo-AnaD. No transthioesterification 
occurred when holo-AnaD was incubated with thioester donor 6.S9. 
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One-pot loading, oxidation, nucleophilic addition and offloading (Figure 6.9): 2 mM KCN, 
50 µM holo-AnaD, 1 mM Pro-SNAC, 1.5 µM AnaB, 2 µM TycF and a 50 µM phenylalanine 
internal standard in 50 mM potassium phosphate pH 6.8 were combined (total volume 200 µL) 
and incubated at 28 °C for 4 h. Every hour, 50 µL aliquots were removed and quenched by diluting 
10x in 1% v/v formic acid in water. Half of the quenched sample was analyzed by intact protein 
MS, and the other half by small molecule MS after filtering out proteins. 
We detected oxidation to 6.43 and a small quantity of acid 6.45, but no aminoacyl-AnaD 6.44 or 
acid 6.47. 
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Oxidation of a six-membered ring (Figure 6.10): 50 µM apo-AnaD, 200 µM thioester 6.S10, 
800 µM ATP, 0.2 mg/mL CoaA, 0.2 mg/mL CoaD, 0.2 mg/mL CoaE, 10 µM Sfp and 2 µM AnaB, 
in 50 mM potassium phosphate pH 6.8 and 10 mM MgCl2 were combined (total volume 50 µL) 
and incubated at 28 °C for 3 h. The reactions were analyzed by intact protein MS. We observed 
59% loading, but no oxidation, both by deconvoluted protein peaks and ejected Ppant ions. 
 
 
Oxidation of D-Pro-AnaD (Figure 6.10): 50 µM holo-AnaD, 2 mM D-Pro-SNAC, 5 µM AnaB, 
2 µM TycF and a 50 µM phenylalanine standard in 50 mM potassium phosphate pH 6.8 were 
combined (total volume 100 µL) and incubated at 28 °C for 3 h. The reactions were analyzed by 
intact protein MS to detect PCP-bound intermediates and small molecule MS for acid products. 
Oxidation by AnaB was slower, and low quantities (seeming less than the L-Pro reaction, but not 
rigorously quantified) of acid 6.45 were observed.  
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Chapter 7: Conclusions and Future Directions 
 
Enzymes from carrier protein-dependent biosynthetic pathways catalyze a wealth of interesting 
transformations but have untapped synthetic potential in the formation of new molecules. Because 
of the CP-dependence, biocatalytic platforms for PEs will require removing the dependence, 
exploiting CP-independent reaction modes or adding loading/offloading steps to recycle CPs. This 
Chapter summarizes the results of the five previous Chapters detailing studies on two PEs, SxtA 
and AnaB, to generate chiral amines chemoenzymatically.  
SxtA is a four-domain polyketide-like synthase which had previously been proposed to initiate 
biosynthesis of the potent paralytic shellfish toxin saxitoxin.1 Bioinformatic searches indicated that 
the SxtA module possesses an α-oxoamine synthase domain, which could serve as a potential tool 
to modify amino acids. We identified the true starter unit of SxtA and characterized its native 
activity, facilitating further synthetic and mechanistic studies with individual domains. We have 
found that SxtA AONS is a promiscuous enzyme for the generation of α-amino ketones in a single 
step, but with overall robustness that requires improvement by directed evolution. The domain 
performs many more protonation/deprotonation turnovers, enabling high levels of deuterium 
incorporation into α-amino acids and their methyl esters and a chemoenzymatic synthesis of an 
isotopically labeled drug. 
SxtA AONS binds and deprotonates the α-carbon of all linear α-amino methyl esters screened, 
but not the cyclic amino acid, L-proline. AnaB, a previously characterized PE-dependent oxidase,2 
provides an opportunity to derivatize this amino acid and efficiently generate chiral cyclic amines 
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through an artificial four-step CP-PE catalytic cycle. The full one-pot cycle cannot be completed 
efficiently due to overoxidation to an unreactive byproduct. These initial studies to explore PE-
mediated non-native reactions both in the presence or absence of CPs will contribute to the 
development of new biocatalytic tools for the synthesis of complex molecules. 
 
Future Directions 
Engineering Dimethylation Activity in SxtA MT 
We were not able identify the residues in SxtA MT that govern the monomethylation activity 
compared to the dimethylation observed in other metal-dependent methyltransferases identified in 
PKS initiation modules (MTLs).
3 Additional variants of SxtA MT-GNAT outside the first sphere 
of interactions with malonyl-ACP will be generated to screen for dimethylating variants. These 
results will contribute to the growing body of literature on MTL domains and natural products 
containing ethyl, isopropyl or t-butyl substituents. For example, the bioactivity of molecules at one 
level of methylation (e.g., one group added in saxitoxin, myxovirescin A)4 could be tuned with 
additional methylation or alkylation with SAM derivatives (Figure 7.1). The methyl 
functionalization activity could also be decreased in the biosynthesis of an originally dimethylated 
natural product such as gephyronic acid.5 Methylation could also be introduced into pathways with 
β-keto-CP intermediates where there is currently no functionalization. 
 
Figure 7.1. Generation of novel natural products through MTL-catalyzed alkylation. 
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Generation of α-amino ketones by SxtA AONS 
Directed evolution of the excised SxtA AONS domain to engineer increased activity on a non-
native Trp substrate is ongoing. These libraries will also be screened for additional activity, such 
as higher conversion in the native ketone-forming reaction with arginine or other amino acids, or 
the generation of increased quantities of α-tetra-substituted amino acid derivatives. The small 
volumes of analytes used in high-throughput droplet screening may allow for miniaturized or 
droplet enzymatic reactions as well to increase efficiency further. Potential product inhibition may 
be relieved in cascade reactions removing or elaborating on the α-amino ketone products (e.g. 
reduction of the carbonyl to a hydroxyl group, see Figure 7.2A).6 
 
 
Figure 7.2. Future work on products generated from SxtA AONS. 
(A) Synthesis from α-amino ketone or α-deuterated amino acid/methyl ester building blocks. (B) 
Increasing the stereoselectivity of deuterated methyl esters. Black dots: L-substrates; red: D-
substrates. 
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α-deuteration of amino acids and methyl esters by SxtA AONS 
Investigations to understand stereoselectivity of the reprotonation step for each D- and L-
methyl ester substrates will continue. Unreactive thioester mimics such as thioethers will be 
synthesized to increase deuterium incorporation into less active substrates,7 and we will also screen 
other α-carbonyl compounds, such as amides. Deuterated products will serve as building blocks in 
labeled peptides/proteins and other amino acid-based scaffolds. Compounds that are metabolized 
at the α-carbon may also be screened for changes in half-lives relative to the protio-compounds. 
Preliminary experiments have suggested that wild-type SxtA AONS could be a catalyst for 
stereoinversion or dynamic kinetic resolution of some α-amino methyl esters (Figure 7.2B). Wider 
screening of methyl esters will identify substrates for this application and members of the AONS 
variant library can be screened for their stereoselectivity. 
In addition, we will elucidate the origin of the broader deuterium incorporation of α-amino 
methyl esters over the corresponding acids by SxtA AONS. Methyl esters possess a decreased pKa 
at the α-carbon and it is not clear if the esterification increases deuterium because of the increased 
acidity or because of structural resemblance to the ethyl ketone product or a combination. 
Comparison of SxtA AONS deuteration to another AOS, serine palmitoyltransferase, on long 
chain aliphatic myristyl esters may reveal the overall effect of esterification on binding to the PLP 
cofactor and deprotonation. 
 
Synthesis of chiral cyclic amines with AnaB and AnaD 
The formation of undesired pyrrole byproducts causes the artificial catalytic cycle to stall in 
multiple ways, halting productive generation of new chiral compounds. Overoxidation may be 
minimized by screening other AnaB homologs, a strategy that was successful in identifying a 
parent for directed evolution in SxtA AONS. The desired electrophilic iminium intermediate can 
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be intercepted more rapidly after screening for more reactive nucleophiles, and then cleaved from 
AnaD by a promiscuous thioesterase. Cyclic amines generated by a productive four-step catalytic 
cycle can be elaborated into more complex small molecules. 
 
Figure 7.3. Synthesis of chiral cyclic amine building blocks after AnaB-mediated oxidation. 
 
 
The strategies presented in this thesis, from enzyme and reaction discovery, to 
chemoenzymatic preparation of valuable compounds demonstrate the possibilities of leveraging 
CP-dependent PEs in synthesis. We anticipate that these approaches, CP-independent modes of 
reactivity and CP recycling with inexpensive acyl and aminoacyl donors, will also be applied to 
other PEs for the efficient, chemo-, site- and stereoselective generation of chiral amines and other 
important synthetic building blocks. 
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